{"PMC7250601": [["Intuitively, these can be seen as functions that, given input values, return output values from a database.", [["input values", "TEST", 56, 68], ["return output values", "TEST", 70, 90], ["a database", "TEST", 96, 106]]]], "PMC6830131": [["IntroductionThe infectious bronchitis virus (IBV) is a prototype coronavirus containing a single-stranded positive-sense RNA genome (Cook et al., 2012).", [["infectious bronchitis virus", "DISEASE", 16, 43], ["infectious bronchitis virus", "ORGANISM", 16, 43], ["IBV", "ORGANISM", 45, 48], ["single-stranded positive-sense RNA genome", "DNA", 90, 131], ["infectious bronchitis virus", "SPECIES", 16, 43], ["infectious bronchitis virus", "SPECIES", 16, 43], ["IBV", "SPECIES", 45, 48], ["The infectious bronchitis virus", "PROBLEM", 12, 43], ["a prototype coronavirus", "PROBLEM", 53, 76], ["infectious", "OBSERVATION_MODIFIER", 16, 26], ["bronchitis", "OBSERVATION", 27, 37]]], ["IBV is the etiologic agent of infectious bronchitis (IB), which is a highly contagious, acute viral respiratory disease of chickens.", [["respiratory", "ANATOMY", 100, 111], ["infectious bronchitis (IB)", "DISEASE", 30, 56], ["viral respiratory disease", "DISEASE", 94, 119], ["IBV", "ORGANISM", 0, 3], ["IB", "CANCER", 53, 55], ["chickens", "ORGANISM", 123, 131], ["chickens", "SPECIES", 123, 131], ["IBV", "SPECIES", 0, 3], ["chickens", "SPECIES", 123, 131], ["IBV", "TREATMENT", 0, 3], ["infectious bronchitis", "PROBLEM", 30, 51], ["acute viral respiratory disease of chickens", "PROBLEM", 88, 131], ["etiologic agent", "OBSERVATION_MODIFIER", 11, 26], ["infectious", "OBSERVATION_MODIFIER", 30, 40], ["bronchitis", "OBSERVATION", 41, 51], ["highly", "OBSERVATION_MODIFIER", 69, 75], ["contagious", "OBSERVATION_MODIFIER", 76, 86], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["viral", "OBSERVATION_MODIFIER", 94, 99], ["respiratory disease", "OBSERVATION", 100, 119]]], ["IBV has been reported by many researchers all over the world (Jungherr and Terrells, 1948; Jungherr et al., 1956; Fabricant, 1998; Yu et al., 2001; Benyeda et al., 2009; Sjaak De Wit et al., 2011; Westerbeck and Machamer, 2019; Wu et al., 2019).", [["IBV", "ORGANISM", 0, 3], ["IBV", "SPECIES", 0, 3], ["IBV", "PROBLEM", 0, 3]]], ["IBV has led to severe losses in the poultry industry (Jordan, 2017), the direct losses are due to highly mortality, poor egg quality, and meat production, and the indirect losses result in increased costs and challenges in IBV prevention (Liang et al., 2019).", [["egg", "ANATOMY", 121, 124], ["meat", "ANATOMY", 138, 142], ["IBV", "ORGANISM", 0, 3], ["egg", "ORGANISM_SUBDIVISION", 121, 124], ["meat", "ORGANISM_SUBDIVISION", 138, 142], ["IBV", "ORGANISM", 223, 226], ["IBV", "SPECIES", 0, 3], ["IBV", "SPECIES", 223, 226], ["IBV", "PROBLEM", 0, 3], ["severe losses", "PROBLEM", 15, 28], ["the direct losses", "PROBLEM", 69, 86], ["poor egg quality", "PROBLEM", 116, 132], ["the indirect losses result", "PROBLEM", 159, 185], ["increased costs", "PROBLEM", 189, 204], ["IBV prevention", "TREATMENT", 223, 237], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["losses", "OBSERVATION", 22, 28], ["increased", "OBSERVATION_MODIFIER", 189, 198], ["costs", "OBSERVATION", 199, 204]]], ["At present, live attenuated vaccines are widely used for the prevention and control of IB.", [["live attenuated vaccines", "TREATMENT", 12, 36]]], ["However, due to extensive genetic diversity of IBV strains, the vaccines are becoming increasingly inefficient, with poor cross-protection effects among different serotypes of vaccines (Mo et al., 2013; Chen et al., 2015; Lin and Chen, 2017; Yan et al., 2018).", [["IBV strains", "ORGANISM", 47, 58], ["IBV", "SPECIES", 47, 50], ["IBV strains", "PROBLEM", 47, 58], ["the vaccines", "TREATMENT", 60, 72], ["increasingly inefficient", "PROBLEM", 86, 110], ["different serotypes of vaccines", "TREATMENT", 153, 184], ["IBV strains", "OBSERVATION", 47, 58]]], ["Meanwhile, due to the lack of coordinated effort to prevent the IBV, and the lack of proper surveillance plus the introduction of foreign strains to combat the IBV in certain regions, the prevention and control of IBV has become very difficult.", [["IBV", "DISEASE", 64, 67], ["IBV", "DISEASE", 160, 163], ["IBV", "DISEASE", 214, 217], ["IBV", "ORGANISM", 64, 67], ["IBV", "ORGANISM", 160, 163], ["IBV", "ORGANISM", 214, 217], ["IBV", "SPECIES", 64, 67], ["IBV", "SPECIES", 160, 163], ["IBV", "SPECIES", 214, 217], ["the IBV", "PROBLEM", 60, 67], ["foreign strains", "PROBLEM", 130, 145], ["the IBV", "TREATMENT", 156, 163], ["IBV", "PROBLEM", 214, 217]]], ["Therefore, it is imperative to find an effective antiviral drug or agent for the prevention of IBV.IntroductionIn order to control drug residues, the Chinese government has banned the use of antiviral drugs in food animals in China.", [["IBV", "DISEASE", 95, 98], ["IBV", "ORGANISM", 95, 98], ["IBV", "SPECIES", 95, 98], ["an effective antiviral drug", "TREATMENT", 36, 63], ["agent", "TREATMENT", 67, 72], ["IBV", "PROBLEM", 95, 98], ["IntroductionIn", "TREATMENT", 99, 113], ["drug residues", "PROBLEM", 131, 144], ["antiviral drugs", "TREATMENT", 191, 206], ["IBV", "OBSERVATION", 95, 98]]], ["Therefore, the use of traditional antiviral herbs with no obvious side effects on the human body is still a major focus.", [["body", "ANATOMY", 92, 96], ["human", "ORGANISM", 86, 91], ["body", "ORGANISM_SUBDIVISION", 92, 96], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["traditional antiviral herbs", "TREATMENT", 22, 49], ["obvious side effects on the human body", "PROBLEM", 58, 96], ["major", "OBSERVATION_MODIFIER", 108, 113], ["focus", "OBSERVATION", 114, 119]]], ["Some reports have confirmed that traditional Chinese herbs could effectively inhibit the infection and replication of various viruses (Li et al., 2009; Wang et al., 2015; Choi et al., 2016; Sun et al., 2016; Choi et al., 2017; Yin et al., 2017; Yi et al., 2018; Luo et al., 2019).", [["infection", "DISEASE", 89, 98], ["traditional Chinese herbs", "TREATMENT", 33, 58], ["the infection", "PROBLEM", 85, 98], ["infection", "OBSERVATION", 89, 98]]], ["Hypericum perforatum L. belongs to the genus Guttiferae, which contains approximately 400 species all over the world.", [["Hypericum perforatum", "CHEMICAL", 0, 20], ["Hypericum perforatum", "ORGANISM", 0, 20], ["L.", "ORGANISM", 21, 23], ["Hypericum perforatum", "SPECIES", 0, 20], ["Hypericum perforatum L.", "SPECIES", 0, 23], ["Hypericum perforatum", "PROBLEM", 0, 20], ["genus Guttiferae", "ANATOMY", 39, 55], ["approximately", "OBSERVATION_MODIFIER", 72, 85], ["400 species", "OBSERVATION_MODIFIER", 86, 97]]], ["The extract of H. perforatum contains several active compounds, including flavonoids, naphthodianthrones, and phloroglucinol derivatives (Napoli et al., 2018; Barnes et al., 2019).", [["extract", "ANATOMY", 4, 11], ["extract of H. perforatum", "CHEMICAL", 4, 28], ["flavonoids", "CHEMICAL", 74, 84], ["naphthodianthrones", "CHEMICAL", 86, 104], ["phloroglucinol", "CHEMICAL", 110, 124], ["flavonoids", "CHEMICAL", 74, 84], ["naphthodianthrones", "CHEMICAL", 86, 104], ["phloroglucinol", "CHEMICAL", 110, 124], ["H. perforatum", "ORGANISM", 15, 28], ["flavonoids", "SIMPLE_CHEMICAL", 74, 84], ["naphthodianthrones", "SIMPLE_CHEMICAL", 86, 104], ["phloroglucinol derivatives", "SIMPLE_CHEMICAL", 110, 136], ["H. perforatum", "SPECIES", 15, 28], ["H. perforatum", "SPECIES", 15, 28], ["H. perforatum", "PROBLEM", 15, 28], ["several active compounds", "PROBLEM", 38, 62], ["flavonoids", "TREATMENT", 74, 84], ["naphthodianthrones", "TREATMENT", 86, 104], ["phloroglucinol derivatives", "TREATMENT", 110, 136], ["H. perforatum", "OBSERVATION_MODIFIER", 15, 28], ["several", "OBSERVATION_MODIFIER", 38, 45], ["active", "OBSERVATION_MODIFIER", 46, 52], ["compounds", "OBSERVATION", 53, 62], ["phloroglucinol derivatives", "OBSERVATION", 110, 136]]], ["Several reports have shown that H. perforatum extract had antiviral effects, such as influenza A virus, porcine respiratory and reproductive syndrome virus (PRRSV), and HIV (Barnes et al., 2001; Birt et al., 2009; Pu et al., 2009a; Pu et al., 2009b; Pu et al., 2012).", [["H. perforatum extract", "CHEMICAL", 32, 53], ["influenza A", "DISEASE", 85, 96], ["porcine respiratory and reproductive syndrome", "DISEASE", 104, 149], ["H. perforatum", "ORGANISM", 32, 45], ["extract", "ORGANISM", 46, 53], ["influenza A virus", "ORGANISM", 85, 102], ["porcine respiratory and reproductive syndrome virus", "ORGANISM", 104, 155], ["PRRSV", "ORGANISM", 157, 162], ["H. perforatum", "SPECIES", 32, 45], ["influenza A virus", "SPECIES", 85, 102], ["porcine", "SPECIES", 104, 111], ["PRRSV", "SPECIES", 157, 162], ["HIV", "SPECIES", 169, 172], ["H. perforatum", "SPECIES", 32, 45], ["influenza A virus", "SPECIES", 85, 102], ["PRRSV", "SPECIES", 157, 162], ["HIV", "SPECIES", 169, 172], ["H. perforatum extract", "PROBLEM", 32, 53], ["antiviral effects", "PROBLEM", 58, 75], ["influenza A virus", "PROBLEM", 85, 102], ["porcine respiratory and reproductive syndrome virus", "PROBLEM", 104, 155], ["antiviral effects", "OBSERVATION", 58, 75]]], ["Like influenza A virus and PRRSV, IBV also belongs to RNA virus, but these PRRSV and IBV belong to different viral families.", [["influenza A virus", "DISEASE", 5, 22], ["influenza A virus", "ORGANISM", 5, 22], ["PRRSV", "ORGANISM", 27, 32], ["IBV", "ORGANISM", 34, 37], ["PRRSV", "ORGANISM", 75, 80], ["IBV", "ORGANISM", 85, 88], ["influenza A virus", "SPECIES", 5, 22], ["PRRSV", "SPECIES", 27, 32], ["PRRSV", "SPECIES", 75, 80], ["influenza A virus", "SPECIES", 5, 22], ["PRRSV", "SPECIES", 27, 32], ["IBV", "SPECIES", 34, 37], ["PRRSV", "SPECIES", 75, 80], ["IBV", "SPECIES", 85, 88], ["influenza A virus", "PROBLEM", 5, 22], ["PRRSV", "PROBLEM", 27, 32], ["IBV", "PROBLEM", 34, 37], ["RNA virus", "PROBLEM", 54, 63], ["these PRRSV", "TREATMENT", 69, 80], ["IBV", "TREATMENT", 85, 88], ["influenza", "OBSERVATION", 5, 14], ["virus", "OBSERVATION", 17, 22]]], ["Since H. perforatum could resist influenza A virus and PRRSV, could it resist IBV?IntroductionIn this study, we investigated the antiviral effects of H. perforatum extract against IBV utilizing several approaches in vitro and in vivo for the first time.", [["influenza A virus", "DISEASE", 33, 50], ["H. perforatum extract", "CHEMICAL", 150, 171], ["H. perforatum", "ORGANISM", 6, 19], ["influenza A virus", "ORGANISM", 33, 50], ["PRRSV", "ORGANISM", 55, 60], ["IBV", "ORGANISM", 78, 81], ["H. perforatum", "ORGANISM", 150, 163], ["IBV", "ORGANISM", 180, 183], ["H. perforatum", "SPECIES", 6, 19], ["influenza A virus", "SPECIES", 33, 50], ["PRRSV", "SPECIES", 55, 60], ["H. perforatum", "SPECIES", 150, 163], ["H. perforatum", "SPECIES", 6, 19], ["influenza A virus", "SPECIES", 33, 50], ["PRRSV", "SPECIES", 55, 60], ["IBV", "SPECIES", 78, 81], ["H. perforatum", "SPECIES", 150, 163], ["IBV", "SPECIES", 180, 183], ["H. perforatum", "PROBLEM", 6, 19], ["influenza A virus", "PROBLEM", 33, 50], ["PRRSV", "PROBLEM", 55, 60], ["this study", "TEST", 97, 107], ["H. perforatum extract", "TREATMENT", 150, 171], ["IBV", "TREATMENT", 180, 183], ["vitro", "TREATMENT", 216, 221], ["perforatum", "OBSERVATION", 9, 19]]], ["Moreover, the purpose of this work was to point out the antiviral active ingredients of H. perforatum and its anti-IBV mechanisms.", [["H. perforatum", "ORGANISM", 88, 101], ["anti-IBV", "CANCER", 110, 118], ["H. perforatum", "SPECIES", 88, 101], ["H. perforatum", "SPECIES", 88, 101], ["H. perforatum", "PROBLEM", 88, 101]]], ["For this purpose, the relative messenger ribonucleic acid (mRNA) expression levels of IBV in CEK cells, tracheas, and kidneys were measured.", [["CEK cells", "ANATOMY", 93, 102], ["tracheas", "ANATOMY", 104, 112], ["kidneys", "ANATOMY", 118, 125], ["ribonucleic acid", "CHEMICAL", 41, 57], ["IBV", "ORGANISM", 86, 89], ["CEK cells", "CELL", 93, 102], ["tracheas", "ORGAN", 104, 112], ["kidneys", "ORGAN", 118, 125], ["messenger ribonucleic acid", "RNA", 31, 57], ["CEK cells", "CELL_LINE", 93, 102], ["IBV", "SPECIES", 86, 89], ["the relative messenger ribonucleic acid", "TEST", 18, 57], ["expression levels", "TEST", 65, 82], ["IBV in CEK cells", "TEST", 86, 102], ["CEK cells", "OBSERVATION", 93, 102], ["tracheas", "ANATOMY", 104, 112], ["kidneys", "ANATOMY", 118, 125]]], ["The positive green immunofluorescence signal of IBV in CEKs was observed.", [["CEKs", "ANATOMY", 55, 59], ["IBV", "ORGANISM", 48, 51], ["CEKs", "CANCER", 55, 59], ["IBV", "SPECIES", 48, 51], ["IBV in CEKs", "TEST", 48, 59], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["green immunofluorescence", "OBSERVATION", 13, 37], ["IBV", "OBSERVATION", 48, 51]]], ["In addition, hematoxylin-eosin (HE) staining of tracheas and kidneys was performed, and the relative mRNA expression of IL-6, tumor necrosis factor alpha (TNF-\u03b1), IFN-\u03b1, IFN-\u03b2, MDA5, MAVS, and nuclear factor kappa beta (NF-\u03baB) in vitro and in vivo were analyzed.", [["tracheas", "ANATOMY", 48, 56], ["kidneys", "ANATOMY", 61, 68], ["hematoxylin-eosin", "CHEMICAL", 13, 30], ["necrosis", "DISEASE", 132, 140], ["hematoxylin", "CHEMICAL", 13, 24], ["eosin", "CHEMICAL", 25, 30], ["hematoxylin-eosin", "SIMPLE_CHEMICAL", 13, 30], ["HE", "SIMPLE_CHEMICAL", 32, 34], ["tracheas", "ORGAN", 48, 56], ["kidneys", "ORGAN", 61, 68], ["IL-6", "GENE_OR_GENE_PRODUCT", 120, 124], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 126, 153], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 155, 160], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 163, 168], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 170, 175], ["MDA5", "GENE_OR_GENE_PRODUCT", 177, 181], ["MAVS", "GENE_OR_GENE_PRODUCT", 183, 187], ["nuclear factor kappa beta", "GENE_OR_GENE_PRODUCT", 193, 218], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 220, 225], ["IL-6", "PROTEIN", 120, 124], ["tumor necrosis factor alpha", "PROTEIN", 126, 153], ["TNF", "PROTEIN", 155, 158], ["IFN", "PROTEIN", 163, 166], ["IFN", "PROTEIN", 170, 173], ["\u03b2", "PROTEIN", 174, 175], ["MDA5", "PROTEIN", 177, 181], ["MAVS", "PROTEIN", 183, 187], ["nuclear factor kappa beta", "PROTEIN", 193, 218], ["NF-\u03baB", "PROTEIN", 220, 225], ["hematoxylin", "TEST", 13, 24], ["IL", "TEST", 120, 122], ["tumor necrosis factor", "PROBLEM", 126, 147], ["alpha", "TEST", 148, 153], ["TNF", "TEST", 155, 158], ["IFN", "TEST", 163, 166], ["\u03b1", "TEST", 167, 168], ["IFN", "TEST", 170, 173], ["MDA5", "TEST", 177, 181], ["MAVS", "TEST", 183, 187], ["NF", "TEST", 220, 222], ["tracheas", "ANATOMY", 48, 56], ["kidneys", "ANATOMY", 61, 68], ["tumor", "OBSERVATION_MODIFIER", 126, 131], ["necrosis", "OBSERVATION", 132, 140]]], ["Finally, the antiviral principal chemical composition of H. perforatum extract was analyzed by high-performance liquid chromatography (HPLC)/ESI-MS.", [["extract", "ANATOMY", 71, 78], ["H. perforatum extract", "CHEMICAL", 57, 78], ["H. perforatum", "ORGANISM", 57, 70], ["H. perforatum", "SPECIES", 57, 70], ["H. perforatum", "SPECIES", 57, 70], ["H. perforatum extract", "TREATMENT", 57, 78]]], ["In summary, our findings for the first time showed that H. perforatum extract had significant antiviral effect on IBV, and it might up-regulate mRNA expression levels of type I interferon via MDA5 pathway and down-regulate mRNA expression levels of IL-6 and TNF-\u03b1 through the NF-\u03baB pathway.", [["H. perforatum extract", "CHEMICAL", 56, 77], ["H. perforatum", "ORGANISM", 56, 69], ["IBV", "ORGANISM", 114, 117], ["type I interferon", "GENE_OR_GENE_PRODUCT", 170, 187], ["MDA5", "GENE_OR_GENE_PRODUCT", 192, 196], ["IL-6", "GENE_OR_GENE_PRODUCT", 249, 253], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 258, 263], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 276, 281], ["type I interferon", "PROTEIN", 170, 187], ["MDA5", "PROTEIN", 192, 196], ["IL-6", "PROTEIN", 249, 253], ["TNF", "PROTEIN", 258, 261], ["NF-\u03baB", "PROTEIN", 276, 281], ["H. perforatum", "SPECIES", 56, 69], ["H. perforatum", "SPECIES", 56, 69], ["IBV", "SPECIES", 114, 117], ["H. perforatum extract", "PROBLEM", 56, 77], ["significant antiviral effect", "PROBLEM", 82, 110], ["IBV", "TREATMENT", 114, 117], ["type I interferon via MDA5 pathway", "TREATMENT", 170, 204], ["IL", "TEST", 249, 251], ["TNF", "TEST", 258, 261], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["antiviral effect", "OBSERVATION", 94, 110]]], ["The HPE was found to be composed mainly of hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin, and a combination of these compounds could mediate the antiviral activities.Virus and Chicken Embryos ::: Materials and MethodsThe IBV M41 strain (GenBank: FJ904723.1) was provided by Key Laboratory for Laboratory Animals and Comparative Medicine, Northeast Agricultural University and propagated in 10-day-old specific pathogen-free (SPF) chicken embryos (Harbin Veterinary Research Institute, CAAS).", [["embryos", "ANATOMY", 458, 465], ["HPE", "DISEASE", 4, 7], ["hyperoside", "CHEMICAL", 43, 53], ["quercitrin", "CHEMICAL", 55, 65], ["quercetin", "CHEMICAL", 67, 76], ["pseudohypericin", "CHEMICAL", 78, 93], ["hypericin", "CHEMICAL", 99, 108], ["hyperoside", "CHEMICAL", 43, 53], ["quercitrin", "CHEMICAL", 55, 65], ["quercetin", "CHEMICAL", 67, 76], ["pseudohypericin", "CHEMICAL", 78, 93], ["hypericin", "CHEMICAL", 99, 108], ["hyperoside", "SIMPLE_CHEMICAL", 43, 53], ["quercitrin", "SIMPLE_CHEMICAL", 55, 65], ["quercetin", "SIMPLE_CHEMICAL", 67, 76], ["pseudohypericin", "SIMPLE_CHEMICAL", 78, 93], ["hypericin", "SIMPLE_CHEMICAL", 99, 108], ["Virus", "ORGANISM", 186, 191], ["Chicken", "ORGANISM", 196, 203], ["IBV", "ORGANISM", 241, 244], ["chicken", "ORGANISM", 450, 457], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 458, 465], ["Chicken", "SPECIES", 196, 203], ["chicken", "SPECIES", 450, 457], ["Chicken", "SPECIES", 196, 203], ["IBV M41 strain", "SPECIES", 241, 255], ["chicken", "SPECIES", 450, 457], ["hyperoside", "TREATMENT", 43, 53], ["quercitrin", "TREATMENT", 55, 65], ["quercetin", "TREATMENT", 67, 76], ["pseudohypericin", "TREATMENT", 78, 93], ["hypericin", "TREATMENT", 99, 108], ["these compounds", "TREATMENT", 131, 146], ["antiviral activities", "OBSERVATION", 165, 185], ["Chicken Embryos", "OBSERVATION", 196, 211]]], ["100 \u00b5l IBV M41 strain was inoculated into SPF chicken embryos under aseptic operation.", [["embryos", "ANATOMY", 54, 61], ["IBV", "ORGANISM", 7, 10], ["chicken", "ORGANISM", 46, 53], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 54, 61], ["chicken", "SPECIES", 46, 53], ["IBV", "SPECIES", 7, 10], ["SPF", "SPECIES", 42, 45], ["chicken", "SPECIES", 46, 53], ["aseptic operation", "TREATMENT", 68, 85], ["SPF chicken embryos", "OBSERVATION", 42, 61], ["aseptic operation", "OBSERVATION", 68, 85]]], ["The survival status of chicken embryos was observed every 12 h, and the chicken embryos that died within 24 h were abandoned.", [["embryos", "ANATOMY", 31, 38], ["embryos", "ANATOMY", 80, 87], ["chicken", "ORGANISM", 23, 30], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 31, 38], ["chicken", "ORGANISM", 72, 79], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 80, 87], ["chicken", "SPECIES", 23, 30], ["chicken", "SPECIES", 72, 79], ["chicken", "SPECIES", 23, 30], ["chicken", "SPECIES", 72, 79], ["chicken embryos", "PROBLEM", 23, 38], ["the chicken embryos", "PROBLEM", 68, 87]]], ["Then allantoic fluid from infected embryos was collected at 72 h post-inoculation and stored at \u221280\u00b0C.Reagents and Animals ::: Materials and MethodsH. perforatum was picked from Tongjiang County, Sichuan Province (east longitude 106\u00b067\u2032\u2013107\u00b073,\u2032 north latitude 32\u00b018\u2032\u201333\u00b071,\u2032 China) and authenticated by Professor Zhongbao Zhang (Jilin Agriculture Science and Technology College, Jilin, PR China).", [["allantoic fluid", "ANATOMY", 5, 20], ["embryos", "ANATOMY", 35, 42], ["perforatum", "CHEMICAL", 151, 161], ["allantoic fluid", "ORGANISM_SUBSTANCE", 5, 20], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 35, 42], ["perforatum", "ORGANISM", 151, 161], ["MethodsH", "DNA", 141, 149], ["perforatum", "SPECIES", 151, 161], ["perforatum", "SPECIES", 151, 161], ["allantoic fluid", "PROBLEM", 5, 20], ["infected embryos", "PROBLEM", 26, 42], ["fluid", "OBSERVATION", 15, 20], ["infected embryos", "OBSERVATION", 26, 42]]], ["The reference specimen (voucher number, 6184) (Supplementary Figure 1) was deposited at Herbarium (herbarium code: PE), Institute of Botany, Chinese Academy of Sciences (no. 20, Xiangshan Nanxincun, Haidian District, Beijing, China).", [["specimen", "ANATOMY", 14, 22], ["PE", "OBSERVATION", 115, 117]]], ["Acetonitrile for HPLC was purchased from Merck (Darmstadt, Germany).", [["Acetonitrile", "CHEMICAL", 0, 12], ["Acetonitrile", "CHEMICAL", 0, 12], ["Acetonitrile", "SIMPLE_CHEMICAL", 0, 12], ["Acetonitrile", "TREATMENT", 0, 12], ["HPLC", "TEST", 17, 21]]], ["Other solvents used for extract preparation, such as methanol and ethyl acetate were analytical grade and obtained from Tianjin Reagent Company (Tianjin, PR China).", [["extract", "ANATOMY", 24, 31], ["methanol and ethyl acetate", "CHEMICAL", 53, 79], ["methanol", "CHEMICAL", 53, 61], ["ethyl acetate", "CHEMICAL", 66, 79], ["methanol", "SIMPLE_CHEMICAL", 53, 61], ["ethyl acetate", "SIMPLE_CHEMICAL", 66, 79], ["Other solvents", "TREATMENT", 0, 14], ["extract preparation", "TREATMENT", 24, 43], ["methanol and ethyl acetate", "TREATMENT", 53, 79]]], ["Ribavirin (RT, H51023508) was purchased from Sichuan Baili Pharmaceutical Co., Ltd., Chengdu, China.", [["Ribavirin", "CHEMICAL", 0, 9], ["H51023508", "CHEMICAL", 15, 24], ["Ribavirin", "CHEMICAL", 0, 9], ["H51023508", "CHEMICAL", 15, 24], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["Ribavirin (RT", "TREATMENT", 0, 13]]], ["The standard compounds of hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin were purchased from National Institute for the Control of Pharmaceutical and Biological Products in China.", [["hyperoside", "CHEMICAL", 26, 36], ["quercitrin", "CHEMICAL", 38, 48], ["quercetin", "CHEMICAL", 50, 59], ["pseudohypericin", "CHEMICAL", 61, 76], ["hypericin", "CHEMICAL", 82, 91], ["hyperoside", "CHEMICAL", 26, 36], ["quercitrin", "CHEMICAL", 38, 48], ["quercetin", "CHEMICAL", 50, 59], ["pseudohypericin", "CHEMICAL", 61, 76], ["hypericin", "CHEMICAL", 82, 91], ["hyperoside", "SIMPLE_CHEMICAL", 26, 36], ["quercitrin", "SIMPLE_CHEMICAL", 38, 48], ["quercetin", "SIMPLE_CHEMICAL", 50, 59], ["pseudohypericin", "SIMPLE_CHEMICAL", 61, 76], ["hypericin", "SIMPLE_CHEMICAL", 82, 91], ["hyperoside", "TREATMENT", 26, 36], ["quercitrin", "TREATMENT", 38, 48], ["quercetin", "TREATMENT", 50, 59], ["pseudohypericin", "TREATMENT", 61, 76], ["hypericin", "TREATMENT", 82, 91], ["Pharmaceutical and Biological Products", "TREATMENT", 150, 188]]], ["Because hypericin, the main active component of H. perforatum, is sensitive to light, all the experiments in this study were carried out under the condition of avoiding light or low light.Reagents and Animals ::: Materials and MethodsOne hundred and forty four 15-day-old (SPF) chickens were purchased from Harbin Veterinary Research Institute, Heilongjiang Province, China.", [["hypericin", "CHEMICAL", 8, 17], ["hypericin", "CHEMICAL", 8, 17], ["hypericin", "SIMPLE_CHEMICAL", 8, 17], ["H. perforatum", "ORGANISM", 48, 61], ["chickens", "ORGANISM", 278, 286], ["H. perforatum", "SPECIES", 48, 61], ["chickens", "SPECIES", 278, 286], ["H. perforatum", "SPECIES", 48, 61], ["chickens", "SPECIES", 278, 286], ["hypericin", "TREATMENT", 8, 17], ["H. perforatum", "PROBLEM", 48, 61], ["this study", "TEST", 109, 119], ["hypericin", "OBSERVATION", 8, 17], ["main", "OBSERVATION_MODIFIER", 23, 27], ["active", "OBSERVATION_MODIFIER", 28, 34], ["component", "OBSERVATION_MODIFIER", 35, 44], ["H. perforatum", "OBSERVATION", 48, 61]]], ["Experimental procedures were approved by the Institutional Animal Ethical Committee of Northeast Agricultural University (no. SRM-08).", [["Experimental procedures", "TREATMENT", 0, 23]]], ["All animal studies were complied with the animal experiment guidelines of the Animal Experimentation Ethics Committee of Northeast Agricultural University.Preparation of the Crude Extract ::: Materials and MethodsThe crude extract of H. perforatum was prepared in the laboratory.", [["extract", "ANATOMY", 223, 230], ["extract of H. perforatum", "CHEMICAL", 223, 247], ["H. perforatum", "ORGANISM", 234, 247], ["H. perforatum", "SPECIES", 234, 247], ["H. perforatum", "SPECIES", 234, 247], ["All animal studies", "TEST", 0, 18], ["Methods", "TREATMENT", 206, 213], ["H. perforatum", "PROBLEM", 234, 247], ["perforatum", "OBSERVATION", 237, 247]]], ["In brief, the drug was pretreated with carbon dioxide supercritical extraction method, and the supercritical extraction extract (SEE) was obtained with a yield of 8.1% (wt/wt).", [["carbon dioxide", "CHEMICAL", 39, 53], ["SEE", "CHEMICAL", 129, 132], ["carbon dioxide", "CHEMICAL", 39, 53], ["carbon dioxide", "SIMPLE_CHEMICAL", 39, 53], ["carbon dioxide supercritical extraction method", "TREATMENT", 39, 85], ["the supercritical extraction extract", "TREATMENT", 91, 127]]], ["Then, 15 g of the pretreated medicinal material was weighed, 1.0 L of 85% methanol was added (Raclariu et al., 2017), ultrasonic extraction was performed twice for 30 min, and ultrasonic power was 400 W. The two extract solutions were combined and filtered, and concentrated under reduced pressure to obtain the crude extract with a yield of 22.4% (wt/wt).Fractionation of the Crude Extract ::: Materials and MethodsApproximately 6 g of the crude extract of H. perforatum was dissolved in 200 ml of distilled water.", [["extract", "ANATOMY", 318, 325], ["extract", "ANATOMY", 447, 454], ["methanol", "CHEMICAL", 74, 82], ["extract of H. perforatum", "CHEMICAL", 447, 471], ["methanol", "CHEMICAL", 74, 82], ["methanol", "SIMPLE_CHEMICAL", 74, 82], ["H. perforatum", "ORGANISM", 458, 471], ["H. perforatum", "SPECIES", 458, 471], ["H. perforatum", "SPECIES", 458, 471], ["the pretreated medicinal material", "TREATMENT", 14, 47], ["85% methanol", "TREATMENT", 70, 82], ["ultrasonic extraction", "TREATMENT", 118, 139], ["ultrasonic power", "TREATMENT", 176, 192], ["The two extract solutions", "TREATMENT", 204, 229], ["the crude extract", "TREATMENT", 308, 325], ["Materials", "TREATMENT", 395, 404], ["MethodsApproximately", "TREATMENT", 409, 429], ["the crude extract of H. perforatum", "TREATMENT", 437, 471], ["perforatum", "OBSERVATION", 461, 471]]], ["An equal volume of ethyl acetate was added before shaking vigorously and separating in a separating funnel.", [["ethyl acetate", "CHEMICAL", 19, 32], ["ethyl acetate", "CHEMICAL", 19, 32], ["ethyl acetate", "SIMPLE_CHEMICAL", 19, 32], ["An equal volume of ethyl acetate", "TREATMENT", 0, 32], ["equal", "OBSERVATION_MODIFIER", 3, 8], ["volume", "OBSERVATION_MODIFIER", 9, 15]]], ["The ethyl acetate layer (upper layer) and the water layer (lower layer) were obtained.", [["upper layer", "ANATOMY", 25, 36], ["ethyl acetate", "CHEMICAL", 4, 17], ["ethyl acetate", "CHEMICAL", 4, 17], ["ethyl acetate", "SIMPLE_CHEMICAL", 4, 17], ["The ethyl acetate layer (upper layer)", "TREATMENT", 0, 37], ["the water layer (lower layer)", "TREATMENT", 42, 71], ["ethyl", "ANATOMY_MODIFIER", 4, 9], ["upper layer", "ANATOMY_MODIFIER", 25, 36], ["lower layer", "ANATOMY", 59, 70]]], ["It was then extracted with ethyl acetate until the upper layer had no color.", [["ethyl acetate", "CHEMICAL", 27, 40], ["ethyl acetate", "CHEMICAL", 27, 40], ["ethyl acetate", "SIMPLE_CHEMICAL", 27, 40], ["ethyl acetate", "TREATMENT", 27, 40], ["upper", "ANATOMY_MODIFIER", 51, 56], ["no", "UNCERTAINTY", 67, 69], ["color", "OBSERVATION", 70, 75]]], ["All ethyl acetate extractions and water extractions were combined and evaporated to obtain extract of H. perforatum ethyl acetate (HPE) and extract of H. perforatum water (HPW).Fractionation of the Crude Extract ::: Materials and MethodsA stock solution of HPE (200 mg/ml), HPW (200 mg/ml) and SEE (200 mg/ml) was prepared with dimethylsulfoxide (DMSO, Sigma), respectively.", [["ethyl acetate", "CHEMICAL", 4, 17], ["extract of H. perforatum ethyl acetate", "CHEMICAL", 91, 129], ["HPE", "CHEMICAL", 131, 134], ["HPE", "CHEMICAL", 257, 260], ["HPW", "CHEMICAL", 274, 277], ["SEE", "CHEMICAL", 294, 297], ["dimethylsulfoxide", "CHEMICAL", 328, 345], ["DMSO", "CHEMICAL", 347, 351], ["ethyl acetate", "CHEMICAL", 4, 17], ["ethyl acetate", "CHEMICAL", 116, 129], ["dimethylsulfoxide", "CHEMICAL", 328, 345], ["DMSO", "CHEMICAL", 347, 351], ["ethyl acetate", "SIMPLE_CHEMICAL", 4, 17], ["H. perforatum", "ORGANISM", 102, 115], ["ethyl acetate", "SIMPLE_CHEMICAL", 116, 129], ["HPE", "SIMPLE_CHEMICAL", 131, 134], ["H. perforatum", "ORGANISM", 151, 164], ["HPE", "SIMPLE_CHEMICAL", 257, 260], ["HPW", "SIMPLE_CHEMICAL", 274, 277], ["SEE", "SIMPLE_CHEMICAL", 294, 297], ["dimethylsulfoxide", "SIMPLE_CHEMICAL", 328, 345], ["DMSO", "SIMPLE_CHEMICAL", 347, 351], ["H. perforatum", "SPECIES", 102, 115], ["H. perforatum", "SPECIES", 151, 164], ["H. perforatum", "SPECIES", 102, 115], ["H. perforatum", "SPECIES", 151, 164], ["All ethyl acetate extractions", "TREATMENT", 0, 29], ["water extractions", "TREATMENT", 34, 51], ["H. perforatum ethyl acetate", "TREATMENT", 102, 129], ["MethodsA stock solution of HPE", "TREATMENT", 230, 260], ["HPW", "TREATMENT", 274, 277], ["dimethylsulfoxide (DMSO", "TREATMENT", 328, 351]]], ["Immediately before each experiment in vitro, the working solution of H. perforatum extract was diluted in M199 medium without serum to obtain a final concentration.", [["extract", "ANATOMY", 83, 90], ["serum", "ANATOMY", 126, 131], ["H. perforatum extract", "CHEMICAL", 69, 90], ["H. perforatum", "ORGANISM", 69, 82], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["H. perforatum", "SPECIES", 69, 82], ["H. perforatum", "SPECIES", 69, 82], ["H. perforatum extract", "TREATMENT", 69, 90]]], ["The HPE was dissolved in 5% DMSO, while ribavirin (RT) was dissolved in physiological saline solution (PSS, 0.86% NaCl) in vivo experiments.Adaptation and Replication of Infectious Bronchitis Virus in Chicken Embryo Kidney Cells ::: Materials and MethodsCEK cells were primary cultured from 18-day-old SPF chicken embryo (Harbin Veterinary Research Institute, CAAS) and prepared according to the standard technique (Schat and Purchase, 1998; Ghetas et al., 2015).", [["Embryo Kidney Cells", "ANATOMY", 209, 228], ["MethodsCEK cells", "ANATOMY", 247, 263], ["embryo", "ANATOMY", 314, 320], ["HPE", "DISEASE", 4, 7], ["DMSO", "CHEMICAL", 28, 32], ["ribavirin", "CHEMICAL", 40, 49], ["NaCl", "CHEMICAL", 114, 118], ["Infectious Bronchitis Virus", "DISEASE", 170, 197], ["DMSO", "CHEMICAL", 28, 32], ["ribavirin", "CHEMICAL", 40, 49], ["NaCl", "CHEMICAL", 114, 118], ["DMSO", "SIMPLE_CHEMICAL", 28, 32], ["ribavirin", "SIMPLE_CHEMICAL", 40, 49], ["Infectious Bronchitis Virus", "ORGANISM", 170, 197], ["Chicken", "ORGANISM", 201, 208], ["Embryo Kidney Cells", "CELL", 209, 228], ["MethodsCEK cells", "CELL", 247, 263], ["SPF", "ORGANISM", 302, 305], ["chicken", "ORGANISM", 306, 313], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 314, 320], ["MethodsCEK cells", "CELL_LINE", 247, 263], ["Chicken", "SPECIES", 201, 208], ["chicken", "SPECIES", 306, 313], ["Infectious Bronchitis Virus", "SPECIES", 170, 197], ["Chicken", "SPECIES", 201, 208], ["chicken", "SPECIES", 306, 313], ["5% DMSO", "TREATMENT", 25, 32], ["ribavirin (RT)", "TREATMENT", 40, 54], ["physiological saline solution", "TREATMENT", 72, 101], ["PSS", "TREATMENT", 103, 106], ["Adaptation", "TREATMENT", 140, 150], ["Infectious Bronchitis Virus", "PROBLEM", 170, 197], ["MethodsCEK cells", "PROBLEM", 247, 263], ["Infectious", "OBSERVATION_MODIFIER", 170, 180], ["Embryo Kidney Cells", "OBSERVATION", 209, 228]]], ["The cells were cultured in M199 medium (Thermo Fisher Scientific, USA) supplemented with penicillin and streptomycin, and 10% serum at 37\u00b0C with 5% CO2.", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 126, 131], ["penicillin", "CHEMICAL", 89, 99], ["streptomycin", "CHEMICAL", 104, 116], ["CO2", "CHEMICAL", 148, 151], ["penicillin", "CHEMICAL", 89, 99], ["streptomycin", "CHEMICAL", 104, 116], ["CO2", "CHEMICAL", 148, 151], ["cells", "CELL", 4, 9], ["penicillin", "SIMPLE_CHEMICAL", 89, 99], ["streptomycin", "SIMPLE_CHEMICAL", 104, 116], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["CO2", "SIMPLE_CHEMICAL", 148, 151], ["penicillin", "TREATMENT", 89, 99], ["streptomycin", "TREATMENT", 104, 116]]], ["Then, IBV M41 strain was passaged in CEK cells for adaption.", [["CEK cells", "ANATOMY", 37, 46], ["IBV", "ORGANISM", 6, 9], ["CEK cells", "CELL", 37, 46], ["CEK cells", "CELL_LINE", 37, 46], ["IBV M41 strain", "SPECIES", 6, 20], ["IBV M41 strain", "PROBLEM", 6, 20]]], ["500 \u00b5l IBV M41 allantoic fluid was inoculated into CEK cells in 5 ml cell culture flask, and the cytopathic effect (CPE) was observed.", [["allantoic fluid", "ANATOMY", 15, 30], ["CEK cells", "ANATOMY", 51, 60], ["cell", "ANATOMY", 69, 73], ["IBV", "ORGANISM", 7, 10], ["CEK cells", "CELL", 51, 60], ["cell", "CELL", 69, 73], ["CEK cells", "CELL_LINE", 51, 60], ["IBV", "SPECIES", 7, 10], ["\u00b5l IBV M41 allantoic fluid", "TEST", 4, 30], ["CEK cells", "TEST", 51, 60], ["cell culture flask", "TEST", 69, 87], ["the cytopathic effect", "PROBLEM", 93, 114], ["CPE", "PROBLEM", 116, 119], ["cytopathic", "OBSERVATION_MODIFIER", 97, 107]]], ["When the cells showed obvious typical CPE, the time and degree of the lesions were recorded and the first generation of IBV was collected by freezing and thawing cells repeatedly.", [["cells", "ANATOMY", 9, 14], ["lesions", "ANATOMY", 70, 77], ["cells", "ANATOMY", 162, 167], ["cells", "CELL", 9, 14], ["lesions", "PATHOLOGICAL_FORMATION", 70, 77], ["IBV", "ORGANISM", 120, 123], ["cells", "CELL", 162, 167], ["IBV", "SPECIES", 120, 123], ["obvious typical CPE", "PROBLEM", 22, 41], ["the lesions", "PROBLEM", 66, 77], ["IBV", "TREATMENT", 120, 123], ["obvious", "OBSERVATION_MODIFIER", 22, 29], ["typical", "OBSERVATION_MODIFIER", 30, 37], ["CPE", "OBSERVATION", 38, 41], ["lesions", "OBSERVATION", 70, 77]]], ["Then, the collected first generation IBV was inoculated into CEK cells according to the above method, and the time and lesion degree of CPE were also recorded.", [["CEK cells", "ANATOMY", 61, 70], ["lesion", "ANATOMY", 119, 125], ["IBV", "ORGANISM", 37, 40], ["CEK cells", "CELL", 61, 70], ["CEK cells", "CELL_LINE", 61, 70], ["IBV", "SPECIES", 37, 40], ["the collected first generation IBV", "TREATMENT", 6, 40], ["CPE", "PROBLEM", 136, 139], ["lesion", "OBSERVATION", 119, 125], ["CPE", "OBSERVATION", 136, 139]]], ["The second generation IBV was collected according to the above method.", [["IBV", "ORGANISM", 22, 25], ["IBV", "SPECIES", 22, 25], ["The second generation IBV", "TREATMENT", 0, 25]]], ["After 10 times of passages of IBV in CEK cells, there appeared typical CPE of cell exfoliation and fusion at same time post inoculation regularly.", [["CEK cells", "ANATOMY", 37, 46], ["cell", "ANATOMY", 78, 82], ["IBV", "ORGANISM", 30, 33], ["CEK cells", "CELL", 37, 46], ["cell", "CELL", 78, 82], ["CEK cells", "CELL_LINE", 37, 46], ["IBV", "SPECIES", 30, 33], ["IBV in CEK cells", "TREATMENT", 30, 46], ["typical CPE of cell exfoliation", "PROBLEM", 63, 94], ["fusion", "TREATMENT", 99, 105], ["typical", "OBSERVATION_MODIFIER", 63, 70], ["CPE of cell exfoliation", "OBSERVATION", 71, 94]]], ["IBV was collected and stored at \u221280\u00b0C until use.", [["IBV", "ORGANISM", 0, 3], ["IBV", "SPECIES", 0, 3], ["IBV", "TREATMENT", 0, 3]]], ["The results of adaptation and replication in CEK cells, such as CPE, reverse transcription polymerase chain reaction (RT-PCR), and IBV growth curve determined by tissue culture infective dose (TCID50) at different time were tested.Cytotoxicity Assay ::: Materials and MethodsThe cytotoxicity test was carried out according to the published method of thiazolyl blue tetrazolium bromide (MTT), and minor modifications were made (Sui et al., 2010).", [["CEK cells", "ANATOMY", 45, 54], ["tissue culture", "ANATOMY", 162, 176], ["thiazolyl blue tetrazolium bromide", "CHEMICAL", 350, 384], ["thiazolyl blue tetrazolium bromide", "CHEMICAL", 350, 384], ["MTT", "CHEMICAL", 386, 389], ["CEK cells", "CELL", 45, 54], ["tissue", "TISSUE", 162, 168], ["thiazolyl blue tetrazolium bromide", "SIMPLE_CHEMICAL", 350, 384], ["MTT", "SIMPLE_CHEMICAL", 386, 389], ["CEK cells", "CELL_LINE", 45, 54], ["IBV", "SPECIES", 131, 134], ["replication in CEK cells", "TREATMENT", 30, 54], ["CPE", "PROBLEM", 64, 67], ["reverse transcription polymerase chain reaction", "PROBLEM", 69, 116], ["RT-PCR", "TEST", 118, 124], ["IBV growth curve", "TEST", 131, 147], ["Methods", "TREATMENT", 268, 275], ["The cytotoxicity test", "TEST", 275, 296], ["thiazolyl blue tetrazolium bromide", "TREATMENT", 350, 384], ["minor modifications", "TREATMENT", 396, 415]]], ["The monolayer of CEK cells plated on 96-well culture plate were washed with D-Hanks solution three times, and then HPE, HPW, and SEE with concentrations of 39.06, 78.13, 156.25, 312.50, and 625.00 \u00b5g/ml were added to the hole (three repeated holes per concentration).", [["monolayer", "ANATOMY", 4, 13], ["CEK cells", "ANATOMY", 17, 26], ["HPW", "CHEMICAL", 120, 123], ["SEE", "CHEMICAL", 129, 132], ["monolayer", "CELL", 4, 13], ["CEK cells", "CELL", 17, 26], ["D-Hanks", "SIMPLE_CHEMICAL", 76, 83], ["HPW", "SIMPLE_CHEMICAL", 120, 123], ["SEE", "SIMPLE_CHEMICAL", 129, 132], ["CEK cells", "CELL_LINE", 17, 26], ["The monolayer of CEK cells", "TEST", 0, 26], ["culture plate", "TEST", 45, 58], ["D-Hanks solution", "TREATMENT", 76, 92], ["concentrations", "TEST", 138, 152], ["the hole", "TREATMENT", 217, 225]]], ["The control cells were incubated in the absence of experimental compounds, but incubated with the same concentration of DMSO.", [["cells", "ANATOMY", 12, 17], ["DMSO", "CHEMICAL", 120, 124], ["DMSO", "CHEMICAL", 120, 124], ["cells", "CELL", 12, 17], ["DMSO", "SIMPLE_CHEMICAL", 120, 124], ["DMSO", "TREATMENT", 120, 124]]], ["The CEK cells were cultured at 37\u00b0C for 48 h, then 20 \u03bcl MTT with concentrations of 5 mg/ml in M199 medium were added, and then the cells were incubated at 37\u00b0C for 4 h.", [["CEK cells", "ANATOMY", 4, 13], ["cells", "ANATOMY", 132, 137], ["MTT", "CHEMICAL", 57, 60], ["MTT", "CHEMICAL", 57, 60], ["CEK cells", "CELL", 4, 13], ["cells", "CELL", 132, 137], ["CEK cells", "CELL_LINE", 4, 13], ["The CEK cells", "TEST", 0, 13], ["concentrations", "TEST", 66, 80]]], ["After washing the CEK cells with D-Hanks, 200 \u03bcl DMSO was added to each well, then the CEK cells were incubated at 37\u00b0C for 10 min, and shaken gently at room temperature for 10 min to dissolved formazan precipitates, and OD570 was determined.", [["CEK cells", "ANATOMY", 18, 27], ["CEK cells", "ANATOMY", 87, 96], ["DMSO", "CHEMICAL", 49, 53], ["formazan", "CHEMICAL", 194, 202], ["DMSO", "CHEMICAL", 49, 53], ["formazan", "CHEMICAL", 194, 202], ["OD570", "CHEMICAL", 221, 226], ["CEK cells", "CELL", 18, 27], ["D-Hanks", "SIMPLE_CHEMICAL", 33, 40], ["DMSO", "SIMPLE_CHEMICAL", 49, 53], ["CEK cells", "CELL", 87, 96], ["formazan", "SIMPLE_CHEMICAL", 194, 202], ["OD570", "SIMPLE_CHEMICAL", 221, 226], ["CEK cells", "CELL_LINE", 18, 27], ["CEK cells", "CELL_LINE", 87, 96], ["the CEK cells", "TEST", 14, 27], ["D-Hanks", "TREATMENT", 33, 40], ["DMSO", "TREATMENT", 49, 53], ["the CEK cells", "TEST", 83, 96]]], ["Using the mean values, the cell survival rate is calculated according to the following formula:Pre-Treatment of Cells Prior to Infection ::: Antiviral Activity Assays ::: Materials and MethodsIn order to analyze the effects of HPE, HPW, and SEE on cells, CEK cells cultured on 96 well plates were incubated with HPE, HPW, and SEE solutions at concentrations of 78.13, 39.06, 19.53 \u03bcg/ml at 37\u00b0C for 2 h, respectively, and then washed with D-Hanks for three times.", [["cell", "ANATOMY", 27, 31], ["Cells", "ANATOMY", 112, 117], ["cells", "ANATOMY", 248, 253], ["CEK cells", "ANATOMY", 255, 264], ["HPE", "DISEASE", 227, 230], ["HPW", "CHEMICAL", 317, 320], ["cell", "CELL", 27, 31], ["Cells", "CELL", 112, 117], ["HPE", "SIMPLE_CHEMICAL", 227, 230], ["HPW", "SIMPLE_CHEMICAL", 232, 235], ["cells", "CELL", 248, 253], ["CEK cells", "CELL", 255, 264], ["HPW", "SIMPLE_CHEMICAL", 317, 320], ["CEK cells", "CELL_LINE", 255, 264], ["the mean values", "TEST", 6, 21], ["the cell survival rate", "TREATMENT", 23, 45], ["Pre-Treatment of Cells", "TREATMENT", 95, 117], ["MethodsIn", "TREATMENT", 185, 194], ["HPE", "PROBLEM", 227, 230], ["CEK cells", "TEST", 255, 264], ["HPE", "TEST", 312, 315], ["HPW", "TEST", 317, 320], ["D-Hanks", "TREATMENT", 439, 446], ["Infection", "OBSERVATION", 127, 136]]], ["The CEK cells were then infected with 100 TCID50 IBV and cultured at 37\u00b0C for 30 h.", [["CEK cells", "ANATOMY", 4, 13], ["CEK cells", "CELL", 4, 13], ["IBV", "ORGANISM", 49, 52], ["CEK cells", "CELL_LINE", 4, 13], ["IBV", "SPECIES", 49, 52], ["The CEK cells", "TEST", 0, 13], ["100 TCID50 IBV", "TREATMENT", 38, 52]]], ["The cell samples were frozen and thawed repeatedly for three times, and the total RNA was extracted and reverse transcribed into complementary deoxyribonucleic acid (cDNA).", [["cell samples", "ANATOMY", 4, 16], ["deoxyribonucleic acid", "CHEMICAL", 143, 164], ["cell samples", "CELL", 4, 16], ["deoxyribonucleic acid", "SIMPLE_CHEMICAL", 143, 164], ["total RNA", "RNA", 76, 85], ["cDNA", "DNA", 166, 170], ["The cell samples", "TEST", 0, 16], ["the total RNA", "TREATMENT", 72, 85]]], ["The relative mRNA expression of IBV N gene was detected by real-time quantitative RT-PCR (qRT-PCR).", [["IBV N", "GENE_OR_GENE_PRODUCT", 32, 37], ["IBV N gene", "DNA", 32, 42], ["IBV", "SPECIES", 32, 35], ["IBV N gene", "TREATMENT", 32, 42], ["PCR", "TEST", 85, 88], ["qRT", "TEST", 90, 93], ["PCR", "TEST", 94, 97]]], ["In addition, according to the conventional method, the virus titer of cell samples was determined by TCID50.", [["cell samples", "ANATOMY", 70, 82], ["cell samples", "ORGANISM_SUBSTANCE", 70, 82], ["cell samples", "TEST", 70, 82]]], ["The specific operations were as follows: CEK cells were cultured in 96-well tissue culture plates, and when the cells were full of monolayer, IBV virus was diluted to 10\u22121, 10\u22122, 10\u22123\u2026, and 10\u221212 times with serum-free M199, respectively.", [["CEK cells", "ANATOMY", 41, 50], ["tissue", "ANATOMY", 76, 82], ["cells", "ANATOMY", 112, 117], ["monolayer", "ANATOMY", 131, 140], ["serum", "ANATOMY", 207, 212], ["CEK cells", "CELL", 41, 50], ["cells", "CELL", 112, 117], ["monolayer", "CELL", 131, 140], ["IBV virus", "ORGANISM", 142, 151], ["serum", "ORGANISM_SUBSTANCE", 207, 212], ["CEK cells", "CELL_LINE", 41, 50], ["IBV virus", "SPECIES", 142, 151], ["CEK cells", "TEST", 41, 50], ["tissue culture plates", "TEST", 76, 97], ["the cells", "TEST", 108, 117], ["IBV virus", "PROBLEM", 142, 151], ["serum", "TEST", 207, 212]]], ["Then the monolayer CEK cells were washed with D-Hanks solution three times, and the D-Hanks solution was discarded.", [["monolayer CEK cells", "ANATOMY", 9, 28], ["monolayer CEK cells", "CELL", 9, 28], ["D-Hanks", "SIMPLE_CHEMICAL", 46, 53], ["D-Hanks", "SIMPLE_CHEMICAL", 84, 91], ["monolayer CEK cells", "CELL_LINE", 9, 28], ["the monolayer CEK cells", "TREATMENT", 5, 28], ["D-Hanks solution", "TREATMENT", 46, 62], ["the D-Hanks solution", "TREATMENT", 80, 100]]], ["Then the 100 \u00b5l IBV virus diluent as mentioned above was added to each hole, and each virus diluent repeated eight holes.", [["IBV", "ORGANISM", 16, 19], ["IBV virus", "SPECIES", 16, 25], ["the 100 \u00b5l IBV virus diluent", "TREATMENT", 5, 33], ["each virus diluent repeated eight holes", "TREATMENT", 81, 120]]], ["The cells were treated by the same method with M199 culture as normal control.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["M199 culture", "TEST", 47, 59]]], ["The culture plate was cultured in 5% CO2 and 37\u00b0C for 48 h.", [["CO2", "CHEMICAL", 37, 40], ["CO2", "CHEMICAL", 37, 40], ["CO2", "SIMPLE_CHEMICAL", 37, 40], ["The culture plate", "TEST", 0, 17]]], ["The cytopathic effect (CPE) was observed every 24 h, and the number of CPE pores and no CPE pores were recorded.", [["The cytopathic effect (CPE", "PROBLEM", 0, 26], ["CPE pores", "PROBLEM", 71, 80], ["CPE pores", "PROBLEM", 88, 97], ["cytopathic", "OBSERVATION_MODIFIER", 4, 14], ["effect", "OBSERVATION_MODIFIER", 15, 21], ["CPE pores", "OBSERVATION", 71, 80], ["no", "UNCERTAINTY", 85, 87], ["CPE pores", "OBSERVATION", 88, 97]]], ["According to the Reed-Muench method as previously described (Guo et al., 2016; Yang et al., 2018b), the TCID50 was calculated according to the number of CPE holes recorded.", [["the TCID50", "TREATMENT", 100, 110], ["CPE holes", "OBSERVATION", 153, 162]]], ["At the same time, the infected CEK cells treated with 10 \u03bcg/ml RT and CEK cells infected with IBV as control.Direct Treatment of Virus-Infected Cells ::: Materials and MethodsIn order to determine the impact of HPE, HPW, and SEE on IBV-infected cells, the CEK cells cultured on 96 well plates were infected with 100 TCID50 IBV at 37\u00b0C for 2 h, and then treated with HPE, HPW, and SEE solution at concentrations of 78.13, 39.06, 19.53 \u03bcg/ml at 37\u00b0C for 30 h.", [["CEK cells", "ANATOMY", 31, 40], ["CEK cells", "ANATOMY", 70, 79], ["Cells", "ANATOMY", 144, 149], ["cells", "ANATOMY", 245, 250], ["CEK cells", "ANATOMY", 256, 265], ["HPE", "DISEASE", 211, 214], ["HPW", "CHEMICAL", 216, 219], ["SEE", "CHEMICAL", 225, 228], ["HPW", "CHEMICAL", 371, 374], ["CEK cells", "CELL", 31, 40], ["CEK cells", "CELL", 70, 79], ["IBV", "ORGANISM", 94, 97], ["Virus", "ORGANISM", 129, 134], ["Cells", "CELL", 144, 149], ["HPW", "SIMPLE_CHEMICAL", 216, 219], ["IBV", "ORGANISM", 232, 235], ["cells", "CELL", 245, 250], ["CEK cells", "CELL", 256, 265], ["HPE", "SIMPLE_CHEMICAL", 366, 369], ["HPW", "SIMPLE_CHEMICAL", 371, 374], ["CEK cells", "CELL_LINE", 31, 40], ["CEK cells", "CELL_LINE", 70, 79], ["IBV-infected cells", "CELL_LINE", 232, 250], ["CEK cells", "CELL_LINE", 256, 265], ["IBV", "SPECIES", 94, 97], ["IBV", "SPECIES", 232, 235], ["IBV", "SPECIES", 323, 326], ["the infected CEK cells", "PROBLEM", 18, 40], ["CEK cells", "TREATMENT", 70, 79], ["IBV", "TREATMENT", 94, 97], ["Virus", "PROBLEM", 129, 134], ["Methods", "TREATMENT", 168, 175], ["HPE", "PROBLEM", 211, 214], ["HPW", "TEST", 216, 219], ["IBV", "TEST", 232, 235], ["infected cells", "PROBLEM", 236, 250], ["the CEK cells", "TEST", 252, 265], ["100 TCID50 IBV", "TREATMENT", 312, 326], ["HPE", "PROBLEM", 366, 369], ["HPW", "TREATMENT", 371, 374], ["infected", "OBSERVATION_MODIFIER", 22, 30], ["CEK cells", "OBSERVATION", 31, 40], ["Infected Cells", "OBSERVATION", 135, 149], ["infected cells", "OBSERVATION", 236, 250]]], ["According to the above description, the relative mRNA expression level and virus titer of IBV were detected.Pre-Treatment of Virus Prior to Infection ::: Materials and MethodsIn order to study the direct effects of HPE, HPW, and SEE on the virus, 100 TCID50 IBV was incubated with 78.13, 39.06, 19.53 \u03bcg/ml HPE, HPW, and SEE solution at 37\u00b0C for 2 h, respectively.", [["HPE", "DISEASE", 215, 218], ["HPW", "CHEMICAL", 220, 223], ["HPW", "CHEMICAL", 312, 315], ["IBV", "ORGANISM", 90, 93], ["HPE", "SIMPLE_CHEMICAL", 215, 218], ["HPW", "SIMPLE_CHEMICAL", 220, 223], ["IBV", "ORGANISM", 258, 261], ["HPW", "SIMPLE_CHEMICAL", 312, 315], ["IBV", "SPECIES", 90, 93], ["IBV", "SPECIES", 258, 261], ["the relative mRNA expression level", "PROBLEM", 36, 70], ["virus titer", "TEST", 75, 86], ["IBV", "PROBLEM", 90, 93], ["Virus", "PROBLEM", 125, 130], ["Infection", "PROBLEM", 140, 149], ["HPE", "PROBLEM", 215, 218], ["HPE", "TEST", 307, 310], ["HPW", "TEST", 312, 315], ["Virus", "OBSERVATION", 125, 130], ["Infection", "OBSERVATION", 140, 149]]], ["Then CEK cells were infected with the drug-treated IBV at 37\u00b0C for 30 h.", [["CEK cells", "ANATOMY", 5, 14], ["CEK cells", "CELL", 5, 14], ["IBV", "ORGANISM", 51, 54], ["CEK cells", "CELL_LINE", 5, 14], ["IBV", "SPECIES", 51, 54], ["CEK cells", "PROBLEM", 5, 14], ["the drug", "TREATMENT", 34, 42], ["IBV", "TREATMENT", 51, 54]]], ["As described above, the relative mRNA expression levels and the virus titer of IBV were detected.Immunofluorescence Assay ::: Materials and MethodsIn the above three experimental designs, the best antiviral way was selected for indirect immunofluorescence assay.", [["IBV", "ORGANISM", 79, 82], ["IBV", "SPECIES", 79, 82], ["the relative mRNA expression levels", "PROBLEM", 20, 55], ["the virus titer", "TEST", 60, 75], ["IBV", "PROBLEM", 79, 82], ["Methods", "TREATMENT", 140, 147], ["indirect immunofluorescence assay", "TEST", 228, 261]]], ["After washing CEK cells with PBS, fixed with 4% paraformaldehyde, then incubated with 0.1% glycine and quenched with 1% Triton-X 100 for 10 min.", [["CEK cells", "ANATOMY", 14, 23], ["glycine", "CHEMICAL", 91, 98], ["Triton-X 100", "CHEMICAL", 120, 132], ["paraformaldehyde", "CHEMICAL", 48, 64], ["glycine", "CHEMICAL", 91, 98], ["CEK cells", "CELL", 14, 23], ["PBS", "SIMPLE_CHEMICAL", 29, 32], ["paraformaldehyde", "SIMPLE_CHEMICAL", 48, 64], ["glycine", "SIMPLE_CHEMICAL", 91, 98], ["Triton-X 100", "SIMPLE_CHEMICAL", 120, 132], ["CEK cells", "CELL_LINE", 14, 23], ["washing CEK cells", "TEST", 6, 23], ["PBS", "TEST", 29, 32], ["4% paraformaldehyde", "TREATMENT", 45, 64], ["0.1% glycine", "TREATMENT", 86, 98], ["1% Triton", "TREATMENT", 117, 126]]], ["After washing CEK cells with PBS for 3 times, the CEK cells were incubated with rabbit anti-IBV antibody (1:200) (prepared and stored in Laboratory of Pathology and Anatomy, Northeast Agricultural University) for 1 h, and then incubated with fluorescent labeled goat anti-rabbit IgG (1:500) (Zhongshan, China) for 30 min in the dark.", [["CEK cells", "ANATOMY", 14, 23], ["CEK cells", "ANATOMY", 50, 59], ["CEK cells", "CELL", 14, 23], ["CEK cells", "CELL", 50, 59], ["rabbit", "ORGANISM", 80, 86], ["goat", "ORGANISM", 262, 266], ["CEK cells", "CELL_LINE", 14, 23], ["CEK cells", "CELL_LINE", 50, 59], ["rabbit anti-IBV antibody", "PROTEIN", 80, 104], ["fluorescent labeled goat anti-rabbit IgG", "PROTEIN", 242, 282], ["rabbit", "SPECIES", 80, 86], ["goat", "SPECIES", 262, 266], ["anti-rabbit", "SPECIES", 267, 278], ["rabbit", "SPECIES", 80, 86], ["goat", "SPECIES", 262, 266], ["washing CEK cells", "TEST", 6, 23], ["PBS", "TEST", 29, 32], ["the CEK cells", "TEST", 46, 59], ["rabbit anti-IBV antibody", "TEST", 80, 104], ["fluorescent labeled goat anti-rabbit IgG", "TREATMENT", 242, 282]]], ["The fluorescent images were examined with a fluorescence microscope (Ti-S, Nikon, Japan).", [["The fluorescent images", "TEST", 0, 22], ["a fluorescence microscope", "TEST", 42, 67]]], ["At the same time, the infected cells treated with 10 \u03bcg/ml RT, and CEK cells infected with IBV, and the mock CEK cells were set as controls.Infection Model and Drug Treatment ::: Materials and MethodsOne hundred and forty four 2-week-old SPF chicks were randomly divided into HPE treated high dose group (HPE-TH), HPE treated middle dose group (HPE-TM), HPE treated low dose group (HPE-TL), the IBV infected group (IBV), the ribavirin treated (RT) group, and normal control (NC) group with 24 chicks in each group.", [["cells", "ANATOMY", 31, 36], ["CEK cells", "ANATOMY", 67, 76], ["CEK cells", "ANATOMY", 109, 118], ["HPE", "DISEASE", 276, 279], ["HPE-TH", "CHEMICAL", 305, 311], ["HPE", "CHEMICAL", 314, 317], ["HPE", "CHEMICAL", 354, 357], ["HPE-TL", "CHEMICAL", 382, 388], ["IBV infected", "DISEASE", 395, 407], ["ribavirin", "CHEMICAL", 425, 434], ["ribavirin", "CHEMICAL", 425, 434], ["cells", "CELL", 31, 36], ["CEK cells", "CELL", 67, 76], ["IBV", "ORGANISM", 91, 94], ["CEK cells", "CELL", 109, 118], ["SPF", "ORGANISM", 238, 241], ["chicks", "ORGANISM", 242, 248], ["IBV", "ORGANISM", 395, 398], ["IBV", "ORGANISM", 415, 418], ["infected cells", "CELL_TYPE", 22, 36], ["CEK cells", "CELL_LINE", 67, 76], ["mock CEK cells", "CELL_LINE", 104, 118], ["chicks", "SPECIES", 242, 248], ["IBV", "SPECIES", 91, 94], ["IBV", "SPECIES", 395, 398], ["IBV", "SPECIES", 415, 418], ["the infected cells", "PROBLEM", 18, 36], ["RT", "TREATMENT", 59, 61], ["CEK cells", "PROBLEM", 67, 76], ["IBV", "TREATMENT", 91, 94], ["the mock CEK cells", "TEST", 100, 118], ["HPE", "PROBLEM", 314, 317], ["HPE", "PROBLEM", 354, 357], ["low dose group (HPE-TL", "TREATMENT", 366, 388], ["the IBV infected group (IBV", "TREATMENT", 391, 418], ["the ribavirin", "TREATMENT", 421, 434], ["infected cells", "OBSERVATION", 22, 36], ["infected", "OBSERVATION", 399, 407], ["normal", "OBSERVATION", 459, 465]]], ["Each group was completely isolated from the other groups, and housed in negative pressure-filtered air isolators under pathogen-free conditions.", [["pressure", "OBSERVATION_MODIFIER", 81, 89], ["air isolators", "OBSERVATION", 99, 112]]], ["Chicks from in three HPE-treated groups, the IBV-infected group, and the RT group were inoculated by nasal drops with 0.1 ml of 100 EID50 of IBV M41 allantoic fluid per chick.", [["nasal", "ANATOMY", 101, 106], ["HPE", "DISEASE", 21, 24], ["IBV-infected", "DISEASE", 45, 57], ["Chicks", "ORGANISM", 0, 6], ["IBV", "ORGANISM", 45, 48], ["IBV", "ORGANISM", 141, 144], ["M41 allantoic fluid", "ORGANISM_SUBSTANCE", 145, 164], ["chick", "ORGANISM", 169, 174], ["Chicks", "SPECIES", 0, 6], ["IBV", "SPECIES", 45, 48], ["IBV", "SPECIES", 141, 144], ["Chicks", "PROBLEM", 0, 6], ["the IBV", "TREATMENT", 41, 48], ["the RT group", "TREATMENT", 69, 81], ["IBV", "TREATMENT", 141, 144], ["infected", "OBSERVATION", 49, 57], ["nasal", "ANATOMY", 101, 106], ["fluid", "OBSERVATION", 159, 164]]], ["Chicks in the control group were inoculated with 0.1 ml sterilized negative allantoic fluid in the same manner.", [["allantoic fluid", "ANATOMY", 76, 91], ["Chicks", "ORGANISM", 0, 6], ["Chicks", "SPECIES", 0, 6], ["allantoic fluid", "OBSERVATION", 76, 91]]], ["The chicks of the three HPE groups and the RT group were orally administered varying doses of three HPE (480 mg/kg, 240 mg/kg, 120 mg/kg) and ribavirin (60 mg/kg), respectively.", [["HPE", "DISEASE", 24, 27], ["HPE", "CHEMICAL", 100, 103], ["ribavirin", "CHEMICAL", 142, 151], ["ribavirin", "CHEMICAL", 142, 151], ["chicks", "ORGANISM", 4, 10], ["ribavirin", "SIMPLE_CHEMICAL", 142, 151], ["chicks", "SPECIES", 4, 10], ["the RT group", "TREATMENT", 39, 51], ["ribavirin", "TREATMENT", 142, 151]]], ["Both agents were administered twice daily for 5 days, beginning at 24 h after exposure to the virus.", [["the virus", "PROBLEM", 90, 99]]], ["At the same time, the chicks of the IBV-infected group and the normal group were orally administered with PSS.", [["IBV-infected", "DISEASE", 36, 48], ["chicks", "ORGANISM", 22, 28], ["IBV", "ORGANISM", 36, 39], ["chicks", "SPECIES", 22, 28], ["IBV", "SPECIES", 36, 39], ["the IBV", "TREATMENT", 32, 39], ["PSS", "TREATMENT", 106, 109], ["infected", "OBSERVATION", 40, 48], ["normal", "OBSERVATION", 63, 69]]], ["At 2, 4, 6, and 8 days post-infection, six chicks in each group were bled before euthanasia and necropsy at each designed day.", [["chicks", "ORGANISM", 43, 49], ["chicks", "SPECIES", 43, 49], ["euthanasia", "TREATMENT", 81, 91], ["necropsy", "TREATMENT", 96, 104]]], ["The trachea and kidney tissues were collected and immediately extracted to obtain the total RNAs.", [["trachea", "ANATOMY", 4, 11], ["kidney tissues", "ANATOMY", 16, 30], ["trachea", "MULTI-TISSUE_STRUCTURE", 4, 11], ["kidney tissues", "TISSUE", 16, 30], ["total RNAs", "RNA", 86, 96], ["trachea", "ANATOMY", 4, 11], ["kidney tissues", "ANATOMY", 16, 30]]], ["At the same time, tracheal and kidney in each group of chickens at 6 days postinfection were fixed in 10% buffer formaldehyde for histopathological assay.Histopathology Assay ::: Materials and MethodsAfter washing in phosphate-buffered saline (PBS), the trachea and kidney tissues were fixed in 10% formaldehyde solution for 7 days, embedded in paraffin wax, cut into 3-\u03bcm-thick sections (Leica RM4450, Germany), and stained with HE using standard histological staining procedure.", [["tracheal", "ANATOMY", 18, 26], ["kidney", "ANATOMY", 31, 37], ["trachea", "ANATOMY", 254, 261], ["kidney tissues", "ANATOMY", 266, 280], ["sections", "ANATOMY", 379, 387], ["formaldehyde", "CHEMICAL", 113, 125], ["phosphate", "CHEMICAL", 217, 226], ["formaldehyde", "CHEMICAL", 299, 311], ["formaldehyde", "CHEMICAL", 113, 125], ["phosphate", "CHEMICAL", 217, 226], ["formaldehyde", "CHEMICAL", 299, 311], ["tracheal", "MULTI-TISSUE_STRUCTURE", 18, 26], ["kidney", "ORGAN", 31, 37], ["chickens", "ORGANISM", 55, 63], ["formaldehyde", "SIMPLE_CHEMICAL", 113, 125], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 217, 242], ["trachea", "MULTI-TISSUE_STRUCTURE", 254, 261], ["kidney tissues", "TISSUE", 266, 280], ["formaldehyde", "SIMPLE_CHEMICAL", 299, 311], ["chickens", "SPECIES", 55, 63], ["chickens", "SPECIES", 55, 63], ["histopathological assay", "TEST", 130, 153], ["Histopathology Assay", "TEST", 154, 174], ["MethodsAfter washing in phosphate", "TREATMENT", 193, 226], ["buffered saline (PBS", "TREATMENT", 227, 247], ["10% formaldehyde solution", "TREATMENT", 295, 320], ["standard histological staining procedure", "TREATMENT", 439, 479], ["tracheal", "ANATOMY", 18, 26], ["kidney", "ANATOMY", 31, 37], ["trachea", "ANATOMY", 254, 261], ["kidney tissues", "ANATOMY", 266, 280]]], ["The slides were examined by light microscopy (Nikon, Japan).", [["The slides", "TEST", 0, 10], ["light microscopy", "TEST", 28, 44]]], ["The tissue slides were examined and evaluated according to the previous histopathologic scoring method for trachea (Levisohn et al., 1986; Todd et al., 1991) and kidney (Reinhard et al., 1991; Laudert et al., 1993; Canales et al., 2012) with minor modification.", [["tissue", "ANATOMY", 4, 10], ["trachea", "ANATOMY", 107, 114], ["kidney", "ANATOMY", 162, 168], ["tissue slides", "CANCER", 4, 17], ["trachea", "MULTI-TISSUE_STRUCTURE", 107, 114], ["kidney", "ORGAN", 162, 168], ["The tissue slides", "TEST", 0, 17], ["trachea", "ANATOMY", 107, 114], ["kidney", "ANATOMY", 162, 168]]], ["For the trachea, the following morphological changes were included: cilia loss of mucous epithelium, extrusion of balloon-like cell and necrotic exfoliation of mucous layer, lymphocyte and heterophil infiltration in submucosal layer, hyperemia, and/or hemorrhage.", [["trachea", "ANATOMY", 8, 15], ["cilia", "ANATOMY", 68, 73], ["mucous epithelium", "ANATOMY", 82, 99], ["balloon-like cell", "ANATOMY", 114, 131], ["mucous layer", "ANATOMY", 160, 172], ["lymphocyte", "ANATOMY", 174, 184], ["heterophil", "ANATOMY", 189, 199], ["submucosal layer", "ANATOMY", 216, 232], ["hyperemia", "DISEASE", 234, 243], ["hemorrhage", "DISEASE", 252, 262], ["trachea", "MULTI-TISSUE_STRUCTURE", 8, 15], ["mucous epithelium", "TISSUE", 82, 99], ["cell", "CELL", 127, 131], ["mucous layer", "TISSUE", 160, 172], ["lymphocyte", "CELL", 174, 184], ["heterophil", "CELL", 189, 199], ["submucosal layer", "TISSUE", 216, 232], ["cilia loss of mucous epithelium", "PROBLEM", 68, 99], ["balloon", "TREATMENT", 114, 121], ["like cell", "PROBLEM", 122, 131], ["necrotic exfoliation", "PROBLEM", 136, 156], ["mucous layer", "PROBLEM", 160, 172], ["lymphocyte", "PROBLEM", 174, 184], ["heterophil infiltration", "PROBLEM", 189, 212], ["submucosal layer", "PROBLEM", 216, 232], ["hyperemia", "PROBLEM", 234, 243], ["hemorrhage", "PROBLEM", 252, 262], ["trachea", "ANATOMY", 8, 15], ["cilia loss", "OBSERVATION", 68, 78], ["mucous epithelium", "OBSERVATION", 82, 99], ["balloon", "OBSERVATION", 114, 121], ["like cell", "OBSERVATION_MODIFIER", 122, 131], ["necrotic", "OBSERVATION_MODIFIER", 136, 144], ["exfoliation", "OBSERVATION_MODIFIER", 145, 156], ["mucous layer", "OBSERVATION", 160, 172], ["lymphocyte", "ANATOMY", 174, 184], ["heterophil infiltration", "OBSERVATION", 189, 212], ["submucosal", "ANATOMY_MODIFIER", 216, 226], ["layer", "OBSERVATION_MODIFIER", 227, 232], ["hyperemia", "OBSERVATION", 234, 243], ["hemorrhage", "OBSERVATION", 252, 262]]], ["For the kidney as followed: glomerular atrophy and fragmentation, tubular degeneration (granular and/or vacuolar degeneration) and necrosis (detached and broken epithelium), interstitial infiltration of lymphocytes and heterophils, hyperemia, and/or hemorrhage.", [["kidney", "ANATOMY", 8, 14], ["glomerular", "ANATOMY", 28, 38], ["tubular", "ANATOMY", 66, 73], ["granular", "ANATOMY", 88, 96], ["vacuolar", "ANATOMY", 104, 112], ["epithelium", "ANATOMY", 161, 171], ["interstitial", "ANATOMY", 174, 186], ["lymphocytes", "ANATOMY", 203, 214], ["heterophils", "ANATOMY", 219, 230], ["glomerular atrophy", "DISEASE", 28, 46], ["necrosis", "DISEASE", 131, 139], ["hyperemia", "DISEASE", 232, 241], ["hemorrhage", "DISEASE", 250, 260], ["kidney", "ORGAN", 8, 14], ["glomerular", "TISSUE", 28, 38], ["tubular", "TISSUE", 66, 73], ["vacuolar", "CELLULAR_COMPONENT", 104, 112], ["epithelium", "TISSUE", 161, 171], ["lymphocytes", "CELL", 203, 214], ["heterophils", "CELL", 219, 230], ["lymphocytes", "CELL_TYPE", 203, 214], ["heterophils", "CELL_TYPE", 219, 230], ["glomerular atrophy", "PROBLEM", 28, 46], ["fragmentation", "PROBLEM", 51, 64], ["tubular degeneration", "PROBLEM", 66, 86], ["granular and/or vacuolar degeneration", "PROBLEM", 88, 125], ["necrosis", "PROBLEM", 131, 139], ["broken epithelium", "PROBLEM", 154, 171], ["interstitial infiltration of lymphocytes", "PROBLEM", 174, 214], ["heterophils", "PROBLEM", 219, 230], ["hyperemia", "PROBLEM", 232, 241], ["hemorrhage", "PROBLEM", 250, 260], ["kidney", "ANATOMY", 8, 14], ["glomerular", "ANATOMY", 28, 38], ["atrophy", "OBSERVATION", 39, 46], ["fragmentation", "OBSERVATION", 51, 64], ["tubular", "OBSERVATION_MODIFIER", 66, 73], ["degeneration", "OBSERVATION", 74, 86], ["granular", "OBSERVATION_MODIFIER", 88, 96], ["vacuolar degeneration", "OBSERVATION", 104, 125], ["necrosis", "OBSERVATION", 131, 139], ["broken epithelium", "OBSERVATION_MODIFIER", 154, 171], ["interstitial", "ANATOMY_MODIFIER", 174, 186], ["infiltration", "OBSERVATION", 187, 199], ["lymphocytes", "ANATOMY", 203, 214], ["heterophils", "OBSERVATION_MODIFIER", 219, 230], ["hyperemia", "OBSERVATION_MODIFIER", 232, 241], ["hemorrhage", "OBSERVATION", 250, 260]]], ["The distribution and extent of the aforementioned lesions in the trachea and kidney of each chicken were scored as followed: 0, absence of lesion; 1, lesion represented in fewer than 10% of the involvement of tissue; 2, lesion represented in 10\u201350% involvement; 3, lesion represented in 50\u201390% involvement; and 4, lesion represented in more than 90% involvement.", [["lesions", "ANATOMY", 50, 57], ["trachea", "ANATOMY", 65, 72], ["kidney", "ANATOMY", 77, 83], ["lesion", "ANATOMY", 139, 145], ["lesion", "ANATOMY", 150, 156], ["tissue", "ANATOMY", 209, 215], ["lesion", "ANATOMY", 220, 226], ["lesion", "ANATOMY", 265, 271], ["lesion", "ANATOMY", 314, 320], ["lesions", "PATHOLOGICAL_FORMATION", 50, 57], ["trachea", "ORGAN", 65, 72], ["kidney", "ORGAN", 77, 83], ["chicken", "ORGANISM", 92, 99], ["tissue", "TISSUE", 209, 215], ["lesion", "CANCER", 220, 226], ["lesion", "CANCER", 265, 271], ["lesion", "CANCER", 314, 320], ["chicken", "SPECIES", 92, 99], ["chicken", "SPECIES", 92, 99], ["the aforementioned lesions in the trachea and kidney of each chicken", "PROBLEM", 31, 99], ["lesion", "PROBLEM", 139, 145], ["lesion", "PROBLEM", 150, 156], ["the involvement of tissue", "PROBLEM", 190, 215], ["lesion", "PROBLEM", 220, 226], ["lesion", "PROBLEM", 265, 271], ["lesion", "PROBLEM", 314, 320], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["extent", "OBSERVATION_MODIFIER", 21, 27], ["aforementioned", "OBSERVATION_MODIFIER", 35, 49], ["lesions", "OBSERVATION", 50, 57], ["trachea", "ANATOMY", 65, 72], ["kidney", "ANATOMY", 77, 83], ["lesion", "OBSERVATION", 139, 145], ["lesion", "OBSERVATION", 150, 156], ["fewer", "OBSERVATION_MODIFIER", 172, 177], ["tissue", "ANATOMY", 209, 215], ["lesion", "OBSERVATION", 314, 320]]], ["The pathological lesions of trachea and kidney were scored by 3 experienced veterinary pathologists (Dr. Guangxing Li, Ruili Zhang, and Xiaodan Huang, Northeast Agricultural University, Harbin, PR China), which were blinded to the identities of the experimental groups.", [["lesions", "ANATOMY", 17, 24], ["trachea", "ANATOMY", 28, 35], ["kidney", "ANATOMY", 40, 46], ["pathological lesions", "CANCER", 4, 24], ["trachea", "ORGAN", 28, 35], ["kidney", "ORGAN", 40, 46], ["The pathological lesions of trachea and kidney", "PROBLEM", 0, 46], ["pathological", "OBSERVATION_MODIFIER", 4, 16], ["lesions", "OBSERVATION", 17, 24], ["trachea", "ANATOMY", 28, 35], ["kidney", "ANATOMY", 40, 46]]], ["The pathological injuries of trachea and kidney were quantitatively analyzed, and the statistical results were given inTables 2 and 3.Ribonucleic Acid Extraction and Reverse Transcription ::: Materials and MethodsTreated cell samples were repeatedly frozen and thawed three times, and the equiponderant trachea and kidney tissues from each chick at various time points were prepared.", [["trachea", "ANATOMY", 29, 36], ["kidney", "ANATOMY", 41, 47], ["cell samples", "ANATOMY", 221, 233], ["trachea", "ANATOMY", 303, 310], ["kidney tissues", "ANATOMY", 315, 329], ["Ribonucleic Acid", "CHEMICAL", 134, 150], ["Ribonucleic Acid", "CHEMICAL", 134, 150], ["trachea", "MULTI-TISSUE_STRUCTURE", 29, 36], ["kidney", "ORGAN", 41, 47], ["cell samples", "CELL", 221, 233], ["equiponderant trachea", "MULTI-TISSUE_STRUCTURE", 289, 310], ["kidney tissues", "TISSUE", 315, 329], ["chick", "ORGANISM", 340, 345], ["The pathological injuries of trachea and kidney", "PROBLEM", 0, 47], ["Ribonucleic Acid Extraction", "TREATMENT", 134, 161], ["MethodsTreated cell samples", "TREATMENT", 206, 233], ["pathological", "OBSERVATION_MODIFIER", 4, 16], ["injuries", "OBSERVATION", 17, 25], ["trachea", "ANATOMY", 29, 36], ["kidney", "ANATOMY", 41, 47], ["trachea", "ANATOMY", 303, 310], ["kidney tissues", "ANATOMY", 315, 329]]], ["Then, the total RNA was extracted using a Universal RNA Extraction Kit (Thermo Fisher Scientific, USA) according to the manufacturer\u2019s instructions.Ribonucleic Acid Extraction and Reverse Transcription ::: Materials and MethodsAll the concentration of RNA and the A260/A280 ratio were determined with NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, USA), and the integrity of the extracted RNA was detected by agarose gel electrophoresis.", [["Ribonucleic Acid", "CHEMICAL", 148, 164], ["Ribonucleic Acid", "CHEMICAL", 148, 164], ["A260", "GENE_OR_GENE_PRODUCT", 264, 268], ["A280", "GENE_OR_GENE_PRODUCT", 269, 273], ["agarose", "SIMPLE_CHEMICAL", 421, 428], ["the total RNA", "TREATMENT", 6, 19], ["a Universal RNA Extraction", "TREATMENT", 40, 66], ["Ribonucleic Acid Extraction", "TREATMENT", 148, 175], ["Methods", "TREATMENT", 220, 227], ["RNA", "TEST", 252, 255], ["the A260/A280 ratio", "TEST", 260, 279], ["the extracted RNA", "PROBLEM", 387, 404], ["agarose gel electrophoresis", "TEST", 421, 448]]], ["The total RNAs were reverse transcribed into cDNAs by PCR instrument (TaKaRa, Japan) for qRT-PCR, and the cDNAs were stored at \u221220\u00b0C.Quantitative Real-Time Polymerase Chain Reaction ::: Materials and MethodsThe relative quantification analyses was used to determine the levels of mRNA expression of target genes, including N gene of IBV, IL-6, TNF-\u03b1, IL-1\u03b2, IFN-\u03b1, IFN-\u03b2, MDA5, MAVS, and NF-\u03baB by an applied LightCycler 96 Real-Time PCR System (Roche, Switzerland).", [["cDNAs", "ORGANISM", 106, 111], ["IBV", "ORGANISM", 333, 336], ["IL-6", "GENE_OR_GENE_PRODUCT", 338, 342], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 344, 349], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 351, 356], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 358, 363], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 365, 370], ["MDA5", "GENE_OR_GENE_PRODUCT", 372, 376], ["MAVS", "GENE_OR_GENE_PRODUCT", 378, 382], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 388, 393], ["cDNAs", "DNA", 45, 50], ["PCR instrument", "DNA", 54, 68], ["qRT", "DNA", 89, 92], ["cDNAs", "DNA", 106, 111], ["target genes", "DNA", 299, 311], ["N gene", "DNA", 323, 329], ["TNF", "PROTEIN", 344, 347], ["IL", "PROTEIN", 351, 353], ["IFN", "PROTEIN", 358, 361], ["\u03b1", "PROTEIN", 362, 363], ["IFN", "PROTEIN", 365, 368], ["\u03b2", "PROTEIN", 369, 370], ["MDA5", "DNA", 372, 376], ["MAVS", "PROTEIN", 378, 382], ["NF-\u03baB", "PROTEIN", 388, 393], ["IBV", "SPECIES", 333, 336], ["The total RNAs", "TREATMENT", 0, 14], ["qRT", "TEST", 89, 92], ["PCR", "TEST", 93, 96], ["the cDNAs", "TEST", 102, 111], ["Methods", "TREATMENT", 200, 207], ["The relative quantification analyses", "TEST", 207, 243], ["IBV", "TEST", 333, 336], ["IL", "TEST", 338, 340], ["TNF", "TEST", 344, 347], ["IL", "TEST", 351, 353], ["IFN", "TEST", 358, 361], ["IFN", "TEST", 365, 368], ["MDA5", "TEST", 372, 376], ["MAVS", "TEST", 378, 382], ["NF", "TEST", 388, 390], ["LightCycler", "TEST", 408, 419]]], ["All primer pairs for real-time PCR detection are listed in Table 1.", [["primer pairs", "DNA", 4, 16], ["All primer pairs", "TEST", 0, 16], ["real-time PCR detection", "TEST", 21, 44]]], ["The relative mRNA expression levels of target genes were calculated by using the 2\u2212\u0394\u0394Ct method (Yu et al., 2017).Quantitative Real-Time Polymerase Chain Reaction ::: Materials and MethodsThe amplification system was 2 \u03bcl cDNA, 0.6 \u03bcl forward and reverse primers, 10 \u03bcl universal SYBR Green (ROX) and 6.8 \u03bcl nuclease-free water, and the final volume of each system was 20 \u03bcl.", [["SYBR Green", "CHEMICAL", 279, 289], ["ROX", "CHEMICAL", 291, 294], ["ROX", "SIMPLE_CHEMICAL", 291, 294], ["target genes", "DNA", 39, 51], ["\u03bcl cDNA", "DNA", 218, 225], ["nuclease", "PROTEIN", 307, 315], ["The amplification system", "TEST", 187, 211], ["reverse primers", "TREATMENT", 246, 261]]], ["The amplification reaction of qRT-PCR assays was conducted according to the following thermal profile: pre-incubation 1 cycles at 95\u00b0C for 600 s, followed by 2 step amplification: 42 cycles at 95\u00b0C for 15 s and 60\u00b0C for 30 s, followed by melting: 1 cycles at 95\u00b0C for 10 s, 65\u00b0C for 60 s, and 97\u00b0C for 1 s, followed by cooling 1 cycles at 37\u00b0C for 30 s.High-Performance Liquid Chromatography/Diode Array Detector/Electrospray Ionization\u2013Mass Spectroscopy Analysis of the Hypericum perforatum Ethyl Acetate ::: Materials and MethodsHPLC/diode array detector/ESI-MS analysis was performed on a Waters 2695 HPLC equipped with diode array detector and Waters Micromass ZQ ESI-electrospray (Waters, USA) operating in positive and negative ion mode.", [["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 471, 505], ["Ethyl Acetate", "CHEMICAL", 492, 505], ["Hypericum perforatum", "ORGANISM", 471, 491], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 492, 505], ["qRT", "DNA", 30, 33], ["Hypericum perforatum", "SPECIES", 471, 491], ["Hypericum perforatum", "SPECIES", 471, 491], ["The amplification reaction", "TEST", 0, 26], ["qRT", "TEST", 30, 33], ["PCR assays", "TEST", 34, 44], ["High-Performance Liquid Chromatography", "TREATMENT", 353, 391], ["Diode Array Detector/Electrospray Ionization", "TREATMENT", 392, 436], ["Mass Spectroscopy", "TEST", 437, 454], ["MethodsHPLC/diode array detector", "TREATMENT", 524, 556], ["ESI", "TEST", 557, 560], ["MS analysis", "TEST", 561, 572], ["diode array detector", "TREATMENT", 623, 643], ["Waters Micromass", "TEST", 648, 664], ["ESI", "TEST", 668, 671], ["Hypericum", "OBSERVATION_MODIFIER", 471, 480]]], ["According to relevant reports (Seger et al., 2004; Jesionek et al., 2015), the HPLC condition was determined with a minor modification.", [["the HPLC condition", "PROBLEM", 75, 93], ["a minor modification", "TREATMENT", 114, 134]]], ["HPE analysis was performed using an eclipse XDB-C18 column (100 mm x 4.6 mm, 5 \u03bcm, Agilent Technologies Inc. USA).", [["HPE analysis", "TEST", 0, 12], ["an eclipse XDB", "TEST", 33, 47]]], ["The mobile phase consisted of water (A) and acetonitrile (B) at a constant flow rate (1.0 ml/min).", [["acetonitrile", "CHEMICAL", 44, 56], ["acetonitrile", "CHEMICAL", 44, 56], ["water", "SIMPLE_CHEMICAL", 30, 35], ["acetonitrile", "SIMPLE_CHEMICAL", 44, 56], ["water (A) and acetonitrile (B)", "TREATMENT", 30, 60], ["a constant flow rate", "TREATMENT", 64, 84], ["mobile phase", "OBSERVATION_MODIFIER", 4, 16]]], ["The solvent gradient elution method was as follows: 0\u20135 min, 5\u201395% B and 5\u20138 min, 95% B. The detection wavelength was 0\u2013700 nm, the column temperature was room temperature, and the injection volume was 10 \u03bcl.High-Performance Liquid Chromatography/Diode Array Detector/Electrospray Ionization\u2013Mass Spectroscopy Analysis of the Hypericum perforatum Ethyl Acetate ::: Materials and MethodsThe operating conditions of the mass spectrometer were dry gas temperature, 350\u00b0C, flow rate, 50 L/min; nebulizer pressure, 30 psi; sheath gas temperature, 250\u00b0C, flow rate, 10 L/min; fragmenter voltage, 100 V; capillary voltage, 3,500 V; mass range, 50 \u20131,100 D.Determination of Hyperoside, Quercitrin, Quercetin, Pseudohypericin, and Hypericin in the Hypericum perforatum Ethyl Acetate ::: Materials and MethodsThe sample solution was prepared by dissolving 100.0 mg dried HPE in 25 ml mobile phase and filtered by 0.22 \u03bcm filter before HPLC analysis.", [["capillary", "ANATOMY", 597, 606], ["sample", "ANATOMY", 803, 809], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 326, 360], ["Hyperoside", "CHEMICAL", 666, 676], ["Quercitrin", "CHEMICAL", 678, 688], ["Quercetin", "CHEMICAL", 690, 699], ["Pseudohypericin", "CHEMICAL", 701, 716], ["Hypericin", "CHEMICAL", 722, 731], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 739, 773], ["Ethyl Acetate", "CHEMICAL", 347, 360], ["Hyperoside", "CHEMICAL", 666, 676], ["Quercitrin", "CHEMICAL", 678, 688], ["Quercetin", "CHEMICAL", 690, 699], ["Pseudohypericin", "CHEMICAL", 701, 716], ["Hypericin", "CHEMICAL", 722, 731], ["Ethyl Acetate", "CHEMICAL", 760, 773], ["Hypericum perforatum", "ORGANISM", 326, 346], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 347, 360], ["capillary", "TISSUE", 597, 606], ["Hyperoside", "SIMPLE_CHEMICAL", 666, 676], ["Quercitrin", "SIMPLE_CHEMICAL", 678, 688], ["Quercetin", "SIMPLE_CHEMICAL", 690, 699], ["Pseudohypericin", "SIMPLE_CHEMICAL", 701, 716], ["Hypericin", "SIMPLE_CHEMICAL", 722, 731], ["Hypericum perforatum", "ORGANISM", 739, 759], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 760, 773], ["Hypericum perforatum", "SPECIES", 326, 346], ["Hypericum perforatum", "SPECIES", 739, 759], ["Hypericum perforatum", "SPECIES", 326, 346], ["Hypericum perforatum", "SPECIES", 739, 759], ["The solvent gradient elution method", "TEST", 0, 35], ["The detection wavelength", "TEST", 89, 113], ["the column temperature", "TEST", 128, 150], ["the injection volume", "TEST", 177, 197], ["High-Performance Liquid Chromatography", "TREATMENT", 208, 246], ["Diode Array Detector/Electrospray Ionization", "TREATMENT", 247, 291], ["Mass Spectroscopy", "TEST", 292, 309], ["the mass spectrometer", "TEST", 414, 435], ["dry gas temperature", "TEST", 441, 460], ["flow rate", "TEST", 469, 478], ["nebulizer pressure", "TEST", 490, 508], ["sheath gas temperature", "TEST", 518, 540], ["flow rate", "TEST", 549, 558], ["fragmenter voltage", "TEST", 570, 588], ["capillary voltage", "TEST", 597, 614], ["mass range", "TEST", 625, 635], ["Hyperoside", "TREATMENT", 666, 676], ["Quercitrin", "TREATMENT", 678, 688], ["Quercetin", "TREATMENT", 690, 699], ["Pseudohypericin", "TREATMENT", 701, 716], ["Hypericin", "TREATMENT", 722, 731], ["Methods", "TREATMENT", 792, 799], ["The sample solution", "TREATMENT", 799, 818], ["HPLC analysis", "TEST", 925, 938], ["Hypericum", "OBSERVATION_MODIFIER", 326, 335]]], ["The content of hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin in the HPE was determined by HPLC instrument and the chromatographic conditions described above.", [["hyperoside", "CHEMICAL", 15, 25], ["quercitrin", "CHEMICAL", 27, 37], ["quercetin", "CHEMICAL", 39, 48], ["pseudohypericin", "CHEMICAL", 50, 65], ["hypericin", "CHEMICAL", 71, 80], ["HPE", "DISEASE", 88, 91], ["hyperoside", "CHEMICAL", 15, 25], ["quercitrin", "CHEMICAL", 27, 37], ["quercetin", "CHEMICAL", 39, 48], ["pseudohypericin", "CHEMICAL", 50, 65], ["hypericin", "CHEMICAL", 71, 80], ["hyperoside", "SIMPLE_CHEMICAL", 15, 25], ["quercitrin", "SIMPLE_CHEMICAL", 27, 37], ["quercetin", "SIMPLE_CHEMICAL", 39, 48], ["pseudohypericin", "SIMPLE_CHEMICAL", 50, 65], ["hypericin", "SIMPLE_CHEMICAL", 71, 80], ["hyperoside", "TREATMENT", 15, 25], ["quercitrin", "TREATMENT", 27, 37], ["quercetin", "TREATMENT", 39, 48], ["pseudohypericin", "TREATMENT", 50, 65], ["hypericin", "TREATMENT", 71, 80], ["the HPE", "PROBLEM", 84, 91], ["HPLC instrument", "TEST", 110, 125], ["the chromatographic conditions", "TEST", 130, 160]]], ["In the 25 ml analytical solvent, the hyperoside standard of 2.5 mg, or the quercitrin standard of 5.0 mg, or the quercetin standard of 2.0 mg, or the pseudohypericin standard of 1.0 mg, or the hypericin standard of 1.0 mg are dissolved to prepared stock solution, respectively.", [["hyperoside", "CHEMICAL", 37, 47], ["quercitrin", "CHEMICAL", 75, 85], ["quercetin", "CHEMICAL", 113, 122], ["hypericin", "CHEMICAL", 193, 202], ["hyperoside", "CHEMICAL", 37, 47], ["quercitrin", "CHEMICAL", 75, 85], ["quercetin", "CHEMICAL", 113, 122], ["hypericin", "CHEMICAL", 193, 202], ["hyperoside", "SIMPLE_CHEMICAL", 37, 47], ["quercitrin", "SIMPLE_CHEMICAL", 75, 85], ["quercetin", "SIMPLE_CHEMICAL", 113, 122], ["pseudohypericin", "SIMPLE_CHEMICAL", 150, 165], ["hypericin", "SIMPLE_CHEMICAL", 193, 202], ["the hyperoside standard", "TREATMENT", 33, 56], ["the quercitrin standard", "TREATMENT", 71, 94], ["the quercetin standard", "TREATMENT", 109, 131], ["the pseudohypericin standard", "TREATMENT", 146, 174], ["the hypericin standard", "TREATMENT", 189, 211]]], ["According to the guide of International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (Singh, 2015; Armutcu et al., 2018; Hsi et al., 2019), the signal-to-noise ratio (S/N) of 3 and 10 were defined as the detection limit (LOD), and the quantitative limit (LOQ), respectively.", [["Human", "ORGANISM", 134, 139], ["Human", "SPECIES", 134, 139], ["the signal", "TEST", 199, 209]]], ["In order to detect the S/N, the stock solution of hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin were diluted to different concentrations, respectively.", [["hyperoside", "CHEMICAL", 50, 60], ["quercitrin", "CHEMICAL", 62, 72], ["quercetin", "CHEMICAL", 74, 83], ["pseudohypericin", "CHEMICAL", 85, 100], ["hypericin", "CHEMICAL", 106, 115], ["hyperoside", "CHEMICAL", 50, 60], ["quercitrin", "CHEMICAL", 62, 72], ["quercetin", "CHEMICAL", 74, 83], ["pseudohypericin", "CHEMICAL", 85, 100], ["hypericin", "CHEMICAL", 106, 115], ["hyperoside", "SIMPLE_CHEMICAL", 50, 60], ["quercitrin", "SIMPLE_CHEMICAL", 62, 72], ["quercetin", "SIMPLE_CHEMICAL", 74, 83], ["pseudohypericin", "SIMPLE_CHEMICAL", 85, 100], ["hypericin", "SIMPLE_CHEMICAL", 106, 115], ["hyperoside", "TREATMENT", 50, 60], ["quercitrin", "TREATMENT", 62, 72], ["quercetin", "TREATMENT", 74, 83], ["pseudohypericin", "TREATMENT", 85, 100], ["hypericin", "TREATMENT", 106, 115]]], ["In order to obtain the standard curve, the stock solution of the above standard compounds was diluted into six appropriate dilution concentrations.", [["the stock solution", "TREATMENT", 39, 57], ["the above standard compounds", "TREATMENT", 61, 89]]], ["Quantification was conducted by using a six-point standard curve and an external standard method.", [["an external standard method", "TREATMENT", 69, 96]]], ["Intra-day and inter-day precision for hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin were used to evaluate the repeatability and reproducibility of the established method.Statistical Analysis ::: Materials and MethodsThe number of the experiment repetition in all the experiment was three times.", [["hyperoside", "CHEMICAL", 38, 48], ["quercitrin", "CHEMICAL", 50, 60], ["quercetin", "CHEMICAL", 62, 71], ["pseudohypericin", "CHEMICAL", 73, 88], ["hypericin", "CHEMICAL", 94, 103], ["hyperoside", "CHEMICAL", 38, 48], ["quercitrin", "CHEMICAL", 50, 60], ["quercetin", "CHEMICAL", 62, 71], ["pseudohypericin", "CHEMICAL", 73, 88], ["hypericin", "CHEMICAL", 94, 103], ["hyperoside", "SIMPLE_CHEMICAL", 38, 48], ["quercitrin", "SIMPLE_CHEMICAL", 50, 60], ["quercetin", "SIMPLE_CHEMICAL", 62, 71], ["pseudohypericin", "SIMPLE_CHEMICAL", 73, 88], ["hypericin", "SIMPLE_CHEMICAL", 94, 103], ["hyperoside", "TREATMENT", 38, 48], ["quercitrin", "TREATMENT", 50, 60], ["quercetin", "TREATMENT", 62, 71], ["pseudohypericin", "TREATMENT", 73, 88], ["hypericin", "TREATMENT", 94, 103]]], ["The experimental data was analyzed with SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).", [["The experimental data", "TEST", 0, 21], ["SPSS", "TEST", 40, 44]]], ["Differences between groups were evaluated using the one-way analysis of variance (ANOVA) of two tailed test. p < 0.05 were considered as statistically significant, and p < 0.01 were considered as highly significant.Maximum Nontoxic Concentration of Hypericum perforatum Ethyl Acetate, Hypericum perforatum Water, and SEE ::: ResultsThe cell viability after trypan blue staining was observed under optical microscope and further confirmed by MTT method.", [["cell", "ANATOMY", 336, 340], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 249, 283], ["Hypericum perforatum", "CHEMICAL", 285, 305], ["trypan blue", "CHEMICAL", 357, 368], ["Ethyl Acetate", "CHEMICAL", 270, 283], ["trypan blue", "CHEMICAL", 357, 368], ["MTT", "CHEMICAL", 441, 444], ["Hypericum perforatum", "ORGANISM", 249, 269], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 270, 283], ["Hypericum perforatum", "ORGANISM", 285, 305], ["Water", "ORGANISM", 306, 311], ["cell", "CELL", 336, 340], ["trypan blue", "SIMPLE_CHEMICAL", 357, 368], ["Hypericum perforatum", "SPECIES", 249, 269], ["Hypericum perforatum", "SPECIES", 285, 305], ["Hypericum perforatum", "SPECIES", 249, 269], ["Hypericum perforatum", "SPECIES", 285, 305], ["two tailed test", "TEST", 92, 107], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 249, 283], ["trypan blue staining", "TEST", 357, 377], ["optical microscope", "TEST", 397, 415], ["MTT method", "TEST", 441, 451], ["Hypericum", "OBSERVATION_MODIFIER", 249, 258], ["cell viability", "OBSERVATION", 336, 350]]], ["The results showed that the maximum nontoxic concentration of HPE, HPW, and SEE was 78.13 \u03bcg/ml.", [["HPW", "CHEMICAL", 67, 70], ["HPW", "SIMPLE_CHEMICAL", 67, 70], ["HPE", "PROBLEM", 62, 65], ["HPW", "TEST", 67, 70]]], ["When the concentration of HPE, HPW, and SEE was lower than 78.13 \u03bcg/ml, trypan blue staining showed cell was survival (Figure 1A).", [["cell", "ANATOMY", 100, 104], ["trypan blue", "CHEMICAL", 72, 83], ["trypan blue", "CHEMICAL", 72, 83], ["HPW", "SIMPLE_CHEMICAL", 31, 34], ["trypan blue", "SIMPLE_CHEMICAL", 72, 83], ["cell", "CELL", 100, 104], ["HPE", "PROBLEM", 26, 29], ["HPW", "TEST", 31, 34], ["trypan blue staining", "TEST", 72, 92]]], ["At the same time, the cell survival rate measured by MTT method was close to 100%, which was further explained that 78 \u03bcg/ml of the drug had no significant effect on the cells (Figure 1B).Adaptation and Replication of Infectious Bronchitis Virus in Chicken Embryo Kidney Cells ::: ResultsWhen IBV was propagated in CEK cells to the tenth generation, stable typical cytopathic effect (CPE) appeared at 36 h after IBV infection (Figure 2A).", [["cell", "ANATOMY", 22, 26], ["cells", "ANATOMY", 170, 175], ["Embryo Kidney Cells", "ANATOMY", 257, 276], ["CEK cells", "ANATOMY", 315, 324], ["Infectious Bronchitis Virus", "DISEASE", 218, 245], ["IBV infection", "DISEASE", 412, 425], ["MTT", "CHEMICAL", 53, 56], ["cell", "CELL", 22, 26], ["cells", "CELL", 170, 175], ["Infectious Bronchitis Virus", "ORGANISM", 218, 245], ["Chicken", "ORGANISM", 249, 256], ["Embryo Kidney Cells", "CELL", 257, 276], ["IBV", "ORGANISM", 293, 296], ["CEK cells", "CELL", 315, 324], ["IBV", "ORGANISM", 412, 415], ["CEK cells", "CELL_LINE", 315, 324], ["Chicken", "SPECIES", 249, 256], ["Infectious Bronchitis Virus", "SPECIES", 218, 245], ["Chicken", "SPECIES", 249, 256], ["IBV", "SPECIES", 293, 296], ["IBV", "SPECIES", 412, 415], ["the cell survival rate", "TEST", 18, 40], ["MTT method", "TEST", 53, 63], ["the drug", "TREATMENT", 128, 136], ["Adaptation", "TREATMENT", 188, 198], ["Infectious Bronchitis Virus", "PROBLEM", 218, 245], ["IBV", "PROBLEM", 293, 296], ["IBV infection", "PROBLEM", 412, 425], ["Infectious", "OBSERVATION_MODIFIER", 218, 228], ["Embryo Kidney Cells", "OBSERVATION", 257, 276], ["stable", "OBSERVATION_MODIFIER", 350, 356], ["typical", "OBSERVATION_MODIFIER", 357, 364], ["cytopathic effect", "OBSERVATION", 365, 382], ["infection", "OBSERVATION", 416, 425]]], ["At the beginning, cells infected with IBV became round and refractive, then some cell exfoliated from the flask and left empty hole, some cells fused together and became multinuclear giant cells, indicating that IBV adapted to CEK cells.", [["cells", "ANATOMY", 18, 23], ["cell", "ANATOMY", 81, 85], ["flask", "ANATOMY", 106, 111], ["cells", "ANATOMY", 138, 143], ["multinuclear giant cells", "ANATOMY", 170, 194], ["CEK cells", "ANATOMY", 227, 236], ["cells", "CELL", 18, 23], ["IBV", "ORGANISM", 38, 41], ["cell", "CELL", 81, 85], ["cells", "CELL", 138, 143], ["multinuclear giant cells", "CELL", 170, 194], ["IBV", "ORGANISM", 212, 215], ["CEK cells", "CELL", 227, 236], ["multinuclear giant cells", "CELL_TYPE", 170, 194], ["CEK cells", "CELL_LINE", 227, 236], ["IBV", "SPECIES", 38, 41], ["IBV", "SPECIES", 212, 215], ["cells infected", "PROBLEM", 18, 32], ["IBV", "PROBLEM", 38, 41], ["some cell", "PROBLEM", 76, 85], ["the flask and left empty hole", "TREATMENT", 102, 131], ["some cells fused", "PROBLEM", 133, 149], ["multinuclear giant cells", "PROBLEM", 170, 194], ["IBV", "PROBLEM", 212, 215], ["cells", "ANATOMY", 18, 23], ["infected", "OBSERVATION", 24, 32], ["round", "OBSERVATION_MODIFIER", 49, 54], ["refractive", "OBSERVATION", 59, 69], ["cell exfoliated", "OBSERVATION", 81, 96], ["left", "ANATOMY_MODIFIER", 116, 120], ["empty hole", "OBSERVATION", 121, 131], ["cells fused", "OBSERVATION", 138, 149], ["multinuclear giant cells", "OBSERVATION", 170, 194], ["IBV", "OBSERVATION", 212, 215]]], ["The results of virus growth curve showed that IBV could infect and replicate in CEK cells and reached the highest titer of 10\u22125.8 TCID50 per 100 \u03bcl at 36 h post-inoculation (Figure 2B).", [["CEK cells", "ANATOMY", 80, 89], ["IBV", "ORGANISM", 46, 49], ["CEK cells", "CELL", 80, 89], ["CEK cells", "CELL_LINE", 80, 89], ["IBV", "SPECIES", 46, 49], ["virus growth curve", "TEST", 15, 33], ["IBV", "PROBLEM", 46, 49], ["CEK cells", "TEST", 80, 89]]], ["At the same time, the existence of IBV M41 was identified by RT-PCR (Figure 2C).Antiviral Effect of Supercritical Extraction Extract, Hypericum perforatum Ethyl Acetate, and Hypericum perforatum Water In Vitro::: ResultsThe relative mRNA expression level of IBV-N gene was detected by qRT-PCR and the virus titer of IBV was determined by TCID50 to analyze the antiviral effect of HPE, HPW and SEE (Figure 3).", [["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 134, 168], ["Hypericum perforatum", "CHEMICAL", 174, 194], ["Ethyl Acetate", "CHEMICAL", 155, 168], ["IBV", "ORGANISM", 35, 38], ["M41", "GENE_OR_GENE_PRODUCT", 39, 42], ["Hypericum perforatum", "ORGANISM", 134, 154], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 155, 168], ["Hypericum perforatum", "ORGANISM", 174, 194], ["IBV-N", "GENE_OR_GENE_PRODUCT", 258, 263], ["IBV", "ORGANISM", 316, 319], ["IBV M41", "DNA", 35, 42], ["IBV-N gene", "DNA", 258, 268], ["Hypericum perforatum", "SPECIES", 134, 154], ["Hypericum perforatum", "SPECIES", 174, 194], ["IBV M41", "SPECIES", 35, 42], ["Hypericum perforatum", "SPECIES", 134, 154], ["Hypericum perforatum", "SPECIES", 174, 194], ["IBV", "SPECIES", 258, 261], ["IBV", "SPECIES", 316, 319], ["IBV M41", "TREATMENT", 35, 42], ["RT", "TEST", 61, 63], ["Antiviral Effect", "TREATMENT", 80, 96], ["Supercritical Extraction Extract", "TREATMENT", 100, 132], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 134, 168], ["IBV", "TEST", 258, 261], ["qRT", "TEST", 285, 288], ["PCR", "TEST", 289, 292], ["the virus titer", "TEST", 297, 312], ["IBV", "TREATMENT", 316, 319], ["HPE", "PROBLEM", 380, 383], ["Supercritical Extraction", "OBSERVATION", 100, 124], ["Hypericum", "OBSERVATION_MODIFIER", 134, 143]]], ["It could be seen fromFigure 3that under the maximum non-toxic concentration of the drug, the inhibition of HPE on IBV was significantly greater than that of HPW and SEE.", [["HPE", "DISEASE", 107, 110], ["IBV", "ORGANISM", 114, 117], ["HPW", "SIMPLE_CHEMICAL", 157, 160], ["IBV", "SPECIES", 114, 117], ["HPE", "PROBLEM", 107, 110], ["IBV", "TREATMENT", 114, 117]]], ["HPW had a very weak effect on IBV and SEE had no effect on IBV.", [["HPW", "CHEMICAL", 0, 3], ["HPW", "SIMPLE_CHEMICAL", 0, 3], ["IBV", "ORGANISM", 30, 33], ["IBV", "ORGANISM", 59, 62], ["IBV", "SPECIES", 30, 33], ["IBV", "SPECIES", 59, 62], ["a very weak effect", "PROBLEM", 8, 26], ["IBV", "TREATMENT", 30, 33], ["IBV", "TREATMENT", 59, 62], ["very", "OBSERVATION_MODIFIER", 10, 14], ["weak", "OBSERVATION", 15, 19]]], ["Therefore, it was determined that the antiviral part of H. perforatum extract was ethyl acetate layer.Antiviral Effect of Supercritical Extraction Extract, Hypericum perforatum Ethyl Acetate, and Hypericum perforatum Water In Vitro::: ResultsAs can be seen from Figure 3A, in the three experimental designs, with the increase of HPE concentration, the mRNA level of IBV decreased significantly in a dose-dependent manner.", [["H. perforatum extract", "CHEMICAL", 56, 77], ["ethyl acetate", "CHEMICAL", 82, 95], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 156, 190], ["Hypericum perforatum", "CHEMICAL", 196, 216], ["ethyl acetate", "CHEMICAL", 82, 95], ["Ethyl Acetate", "CHEMICAL", 177, 190], ["H. perforatum", "ORGANISM", 56, 69], ["ethyl acetate layer", "SIMPLE_CHEMICAL", 82, 101], ["Hypericum perforatum", "ORGANISM", 156, 176], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 177, 190], ["Hypericum perforatum", "ORGANISM", 196, 216], ["HPE", "SIMPLE_CHEMICAL", 329, 332], ["IBV", "ORGANISM", 366, 369], ["H. perforatum", "SPECIES", 56, 69], ["Hypericum perforatum", "SPECIES", 156, 176], ["Hypericum perforatum", "SPECIES", 196, 216], ["H. perforatum", "SPECIES", 56, 69], ["Hypericum perforatum", "SPECIES", 156, 176], ["Hypericum perforatum", "SPECIES", 196, 216], ["IBV", "SPECIES", 366, 369], ["H. perforatum extract", "TREATMENT", 56, 77], ["ethyl acetate layer", "TREATMENT", 82, 101], ["Antiviral Effect", "TREATMENT", 102, 118], ["Supercritical Extraction Extract", "TREATMENT", 122, 154], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 156, 190], ["HPE concentration", "TREATMENT", 329, 346], ["the mRNA level", "TEST", 348, 362], ["IBV", "PROBLEM", 366, 369], ["Supercritical Extraction", "OBSERVATION", 122, 146], ["Hypericum", "OBSERVATION_MODIFIER", 156, 165], ["increase", "OBSERVATION_MODIFIER", 317, 325], ["decreased", "OBSERVATION_MODIFIER", 370, 379]]], ["In addition, at the same drug concentration, the relative expression level of virus mRNA was the lowest when HPE directly treated the infected virus cells, followed by HPE pre-treated cells before infection, and then HPE pre-treated virus before infection.Antiviral Effect of Supercritical Extraction Extract, Hypericum perforatum Ethyl Acetate, and Hypericum perforatum Water In Vitro::: ResultsIt can be known from the Figure 3B, with the increase of HPE concentration, the titer of IBV decreased gradually in a dose-dependent manner.", [["cells", "ANATOMY", 149, 154], ["cells", "ANATOMY", 184, 189], ["infection", "DISEASE", 197, 206], ["infection", "DISEASE", 246, 255], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 310, 344], ["Hypericum perforatum", "CHEMICAL", 350, 370], ["HPE", "DISEASE", 453, 456], ["Ethyl Acetate", "CHEMICAL", 331, 344], ["cells", "CELL", 149, 154], ["cells", "CELL", 184, 189], ["Hypericum perforatum", "ORGANISM", 310, 330], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 331, 344], ["Hypericum perforatum", "ORGANISM", 350, 370], ["HPE", "SIMPLE_CHEMICAL", 453, 456], ["IBV", "ORGANISM", 485, 488], ["virus mRNA", "RNA", 78, 88], ["infected virus cells", "CELL_TYPE", 134, 154], ["HPE pre-treated cells", "CELL_LINE", 168, 189], ["Hypericum perforatum", "SPECIES", 310, 330], ["Hypericum perforatum", "SPECIES", 350, 370], ["Hypericum perforatum", "SPECIES", 310, 330], ["Hypericum perforatum", "SPECIES", 350, 370], ["IBV", "SPECIES", 485, 488], ["virus mRNA", "PROBLEM", 78, 88], ["HPE", "PROBLEM", 109, 112], ["the infected virus cells", "PROBLEM", 130, 154], ["HPE pre-treated cells", "PROBLEM", 168, 189], ["infection", "PROBLEM", 197, 206], ["HPE pre-treated virus", "PROBLEM", 217, 238], ["infection", "PROBLEM", 246, 255], ["Antiviral Effect", "TREATMENT", 256, 272], ["Supercritical Extraction Extract", "TREATMENT", 276, 308], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 310, 344], ["HPE concentration", "TREATMENT", 453, 470], ["IBV", "PROBLEM", 485, 488], ["infected virus cells", "OBSERVATION", 134, 154], ["Supercritical Extraction", "OBSERVATION", 276, 300], ["Hypericum", "OBSERVATION_MODIFIER", 310, 319], ["increase", "OBSERVATION_MODIFIER", 441, 449], ["HPE", "OBSERVATION_MODIFIER", 453, 456], ["concentration", "OBSERVATION_MODIFIER", 457, 470]]], ["While, at the same drug concentration, the virus titer was the lowest when HPE directly treated the infected virus cells, followed by HPE pre-treated cells before infection, and followed by HPE pre-treated virus before infection.", [["cells", "ANATOMY", 115, 120], ["cells", "ANATOMY", 150, 155], ["infection", "DISEASE", 163, 172], ["infection", "DISEASE", 219, 228], ["cells", "CELL", 115, 120], ["cells", "CELL", 150, 155], ["infected virus cells", "CELL_TYPE", 100, 120], ["HPE pre-treated cells", "CELL_LINE", 134, 155], ["the virus titer", "TEST", 39, 54], ["the infected virus cells", "PROBLEM", 96, 120], ["HPE pre-treated cells", "PROBLEM", 134, 155], ["infection", "PROBLEM", 163, 172], ["HPE pre-treated virus", "PROBLEM", 190, 211], ["infection", "PROBLEM", 219, 228], ["infected", "OBSERVATION_MODIFIER", 100, 108], ["virus cells", "OBSERVATION", 109, 120]]], ["At the same time, the antiviral impact of HPE directly treated the IBV-infected cells at the concentration of 78.13 \u00b5g/ml, was similar to RT at the concentration of 10 \u00b5g/ml.", [["cells", "ANATOMY", 80, 85], ["HPE", "CHEMICAL", 42, 45], ["IBV-infected", "DISEASE", 67, 79], ["HPE", "SIMPLE_CHEMICAL", 42, 45], ["IBV", "ORGANISM", 67, 70], ["cells", "CELL", 80, 85], ["IBV", "SPECIES", 67, 70], ["the antiviral impact of HPE", "TREATMENT", 18, 45], ["the IBV", "TREATMENT", 63, 70], ["infected cells", "TREATMENT", 71, 85], ["infected cells", "OBSERVATION", 71, 85]]], ["Therefore, HPE was selected for subsequent experiments in vivo and in vitro, furthermore the HPE directly treated the IBV-infected cells was selected in vitro experiments.IFA Analysis Confirmed Inhibitory Effect of Hypericum perforatum Ethyl Acetate ::: ResultsIn order to further confirm the inhibitory effect of HPE on IBV-infected cells, the fluorescent signal of virus was detected by IFA (Figure 4).", [["cells", "ANATOMY", 131, 136], ["cells", "ANATOMY", 334, 339], ["HPE", "DISEASE", 93, 96], ["IBV-infected", "DISEASE", 118, 130], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 215, 249], ["HPE", "CHEMICAL", 314, 317], ["IBV-infected", "DISEASE", 321, 333], ["Ethyl Acetate", "CHEMICAL", 236, 249], ["IBV", "ORGANISM", 118, 121], ["cells", "CELL", 131, 136], ["Hypericum perforatum Ethyl Acetate", "SIMPLE_CHEMICAL", 215, 249], ["HPE", "SIMPLE_CHEMICAL", 314, 317], ["IBV", "ORGANISM", 321, 324], ["cells", "CELL", 334, 339], ["IBV-infected cells", "CELL_LINE", 118, 136], ["IBV-infected cells", "CELL_TYPE", 321, 339], ["Hypericum perforatum", "SPECIES", 215, 235], ["IBV", "SPECIES", 118, 121], ["Hypericum perforatum", "SPECIES", 215, 235], ["IBV", "SPECIES", 321, 324], ["the IBV", "TREATMENT", 114, 121], ["infected cells", "PROBLEM", 122, 136], ["IFA Analysis", "TEST", 171, 183], ["HPE", "PROBLEM", 314, 317], ["IBV", "TREATMENT", 321, 324], ["infected cells", "PROBLEM", 325, 339], ["the fluorescent signal of virus", "PROBLEM", 341, 372], ["infected cells", "OBSERVATION", 122, 136], ["infected cells", "OBSERVATION", 325, 339]]], ["From the Figure 4, it can be seen that the CEK cells infected with IBV produced a strong fluorescence signal at 30 h after infection.", [["CEK cells", "ANATOMY", 43, 52], ["infection", "DISEASE", 123, 132], ["CEK cells", "CELL", 43, 52], ["IBV", "ORGANISM", 67, 70], ["CEK cells", "CELL_LINE", 43, 52], ["IBV", "SPECIES", 67, 70], ["the CEK cells", "PROBLEM", 39, 52], ["IBV", "PROBLEM", 67, 70], ["infection", "PROBLEM", 123, 132], ["infection", "OBSERVATION", 123, 132]]], ["On the contrary, the fluorescence signal of CEK cells infected with IBV and treated with HPE was weakened, and the fluorescence signal decreased in a dose-dependent manner with the increase of HPE concentration.", [["CEK cells", "ANATOMY", 44, 53], ["HPE", "DISEASE", 193, 196], ["CEK cells", "CELL", 44, 53], ["IBV", "ORGANISM", 68, 71], ["HPE", "SIMPLE_CHEMICAL", 193, 196], ["CEK cells", "CELL_LINE", 44, 53], ["IBV", "SPECIES", 68, 71], ["the fluorescence signal", "TEST", 17, 40], ["CEK cells", "PROBLEM", 44, 53], ["IBV", "TREATMENT", 68, 71], ["HPE", "PROBLEM", 89, 92], ["the fluorescence signal", "TEST", 111, 134], ["HPE concentration", "TREATMENT", 193, 210], ["decreased", "OBSERVATION_MODIFIER", 135, 144], ["increase", "OBSERVATION_MODIFIER", 181, 189], ["HPE concentration", "OBSERVATION", 193, 210]]], ["This further confirmed that HPE has a very good inhibitory effect on IBV infected cells.Effect of Hypericum perforatum Ethyl Acetate on the Messenger Ribonucleic Acid Expression Level of Gene In Vitro ::: ResultsIn order to study the effect of HPE on gene mRNA expression induced by IBV infection in CEK cells, the mRNA expression level of related genes were determined, including MDA5, MAVS, IFN-\u03b1, IFN-\u03b2, NF-\u03baB, IL-6, and TNF-\u03b1.", [["cells", "ANATOMY", 82, 87], ["CEK cells", "ANATOMY", 300, 309], ["HPE", "CHEMICAL", 28, 31], ["IBV infected", "DISEASE", 69, 81], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 98, 132], ["IBV infection", "DISEASE", 283, 296], ["Ethyl Acetate", "CHEMICAL", 119, 132], ["HPE", "SIMPLE_CHEMICAL", 28, 31], ["IBV", "ORGANISM", 69, 72], ["cells", "CELL", 82, 87], ["Hypericum perforatum", "ORGANISM", 98, 118], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 119, 132], ["HPE", "SIMPLE_CHEMICAL", 244, 247], ["IBV", "ORGANISM", 283, 286], ["CEK cells", "CELL", 300, 309], ["MDA5", "GENE_OR_GENE_PRODUCT", 381, 385], ["MAVS", "GENE_OR_GENE_PRODUCT", 387, 391], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 393, 398], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 400, 405], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 407, 412], ["IL-6", "GENE_OR_GENE_PRODUCT", 414, 418], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 424, 430], ["IBV infected cells", "CELL_TYPE", 69, 87], ["CEK cells", "CELL_LINE", 300, 309], ["MDA5", "PROTEIN", 381, 385], ["MAVS", "PROTEIN", 387, 391], ["IFN", "PROTEIN", 393, 396], ["IFN", "PROTEIN", 400, 403], ["TNF", "PROTEIN", 424, 427], ["Hypericum perforatum", "SPECIES", 98, 118], ["IBV", "SPECIES", 69, 72], ["Hypericum perforatum", "SPECIES", 98, 118], ["IBV", "SPECIES", 283, 286], ["HPE", "PROBLEM", 28, 31], ["IBV infected cells", "PROBLEM", 69, 87], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 98, 132], ["HPE", "PROBLEM", 244, 247], ["gene mRNA expression", "TREATMENT", 251, 271], ["IBV infection in CEK cells", "PROBLEM", 283, 309], ["the mRNA expression level", "TEST", 311, 336], ["MDA5", "TEST", 381, 385], ["MAVS", "TEST", 387, 391], ["IFN", "TEST", 393, 396], ["\u03b1", "TEST", 397, 398], ["IFN", "TEST", 400, 403], ["\u03b2", "TEST", 404, 405], ["NF", "TEST", 407, 409], ["IL", "TEST", 414, 416], ["TNF", "TEST", 424, 427], ["very", "OBSERVATION_MODIFIER", 38, 42], ["good inhibitory", "OBSERVATION_MODIFIER", 43, 58], ["infected cells", "OBSERVATION", 73, 87], ["Hypericum", "OBSERVATION_MODIFIER", 98, 107], ["IBV", "OBSERVATION_MODIFIER", 283, 286], ["infection", "OBSERVATION", 287, 296], ["TNF", "ANATOMY", 424, 427]]], ["As can be seen from Figure 5, HPE treatment significantly affected the mRNA levels of MDA5, MAVS, IFN-\u03b1, and IFN-\u03b2 after IBV infection at 30 and 36 h, and the mRNA expression levels of these genes changed similarly.", [["IBV infection", "DISEASE", 121, 134], ["MDA5", "GENE_OR_GENE_PRODUCT", 86, 90], ["MAVS", "GENE_OR_GENE_PRODUCT", 92, 96], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 98, 103], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 109, 114], ["IBV", "ORGANISM", 121, 124], ["MDA5", "PROTEIN", 86, 90], ["MAVS", "PROTEIN", 92, 96], ["IFN", "PROTEIN", 98, 101], ["\u03b1", "PROTEIN", 102, 103], ["IFN", "PROTEIN", 109, 112], ["IBV", "SPECIES", 121, 124], ["HPE treatment", "TREATMENT", 30, 43], ["MDA5", "TEST", 86, 90], ["MAVS", "TEST", 92, 96], ["IFN", "TEST", 98, 101], ["IFN", "TEST", 109, 112], ["IBV infection", "PROBLEM", 121, 134], ["the mRNA expression levels", "TEST", 155, 181], ["MDA5", "ANATOMY", 86, 90], ["infection", "OBSERVATION", 125, 134]]], ["These data suggested that HPE could increase mRNA expression level of type I interferon in the late stages of IBV infection, which is possibly related to MDA5 signaling pathway.", [["HPE", "DISEASE", 26, 29], ["IBV infection", "DISEASE", 110, 123], ["HPE", "SIMPLE_CHEMICAL", 26, 29], ["type I interferon", "GENE_OR_GENE_PRODUCT", 70, 87], ["IBV", "ORGANISM", 110, 113], ["MDA5", "GENE_OR_GENE_PRODUCT", 154, 158], ["type I interferon", "PROTEIN", 70, 87], ["MDA5", "PROTEIN", 154, 158], ["IBV", "SPECIES", 110, 113], ["HPE", "PROBLEM", 26, 29], ["type I interferon", "PROBLEM", 70, 87], ["IBV infection", "PROBLEM", 110, 123], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["mRNA expression", "OBSERVATION", 45, 60], ["type I interferon", "OBSERVATION_MODIFIER", 70, 87], ["late stages", "OBSERVATION_MODIFIER", 95, 106], ["IBV", "OBSERVATION_MODIFIER", 110, 113], ["infection", "OBSERVATION", 114, 123], ["possibly related to", "UNCERTAINTY", 134, 153]]], ["In addition, HPE treatment significantly reduced the mRNA expression levels of NF-\u03baB, IL-6, and TNF-\u03b1, which were up-regulated after IBV infection at 30 and 36 h.", [["HPE", "CHEMICAL", 13, 16], ["IBV infection", "DISEASE", 133, 146], ["HPE", "SIMPLE_CHEMICAL", 13, 16], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 79, 84], ["IL-6", "GENE_OR_GENE_PRODUCT", 86, 90], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 96, 101], ["IBV", "ORGANISM", 133, 136], ["NF-\u03baB", "PROTEIN", 79, 84], ["IL-6", "PROTEIN", 86, 90], ["TNF", "PROTEIN", 96, 99], ["IBV", "SPECIES", 133, 136], ["HPE treatment", "TREATMENT", 13, 26], ["the mRNA expression levels", "TEST", 49, 75], ["NF", "TEST", 79, 81], ["IL", "TEST", 86, 88], ["TNF", "TEST", 96, 99], ["IBV infection", "PROBLEM", 133, 146], ["TNF", "ANATOMY", 96, 99], ["infection", "OBSERVATION", 137, 146]]], ["These data demonstrated that HPE could decrease the mRNA expression of pro-inflammatory genes, which is possibly related to NF-\u03baB signaling pathway.Effect of Hypericum perforatum Ethyl Acetate on Pathological Injury of Trachea and Kidney Caused by Infectious Bronchitis Virus ::: Antiviral Effect of Hypericum perforatum Ethyl Acetate In Vivo::: ResultsAt 6 days after infection, the symptoms that appeared in the IBV infected group were sneezing, tracheal wet rales, mouth breathing, coughing, ruffled feathers, and frequently shaking.", [["Kidney", "ANATOMY", 231, 237], ["tracheal wet", "ANATOMY", 448, 460], ["mouth", "ANATOMY", 468, 473], ["HPE", "CHEMICAL", 29, 32], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 158, 192], ["Injury of Trachea", "DISEASE", 209, 226], ["Infectious Bronchitis Virus", "DISEASE", 248, 275], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 300, 334], ["infection", "DISEASE", 369, 378], ["IBV infected", "DISEASE", 414, 426], ["sneezing", "DISEASE", 438, 446], ["Ethyl Acetate", "CHEMICAL", 179, 192], ["Ethyl Acetate", "CHEMICAL", 321, 334], ["HPE", "SIMPLE_CHEMICAL", 29, 32], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 124, 129], ["Hypericum perforatum", "ORGANISM", 158, 178], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 179, 192], ["Kidney", "ORGAN", 231, 237], ["Hypericum perforatum", "ORGANISM", 300, 320], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 321, 334], ["IBV", "ORGANISM", 414, 417], ["mouth", "ORGANISM_SUBDIVISION", 468, 473], ["pro-inflammatory genes", "DNA", 71, 93], ["NF-\u03baB", "PROTEIN", 124, 129], ["Hypericum perforatum", "SPECIES", 158, 178], ["Hypericum perforatum", "SPECIES", 300, 320], ["Hypericum perforatum", "SPECIES", 158, 178], ["Infectious Bronchitis Virus", "SPECIES", 248, 275], ["Hypericum perforatum", "SPECIES", 300, 320], ["IBV", "SPECIES", 414, 417], ["These data", "TEST", 0, 10], ["HPE", "PROBLEM", 29, 32], ["the mRNA expression of pro-inflammatory genes", "PROBLEM", 48, 93], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 158, 192], ["Pathological Injury of Trachea and Kidney", "PROBLEM", 196, 237], ["Infectious Bronchitis Virus", "PROBLEM", 248, 275], ["Antiviral Effect", "TREATMENT", 280, 296], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 300, 334], ["infection", "PROBLEM", 369, 378], ["the symptoms", "PROBLEM", 380, 392], ["sneezing", "PROBLEM", 438, 446], ["tracheal wet rales", "PROBLEM", 448, 466], ["mouth breathing", "PROBLEM", 468, 483], ["coughing", "PROBLEM", 485, 493], ["ruffled feathers", "PROBLEM", 495, 511], ["frequently shaking", "PROBLEM", 517, 535], ["mRNA expression", "OBSERVATION", 52, 67], ["pro-inflammatory genes", "OBSERVATION", 71, 93], ["possibly related to", "UNCERTAINTY", 104, 123], ["Hypericum", "OBSERVATION_MODIFIER", 158, 167], ["perforatum", "OBSERVATION_MODIFIER", 168, 178], ["Injury", "OBSERVATION", 209, 215], ["Trachea", "ANATOMY", 219, 226], ["Kidney", "ANATOMY", 231, 237], ["Infectious", "OBSERVATION", 248, 258], ["Hypericum", "OBSERVATION_MODIFIER", 300, 309], ["tracheal", "ANATOMY", 448, 456], ["wet", "OBSERVATION_MODIFIER", 457, 460], ["rales", "OBSERVATION", 461, 466], ["mouth breathing", "ANATOMY", 468, 483], ["ruffled feathers", "OBSERVATION", 495, 511]]], ["But the symptoms that appeared in the HPE and RT treatment group such as sneezing, tracheal wet rales, mouth breathing, coughing, feather wrinkling, and frequent trembling were mild.", [["tracheal", "ANATOMY", 83, 91], ["mouth", "ANATOMY", 103, 108], ["HPE", "DISEASE", 38, 41], ["sneezing", "DISEASE", 73, 81], ["mouth breathing", "DISEASE", 103, 118], ["coughing", "DISEASE", 120, 128], ["feather wrinkling", "DISEASE", 130, 147], ["trembling", "DISEASE", 162, 171], ["mouth", "ORGANISM_SUBDIVISION", 103, 108], ["the symptoms", "PROBLEM", 4, 16], ["the HPE", "PROBLEM", 34, 41], ["RT treatment group", "TREATMENT", 46, 64], ["sneezing", "PROBLEM", 73, 81], ["tracheal wet rales", "PROBLEM", 83, 101], ["mouth breathing", "PROBLEM", 103, 118], ["coughing", "PROBLEM", 120, 128], ["feather wrinkling", "PROBLEM", 130, 147], ["frequent trembling", "PROBLEM", 153, 171], ["tracheal", "ANATOMY", 83, 91], ["wet", "OBSERVATION_MODIFIER", 92, 95], ["rales", "OBSERVATION", 96, 101], ["mouth breathing", "ANATOMY", 103, 118], ["mild", "OBSERVATION_MODIFIER", 177, 181]]], ["And the trachea and kidneys of different groups of SPF chickens were conducted for histopathology assay.", [["trachea", "ANATOMY", 8, 15], ["kidneys", "ANATOMY", 20, 27], ["trachea", "MULTI-TISSUE_STRUCTURE", 8, 15], ["kidneys", "ORGAN", 20, 27], ["chickens", "ORGANISM", 55, 63], ["chickens", "SPECIES", 55, 63], ["SPF", "SPECIES", 51, 54], ["chickens", "SPECIES", 55, 63], ["SPF chickens", "TREATMENT", 51, 63], ["histopathology assay", "TEST", 83, 103], ["trachea", "ANATOMY", 8, 15], ["kidneys", "ANATOMY", 20, 27], ["different", "OBSERVATION_MODIFIER", 31, 40], ["groups", "OBSERVATION_MODIFIER", 41, 47], ["SPF chickens", "OBSERVATION", 51, 63]]], ["As can be seen fromFigure 6, most of the tracheal cilia in the IBV infected group fell off, the mucosal epithelial cells exfoliated and disappeared, the submucosal structure was loosely arranged, and there was a certain amount of serous exudation, inflammatory cells, and red blood cells.", [["tracheal cilia", "ANATOMY", 41, 55], ["mucosal epithelial cells", "ANATOMY", 96, 120], ["submucosal structure", "ANATOMY", 153, 173], ["serous", "ANATOMY", 230, 236], ["inflammatory cells", "ANATOMY", 248, 266], ["red blood cells", "ANATOMY", 272, 287], ["tracheal cilia", "MULTI-TISSUE_STRUCTURE", 41, 55], ["IBV", "ORGANISM", 63, 66], ["mucosal epithelial cells", "CELL", 96, 120], ["submucosal structure", "MULTI-TISSUE_STRUCTURE", 153, 173], ["serous", "ORGANISM_SUBSTANCE", 230, 236], ["inflammatory cells", "CELL", 248, 266], ["red blood cells", "CELL", 272, 287], ["mucosal epithelial cells", "CELL_TYPE", 96, 120], ["inflammatory cells", "CELL_TYPE", 248, 266], ["red blood cells", "CELL_TYPE", 272, 287], ["IBV", "SPECIES", 63, 66], ["the mucosal epithelial cells", "PROBLEM", 92, 120], ["serous exudation", "PROBLEM", 230, 246], ["inflammatory cells", "PROBLEM", 248, 266], ["red blood cells", "TEST", 272, 287], ["tracheal cilia", "ANATOMY", 41, 55], ["IBV", "OBSERVATION_MODIFIER", 63, 66], ["infected", "OBSERVATION", 67, 75], ["mucosal", "ANATOMY", 96, 103], ["epithelial cells", "OBSERVATION", 104, 120], ["submucosal", "ANATOMY", 153, 163], ["amount", "OBSERVATION_MODIFIER", 220, 226], ["serous", "OBSERVATION_MODIFIER", 230, 236], ["exudation", "OBSERVATION", 237, 246], ["inflammatory cells", "OBSERVATION", 248, 266], ["red blood cells", "OBSERVATION", 272, 287]]], ["In the HPE treatment group, with the gradual increase of the dosage, the shedding of tracheal cilia and epithelial cells was gradually decreased, there were a small number of inflammatory cells and erythrocytes, and the exudation of inflammatory serous fluid decreased.Effect of Hypericum perforatum Ethyl Acetate on Pathological Injury of Trachea and Kidney Caused by Infectious Bronchitis Virus ::: Antiviral Effect of Hypericum perforatum Ethyl Acetate In Vivo::: ResultsAs shown in Figure 7, in the IBV infected group, a large number of renal tubular epithelial cells were degenerated and necrotic, the nucleus were concentrated, fragmented and dissolved, the renal tubular epithelial cells fell off into the lumen, dissolved or disappeared, the structure of renal tubules was incomplete, and there were a certain number of inflammatory cells and red blood cells in the interstitium.", [["tracheal cilia", "ANATOMY", 85, 99], ["epithelial cells", "ANATOMY", 104, 120], ["inflammatory cells", "ANATOMY", 175, 193], ["erythrocytes", "ANATOMY", 198, 210], ["inflammatory serous fluid", "ANATOMY", 233, 258], ["Kidney", "ANATOMY", 352, 358], ["renal tubular epithelial cells", "ANATOMY", 541, 571], ["nucleus", "ANATOMY", 607, 614], ["renal tubular epithelial cells", "ANATOMY", 664, 694], ["lumen", "ANATOMY", 713, 718], ["renal tubules", "ANATOMY", 763, 776], ["inflammatory cells", "ANATOMY", 828, 846], ["red blood cells", "ANATOMY", 851, 866], ["interstitium", "ANATOMY", 874, 886], ["HPE", "DISEASE", 7, 10], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 279, 313], ["Injury of Trachea", "DISEASE", 330, 347], ["Infectious Bronchitis Virus", "DISEASE", 369, 396], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 421, 455], ["IBV infected", "DISEASE", 503, 515], ["necrotic", "DISEASE", 593, 601], ["Ethyl Acetate", "CHEMICAL", 300, 313], ["Ethyl Acetate", "CHEMICAL", 442, 455], ["tracheal cilia", "CELL", 85, 99], ["epithelial cells", "CELL", 104, 120], ["inflammatory cells", "CELL", 175, 193], ["erythrocytes", "CELL", 198, 210], ["serous fluid", "ORGANISM_SUBSTANCE", 246, 258], ["Hypericum perforatum", "ORGANISM", 279, 299], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 300, 313], ["Kidney", "ORGAN", 352, 358], ["Hypericum perforatum", "ORGANISM", 421, 441], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 442, 455], ["IBV", "ORGANISM", 503, 506], ["renal tubular epithelial cells", "CELL", 541, 571], ["nucleus", "CELLULAR_COMPONENT", 607, 614], ["renal tubular epithelial cells", "CELL", 664, 694], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 713, 718], ["renal tubules", "MULTI-TISSUE_STRUCTURE", 763, 776], ["inflammatory cells", "CELL", 828, 846], ["red blood cells", "CELL", 851, 866], ["interstitium", "TISSUE", 874, 886], ["tracheal cilia", "CELL_TYPE", 85, 99], ["epithelial cells", "CELL_TYPE", 104, 120], ["inflammatory cells", "CELL_TYPE", 175, 193], ["erythrocytes", "CELL_TYPE", 198, 210], ["renal tubular epithelial cells", "CELL_TYPE", 541, 571], ["renal tubular epithelial cells", "CELL_TYPE", 664, 694], ["inflammatory cells", "CELL_TYPE", 828, 846], ["red blood cells", "CELL_TYPE", 851, 866], ["Hypericum perforatum", "SPECIES", 279, 299], ["Hypericum perforatum", "SPECIES", 421, 441], ["Hypericum perforatum", "SPECIES", 279, 299], ["Infectious Bronchitis Virus", "SPECIES", 369, 396], ["Hypericum perforatum", "SPECIES", 421, 441], ["IBV", "SPECIES", 503, 506], ["the dosage", "TREATMENT", 57, 67], ["epithelial cells", "PROBLEM", 104, 120], ["inflammatory cells", "PROBLEM", 175, 193], ["erythrocytes", "PROBLEM", 198, 210], ["inflammatory serous fluid", "PROBLEM", 233, 258], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 279, 313], ["Pathological Injury of Trachea and Kidney", "PROBLEM", 317, 358], ["Infectious Bronchitis Virus", "PROBLEM", 369, 396], ["Antiviral Effect", "TREATMENT", 401, 417], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 421, 455], ["renal tubular epithelial cells", "PROBLEM", 541, 571], ["necrotic", "PROBLEM", 593, 601], ["the renal tubular epithelial cells", "PROBLEM", 660, 694], ["inflammatory cells", "PROBLEM", 828, 846], ["red blood cells", "TEST", 851, 866], ["HPE", "OBSERVATION_MODIFIER", 7, 10], ["treatment", "OBSERVATION", 11, 20], ["gradual", "OBSERVATION_MODIFIER", 37, 44], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["tracheal cilia", "ANATOMY", 85, 99], ["epithelial cells", "OBSERVATION", 104, 120], ["gradually", "OBSERVATION_MODIFIER", 125, 134], ["decreased", "OBSERVATION_MODIFIER", 135, 144], ["small", "OBSERVATION_MODIFIER", 159, 164], ["number", "OBSERVATION_MODIFIER", 165, 171], ["inflammatory cells", "OBSERVATION", 175, 193], ["erythrocytes", "ANATOMY", 198, 210], ["exudation", "OBSERVATION_MODIFIER", 220, 229], ["inflammatory", "OBSERVATION_MODIFIER", 233, 245], ["serous", "OBSERVATION_MODIFIER", 246, 252], ["fluid", "OBSERVATION", 253, 258], ["decreased", "OBSERVATION_MODIFIER", 259, 268], ["Hypericum", "OBSERVATION_MODIFIER", 279, 288], ["perforatum", "OBSERVATION_MODIFIER", 289, 299], ["Injury", "OBSERVATION", 330, 336], ["Trachea", "ANATOMY", 340, 347], ["Kidney", "ANATOMY", 352, 358], ["Infectious", "OBSERVATION", 369, 379], ["Hypericum", "OBSERVATION_MODIFIER", 421, 430], ["infected", "OBSERVATION", 507, 515], ["large", "OBSERVATION_MODIFIER", 525, 530], ["number", "OBSERVATION_MODIFIER", 531, 537], ["renal", "ANATOMY", 541, 546], ["tubular", "ANATOMY_MODIFIER", 547, 554], ["epithelial cells", "OBSERVATION", 555, 571], ["necrotic", "OBSERVATION_MODIFIER", 593, 601], ["nucleus", "ANATOMY", 607, 614], ["concentrated", "OBSERVATION_MODIFIER", 620, 632], ["fragmented", "OBSERVATION_MODIFIER", 634, 644], ["dissolved", "OBSERVATION_MODIFIER", 649, 658], ["renal", "ANATOMY", 664, 669], ["tubular", "ANATOMY_MODIFIER", 670, 677], ["epithelial cells", "OBSERVATION", 678, 694], ["lumen", "ANATOMY_MODIFIER", 713, 718], ["dissolved", "OBSERVATION_MODIFIER", 720, 729], ["renal tubules", "ANATOMY", 763, 776], ["incomplete", "OBSERVATION", 781, 791], ["certain", "OBSERVATION_MODIFIER", 810, 817], ["number", "OBSERVATION_MODIFIER", 818, 824], ["inflammatory cells", "OBSERVATION", 828, 846], ["red blood cells", "OBSERVATION", 851, 866], ["interstitium", "ANATOMY", 874, 886]]], ["The wall of renal capsule was ruptured and a certain amount of inflammatory cells and serous exudation could be seen in the lumen of renal capsule.", [["wall", "ANATOMY", 4, 8], ["renal capsule", "ANATOMY", 12, 25], ["inflammatory cells", "ANATOMY", 63, 81], ["serous", "ANATOMY", 86, 92], ["lumen", "ANATOMY", 124, 129], ["renal capsule", "ANATOMY", 133, 146], ["wall", "TISSUE", 4, 8], ["renal capsule", "CANCER", 12, 25], ["inflammatory cells", "CELL", 63, 81], ["serous", "ORGANISM_SUBSTANCE", 86, 92], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 129], ["renal capsule", "CANCER", 133, 146], ["inflammatory cells", "CELL_TYPE", 63, 81], ["ruptured", "PROBLEM", 30, 38], ["inflammatory cells", "PROBLEM", 63, 81], ["serous exudation", "PROBLEM", 86, 102], ["wall", "ANATOMY_MODIFIER", 4, 8], ["renal capsule", "ANATOMY", 12, 25], ["ruptured", "OBSERVATION", 30, 38], ["certain", "OBSERVATION_MODIFIER", 45, 52], ["amount", "OBSERVATION_MODIFIER", 53, 59], ["inflammatory cells", "OBSERVATION", 63, 81], ["serous exudation", "OBSERVATION", 86, 102], ["lumen", "ANATOMY_MODIFIER", 124, 129], ["renal", "ANATOMY", 133, 138], ["capsule", "ANATOMY_MODIFIER", 139, 146]]], ["In the HPE treatment group, with the increase of the dosage, the exfoliation and dissolution of renal tubular epithelial cells decreased gradually, the structure of renal tubule was gradually complete, the number of red blood cells and inflammatory cells in the stroma was less, and the structure of renal capsule wall was more complete.", [["renal tubular epithelial cells", "ANATOMY", 96, 126], ["renal tubule", "ANATOMY", 165, 177], ["red blood cells", "ANATOMY", 216, 231], ["inflammatory cells", "ANATOMY", 236, 254], ["stroma", "ANATOMY", 262, 268], ["renal capsule wall", "ANATOMY", 300, 318], ["HPE", "DISEASE", 7, 10], ["exfoliation", "DISEASE", 65, 76], ["renal tubular epithelial cells", "CELL", 96, 126], ["renal tubule", "MULTI-TISSUE_STRUCTURE", 165, 177], ["red blood cells", "CELL", 216, 231], ["inflammatory cells", "CELL", 236, 254], ["stroma", "TISSUE", 262, 268], ["renal capsule wall", "MULTI-TISSUE_STRUCTURE", 300, 318], ["renal tubular epithelial cells", "CELL_TYPE", 96, 126], ["red blood cells", "CELL_TYPE", 216, 231], ["inflammatory cells", "CELL_TYPE", 236, 254], ["the dosage", "TREATMENT", 49, 59], ["the exfoliation", "PROBLEM", 61, 76], ["renal tubular epithelial cells", "PROBLEM", 96, 126], ["red blood cells", "TEST", 216, 231], ["inflammatory cells in the stroma", "PROBLEM", 236, 268], ["HPE", "OBSERVATION_MODIFIER", 7, 10], ["treatment", "OBSERVATION", 11, 20], ["renal", "ANATOMY", 96, 101], ["tubular", "ANATOMY_MODIFIER", 102, 109], ["epithelial cells", "OBSERVATION", 110, 126], ["decreased", "OBSERVATION_MODIFIER", 127, 136], ["renal tubule", "ANATOMY", 165, 177], ["gradually", "OBSERVATION_MODIFIER", 182, 191], ["complete", "OBSERVATION_MODIFIER", 192, 200], ["red blood cells", "OBSERVATION", 216, 231], ["inflammatory cells", "OBSERVATION", 236, 254], ["stroma", "ANATOMY", 262, 268], ["less", "OBSERVATION_MODIFIER", 273, 277], ["renal", "ANATOMY", 300, 305], ["capsule", "ANATOMY_MODIFIER", 306, 313], ["wall", "ANATOMY_MODIFIER", 314, 318]]], ["There was little infiltration of inflammatory cells in the renal vesicle cavity.Effect of Hypericum perforatum Ethyl Acetate on Pathological Injury of Trachea and Kidney Caused by Infectious Bronchitis Virus ::: Antiviral Effect of Hypericum perforatum Ethyl Acetate In Vivo::: ResultsAs can be seen from Tables 2 and 3, the pathological scores of trachea and kidney in IBV group were highly significantly higher than those in NC group (p < 0.01).", [["inflammatory cells", "ANATOMY", 33, 51], ["renal vesicle", "ANATOMY", 59, 72], ["Kidney", "ANATOMY", 163, 169], ["trachea", "ANATOMY", 348, 355], ["kidney", "ANATOMY", 360, 366], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 90, 124], ["Injury of Trachea", "DISEASE", 141, 158], ["Infectious Bronchitis Virus", "DISEASE", 180, 207], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 232, 266], ["Ethyl Acetate", "CHEMICAL", 111, 124], ["Ethyl Acetate", "CHEMICAL", 253, 266], ["inflammatory cells", "CELL", 33, 51], ["renal vesicle cavity", "MULTI-TISSUE_STRUCTURE", 59, 79], ["Hypericum perforatum", "ORGANISM", 90, 110], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 111, 124], ["Kidney", "ORGAN", 163, 169], ["Hypericum perforatum", "ORGANISM", 232, 252], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 253, 266], ["trachea", "MULTI-TISSUE_STRUCTURE", 348, 355], ["kidney", "ORGAN", 360, 366], ["IBV", "ORGANISM", 370, 373], ["inflammatory cells", "CELL_TYPE", 33, 51], ["Hypericum perforatum", "SPECIES", 90, 110], ["Hypericum perforatum", "SPECIES", 232, 252], ["Hypericum perforatum", "SPECIES", 90, 110], ["Infectious Bronchitis Virus", "SPECIES", 180, 207], ["Hypericum perforatum", "SPECIES", 232, 252], ["IBV", "SPECIES", 370, 373], ["little infiltration of inflammatory cells in the renal vesicle cavity", "PROBLEM", 10, 79], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 90, 124], ["Pathological Injury of Trachea and Kidney", "PROBLEM", 128, 169], ["Infectious Bronchitis Virus", "PROBLEM", 180, 207], ["Antiviral Effect", "TREATMENT", 212, 228], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 232, 266], ["little", "OBSERVATION_MODIFIER", 10, 16], ["infiltration", "OBSERVATION", 17, 29], ["inflammatory cells", "OBSERVATION", 33, 51], ["renal vesicle", "ANATOMY", 59, 72], ["cavity", "ANATOMY_MODIFIER", 73, 79], ["Hypericum", "OBSERVATION_MODIFIER", 90, 99], ["perforatum", "OBSERVATION_MODIFIER", 100, 110], ["Injury", "OBSERVATION", 141, 147], ["Trachea", "ANATOMY", 151, 158], ["Kidney", "ANATOMY", 163, 169], ["Infectious", "OBSERVATION", 180, 190], ["Hypericum", "OBSERVATION_MODIFIER", 232, 241], ["trachea", "ANATOMY", 348, 355], ["kidney", "ANATOMY", 360, 366], ["IBV", "OBSERVATION", 370, 373], ["significantly", "OBSERVATION_MODIFIER", 392, 405], ["higher", "OBSERVATION_MODIFIER", 406, 412]]], ["Compared with the IBV group, the pathological scores of trachea and kidney in the HPE-TH group and the HPE-TM group decreased highly significantly (p < 0.01), and the score was similar to that of the RT group.", [["trachea", "ANATOMY", 56, 63], ["kidney", "ANATOMY", 68, 74], ["HPE", "DISEASE", 82, 85], ["HPE", "DISEASE", 103, 106], ["IBV", "ORGANISM", 18, 21], ["trachea", "MULTI-TISSUE_STRUCTURE", 56, 63], ["kidney", "ORGAN", 68, 74], ["IBV", "SPECIES", 18, 21], ["the HPE", "TEST", 99, 106], ["pathological", "OBSERVATION", 33, 45], ["trachea", "ANATOMY", 56, 63], ["kidney", "ANATOMY", 68, 74], ["HPE", "OBSERVATION_MODIFIER", 82, 85], ["TH group", "ANATOMY_MODIFIER", 86, 94], ["HPE", "OBSERVATION_MODIFIER", 103, 106], ["TM", "ANATOMY_MODIFIER", 107, 109], ["decreased", "OBSERVATION_MODIFIER", 116, 125], ["highly", "OBSERVATION_MODIFIER", 126, 132], ["significantly", "OBSERVATION_MODIFIER", 133, 146]]], ["At the same time, with the increase of HPE dose, the score decreased in a dose-dependent manner.", [["HPE", "DISEASE", 39, 42], ["HPE dose", "TREATMENT", 39, 47], ["the score", "TEST", 49, 58]]], ["This indicated that HPE had better anti-IBV effect.The Effect of Hypericum perforatum Ethyl Acetate on the Relative Messenger Ribonucleic Acid Expression of IBV in Trachea and Kidney ::: ResultsTo confirm the inhibitory effect of HPE, IBV mRNA levels in trachea and kidney of different groups were measured by real-time qRT-PCR.", [["Kidney", "ANATOMY", 176, 182], ["trachea", "ANATOMY", 254, 261], ["kidney", "ANATOMY", 266, 272], ["HPE", "DISEASE", 20, 23], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 65, 99], ["Ribonucleic Acid", "CHEMICAL", 126, 142], ["Ethyl Acetate", "CHEMICAL", 86, 99], ["anti-IBV", "CANCER", 35, 43], ["Hypericum perforatum", "ORGANISM", 65, 85], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 86, 99], ["IBV", "ORGANISM", 157, 160], ["Kidney", "ORGAN", 176, 182], ["IBV", "ORGANISM", 235, 238], ["trachea", "MULTI-TISSUE_STRUCTURE", 254, 261], ["kidney", "ORGAN", 266, 272], ["IBV mRNA", "RNA", 235, 243], ["Hypericum perforatum", "SPECIES", 65, 85], ["Hypericum perforatum", "SPECIES", 65, 85], ["IBV", "SPECIES", 235, 238], ["HPE", "PROBLEM", 20, 23], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 65, 99], ["the Relative Messenger Ribonucleic Acid Expression", "TREATMENT", 103, 153], ["HPE", "PROBLEM", 230, 233], ["IBV mRNA levels", "TEST", 235, 250], ["PCR", "TEST", 324, 327], ["Hypericum", "OBSERVATION_MODIFIER", 65, 74], ["Ribonucleic Acid", "OBSERVATION", 126, 142], ["Trachea", "ANATOMY", 164, 171], ["Kidney", "ANATOMY", 176, 182], ["trachea", "ANATOMY", 254, 261], ["kidney", "ANATOMY", 266, 272]]], ["As shown inFigure 8, Compared with NC group, the expression level of mRNA in trachea and kidney of SPF chicks infected with IBV increased significantly.", [["trachea", "ANATOMY", 77, 84], ["kidney", "ANATOMY", 89, 95], ["trachea", "MULTI-TISSUE_STRUCTURE", 77, 84], ["kidney", "ORGAN", 89, 95], ["SPF chicks", "ORGANISM", 99, 109], ["IBV", "ORGANISM", 124, 127], ["mRNA", "RNA", 69, 73], ["SPF", "SPECIES", 99, 102], ["IBV", "SPECIES", 124, 127], ["mRNA in trachea", "PROBLEM", 69, 84], ["SPF chicks infected", "PROBLEM", 99, 118], ["IBV", "PROBLEM", 124, 127], ["trachea", "ANATOMY", 77, 84], ["kidney", "ANATOMY", 89, 95], ["SPF chicks", "OBSERVATION_MODIFIER", 99, 109], ["infected", "OBSERVATION", 110, 118], ["IBV", "OBSERVATION_MODIFIER", 124, 127], ["increased", "OBSERVATION_MODIFIER", 128, 137], ["significantly", "OBSERVATION_MODIFIER", 138, 151]]], ["Compared with IBV group, the expression level of mRNA in trachea and kidney of SPF chicks treated with HPE decreased significantly.", [["trachea", "ANATOMY", 57, 64], ["kidney", "ANATOMY", 69, 75], ["IBV", "ORGANISM", 14, 17], ["trachea", "MULTI-TISSUE_STRUCTURE", 57, 64], ["kidney", "ORGAN", 69, 75], ["mRNA", "RNA", 49, 53], ["IBV", "SPECIES", 14, 17], ["SPF", "SPECIES", 79, 82], ["mRNA in trachea", "PROBLEM", 49, 64], ["SPF chicks", "TREATMENT", 79, 89], ["HPE", "PROBLEM", 103, 106], ["trachea", "ANATOMY", 57, 64], ["kidney", "ANATOMY", 69, 75], ["SPF chicks", "OBSERVATION", 79, 89], ["decreased", "OBSERVATION_MODIFIER", 107, 116]]], ["With the decrease of HPE concentration, the expression level of mRNA increased in a dose-dependent manner.", [["HPE", "SIMPLE_CHEMICAL", 21, 24], ["mRNA", "RNA", 64, 68], ["HPE concentration", "TREATMENT", 21, 38], ["decrease", "OBSERVATION_MODIFIER", 9, 17], ["HPE", "OBSERVATION_MODIFIER", 21, 24], ["concentration", "OBSERVATION_MODIFIER", 25, 38], ["increased", "OBSERVATION_MODIFIER", 69, 78]]], ["With the increase of the days of IBV infection, the effect of HPE-TH and HPE-TM group on the level of mRNA expression was similar to that of RT group.", [["IBV infection", "DISEASE", 33, 46], ["HPE-TH", "CHEMICAL", 62, 68], ["IBV", "ORGANISM", 33, 36], ["HPE-TH", "GENE_OR_GENE_PRODUCT", 62, 68], ["HPE-TM", "GENE_OR_GENE_PRODUCT", 73, 79], ["IBV", "SPECIES", 33, 36], ["IBV infection", "PROBLEM", 33, 46], ["HPE", "TEST", 62, 65], ["HPE", "TEST", 73, 76], ["mRNA expression", "PROBLEM", 102, 117], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["infection", "OBSERVATION", 37, 46]]], ["These data indicated that infected chickens treated with HPE exhibited an overall reduction in viral mRNA levels.Effect of Hypericum perforatum Ethyl Acetate on the Messenger Ribonucleic Acid Expression Level of Gene in the Trachea and Kidney ::: ResultsIt is well known that type I interferon, including IFN-\u03b1 and IFN-\u03b2, plays a very important role in antiviral activity.", [["Kidney", "ANATOMY", 236, 242], ["HPE", "CHEMICAL", 57, 60], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 123, 157], ["Ethyl Acetate", "CHEMICAL", 144, 157], ["chickens", "ORGANISM", 35, 43], ["Hypericum perforatum", "ORGANISM", 123, 143], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 144, 157], ["Kidney", "ORGAN", 236, 242], ["type I interferon", "GENE_OR_GENE_PRODUCT", 276, 293], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 305, 310], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 315, 320], ["viral mRNA", "RNA", 95, 105], ["type I interferon", "PROTEIN", 276, 293], ["IFN", "PROTEIN", 305, 308], ["IFN", "PROTEIN", 315, 318], ["\u03b2", "PROTEIN", 319, 320], ["chickens", "SPECIES", 35, 43], ["Hypericum perforatum", "SPECIES", 123, 143], ["chickens", "SPECIES", 35, 43], ["Hypericum perforatum", "SPECIES", 123, 143], ["infected chickens", "PROBLEM", 26, 43], ["HPE", "PROBLEM", 57, 60], ["an overall reduction in viral mRNA levels", "PROBLEM", 71, 112], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 123, 157], ["the Messenger Ribonucleic Acid Expression", "TEST", 161, 202], ["type I interferon", "TREATMENT", 276, 293], ["infected", "OBSERVATION_MODIFIER", 26, 34], ["overall", "OBSERVATION_MODIFIER", 74, 81], ["reduction", "OBSERVATION_MODIFIER", 82, 91], ["viral mRNA", "OBSERVATION", 95, 105], ["Hypericum", "OBSERVATION_MODIFIER", 123, 132], ["perforatum", "OBSERVATION_MODIFIER", 133, 143], ["Trachea", "ANATOMY", 224, 231], ["Kidney", "ANATOMY", 236, 242], ["antiviral activity", "OBSERVATION", 353, 371]]], ["As can be seen fromFigures 9 and 10, the relative mRNA expression of IL-6, TNF-\u03b1, IFN-\u03b1, IFN-\u03b2, MDA5, MAVS, and NF-\u03baB in the trachea and kidney were up-regulated after IBV infection, which was consistent with previous studies (He et al., 2016; Chhabra et al., 2018).", [["trachea", "ANATOMY", 125, 132], ["kidney", "ANATOMY", 137, 143], ["IBV infection", "DISEASE", 168, 181], ["IL-6", "GENE_OR_GENE_PRODUCT", 69, 73], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 75, 80], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 82, 87], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 89, 94], ["MDA5", "GENE_OR_GENE_PRODUCT", 96, 100], ["MAVS", "GENE_OR_GENE_PRODUCT", 102, 106], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 112, 117], ["trachea", "ORGAN", 125, 132], ["kidney", "ORGAN", 137, 143], ["IBV", "ORGANISM", 168, 171], ["IL-6", "PROTEIN", 69, 73], ["TNF", "PROTEIN", 75, 78], ["IFN", "PROTEIN", 82, 85], ["IFN", "PROTEIN", 89, 92], ["\u03b2", "PROTEIN", 93, 94], ["MDA5", "PROTEIN", 96, 100], ["MAVS", "PROTEIN", 102, 106], ["NF-\u03baB", "PROTEIN", 112, 117], ["IBV", "SPECIES", 168, 171], ["IL", "TEST", 69, 71], ["TNF", "TEST", 75, 78], ["\u03b1", "TEST", 79, 80], ["IFN", "TEST", 82, 85], ["\u03b1", "TEST", 86, 87], ["IFN", "TEST", 89, 92], ["MDA5", "TEST", 96, 100], ["MAVS", "TEST", 102, 106], ["NF", "TEST", 112, 114], ["IBV infection", "PROBLEM", 168, 181], ["previous studies", "TEST", 209, 225], ["MDA5", "ANATOMY", 96, 100], ["trachea", "ANATOMY", 125, 132], ["kidney", "ANATOMY", 137, 143], ["infection", "OBSERVATION", 172, 181], ["consistent with", "UNCERTAINTY", 193, 208]]], ["In HPE treatment group, the mRNA expression levels of IFN-\u03b1 and IFN-\u03b2 in the trachea were up-regulated in the early stage of IBV infection, and the changes of IFN-\u03b1 and IFN-\u03b2 were consistent with the mRNA expression of MDA5 and MAVS in the trachea.", [["trachea", "ANATOMY", 77, 84], ["trachea", "ANATOMY", 240, 247], ["HPE", "DISEASE", 3, 6], ["IBV infection", "DISEASE", 125, 138], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 54, 59], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 64, 69], ["trachea", "ORGAN", 77, 84], ["IBV", "ORGANISM", 125, 128], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 159, 164], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 169, 174], ["MDA5", "GENE_OR_GENE_PRODUCT", 219, 223], ["MAVS", "GENE_OR_GENE_PRODUCT", 228, 232], ["trachea", "ORGAN", 240, 247], ["IFN", "PROTEIN", 54, 57], ["IFN-\u03b2", "PROTEIN", 64, 69], ["IFN", "PROTEIN", 159, 162], ["IFN", "PROTEIN", 169, 172], ["MDA5", "PROTEIN", 219, 223], ["MAVS", "PROTEIN", 228, 232], ["IBV", "SPECIES", 125, 128], ["HPE treatment group", "TREATMENT", 3, 22], ["the mRNA expression levels", "TEST", 24, 50], ["IFN", "TEST", 54, 57], ["IFN", "TEST", 64, 67], ["IBV infection", "PROBLEM", 125, 138], ["IFN", "TEST", 159, 162], ["IFN", "TEST", 169, 172], ["the mRNA expression of MDA5", "PROBLEM", 196, 223], ["MAVS in the trachea", "PROBLEM", 228, 247], ["trachea", "ANATOMY", 77, 84], ["early stage", "OBSERVATION_MODIFIER", 110, 121], ["IBV", "OBSERVATION_MODIFIER", 125, 128], ["infection", "OBSERVATION", 129, 138], ["consistent with", "UNCERTAINTY", 180, 195], ["MDA5", "OBSERVATION", 219, 223], ["trachea", "ANATOMY", 240, 247]]], ["Meanwhile, in the HPE-treated group, the mRNA expression levels of IFN-\u03b1 and IFN-\u03b2 in the kidney were up-regulated in the late stage of IBV infection.", [["kidney", "ANATOMY", 90, 96], ["HPE", "DISEASE", 18, 21], ["IBV infection", "DISEASE", 136, 149], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 67, 72], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 77, 82], ["kidney", "ORGAN", 90, 96], ["IBV", "ORGANISM", 136, 139], ["IFN", "PROTEIN", 67, 70], ["IFN-\u03b2", "PROTEIN", 77, 82], ["IBV", "SPECIES", 136, 139], ["the mRNA expression levels", "TEST", 37, 63], ["IFN", "TEST", 67, 70], ["IFN", "TEST", 77, 80], ["IBV infection", "PROBLEM", 136, 149], ["kidney", "ANATOMY", 90, 96], ["late stage", "OBSERVATION_MODIFIER", 122, 132], ["IBV", "OBSERVATION_MODIFIER", 136, 139], ["infection", "OBSERVATION", 140, 149]]], ["In addition, the changes of IFN-\u03b1 and IFN-\u03b2 were similar to the mRNA expression levels of MDA5 and MAVS in the kidney.", [["kidney", "ANATOMY", 111, 117], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 28, 33], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 38, 43], ["MDA5", "GENE_OR_GENE_PRODUCT", 90, 94], ["MAVS", "GENE_OR_GENE_PRODUCT", 99, 103], ["kidney", "ORGAN", 111, 117], ["IFN", "PROTEIN", 28, 31], ["IFN-\u03b2", "PROTEIN", 38, 43], ["MDA5", "PROTEIN", 90, 94], ["MAVS", "PROTEIN", 99, 103], ["IFN", "TEST", 28, 31], ["IFN", "TEST", 38, 41], ["the mRNA expression levels of MDA5 and MAVS in the kidney", "PROBLEM", 60, 117], ["MAVS", "OBSERVATION", 99, 103], ["kidney", "ANATOMY", 111, 117]]], ["These data suggested that HPE may up-regulate mRNA expression levels of IFN-\u03b1 and IFN-\u03b2 in trachea and kidney via the MDA5 signaling pathway.Effect of Hypericum perforatum Ethyl Acetate on the Messenger Ribonucleic Acid Expression Level of Gene in the Trachea and Kidney ::: ResultsAt the same time, it is well known that inflammatory factors play an important role in inflammation.", [["trachea", "ANATOMY", 91, 98], ["kidney", "ANATOMY", 103, 109], ["Kidney", "ANATOMY", 264, 270], ["HPE", "DISEASE", 26, 29], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 151, 185], ["inflammation", "DISEASE", 369, 381], ["Ethyl Acetate", "CHEMICAL", 172, 185], ["HPE", "SIMPLE_CHEMICAL", 26, 29], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 82, 87], ["trachea", "ORGAN", 91, 98], ["kidney", "ORGAN", 103, 109], ["MDA5", "GENE_OR_GENE_PRODUCT", 118, 122], ["Hypericum perforatum", "ORGANISM", 151, 171], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 172, 185], ["Kidney", "ORGAN", 264, 270], ["IFN", "PROTEIN", 72, 75], ["IFN-\u03b2", "PROTEIN", 82, 87], ["MDA5", "PROTEIN", 118, 122], ["inflammatory factors", "PROTEIN", 322, 342], ["Hypericum perforatum", "SPECIES", 151, 171], ["Hypericum perforatum", "SPECIES", 151, 171], ["HPE", "PROBLEM", 26, 29], ["IFN", "TEST", 72, 75], ["IFN", "TEST", 82, 85], ["Hypericum perforatum Ethyl Acetate", "TREATMENT", 151, 185], ["the Messenger Ribonucleic Acid Expression", "TEST", 189, 230], ["inflammatory factors", "PROBLEM", 322, 342], ["inflammation", "PROBLEM", 369, 381], ["trachea", "ANATOMY", 91, 98], ["kidney", "ANATOMY", 103, 109], ["Hypericum", "OBSERVATION_MODIFIER", 151, 160], ["perforatum", "OBSERVATION_MODIFIER", 161, 171], ["Trachea", "ANATOMY", 252, 259], ["Kidney", "ANATOMY", 264, 270], ["inflammatory", "OBSERVATION", 322, 334], ["inflammation", "OBSERVATION", 369, 381]]], ["It also plays a very important role in IBV infection.", [["IBV infection", "DISEASE", 39, 52], ["IBV", "ORGANISM", 39, 42], ["IBV", "SPECIES", 39, 42], ["IBV infection", "PROBLEM", 39, 52], ["IBV", "OBSERVATION_MODIFIER", 39, 42], ["infection", "OBSERVATION", 43, 52]]], ["As can be seen from Figures 8 and9, in the HPE-treated group, the mRNA expression levels of IL-6 and TNF-\u03b1 in the trachea and kidney were down-regulated, and the changes were consistent to NF-\u03baB mRNA expression levels, indicating that HPE may be down-regulated the mRNA expression levels of IL-6 and TNF-\u03b1 by NF-\u03baB signaling pathway.", [["trachea", "ANATOMY", 114, 121], ["kidney", "ANATOMY", 126, 132], ["HPE", "DISEASE", 43, 46], ["HPE", "DISEASE", 235, 238], ["IL-6", "GENE_OR_GENE_PRODUCT", 92, 96], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 101, 106], ["trachea", "MULTI-TISSUE_STRUCTURE", 114, 121], ["kidney", "ORGAN", 126, 132], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 189, 194], ["HPE", "SIMPLE_CHEMICAL", 235, 238], ["IL-6", "GENE_OR_GENE_PRODUCT", 291, 295], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 300, 305], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 309, 314], ["IL-6", "PROTEIN", 92, 96], ["TNF-\u03b1", "PROTEIN", 101, 106], ["IL-6", "PROTEIN", 291, 295], ["TNF", "PROTEIN", 300, 303], ["NF-\u03baB", "PROTEIN", 309, 314], ["Figures", "TEST", 20, 27], ["the mRNA expression levels", "TEST", 62, 88], ["IL", "TEST", 92, 94], ["TNF", "TEST", 101, 104], ["NF", "TEST", 189, 191], ["B mRNA expression levels", "PROBLEM", 193, 217], ["HPE", "PROBLEM", 235, 238], ["IL", "TEST", 291, 293], ["TNF", "TEST", 300, 303], ["trachea", "ANATOMY", 114, 121], ["kidney", "ANATOMY", 126, 132]]], ["Therefore, HPE may exert an anti-IBV effect by increasing the mRNA expression levels of type I interferon and reducing mRNA expression levels of pro-inflammatory factors IL-6 and TNF-\u03b1, and this may be related to the MDA5 signal pathway and NF-\u03baB signal pathway.High-Performance Liquid Chromatography/Electrospray Ionization\u2013Mass Spectroscopy Analysis of the Hypericum perforatum Ethyl Acetate ::: ResultsIn order to determine the structure of the main components in the HPE, the samples were analyzed by positive and negative modes using HPLC/ESI-MS.", [["samples", "ANATOMY", 480, 487], ["HPE", "DISEASE", 11, 14], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 359, 393], ["Ethyl Acetate", "CHEMICAL", 380, 393], ["type I interferon", "GENE_OR_GENE_PRODUCT", 88, 105], ["IL-6", "GENE_OR_GENE_PRODUCT", 170, 174], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 179, 184], ["MDA5", "GENE_OR_GENE_PRODUCT", 217, 221], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 241, 246], ["Hypericum perforatum", "ORGANISM", 359, 379], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 380, 393], ["type I interferon", "PROTEIN", 88, 105], ["pro-inflammatory factors", "PROTEIN", 145, 169], ["IL-6", "PROTEIN", 170, 174], ["TNF", "PROTEIN", 179, 182], ["MDA5", "PROTEIN", 217, 221], ["NF-\u03baB", "PROTEIN", 241, 246], ["Hypericum perforatum", "SPECIES", 359, 379], ["Hypericum perforatum", "SPECIES", 359, 379], ["HPE", "PROBLEM", 11, 14], ["an anti-IBV effect", "PROBLEM", 25, 43], ["type I interferon", "TREATMENT", 88, 105], ["pro-inflammatory factors IL", "TEST", 145, 172], ["TNF", "TEST", 179, 182], ["the MDA5 signal pathway", "TEST", 213, 236], ["NF", "TEST", 241, 243], ["High-Performance Liquid Chromatography", "TREATMENT", 262, 300], ["Electrospray Ionization", "TREATMENT", 301, 324], ["Mass Spectroscopy", "TEST", 325, 342], ["Analysis", "TEST", 343, 351], ["the samples", "TEST", 476, 487], ["HPLC", "TEST", 539, 543], ["pro-inflammatory", "OBSERVATION_MODIFIER", 145, 161], ["main", "OBSERVATION_MODIFIER", 448, 452], ["components", "OBSERVATION_MODIFIER", 453, 463], ["HPE", "OBSERVATION_MODIFIER", 471, 474]]], ["All tested components showed their HPLC chromatogram and quasi-molecular ions [(M-H)+ and (M-H)\u2212] (Figure 11).", [["H", "CHEMICAL", 82, 83], ["M-H)+", "SIMPLE_CHEMICAL", 80, 85], ["(M-H)\u2212", "SIMPLE_CHEMICAL", 90, 96], ["All tested components", "TEST", 0, 21], ["their HPLC chromatogram", "TEST", 29, 52], ["quasi-molecular ions", "TEST", 57, 77]]], ["The mass spectra of these compounds were carefully examined (Figure 12) and compared with the standard and reference data (Seger et al., 2004;Cao et al., 2011) and found to have five peaks in the HPE (Table 4).", [["HPE", "DISEASE", 196, 199], ["The mass spectra of these compounds", "PROBLEM", 0, 35], ["mass", "OBSERVATION", 4, 8], ["five", "OBSERVATION_MODIFIER", 178, 182], ["peaks", "OBSERVATION", 183, 188]]], ["These peaks corresponded to hyperoside (peak 1), quercitrin (peak 2), quercetin (peak 3), pseudohypericin (peak 4), and hypericin (peak 5).Determination of Hyperoside, Quercitrin, Quercetin, Pseudohypericin, and Hypericin in the Hypericum perforatum Ethyl Acetate ::: ResultsThe calibration curves of hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin were as followed: y = 20,579x + 25,971, y = 18,877x + 41,654, y = 250,933x\u2212272,745, y = 76,343x + 16,472, and y = 73,815x + 3,490.7, where y is peak area, x is sample concentration, and the concentration ranges were 10\u201360, 40\u2013140, 10\u201360, 1\u20136, and 6\u201336 \u03bcg/ml, respectively.", [["hyperoside", "CHEMICAL", 28, 38], ["quercitrin", "CHEMICAL", 49, 59], ["quercetin", "CHEMICAL", 70, 79], ["pseudohypericin", "CHEMICAL", 90, 105], ["hypericin", "CHEMICAL", 120, 129], ["Hyperoside", "CHEMICAL", 156, 166], ["Quercitrin", "CHEMICAL", 168, 178], ["Quercetin", "CHEMICAL", 180, 189], ["Pseudohypericin", "CHEMICAL", 191, 206], ["Hypericin", "CHEMICAL", 212, 221], ["Hypericum perforatum Ethyl Acetate", "CHEMICAL", 229, 263], ["hyperoside", "CHEMICAL", 301, 311], ["quercitrin", "CHEMICAL", 313, 323], ["quercetin", "CHEMICAL", 325, 334], ["pseudohypericin", "CHEMICAL", 336, 351], ["hypericin", "CHEMICAL", 357, 366], ["hyperoside", "CHEMICAL", 28, 38], ["quercitrin", "CHEMICAL", 49, 59], ["quercetin", "CHEMICAL", 70, 79], ["pseudohypericin", "CHEMICAL", 90, 105], ["hypericin", "CHEMICAL", 120, 129], ["Hyperoside", "CHEMICAL", 156, 166], ["Quercitrin", "CHEMICAL", 168, 178], ["Quercetin", "CHEMICAL", 180, 189], ["Pseudohypericin", "CHEMICAL", 191, 206], ["Hypericin", "CHEMICAL", 212, 221], ["Ethyl Acetate", "CHEMICAL", 250, 263], ["hyperoside", "CHEMICAL", 301, 311], ["quercitrin", "CHEMICAL", 313, 323], ["quercetin", "CHEMICAL", 325, 334], ["pseudohypericin", "CHEMICAL", 336, 351], ["hypericin", "CHEMICAL", 357, 366], ["hyperoside", "SIMPLE_CHEMICAL", 28, 38], ["quercitrin", "SIMPLE_CHEMICAL", 49, 59], ["quercetin", "SIMPLE_CHEMICAL", 70, 79], ["pseudohypericin", "SIMPLE_CHEMICAL", 90, 105], ["hypericin", "SIMPLE_CHEMICAL", 120, 129], ["Hyperoside", "SIMPLE_CHEMICAL", 156, 166], ["Quercitrin", "SIMPLE_CHEMICAL", 168, 178], ["Quercetin", "SIMPLE_CHEMICAL", 180, 189], ["Pseudohypericin", "SIMPLE_CHEMICAL", 191, 206], ["Hypericin", "SIMPLE_CHEMICAL", 212, 221], ["Hypericum perforatum", "ORGANISM", 229, 249], ["Ethyl Acetate", "SIMPLE_CHEMICAL", 250, 263], ["hyperoside", "SIMPLE_CHEMICAL", 301, 311], ["quercitrin", "SIMPLE_CHEMICAL", 313, 323], ["quercetin", "SIMPLE_CHEMICAL", 325, 334], ["pseudohypericin", "SIMPLE_CHEMICAL", 336, 351], ["hypericin", "SIMPLE_CHEMICAL", 357, 366], ["Hypericum perforatum", "SPECIES", 229, 249], ["Hypericum perforatum", "SPECIES", 229, 249], ["hyperoside (peak", "TEST", 28, 44], ["quercitrin (peak", "TEST", 49, 65], ["quercetin", "TREATMENT", 70, 79], ["pseudohypericin", "TEST", 90, 105], ["hypericin (peak", "TEST", 120, 135], ["Hyperoside", "TREATMENT", 156, 166], ["Quercitrin", "TREATMENT", 168, 178], ["Quercetin", "TREATMENT", 180, 189], ["Pseudohypericin", "TREATMENT", 191, 206], ["Hypericin", "TREATMENT", 212, 221], ["The calibration curves", "TEST", 275, 297], ["hyperoside", "TREATMENT", 301, 311], ["quercitrin", "TREATMENT", 313, 323], ["quercetin", "TREATMENT", 325, 334], ["pseudohypericin", "TREATMENT", 336, 351], ["hypericin", "TREATMENT", 357, 366], ["y", "TEST", 451, 452], ["y", "TEST", 477, 478], ["sample concentration", "TEST", 527, 547], ["the concentration ranges", "TEST", 553, 577]]], ["And the calibration curve was in accordance with a linear regression (R2 = 0.9993\u20130.9997).", [["the calibration curve", "TEST", 4, 25], ["a linear regression", "TEST", 49, 68]]], ["The LOD (S/N = 3) of hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin was in the range of 0.64 to 0.78 \u03bcg/ml.", [["hyperoside", "CHEMICAL", 21, 31], ["quercitrin", "CHEMICAL", 33, 43], ["quercetin", "CHEMICAL", 45, 54], ["pseudohypericin", "CHEMICAL", 56, 71], ["hypericin", "CHEMICAL", 77, 86], ["hyperoside", "CHEMICAL", 21, 31], ["quercitrin", "CHEMICAL", 33, 43], ["quercetin", "CHEMICAL", 45, 54], ["pseudohypericin", "CHEMICAL", 56, 71], ["hypericin", "CHEMICAL", 77, 86], ["hyperoside", "SIMPLE_CHEMICAL", 21, 31], ["quercitrin", "SIMPLE_CHEMICAL", 33, 43], ["quercetin", "SIMPLE_CHEMICAL", 45, 54], ["pseudohypericin", "SIMPLE_CHEMICAL", 56, 71], ["hypericin", "SIMPLE_CHEMICAL", 77, 86], ["The LOD (S/N", "TEST", 0, 12], ["hyperoside", "TREATMENT", 21, 31], ["quercitrin", "TREATMENT", 33, 43], ["quercetin", "TREATMENT", 45, 54], ["pseudohypericin", "TREATMENT", 56, 71], ["hypericin", "TREATMENT", 77, 86]]], ["The LOQ (S/N = 10) of hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin was in the range of 0.16 to 0.22 \u03bcg/ml.", [["LOQ", "CHEMICAL", 4, 7], ["hyperoside", "CHEMICAL", 22, 32], ["quercitrin", "CHEMICAL", 34, 44], ["quercetin", "CHEMICAL", 46, 55], ["pseudohypericin", "CHEMICAL", 57, 72], ["hypericin", "CHEMICAL", 78, 87], ["hyperoside", "CHEMICAL", 22, 32], ["quercitrin", "CHEMICAL", 34, 44], ["quercetin", "CHEMICAL", 46, 55], ["pseudohypericin", "CHEMICAL", 57, 72], ["hypericin", "CHEMICAL", 78, 87], ["hyperoside", "SIMPLE_CHEMICAL", 22, 32], ["quercitrin", "SIMPLE_CHEMICAL", 34, 44], ["quercetin", "SIMPLE_CHEMICAL", 46, 55], ["pseudohypericin", "SIMPLE_CHEMICAL", 57, 72], ["hypericin", "SIMPLE_CHEMICAL", 78, 87], ["The LOQ (S/N", "TREATMENT", 0, 12], ["hyperoside", "TREATMENT", 22, 32], ["quercitrin", "TREATMENT", 34, 44], ["quercetin", "TREATMENT", 46, 55], ["pseudohypericin", "TREATMENT", 57, 72], ["hypericin", "TREATMENT", 78, 87]]], ["By measuring the peak area and retention time of standard compounds to evaluate the intra-day and inter-day precision, their relative SD was less than 1%.", [["peak", "OBSERVATION_MODIFIER", 17, 21], ["area", "OBSERVATION_MODIFIER", 22, 26], ["retention", "OBSERVATION_MODIFIER", 31, 40]]], ["The results showed that the HPE contained 0.92% hyperoside, 1.37% quercitrin, 10.16% quercetin, 2.55% pseudohypericin, and 3.46% hypericin.DiscussionIBV has a variety of known strains, these strains continue to mutate, and more mutants continue to recombine, resulting in more diverse and complex genotypes and serotypes of IBV (Bande et al., 2015; Feng et al., 2015; Laconi et al., 2019).", [["HPE", "DISEASE", 28, 31], ["hyperoside", "CHEMICAL", 48, 58], ["quercitrin", "CHEMICAL", 66, 76], ["quercetin", "CHEMICAL", 85, 94], ["pseudohypericin", "CHEMICAL", 102, 117], ["hypericin", "CHEMICAL", 129, 138], ["DiscussionIBV", "CHEMICAL", 139, 152], ["hyperoside", "CHEMICAL", 48, 58], ["quercitrin", "CHEMICAL", 66, 76], ["quercetin", "CHEMICAL", 85, 94], ["pseudohypericin", "CHEMICAL", 102, 117], ["hypericin", "CHEMICAL", 129, 138], ["hyperoside", "SIMPLE_CHEMICAL", 48, 58], ["quercitrin", "SIMPLE_CHEMICAL", 66, 76], ["quercetin", "SIMPLE_CHEMICAL", 85, 94], ["pseudohypericin", "SIMPLE_CHEMICAL", 102, 117], ["hypericin", "SIMPLE_CHEMICAL", 129, 138], ["IBV", "ORGANISM", 324, 327], ["IBV", "SPECIES", 324, 327], ["the HPE", "TEST", 24, 31], ["hyperoside", "TEST", 48, 58], ["quercitrin", "TREATMENT", 66, 76], ["quercetin", "TREATMENT", 85, 94], ["pseudohypericin", "TREATMENT", 102, 117], ["hypericin", "TREATMENT", 129, 138], ["known strains", "PROBLEM", 170, 183], ["these strains", "PROBLEM", 185, 198]]], ["Due to the poor cross-protection of vaccines between different serotypes, it is difficult to prevent and control IBV infection.", [["IBV infection", "DISEASE", 113, 126], ["IBV", "ORGANISM", 113, 116], ["IBV", "SPECIES", 113, 116], ["vaccines", "TREATMENT", 36, 44], ["different serotypes", "PROBLEM", 53, 72], ["IBV infection", "PROBLEM", 113, 126], ["IBV", "OBSERVATION_MODIFIER", 113, 116], ["infection", "OBSERVATION", 117, 126]]], ["Therefore, development of an effective antiviral therapy is a crucial strategy for treating IBV infection.", [["IBV infection", "DISEASE", 92, 105], ["IBV", "ORGANISM", 92, 95], ["IBV", "SPECIES", 92, 95], ["an effective antiviral therapy", "TREATMENT", 26, 56], ["a crucial strategy", "TREATMENT", 60, 78], ["IBV infection", "PROBLEM", 92, 105], ["effective", "OBSERVATION_MODIFIER", 29, 38], ["antiviral therapy", "OBSERVATION", 39, 56], ["infection", "OBSERVATION", 96, 105]]], ["In this study, the anti-IBV effect of the drug was studied by three kinds of methods, qRT-PCR, determination of TCID50, and indirect immunofluorescence (IFA). qRT-PCR is a method of measuring the total amount of products after each reaction cycle with fluorescent chemicals in DNA amplification.", [["DNA", "CELLULAR_COMPONENT", 277, 280], ["this study", "TEST", 3, 13], ["methods", "TEST", 77, 84], ["qRT", "TEST", 86, 89], ["PCR", "TEST", 90, 93], ["TCID50", "TREATMENT", 112, 118], ["indirect immunofluorescence", "TEST", 124, 151], ["PCR", "TEST", 163, 166], ["the total amount of products", "TREATMENT", 192, 220], ["each reaction cycle", "TREATMENT", 227, 246], ["fluorescent chemicals", "TREATMENT", 252, 273], ["DNA amplification", "TREATMENT", 277, 294]]], ["IFA is a method to detect the presence of specific antigens in cells after the cells were treated with fluorescent-antibodies.", [["cells", "ANATOMY", 63, 68], ["cells", "ANATOMY", 79, 84], ["cells", "CELL", 63, 68], ["cells", "CELL", 79, 84], ["fluorescent-antibodies", "PROTEIN", 103, 125], ["specific antigens in cells", "PROBLEM", 42, 68], ["the cells", "PROBLEM", 75, 84], ["fluorescent-antibodies", "TEST", 103, 125]]], ["TCID50 is the amount of infection in which 50% of the cells are infected by the virus.", [["cells", "ANATOMY", 54, 59], ["infection", "DISEASE", 24, 33], ["cells", "CELL", 54, 59], ["infection", "PROBLEM", 24, 33], ["the virus", "PROBLEM", 76, 85], ["amount", "OBSERVATION_MODIFIER", 14, 20], ["infection", "OBSERVATION", 24, 33]]], ["The anti-virus effect of drugs is often detected by qRT-PCR (Schnepf et al., 2009; Li et al., 2011; Zhang et al., 2018), IFA (Xu et al., 2008; Zhang et al., 2017a) and TCID50 (Xu et al., 2008; Zhang et al., 2013) in antiviral research.", [["The anti-virus effect of drugs", "TREATMENT", 0, 30], ["antiviral research", "TREATMENT", 216, 234]]], ["And these antiviral drug reports are similar to our research, so we also used these methods to detect the anti-IBV effect of H. perforatum.", [["H. perforatum", "ORGANISM", 125, 138], ["H. perforatum", "SPECIES", 125, 138], ["H. perforatum", "SPECIES", 125, 138], ["these methods", "TREATMENT", 78, 91], ["H. perforatum", "PROBLEM", 125, 138], ["perforatum", "OBSERVATION", 128, 138]]], ["Although qRT-PCR and IFA could not detect live viral particles, they were used as a supplement in this study, and in this study we used the method of TCID50, which is a general method for the detection of live virus (Leclercq et al., 2014; Petiot et al., 2018).", [["qRT", "TEST", 9, 12], ["PCR", "TEST", 13, 16], ["IFA", "TEST", 21, 24], ["live viral particles", "PROBLEM", 42, 62], ["this study", "TEST", 98, 108], ["this study", "TEST", 117, 127], ["TCID50", "TREATMENT", 150, 156]]], ["Therefore, the results of antiviral studies in vitro are also credible in this study.", [["antiviral studies", "TEST", 26, 43], ["this study", "TEST", 74, 84]]], ["In addition, although the best way to culture IBV is to use chicken embryos or chickens, the IBV replication in CEK cells was tested in this study.", [["embryos", "ANATOMY", 68, 75], ["CEK cells", "ANATOMY", 112, 121], ["IBV", "ORGANISM", 46, 49], ["chicken", "ORGANISM", 60, 67], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 68, 75], ["chickens", "ORGANISM", 79, 87], ["IBV", "ORGANISM", 93, 96], ["CEK cells", "CELL", 112, 121], ["CEK cells", "CELL_LINE", 112, 121], ["chicken", "SPECIES", 60, 67], ["chickens", "SPECIES", 79, 87], ["IBV", "SPECIES", 46, 49], ["chicken", "SPECIES", 60, 67], ["chickens", "SPECIES", 79, 87], ["IBV", "SPECIES", 93, 96], ["culture IBV", "TREATMENT", 38, 49], ["chicken embryos", "TREATMENT", 60, 75], ["chickens", "TREATMENT", 79, 87], ["the IBV replication in CEK cells", "TREATMENT", 89, 121], ["this study", "TEST", 136, 146]]], ["Because if the virus doesn\u2019t replicate well, viral particles can also be reduced or even die, which in turn affects the antiviral effect of the drug.", [["the virus", "PROBLEM", 11, 20], ["viral particles", "PROBLEM", 45, 60], ["the drug", "TREATMENT", 140, 148], ["antiviral effect", "OBSERVATION", 120, 136]]], ["In this study, we showed that IBV can replicate well in CEK cells (Figure 2), which is consistent with the research report (Zhang et al., 2018), and HPE had potential utility as antiviral agents against IBV.", [["CEK cells", "ANATOMY", 56, 65], ["HPE", "DISEASE", 149, 152], ["IBV", "ORGANISM", 30, 33], ["CEK cells", "CELL", 56, 65], ["IBV", "ORGANISM", 203, 206], ["CEK cells", "CELL_LINE", 56, 65], ["IBV", "SPECIES", 30, 33], ["IBV", "SPECIES", 203, 206], ["this study", "TEST", 3, 13], ["IBV", "PROBLEM", 30, 33], ["antiviral agents", "TREATMENT", 178, 194], ["IBV", "PROBLEM", 203, 206], ["IBV", "OBSERVATION", 30, 33], ["consistent with", "UNCERTAINTY", 87, 102]]], ["Our results showed that the HPE can reduce virus mRNA expression level (Figures 3A and 8) and virus titer (Figure 3A).", [["HPE", "DISEASE", 28, 31], ["virus mRNA", "RNA", 43, 53], ["the HPE", "PROBLEM", 24, 31], ["virus mRNA expression level", "PROBLEM", 43, 70], ["Figures 3A", "TEST", 72, 82], ["virus titer", "TEST", 94, 105]]], ["Additionally, the SEE had no inhibitory effects and the HPW had poor inhibitory effects (Figure 3).", [["HPW", "CHEMICAL", 56, 59], ["HPW", "SIMPLE_CHEMICAL", 56, 59], ["inhibitory effects", "PROBLEM", 29, 47], ["poor inhibitory effects", "PROBLEM", 64, 87]]], ["The results suggest that the HPE, which contains an enrichment of the main effective substances, was the bioactive fraction of H. perforatum extracts.DiscussionMoreover, the HPE had anti-IBV activity, such as reducing the fluorescence signal produced by IBV (Figure 4), and alleviating the pathological injury of trachea and kidney caused by IBV in chickens (Figures 6and7).", [["extracts", "ANATOMY", 141, 149], ["trachea", "ANATOMY", 313, 320], ["kidney", "ANATOMY", 325, 331], ["HPE", "DISEASE", 29, 32], ["HPE", "DISEASE", 174, 177], ["injury of trachea and kidney", "DISEASE", 303, 331], ["H. perforatum", "ORGANISM", 127, 140], ["extracts", "ORGANISM_SUBSTANCE", 141, 149], ["trachea", "ORGAN", 313, 320], ["kidney", "ORGAN", 325, 331], ["IBV", "ORGANISM", 342, 345], ["chickens", "ORGANISM", 349, 357], ["H. perforatum", "SPECIES", 127, 140], ["chickens", "SPECIES", 349, 357], ["H. perforatum", "SPECIES", 127, 140], ["IBV", "SPECIES", 254, 257], ["IBV", "SPECIES", 342, 345], ["chickens", "SPECIES", 349, 357], ["the HPE", "PROBLEM", 25, 32], ["the fluorescence signal", "TEST", 218, 241], ["the pathological injury of trachea and kidney", "PROBLEM", 286, 331], ["IBV", "PROBLEM", 342, 345], ["HPE", "OBSERVATION_MODIFIER", 29, 32], ["enrichment", "OBSERVATION_MODIFIER", 52, 62], ["main", "OBSERVATION_MODIFIER", 70, 74], ["effective", "OBSERVATION_MODIFIER", 75, 84], ["substances", "OBSERVATION", 85, 95], ["bioactive fraction", "OBSERVATION", 105, 123], ["injury", "OBSERVATION", 303, 309], ["trachea", "ANATOMY", 313, 320], ["kidney", "ANATOMY", 325, 331], ["IBV", "OBSERVATION", 342, 345]]], ["When came to evaluation of antiviral effects, ribavirin was used as control drugs.", [["ribavirin", "CHEMICAL", 46, 55], ["ribavirin", "CHEMICAL", 46, 55], ["ribavirin", "SIMPLE_CHEMICAL", 46, 55], ["evaluation", "TEST", 13, 23], ["antiviral effects", "TREATMENT", 27, 44], ["ribavirin", "TREATMENT", 46, 55]]], ["The inhibitory effect of 78.13 \u00b5g/ml HPE was comparable to that of 10 \u00b5g/ml ribavirin in vitro, and 480 mg/kg HPE was comparable to that of 60 mg/kg ribavirin in vivo.", [["ribavirin", "CHEMICAL", 76, 85], ["HPE", "CHEMICAL", 110, 113], ["ribavirin", "CHEMICAL", 149, 158], ["ribavirin", "CHEMICAL", 76, 85], ["ribavirin", "CHEMICAL", 149, 158], ["ribavirin", "SIMPLE_CHEMICAL", 76, 85], ["ribavirin", "SIMPLE_CHEMICAL", 149, 158], ["HPE", "TEST", 37, 40], ["ribavirin", "TREATMENT", 76, 85], ["vitro", "TREATMENT", 89, 94], ["ribavirin", "TREATMENT", 149, 158]]], ["In the efficacy of antiviral effects, as in the reporting of others herbs (Choi et al., 2016; Sun et al., 2016; Choi et al., 2017; Yi et al., 2018; Luo et al., 2019), the effects of the herbal extract were lower than ribavirin even under several times higher dosage against IBV mRNA level, virus titer, and histopathological injury caused by IBV.", [["extract", "ANATOMY", 193, 200], ["ribavirin", "CHEMICAL", 217, 226], ["ribavirin", "CHEMICAL", 217, 226], ["ribavirin", "SIMPLE_CHEMICAL", 217, 226], ["IBV", "ORGANISM", 274, 277], ["IBV", "ORGANISM", 342, 345], ["IBV mRNA", "RNA", 274, 282], ["IBV", "SPECIES", 274, 277], ["IBV", "SPECIES", 342, 345], ["antiviral effects", "TREATMENT", 19, 36], ["the herbal extract", "TREATMENT", 182, 200], ["ribavirin", "TREATMENT", 217, 226], ["IBV mRNA level", "PROBLEM", 274, 288], ["virus titer", "PROBLEM", 290, 301], ["histopathological injury", "PROBLEM", 307, 331], ["IBV", "PROBLEM", 342, 345], ["antiviral effects", "OBSERVATION", 19, 36]]], ["However, it is logical since ribavirin is pure compared to the extracts containing many inactive compounds.DiscussionSome studies have shown that H. perforatum extract have an antiviral effect on influenza A virus and HIV (Barnes et al., 2001; Birt et al., 2009; Pu et al., 2012), suggesting that HPE have the potential to be developed and used as antiviral drugs.", [["extracts", "ANATOMY", 63, 71], ["ribavirin", "CHEMICAL", 29, 38], ["H. perforatum extract", "CHEMICAL", 146, 167], ["influenza A virus", "DISEASE", 196, 213], ["HPE", "CHEMICAL", 297, 300], ["ribavirin", "CHEMICAL", 29, 38], ["ribavirin", "SIMPLE_CHEMICAL", 29, 38], ["extracts", "ORGANISM_SUBSTANCE", 63, 71], ["H. perforatum", "ORGANISM", 146, 159], ["extract", "ORGANISM", 160, 167], ["influenza A virus", "ORGANISM", 196, 213], ["HIV", "ORGANISM", 218, 221], ["HPE", "SIMPLE_CHEMICAL", 297, 300], ["H. perforatum", "SPECIES", 146, 159], ["influenza A virus", "SPECIES", 196, 213], ["HIV", "SPECIES", 218, 221], ["H. perforatum", "SPECIES", 146, 159], ["influenza A virus", "SPECIES", 196, 213], ["HIV", "SPECIES", 218, 221], ["ribavirin", "TREATMENT", 29, 38], ["DiscussionSome studies", "TEST", 107, 129], ["H. perforatum extract", "PROBLEM", 146, 167], ["an antiviral effect", "PROBLEM", 173, 192], ["influenza A virus", "PROBLEM", 196, 213], ["HPE", "PROBLEM", 297, 300], ["antiviral drugs", "TREATMENT", 348, 363], ["ribavirin", "OBSERVATION", 29, 38], ["many", "OBSERVATION_MODIFIER", 83, 87], ["inactive compounds", "OBSERVATION", 88, 106], ["antiviral effect", "OBSERVATION", 176, 192]]], ["In this study, we found that H. perforatum extract had significantly antiviral effect on IBV in vitro and in vivo, respectively.", [["H. perforatum extract", "CHEMICAL", 29, 50], ["H. perforatum", "ORGANISM", 29, 42], ["IBV", "ORGANISM", 89, 92], ["H. perforatum", "SPECIES", 29, 42], ["H. perforatum", "SPECIES", 29, 42], ["IBV", "SPECIES", 89, 92], ["this study", "TEST", 3, 13], ["H. perforatum extract", "PROBLEM", 29, 50], ["significantly antiviral effect", "PROBLEM", 55, 85], ["IBV in vitro", "TREATMENT", 89, 101], ["antiviral effect", "OBSERVATION", 69, 85]]], ["In addition, anti-IBV effect of HPE might correlate with MDA5 and NF-\u03baB signaling pathway.", [["HPE", "DISEASE", 32, 35], ["HPE", "SIMPLE_CHEMICAL", 32, 35], ["MDA5", "GENE_OR_GENE_PRODUCT", 57, 61], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 66, 71], ["MDA5", "PROTEIN", 57, 61], ["NF-\u03baB", "PROTEIN", 66, 71], ["HPE", "PROBLEM", 32, 35], ["MDA5", "TREATMENT", 57, 61]]], ["Belonging to acid inducible gene I (RIG-I)-like receptors (RLRs) in pattern recognition receptors (PRRs), it is well known that MDA5 plays a crucial role in avian respiratory disease progression (Yu et al., 2017), whose function is to identify various pathogen-associated molecular patterns (PAMPs), and activates mitochondrial antiviral signaling gene (MAVS, also called IPS-1/VISA/CARDIF) (Lin et al., 2006), activated MAVS can recruit downstream interferon regulatory factor-3/7 (IRF3/IRF7) (Shi et al., 2015), leading to the rapid production of type I IFNs (Xu et al., 2005; Soulat et al., 2008).", [["respiratory", "ANATOMY", 163, 174], ["mitochondrial", "ANATOMY", 314, 327], ["respiratory disease", "DISEASE", 163, 182], ["Belonging to acid inducible gene I", "GENE_OR_GENE_PRODUCT", 0, 34], ["RIG-I)-like receptors", "GENE_OR_GENE_PRODUCT", 36, 57], ["RLRs", "GENE_OR_GENE_PRODUCT", 59, 63], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 68, 97], ["MDA5", "GENE_OR_GENE_PRODUCT", 128, 132], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 252, 290], ["PAMPs", "GENE_OR_GENE_PRODUCT", 292, 297], ["mitochondrial", "CELLULAR_COMPONENT", 314, 327], ["MAVS", "GENE_OR_GENE_PRODUCT", 354, 358], ["IPS-1", "GENE_OR_GENE_PRODUCT", 372, 377], ["VISA", "GENE_OR_GENE_PRODUCT", 378, 382], ["CARDIF", "GENE_OR_GENE_PRODUCT", 383, 389], ["MAVS", "GENE_OR_GENE_PRODUCT", 421, 425], ["interferon regulatory factor-3/7", "GENE_OR_GENE_PRODUCT", 449, 481], ["IRF3", "GENE_OR_GENE_PRODUCT", 483, 487], ["IRF7", "GENE_OR_GENE_PRODUCT", 488, 492], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 549, 560], ["acid inducible gene I (RIG-I)-like receptors", "PROTEIN", 13, 57], ["RLRs", "PROTEIN", 59, 63], ["pattern recognition receptors", "PROTEIN", 68, 97], ["PRRs", "PROTEIN", 99, 103], ["MDA5", "PROTEIN", 128, 132], ["PAMPs", "PROTEIN", 292, 297], ["mitochondrial antiviral signaling gene", "DNA", 314, 352], ["MAVS", "PROTEIN", 354, 358], ["IPS", "DNA", 372, 375], ["VISA", "DNA", 378, 382], ["CARDIF", "DNA", 383, 389], ["MAVS", "PROTEIN", 421, 425], ["interferon regulatory factor-3/7", "PROTEIN", 449, 481], ["IRF3", "PROTEIN", 483, 487], ["IRF7", "PROTEIN", 488, 492], ["type I IFNs", "PROTEIN", 549, 560], ["respiratory disease progression", "PROBLEM", 163, 194], ["various pathogen", "PROBLEM", 244, 260], ["IPS", "TEST", 372, 375], ["activated MAVS", "PROBLEM", 411, 425]]], ["NF-\u03baB system is a master transcription factor in the recognition signaling and host responses to immune attacks (Deng et al., 2018).", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["NF-\u03baB", "PROTEIN", 0, 5], ["master transcription factor", "PROTEIN", 18, 45], ["immune attacks", "PROBLEM", 97, 111]]], ["It is well known that NF-\u03baB mediates inflammation, and several cytokine are also linked to NF-\u03baB signaling to enhance the inflammatory responses, such as TNF-\u03b1, IL-6, and IL-1\u03b2 (Salminen et al., 2008).DiscussionSeveral reports have pointed out the MDA5 signaling pathways and innate immune cytokines were activated after infection with IBV M41 strain (He et al., 2016).", [["inflammation", "DISEASE", 37, 49], ["infection", "DISEASE", 321, 330], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 22, 27], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 91, 96], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 154, 159], ["IL-6", "GENE_OR_GENE_PRODUCT", 161, 165], ["IL-1", "GENE_OR_GENE_PRODUCT", 171, 175], ["MDA5", "GENE_OR_GENE_PRODUCT", 248, 252], ["IBV", "ORGANISM", 336, 339], ["NF-\u03baB", "PROTEIN", 22, 27], ["cytokine", "PROTEIN", 63, 71], ["NF-\u03baB", "PROTEIN", 91, 96], ["TNF", "PROTEIN", 154, 157], ["MDA5", "PROTEIN", 248, 252], ["innate immune cytokines", "PROTEIN", 276, 299], ["IBV", "SPECIES", 336, 339], ["NF", "PROBLEM", 22, 24], ["B mediates inflammation", "PROBLEM", 26, 49], ["the inflammatory responses", "PROBLEM", 118, 144], ["TNF", "TEST", 154, 157], ["IL", "TEST", 161, 163], ["innate immune cytokines", "TREATMENT", 276, 299], ["infection", "PROBLEM", 321, 330], ["IBV M41 strain", "PROBLEM", 336, 350], ["inflammation", "OBSERVATION", 37, 49], ["inflammatory", "OBSERVATION", 122, 134]]], ["MDA5 signaling pathway was disrupted by cleavage of the adaptor protein MAVS in the JS/2010/12 strain of IBV infection (Yu et al., 2017).", [["IBV infection", "DISEASE", 105, 118], ["MDA5", "GENE_OR_GENE_PRODUCT", 0, 4], ["MAVS", "GENE_OR_GENE_PRODUCT", 72, 76], ["IBV", "ORGANISM", 105, 108], ["MDA5", "PROTEIN", 0, 4], ["adaptor protein", "PROTEIN", 56, 71], ["MAVS", "PROTEIN", 72, 76], ["IBV", "SPECIES", 105, 108], ["MDA5 signaling pathway", "PROBLEM", 0, 22], ["the adaptor protein MAVS", "PROBLEM", 52, 76], ["IBV infection", "PROBLEM", 105, 118], ["JS", "ANATOMY", 84, 86], ["IBV infection", "OBSERVATION", 105, 118]]], ["The type I IFN response plays a critical role in resisting SAIBK2 strain of IBV (Yang et al., 2018a).", [["type I IFN", "GENE_OR_GENE_PRODUCT", 4, 14], ["SAIBK2", "GENE_OR_GENE_PRODUCT", 59, 65], ["IBV", "ORGANISM", 76, 79], ["IFN", "PROTEIN", 11, 14], ["IBV", "SPECIES", 76, 79]]], ["MDA5 signaling pathways and innate immune cytokine (NF-\u03baB and IRF3) were induced after IBV-M41 strain infection (Zhang et al., 2017b).", [["infection", "DISEASE", 102, 111], ["MDA5", "GENE_OR_GENE_PRODUCT", 0, 4], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 52, 57], ["IRF3", "GENE_OR_GENE_PRODUCT", 62, 66], ["IBV-M41 strain", "ORGANISM", 87, 101], ["MDA5", "PROTEIN", 0, 4], ["innate immune cytokine", "PROTEIN", 28, 50], ["NF-\u03baB", "PROTEIN", 52, 57], ["IRF3", "PROTEIN", 62, 66], ["IBV-M41", "SPECIES", 87, 94], ["MDA5 signaling pathways", "TEST", 0, 23], ["innate immune cytokine", "TEST", 28, 50], ["NF", "TEST", 52, 54], ["IBV", "PROBLEM", 87, 90], ["strain infection", "PROBLEM", 95, 111]]], ["On the other hand, the report had shown that H. perforatum extract significantly downregulated the concentration of IL-6 and TNF-\u03b1 in lung tissue for mice infected with an influenza A virus (Pu et al., 2012).", [["lung tissue", "ANATOMY", 134, 145], ["H. perforatum extract", "CHEMICAL", 45, 66], ["H. perforatum", "ORGANISM", 45, 58], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 125, 130], ["lung tissue", "TISSUE", 134, 145], ["mice", "ORGANISM", 150, 154], ["influenza A virus", "ORGANISM", 172, 189], ["IL-6", "PROTEIN", 116, 120], ["TNF-\u03b1", "PROTEIN", 125, 130], ["H. perforatum", "SPECIES", 45, 58], ["mice", "SPECIES", 150, 154], ["influenza A virus", "SPECIES", 172, 189], ["H. perforatum", "SPECIES", 45, 58], ["mice", "SPECIES", 150, 154], ["influenza A virus", "SPECIES", 172, 189], ["H. perforatum extract", "PROBLEM", 45, 66], ["IL", "TEST", 116, 118], ["TNF", "TEST", 125, 128], ["mice infected", "PROBLEM", 150, 163], ["an influenza A virus", "PROBLEM", 169, 189], ["lung tissue", "ANATOMY", 134, 145]]], ["In this study, we found that mRNA expression levels of MDA5, MAVS, IFN-\u03b1, IFN-\u03b2, NF-\u03baB, TNF-\u03b1, and IL-6 were significantly up-regulated after IBV infection in vitro and in vivo (Figures 5,9, and10).", [["IBV infection", "DISEASE", 142, 155], ["MDA5", "GENE_OR_GENE_PRODUCT", 55, 59], ["MAVS", "GENE_OR_GENE_PRODUCT", 61, 65], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 67, 72], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 74, 79], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 81, 86], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 88, 93], ["IL-6", "GENE_OR_GENE_PRODUCT", 99, 103], ["IBV", "ORGANISM", 142, 145], ["MDA5", "PROTEIN", 55, 59], ["MAVS", "PROTEIN", 61, 65], ["IFN", "PROTEIN", 67, 70], ["IFN", "PROTEIN", 74, 77], ["NF-\u03baB", "PROTEIN", 81, 86], ["TNF", "PROTEIN", 88, 91], ["IL-6", "PROTEIN", 99, 103], ["IBV", "SPECIES", 142, 145], ["this study", "TEST", 3, 13], ["mRNA expression levels", "TEST", 29, 51], ["MDA5", "TEST", 55, 59], ["MAVS", "TEST", 61, 65], ["IFN", "TEST", 67, 70], ["\u03b1", "TEST", 71, 72], ["IFN", "TEST", 74, 77], ["\u03b2", "TEST", 78, 79], ["NF", "TEST", 81, 83], ["B", "TEST", 85, 86], ["TNF", "TEST", 88, 91], ["IL", "TEST", 99, 101], ["IBV infection", "PROBLEM", 142, 155], ["Figures", "TEST", 178, 185], ["infection", "OBSERVATION", 146, 155]]], ["Meanwhile, we found that HPE may be up-regulate mRNA levels of IFN-\u03b1 and IFN-\u03b2 by MDA5 signaling pathway, and down-regulate mRNA expression levels of IL-6 and TNF-\u03b1 through the NF-\u03baB signaling pathway (Figures 5,9, and10), suggesting that HPE may be inhibit IBV by affecting innate immune cytokines.DiscussionBecause of remarkable antiviral effect on IBV, we analyzed the active components of HPE.", [["HPE", "DISEASE", 25, 28], ["HPE", "DISEASE", 239, 242], ["HPE", "DISEASE", 393, 396], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 63, 68], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 73, 78], ["MDA5", "GENE_OR_GENE_PRODUCT", 82, 86], ["IL-6", "GENE_OR_GENE_PRODUCT", 150, 154], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 159, 164], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 177, 182], ["and10", "GENE_OR_GENE_PRODUCT", 215, 220], ["HPE", "SIMPLE_CHEMICAL", 239, 242], ["IBV", "ORGANISM", 258, 261], ["IBV", "ORGANISM", 351, 354], ["IFN", "PROTEIN", 63, 66], ["\u03b1", "PROTEIN", 67, 68], ["IFN", "PROTEIN", 73, 76], ["MDA5", "PROTEIN", 82, 86], ["IL-6", "PROTEIN", 150, 154], ["TNF", "PROTEIN", 159, 162], ["NF-\u03baB", "PROTEIN", 177, 182], ["innate immune cytokines", "PROTEIN", 275, 298], ["IBV", "SPECIES", 258, 261], ["IBV", "SPECIES", 351, 354], ["HPE", "PROBLEM", 25, 28], ["mRNA levels", "TEST", 48, 59], ["IFN", "TEST", 63, 66], ["IFN", "TEST", 73, 76], ["MDA5 signaling pathway", "TEST", 82, 104], ["IL", "TEST", 150, 152], ["TNF", "TEST", 159, 162], ["the NF", "TEST", 173, 179], ["Figures", "TEST", 202, 209], ["HPE", "PROBLEM", 239, 242], ["IBV", "PROBLEM", 258, 261], ["remarkable antiviral effect", "PROBLEM", 320, 347], ["IBV", "TREATMENT", 351, 354], ["HPE", "PROBLEM", 393, 396], ["remarkable", "OBSERVATION_MODIFIER", 320, 330], ["antiviral effect", "OBSERVATION", 331, 347], ["active", "OBSERVATION_MODIFIER", 372, 378], ["components", "OBSERVATION_MODIFIER", 379, 389], ["HPE", "OBSERVATION", 393, 396]]], ["The mass spectrum of hyperoside contained a negative quasi-molecular ion at 463.74 m/z [M\u2013H]\u2212 (Figure 12B), in accordance with the previous literature (Cao et al., 2011).", [["hyperoside", "CHEMICAL", 21, 31], ["hyperoside", "CHEMICAL", 21, 31], ["H", "CHEMICAL", 90, 91], ["hyperoside", "SIMPLE_CHEMICAL", 21, 31], ["hyperoside", "TEST", 21, 31], ["z", "TEST", 85, 86], ["M\u2013H", "TEST", 88, 91], ["Figure", "TEST", 95, 101], ["mass", "OBSERVATION", 4, 8]]], ["The mass spectrum ofFigure 12Bshowed a quasi-molecular ion at 447.44 m/z [M\u2013H]\u2212.", [["H", "CHEMICAL", 76, 77], ["The mass spectrum ofFigure", "TEST", 0, 26], ["a quasi-molecular ion", "TEST", 37, 58], ["mass", "OBSERVATION", 4, 8]]], ["This corresponds to the fragmentation regularity of quercitrin (Oliveira et al., 2014).", [["quercitrin", "CHEMICAL", 52, 62], ["quercitrin", "CHEMICAL", 52, 62], ["quercitrin", "SIMPLE_CHEMICAL", 52, 62], ["quercitrin", "TREATMENT", 52, 62], ["fragmentation", "OBSERVATION_MODIFIER", 24, 37], ["regularity", "OBSERVATION_MODIFIER", 38, 48]]], ["Moreover, a quasi-molecular ion [M\u2013H]\u2212 at 301.72 m/z confirms the presence of the quercetin (Stierlin et al., 2018) (Figure 12C).", [["M\u2013H", "CHEMICAL", 33, 36], ["quercetin", "CHEMICAL", 82, 91], ["H", "CHEMICAL", 35, 36], ["quercetin", "CHEMICAL", 82, 91], ["quercetin", "SIMPLE_CHEMICAL", 82, 91], ["a quasi-molecular ion [M\u2013H", "TEST", 10, 36], ["m/z", "TEST", 49, 52], ["the quercetin", "TREATMENT", 78, 91]]], ["In addition to a positive quasi- molecular ion at 543.29 m/z [M+Na]+ (Figure 12D) and a negative quasi-molecular ion [M\u2013H]\u2212 at 519.08 m/z (Figure 12E), confirming the presence of the pseudohypericin.", [["Na", "CHEMICAL", 64, 66], ["M\u2013H", "CHEMICAL", 118, 121], ["pseudohypericin", "CHEMICAL", 183, 198], ["[M+Na]+", "CHEMICAL", 61, 68], ["H", "CHEMICAL", 120, 121], ["pseudohypericin", "CHEMICAL", 183, 198], ["pseudohypericin", "SIMPLE_CHEMICAL", 183, 198], ["Na", "TEST", 64, 66], ["Figure", "TEST", 70, 76], ["\u2212", "TEST", 122, 123], ["Figure", "TEST", 139, 145], ["the pseudohypericin", "TREATMENT", 179, 198]]], ["Finally, the mass spectrum of hypericin shows a positive quasi-molecular ion [M+H]\u2212 at 505.44 m/z (Figure 12F) and a negative quasi-molecular ion [M\u2013H]\u2212 at 503.33 m/z (Figure 12G).", [["hypericin", "CHEMICAL", 30, 39], ["hypericin", "CHEMICAL", 30, 39], ["H", "CHEMICAL", 80, 81], ["H", "CHEMICAL", 149, 150], ["hypericin", "SIMPLE_CHEMICAL", 30, 39], ["the mass spectrum of hypericin", "PROBLEM", 9, 39], ["a positive quasi-molecular ion", "PROBLEM", 46, 76], ["Figure", "TEST", 99, 105], ["\u2212", "TEST", 151, 152], ["z", "TEST", 165, 166], ["Figure", "TEST", 168, 174], ["mass", "OBSERVATION", 13, 17]]], ["According to the results inFigure 3, the HPE is the main active fraction, containing abundant levels of hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin (Table 4 and Figure 11).ConclusionsOur study provides, for the first time, clear evidence that the extract of H. perforatum, containing hyperoside, quercitrin, quercetin, pseudohypericin, and hypericin, possess anti-IBV activities.", [["HPE", "DISEASE", 41, 44], ["hyperoside", "CHEMICAL", 104, 114], ["quercitrin", "CHEMICAL", 116, 126], ["quercetin", "CHEMICAL", 128, 137], ["pseudohypericin", "CHEMICAL", 139, 154], ["hypericin", "CHEMICAL", 160, 169], ["extract of H. perforatum", "CHEMICAL", 269, 293], ["hyperoside", "CHEMICAL", 306, 316], ["quercitrin", "CHEMICAL", 318, 328], ["quercetin", "CHEMICAL", 330, 339], ["pseudohypericin", "CHEMICAL", 341, 356], ["hypericin", "CHEMICAL", 362, 371], ["hyperoside", "CHEMICAL", 104, 114], ["quercitrin", "CHEMICAL", 116, 126], ["quercetin", "CHEMICAL", 128, 137], ["pseudohypericin", "CHEMICAL", 139, 154], ["hypericin", "CHEMICAL", 160, 169], ["hyperoside", "CHEMICAL", 306, 316], ["quercitrin", "CHEMICAL", 318, 328], ["quercetin", "CHEMICAL", 330, 339], ["pseudohypericin", "CHEMICAL", 341, 356], ["hypericin", "CHEMICAL", 362, 371], ["hyperoside", "SIMPLE_CHEMICAL", 104, 114], ["quercitrin", "SIMPLE_CHEMICAL", 116, 126], ["quercetin", "SIMPLE_CHEMICAL", 128, 137], ["pseudohypericin", "SIMPLE_CHEMICAL", 139, 154], ["hypericin", "SIMPLE_CHEMICAL", 160, 169], ["H. perforatum", "ORGANISM", 280, 293], ["hyperoside", "SIMPLE_CHEMICAL", 306, 316], ["quercitrin", "SIMPLE_CHEMICAL", 318, 328], ["quercetin", "SIMPLE_CHEMICAL", 330, 339], ["pseudohypericin", "SIMPLE_CHEMICAL", 341, 356], ["hypericin", "SIMPLE_CHEMICAL", 362, 371], ["anti-IBV", "CANCER", 381, 389], ["H. perforatum", "SPECIES", 280, 293], ["H. perforatum", "SPECIES", 280, 293], ["hyperoside", "TREATMENT", 104, 114], ["quercitrin", "TREATMENT", 116, 126], ["quercetin", "TREATMENT", 128, 137], ["pseudohypericin", "TREATMENT", 139, 154], ["hypericin", "TREATMENT", 160, 169], ["Our study", "TEST", 205, 214], ["H. perforatum", "PROBLEM", 280, 293], ["hyperoside", "TREATMENT", 306, 316], ["quercitrin", "TREATMENT", 318, 328], ["quercetin", "TREATMENT", 330, 339], ["pseudohypericin", "TREATMENT", 341, 356], ["hypericin", "TREATMENT", 362, 371], ["anti-IBV activities", "TREATMENT", 381, 400], ["main", "OBSERVATION_MODIFIER", 52, 56], ["active fraction", "OBSERVATION", 57, 72], ["perforatum", "OBSERVATION", 283, 293]]], ["Furthermore, its anti-IBV effect may be associated with reduced mRNA expression levels of the pro-inflammatory cytokines IL-6, TNF-\u03b1 by NF-\u03baB signaling pathway, and related to up-regulate mRNA expression levels of type I interferon through the MDA5 signaling pathway, and could be useful for the development of new antiviral agents.", [["IL-6", "GENE_OR_GENE_PRODUCT", 121, 125], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 136, 141], ["type I interferon", "GENE_OR_GENE_PRODUCT", 214, 231], ["MDA5", "GENE_OR_GENE_PRODUCT", 244, 248], ["pro-inflammatory cytokines", "PROTEIN", 94, 120], ["IL-6", "PROTEIN", 121, 125], ["TNF", "PROTEIN", 127, 130], ["NF-\u03baB", "PROTEIN", 136, 141], ["type I interferon", "PROTEIN", 214, 231], ["MDA5", "PROTEIN", 244, 248], ["reduced mRNA expression levels", "PROBLEM", 56, 86], ["the pro-inflammatory cytokines IL", "TEST", 90, 123], ["TNF", "TEST", 127, 130], ["type I interferon", "TREATMENT", 214, 231], ["the MDA5 signaling pathway", "TEST", 240, 266], ["new antiviral agents", "TREATMENT", 311, 331], ["pro-inflammatory", "OBSERVATION_MODIFIER", 94, 110], ["new", "OBSERVATION_MODIFIER", 311, 314], ["antiviral agents", "OBSERVATION", 315, 331]]], ["However, further studies are required to elucidate its detail mechanism of action.Data Availability StatementAll datasets generated for this study are included in the article/Supplementary Material.Author ContributionHC wrote the manuscript and carried out most of the studies.", [["further studies", "TEST", 9, 24], ["this study", "TEST", 136, 146], ["the studies", "TEST", 265, 276]]], ["RZ, XH, LD, HL, XL, XS, and GA participated in the animal experiments.", [["GA", "CHEMICAL", 28, 30], ["XL", "ANATOMY", 16, 18]]], ["GL designed the experiment and made valuable revision.", [["valuable revision", "TREATMENT", 36, 53], ["revision", "OBSERVATION", 45, 53]]]], "c581d8f0c389d6588db99085a2e392fd4ef2aea0": [["This ecological deficit has been growing for decades and diminishing the planet's ability to support life as we know it.", [["This ecological deficit", "PROBLEM", 0, 23], ["deficit", "OBSERVATION", 16, 23]]], ["From climate change, to plummeting insect populations, we face a global environmental crisis requiring mitigation and adaptation on a massive scale.", [["plummeting insect populations", "PROBLEM", 24, 53], ["a global environmental crisis", "PROBLEM", 63, 92], ["mitigation", "TREATMENT", 103, 113], ["a massive scale", "TREATMENT", 132, 147], ["climate change", "OBSERVATION", 5, 19], ["global", "OBSERVATION_MODIFIER", 65, 71], ["environmental crisis", "OBSERVATION", 72, 92]]], ["By 2050, for example, analysts argue we need to invest $US 3.95 trillion per annum in low-carbon energy, transport, and building projects (Fulton & Reid, 2018; IEA, 2019) .", [["carbon", "CHEMICAL", 90, 96]]], ["Current flows of low-carbon capital are dwarfed by such figures (Buchner et al., 2019) and many believe public money cannot close the gap on its own (Castree & Christophers, 2015; Clark et al., 2018) .", [["carbon", "CHEMICAL", 21, 27], ["flows", "OBSERVATION_MODIFIER", 8, 13], ["low", "OBSERVATION_MODIFIER", 17, 20], ["carbon capital", "OBSERVATION", 21, 35]]], ["With signatories endorsing this approach in the Paris Agreement (UNFCCC, 2015) , the burgeoning field of green finance is tasked with scaling up capital flows that can be used to address the environmental crisis (G20 GFSG, 2016) .IntroductionTo this end, green finance policymakers and practitioners are investing ample resources into the rapidly growing market for green bonds.", [["scaling up capital flows", "TREATMENT", 134, 158], ["green bonds", "OBSERVATION", 366, 377]]], ["Green bonds are part of a trillion dollar sustainable debt market that includes other thematically labelled credit instruments (BNEF, 2019) .", [["bonds", "OBSERVATION_MODIFIER", 6, 11], ["trillion dollar", "OBSERVATION", 26, 41]]], ["They account for 77% of this market after averaging annual growth of 54% in their first ten years (BNEF, 2019; Counihan, 2019) .", [["growth", "OBSERVATION_MODIFIER", 59, 65]]], ["Green bonds are reportedly \"flying off the shelves\" with the average offering three times over-subscribed (Nauman, 2020) .", [["bonds", "OBSERVATION", 6, 11]]], ["As well as this investment capital, green bonds are attracting optimism about their social, environmental, and economic impacts.", [["green bonds", "OBSERVATION", 36, 47]]], ["A triple bottom line for post-Paris finance, perhaps.IntroductionGreen bonds ostensibly herald the promise of treating our ecological deficit with debt.", [["Green bonds", "SIMPLE_CHEMICAL", 65, 76], ["A triple bottom line", "TREATMENT", 0, 20], ["post-Paris finance", "TREATMENT", 25, 43], ["Green bonds", "OBSERVATION", 65, 76]]], ["At the local scale, green bonds partially finance public services that (re)produce uneven landscapes of racial and class-based disadvantage (Bigger & Millington, 2019) .", [["green bonds", "OBSERVATION", 20, 31], ["racial", "OBSERVATION_MODIFIER", 104, 110]]], ["At the regional scale, green bonds are already financing electricity, transport, and building projects that aim to decarbonise our infrastructure networks and support the transition towards sustainability.", [["green bonds", "OBSERVATION", 23, 34]]], ["This will not only reshape the built environments where people live, it may also have national and global implications by mediating our exposure to the environmental risks of a warming planet.IntroductionThis potential power is why a nascent geographical literature is beginning to coalesce around the green bond market.", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62], ["a warming planet", "TREATMENT", 175, 191], ["a nascent geographical literature", "PROBLEM", 232, 265], ["green bond", "OBSERVATION", 302, 312]]], ["Existing research has rightfully illustrated the undesirable social, spatial, and political costs of green bond financing (Bigger & Millington, 2019; Christophers, 2018a) .", [["undesirable", "OBSERVATION_MODIFIER", 49, 60]]], ["Castree and Christophers (2015) also find cautious optimism for green finance in historical precedents and the rise of 'patient capital'.", [["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127]]], ["This leads them to bounce off Blackburn (2013) in calling for us to consider 'healthy credit' alongside 'bad debt'.IntroductionIn this paper, we bring this approach to the burgeoning green bond market.", [["this approach", "TREATMENT", 151, 164]]], ["The paper primarily maps the discursive architecture through which green bonds are being engaged as an ostensible fix for our ecological deficit.", [["an ostensible fix", "TREATMENT", 100, 117], ["our ecological deficit", "PROBLEM", 122, 144], ["green bonds", "OBSERVATION", 67, 78]]], ["Secondly, it attempts to provide a platform for further green debt research by delineating the major practical and political concerns with green bonds.", [["green bonds", "SIMPLE_CHEMICAL", 139, 150], ["further green debt research", "TREATMENT", 48, 75], ["green bonds", "OBSERVATION", 139, 150]]], ["Finally, it aims to widen our view of the green bond market by putting applied and critical research agendas into direct conversation.IntroductionThis article represents the first foray into a wider project examining green bond market development in Australia and New Zealand.", [["the green bond market", "TREATMENT", 38, 59], ["New Zealand", "TREATMENT", 264, 275], ["green bond", "OBSERVATION", 217, 227], ["New", "OBSERVATION_MODIFIER", 264, 267], ["Zealand", "OBSERVATION_MODIFIER", 268, 275]]], ["While the broader project includes interviews with green bond issuers and investors, this paper draws on our analysis of publicly available documents.", [["green bond issuers", "TREATMENT", 51, 69], ["our analysis", "TEST", 105, 117]]], ["The four clusters were Critical Academic Research in human geography and allied disciplines; Applied Academic Research in economics, finance, and law; Policy Papers and Market Reports from (non)governmental agencies such as The World Bank, Climate Bonds Initiative, and the European Commission's High-Level Expert Group on Sustainable Finance; and News Articles and Commentary from trade publications such as Environmental Finance, KangaNews, and the Financial Times.", [["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58]]], ["These four clusters were then used as focal points to concentrate the review on outlets and publications where green bonds were discussed in-depth.", [["green bonds", "SIMPLE_CHEMICAL", 111, 122]]], ["In other cases, such as News Articles and Commentary, 'data' collection was relaxed when documents ceased to reveal new information about the current obstacles, opportunities, or socio-environmental impacts of green bonds.IntroductionThe paper begins with a short introduction to green bonds' structure and development.", [["green bonds", "SIMPLE_CHEMICAL", 210, 221], ["a short introduction to green bonds' structure", "TREATMENT", 256, 302], ["new", "OBSERVATION_MODIFIER", 116, 119], ["green bonds", "OBSERVATION", 210, 221]]], ["This section describes their similarities and differences to conventional bonds, before recounting some major milestones in the market's evolution.", [["major", "OBSERVATION_MODIFIER", 104, 109], ["milestones", "OBSERVATION_MODIFIER", 110, 120]]], ["The second section reviews the key practical challenges for enhancing the green bond market.", [["green bond", "OBSERVATION", 74, 84]]], ["The paper narrates these key challenges as protecting product integrity, enhancing product performance, and globalising the market.", [["integrity", "OBSERVATION_MODIFIER", 62, 71], ["enhancing", "OBSERVATION_MODIFIER", 73, 82], ["product", "OBSERVATION_MODIFIER", 83, 90], ["performance", "OBSERVATION_MODIFIER", 91, 102]]], ["In this case, research has focused on the (re) production of value and risk in green bonds.", [["green bonds", "SIMPLE_CHEMICAL", 79, 90], ["green bonds", "OBSERVATION", 79, 90]]], ["This has led critical scholars to suggest green bonds risk amplifying social inequality and prioritising financial incomes over environmental outcomes.", [["green bonds", "OBSERVATION", 42, 53]]], ["A bond is a traditional financial instrument that dates back to the 13th century prestiti (loans) issued by the Venetian government (Mobius, 2012) .", [["a traditional financial instrument", "PROBLEM", 10, 44], ["bond", "OBSERVATION_MODIFIER", 2, 6]]], ["In return, investors receive regular interest payments until the bond 'matures' and the issuer repays the principal in full.", [["regular interest payments", "TREATMENT", 29, 54]]], ["This makes them an attractive option for financing capital intensive projects like renewable energy or public transport infrastructure (OECD, 2017) .StructureGreen bonds retain this loan structure and follow convention in the construction of risk and recourse if the borrower defaults on their debt.", [["StructureGreen bonds", "PROBLEM", 149, 169]]], ["There are four types of green bond in use and they are primarily differentiated by the scope of legal recourse (Table 1) .", [["four types", "OBSERVATION_MODIFIER", 10, 20], ["green bond", "OBSERVATION", 24, 34]]], ["Most green bonds are standard use-of-proceeds bonds.", [["green bonds", "SIMPLE_CHEMICAL", 5, 16], ["bonds", "OBSERVATION_MODIFIER", 11, 16]]], ["This typically translates into cheaper capital for issuers and lower, but more secure, returns for investors.StructureThe financial structure of green bonds, then, is basically identical to conventional 'vanilla' bonds.", [["green bonds", "SIMPLE_CHEMICAL", 145, 156], ["lower", "OBSERVATION_MODIFIER", 63, 68], ["financial structure", "OBSERVATION", 122, 141], ["green bonds", "OBSERVATION", 145, 156]]], ["The first and most obvious difference is green bond proceeds are pledged to (re)finance projects that should have environmental benefits.", [["green bond", "OBSERVATION", 41, 51]]], ["Should is the operative word as what projects qualify for green bond labelling has primarily been a matter of self-regulation 1 .", [["green bond labelling", "PROBLEM", 58, 78]]], ["These are known as the Green Bond Principles (GBPs) and the Climate Bond Standard (CBS).", [["GBPs", "TEST", 46, 50]]], ["Both frameworks have a taxonomy of sector eligibility, although the CBS provides stronger thresholds and project level prescription (cf: Climate Bonds Initiative, 2019b; ICMA, 2018).", [["the CBS", "TEST", 64, 71]]], ["Some of the eligible sectors include transportation, renewable energy, green buildings, industrial efficiency, biodiversity conservation, waste and pollution control, and sustainable land-use and water management.", [["industrial efficiency", "PROBLEM", 88, 109], ["biodiversity conservation", "TREATMENT", 111, 136], ["pollution control", "TREATMENT", 148, 165], ["water management", "TREATMENT", 196, 212], ["industrial efficiency", "OBSERVATION", 88, 109]]], ["In 2017 and 2018, almost 80% of newly issued green bonds directed proceeds to energy, transport, and building projects (Climate Bonds Initiative, 2019a).StructureThe pledge of environmental benefit leads to a second point of difference between green and vanilla bonds.", [["vanilla bonds", "SIMPLE_CHEMICAL", 254, 267], ["vanilla bonds", "OBSERVATION", 254, 267]]], ["As well as the standard credit rating process, green bonds are increasingly issued with additional environmental assurance.", [["green bonds", "SIMPLE_CHEMICAL", 47, 58], ["green bonds", "OBSERVATION", 47, 58]]], ["Most green bonds are self-labelled by the issuer with a second party commissioned to confirm the bond complies with the GBPs (Climate Bonds Initiative, 2019c; Karpf & Mandel, 2018) .", [["green bonds", "SIMPLE_CHEMICAL", 5, 16]]], ["A much smaller portion of issuers have their green bond verified for CBS certification (Climate Bonds Initiative, 2019c).", [["issuers", "CANCER", 26, 33], ["A much smaller portion of issuers", "PROBLEM", 0, 33], ["smaller", "OBSERVATION_MODIFIER", 7, 14]]], ["Certification indicates compliance with the GBPs, confirms the proceeds are pledged to CBS eligible projects, and indicates the bond is aligned with the Paris Agreement goal of keeping global warming under 2 \u2022 C (Climate Bonds Initiative, 2019c).", [["the GBPs", "TEST", 40, 48], ["global warming", "TREATMENT", 185, 199]]], ["The GBPs, for example, suggest bond issuers should provide an annual report that details how proceeds were used and the impact of the projects they (re)financed (ICMA, 2018).DevelopmentThe first green bonds were issued in 2007 and 2008 by two supranational agencies: the European Investment Bank (EIB) and the World Bank (Stoian & Iorgulescu, 2019) .", [["The GBPs", "TEST", 0, 8]]], ["The latter bond was issued after a group of Swedish pension funds inquired about investment products that addressed climate change (World Bank, 2019) .", [["investment products", "TREATMENT", 81, 100]]], ["The first billion dollar offering was made by the International Finance Corporation and sold out within the first hour of issuance (Wang, 2018) .", [["billion dollar", "OBSERVATION", 10, 24]]], ["With another big green bond from the EIB, this prompted the first run of corporate green bonds and new issues grew from $US 3.1 billion to $36.6 billion inside two years (Stoian & Iorgulescu, 2019) .", [["EIB", "DISEASE", 37, 40], ["EIB", "ANATOMY", 37, 40]]], ["This rapid growth increased demand for green bond performance data.", [["This rapid growth increased demand", "PROBLEM", 0, 34], ["green bond performance data", "TEST", 39, 66]]], ["The first green bond indices were launched in 2014 and signalled the market was beginning to mature (Stoian & Iorgulescu, 2019) .", [["green bond indices", "TEST", 10, 28], ["bond", "OBSERVATION_MODIFIER", 16, 20]]], ["Finally, the GBPs were formally released in 2014 (Ehlers & Packer, 2017) .", [["GBPs", "SIMPLE_CHEMICAL", 13, 17], ["the GBPs", "TEST", 9, 17]]], ["The GBPs were backed by a consortium of major banks and sought to create transparent standards for the burgeoning product (Kidney, 2014) .", [["GBPs", "SIMPLE_CHEMICAL", 4, 8], ["The GBPs", "TEST", 0, 8], ["Kidney", "ANATOMY", 123, 129]]], ["Their introduction was a catalyst for market development and quickly became the basis for other green labels and indices (Ehlers & Packer, 2017) .DevelopmentAnother major turning point was the 2015 Paris Agreement.", [["a catalyst", "TREATMENT", 23, 33]]], ["The agreement calls for global warming to be kept within 2 \u25cb C and to make finance flows consistent with a pathway to that goal (UNFCCC, 2015) .", [["global warming", "TREATMENT", 24, 38]]], ["It also called on governments, bond issuers, and other stakeholders to develop projects that can be financed by green bonds, ensure transparency around the use of bond proceeds, and to develop clear standards for climate change impacts and the benefits of green bond financed projects (Whiley, 2015) .DevelopmentBetween 2015 and 2016, the number of new issues doubled and the market diversified in terms of countries, issuers, and the use-of-proceeds (Stoian & Iorgulescu, 2019) .", [["climate change impacts", "PROBLEM", 213, 235], ["new", "OBSERVATION_MODIFIER", 349, 352]]], ["A new sign of market maturity was the launch of the world's first green stock exchange in Luxembourg (Medland, 2016) .", [["A new sign of market maturity", "PROBLEM", 0, 29], ["new", "OBSERVATION_MODIFIER", 2, 5], ["market maturity", "OBSERVATION", 14, 29]]], ["Eligibility was linked to the GBPs and the CBS to improve disclosure (Medland, 2016) , with the exchange listing \u20ac63 billion of green bonds in its first year (Hirtenstein, 2017) .", [["the GBPs", "TEST", 26, 34], ["the CBS", "TEST", 39, 46]]], ["France followed in 2017 and sovereign issues from Fiji and Nigeria represented the increasing involvement of emerging economies (Stoian & Iorgulescu, 2019) .", [["increasing", "OBSERVATION_MODIFIER", 83, 93]]], ["Rapid market growth continued in 2017 with an 86% increase in new issues.", [["Rapid market growth", "TEST", 0, 19], ["new", "OBSERVATION_MODIFIER", 62, 65]]], ["A noticeable change, however, were the development banks shifting from key issuers to key investors in green bonds.", [["green bonds", "SIMPLE_CHEMICAL", 103, 114], ["A noticeable change", "PROBLEM", 0, 19], ["noticeable", "OBSERVATION_MODIFIER", 2, 12], ["change", "OBSERVATION", 13, 19], ["green bonds", "OBSERVATION", 103, 114]]], ["The green label also started to find its way onto Islamic finance products (Stoian & Iorgulescu, 2019) .DevelopmentDebt markets had a difficult year in 2018, with the Bloomberg Barclays Global Aggregate Bond Index falling 1% (Robins, 2019) .", [["Global Aggregate Bond Index", "TEST", 186, 213]]], ["Green bonds, nonetheless, showed remarkable resilience in volatile conditions.", [["Green bonds", "SIMPLE_CHEMICAL", 0, 11], ["bonds", "OBSERVATION", 6, 11], ["remarkable", "OBSERVATION_MODIFIER", 33, 43], ["resilience", "OBSERVATION", 44, 54], ["volatile conditions", "OBSERVATION", 58, 77]]], ["Green bonds recorded 5% growth for the year as total issuance passed the $US 500 billion milestone (Counihan, 2019; Hurley & Durrieu, 2018) .", [["bonds", "OBSERVATION_MODIFIER", 6, 11]]], ["The Action Plan aims to scale up sustainable investment with \u2022 Proceeds are earmarked for green projects in the issuer's portfolio.Development\u2022 Recourse is to the issuer's entire balance sheet.Use-of-Proceeds Revenue Bond\u2022 Proceeds are earmarked for green projects in the issuer's portfolio.Use-of-Proceeds Revenue Bond\u2022 Recourse is limited to an issuer's pledged revenue streams, not their entire balance sheet.Project Bond\u2022 Proceeds are earmarked for a specific project or group of projects.Project Bond\u2022 Recourse is limited to those project(s) assets and balance sheet.Securitised Bond\u2022 Bond is collateralised by one or more revenue generating green projects e.g. loan repayments on rooftop solar packages.Securitised Bond\u2022 Project revenue is used to repay the bond and recourse is limited to the collateralised assets.Securitised BondSource: (Banga, 2019; Berensmann et al., 2018; ICMA, 2018) .Securitised Bond(footnote continued) regulation has allowed environmentally dubious coal power and petrochemical projects to be funded by green bonds (EuroMoney, 2019) measures addressing fiduciary duty, benchmarks and product labels, and the incorporation of environmental factors into the management of financial risk (European Commission, 2020).", [["coal", "CHEMICAL", 982, 986], ["rooftop solar packages", "TREATMENT", 686, 708], ["petrochemical projects", "TREATMENT", 997, 1019]]], ["Alongside controversial bond issues from major energy companies (Dupr\u00e9, 2019) , this fed into a wider debate about whether transitional activities-such as moving from coal to gas-fired power-have a place in the labelled bond universe (Cripps, 2019b) .", [["coal", "CHEMICAL", 167, 171], ["transitional activities", "PROBLEM", 123, 146], ["bond", "OBSERVATION_MODIFIER", 24, 28]]], ["Several new bond labels emerged as the market reportedly evolves in response to the environmental crisis (Cripps, 2019c) .", [["Several new bond labels", "PROBLEM", 0, 23], ["the environmental crisis", "PROBLEM", 80, 104], ["new", "OBSERVATION_MODIFIER", 8, 11], ["bond labels", "OBSERVATION", 12, 23]]], ["Despite concerns this was splitting hairs (Hurley, 2019a) , green bond growth returned to form in 2019.", [["hairs", "ANATOMY", 36, 41], ["hairs", "TISSUE", 36, 41], ["green bond growth", "TEST", 60, 77]]], ["Non-financial corporates became the dominant issuers, though sovereign participation is growing too.", [["dominant", "OBSERVATION_MODIFIER", 36, 44]]], ["The size of their deals is one reason the market was predicted to pass one trillion in annual issuances within four years (Cooper, 2020b) .Securitised BondThe Covid-19 pandemic, of course, had immediate impact on the green bond market.", [["The Covid", "TEST", 155, 164], ["size", "OBSERVATION_MODIFIER", 4, 8]]], ["New issues in March slumped to $US 5 billion after $29 billion was recorded in January and February (Cooper, 2020a) .", [["New issues", "PROBLEM", 0, 10]]], ["Overall supply in the first four months of 2020 was subsequently down 9% on the same period last year (Hurley, 2020) .", [["supply", "OBSERVATION_MODIFIER", 8, 14]]], ["A quick rebound was anticipated as Europe moved to implement its 'Green Deal' and preparations for the COP26 climate change summit got underway (Hurley, 2020) .", [["A quick rebound", "PROBLEM", 0, 15]]], ["There was also some evidence green bonds outperformed vanilla bonds in March's tumultuous market conditions (Avery, 2020) .", [["green bonds", "OBSERVATION", 29, 40], ["vanilla bonds", "OBSERVATION", 54, 67]]], ["Finally, market leadership was observed in the way some recent vanilla bonds, issued in response to the health crisis, eschewed the standard practice of declaring proceeds were for \"general corporate purposes\" (Cripps, 2020; Eckhart, 2020) .", [["vanilla bonds", "OBSERVATION", 63, 76]]], ["They were, instead, following the use-of-proceeds model green bonds promoted by declaring how the credit would be spent (Cripps, 2020) .Practical ChallengesThe green bond market has experienced rapid growth since the first issue in 2007.", [["Practical Challenges", "TREATMENT", 136, 156], ["rapid growth", "PROBLEM", 194, 206], ["green bond", "OBSERVATION", 160, 170], ["rapid", "OBSERVATION_MODIFIER", 194, 199], ["growth", "OBSERVATION_MODIFIER", 200, 206]]], ["Green bond demand routinely outstrips supply and the market's infrastructure continues to mature.", [["bond demand", "OBSERVATION", 6, 17]]], ["The Chief Investment Officer of a trillion dollar pension fund described green bonds as a \"lose-lose product\" because they cost more to issue and are harder to trade than conventional bonds (Cooper, 2018) .", [["a trillion dollar pension", "TREATMENT", 32, 57]]], ["There is also a growing academic and grey literature focused on the barriers to green bond market development in politics (Chiang, 2017) , law (Wang, 2018) , finance (Banga, 2019) and economics (Shishlov et al., 2016) .", [["a growing academic and grey literature", "PROBLEM", 14, 52], ["growing", "OBSERVATION_MODIFIER", 16, 23]]], ["This literature focuses on the potential benefits of green bonds and considers the measures needed to grow its size and impact.", [["green bonds", "PROBLEM", 53, 64], ["size", "OBSERVATION_MODIFIER", 111, 115]]], ["Below we describe the key practical challenges identified in this work.Protecting Product IntegrityA commonly cited challenge for green bond market development is protecting the integrity of the financial product.", [["Product IntegrityA", "TREATMENT", 82, 100], ["green bond market", "TREATMENT", 130, 147]]], ["There is no universally accepted definition of what green means or a common international standard for determining green bond eligibility (Shishlov et al., 2016; Talbot, 2017) .", [["no universally", "UNCERTAINTY", 9, 23]]], ["Externally assured compliance with industry standards is considered good practice, but it is not legally mandated and there is no strong enforcement mechanism to hold issuers accountable to them (Wang, 2018) .", [["no", "UNCERTAINTY", 127, 129]]], ["Observers argue this differentiated, self-regulating environment is creating reputational and legal risks that undermine the integrity of green bonds (Berensmann et al., 2018; Talbot, 2017) .Protecting Product IntegrityReputational risk stems primarily from the potential for greenwashing, where green bonds are implicated in superficial displays of environmental concern.", [["green bonds", "SIMPLE_CHEMICAL", 296, 307], ["greenwashing", "PROBLEM", 276, 288], ["green bonds", "PROBLEM", 296, 307], ["IntegrityReputational risk stems", "OBSERVATION", 210, 242]]], ["There are already controversial cases where green bonds have financed environmentally dubious or destructive projects.", [["green bonds", "OBSERVATION", 44, 55], ["destructive", "OBSERVATION_MODIFIER", 97, 108]]], ["This includes a 725 space parking garage in the U.S. (Berensmann et al., 2018) , coal-fired power and petrochemical factories in China (EuroMoney, 2019), and a Brazilian hydropower dam with negative social and ecological impacts (Bracking, 2015) .", [["petrochemical factories", "OBSERVATION", 102, 125]]], ["The absence of strong and consistent regulation means issuers are not prevented from financing these projects with green bonds (Talbot, 2017) .", [["strong", "OBSERVATION_MODIFIER", 15, 21]]], ["A lack of uniform and enforceable standards also makes it difficult to assess the environmental benefits of a green bond (Berensmann et al., 2018) .", [["A lack of uniform and enforceable standards", "PROBLEM", 0, 43], ["uniform", "OBSERVATION_MODIFIER", 10, 17]]], ["There are no legally binding standards for disclosing how proceeds are used or reporting on the environmental impact of green bond projects (Berensmann et al., 2018) .", [["no", "UNCERTAINTY", 10, 12]]], ["This can undermine the product's credibility and diminish investor confidence in the market (Berensmann et al., 2018; Talbot, 2017; Wang, 2018) .Protecting Product IntegrityThe second concern with green bond integrity is the legal risk of \"green default\" or environmental non-performance (Shishlov et al., 2016, p.", [["green bond integrity", "PROBLEM", 197, 217], ["Integrity", "OBSERVATION_MODIFIER", 164, 173], ["green bond integrity", "OBSERVATION", 197, 217]]], ["If an investor purchased green bonds, and the use of proceeds did not satisfy standards of green-ness, this may constitute a legal case of misguiding the customer using false information (Shishlov et al., 2016) .", [["green bonds", "OBSERVATION", 25, 36]]], ["The risk for investors is a lack of firm, harmonised standards may diminish their legal recourse for green default.", [["a lack of firm", "PROBLEM", 26, 40], ["green default", "PROBLEM", 101, 114], ["firm", "OBSERVATION", 36, 40]]], ["This would make it difficult for the court to assess damages in the event of environmental non-performance.", [["damages", "PROBLEM", 53, 60]]], ["This lack of accountability harms the market's credibility and diminishes investor confidence in the integrity of green bonds (Ludvigsen, 2015; Talbot, 2017) .", [["green bonds", "OBSERVATION", 114, 125]]], ["Dishonest borrowers may feel confident in building environmentally dubious infrastructure without fear of green default.", [["green default", "PROBLEM", 106, 119], ["green default", "OBSERVATION", 106, 119]]], ["On the other hand, bona fide low-carbon infrastructure may be harder to finance if poor product integrity convinces investors that green projects have higher risks and lower returns (see : Campiglio, 2016) .Enhancing Product PerformanceThe second practical challenge for green bonds is improving their environmental and financial performance.", [["carbon", "CHEMICAL", 33, 39], ["The second practical challenge", "TREATMENT", 236, 266], ["green bonds", "PROBLEM", 271, 282], ["low", "OBSERVATION_MODIFIER", 29, 32], ["carbon infrastructure", "OBSERVATION", 33, 54], ["green bonds", "OBSERVATION", 271, 282]]], ["Green bonds have thus been criticised for repackaging regular bonds without achieving additionality (Dupre et al., 2018; Shishlov et al., 2016) .", [["Green bonds", "SIMPLE_CHEMICAL", 0, 11]]], ["This has profound spatial implications because our ability to instigate new mitigation and adaptation projects will shape climate change's severity in our cities and regions.", [["profound", "OBSERVATION_MODIFIER", 9, 17], ["spatial", "OBSERVATION_MODIFIER", 18, 25]]], ["The assumption, then, is that improving green bonds' financial performance will enhance their environmental impact.Enhancing Product PerformanceThree key elements identified for improvement are lowering capital costs for issuers, increasing liquidity for investors, and integrating environmental risk into fixed-income indices and credit ratings.Enhancing Product PerformanceTo achieve additionality, green bonds will need to lower the cost of capital so they can finance projects that would otherwise be too expensive (Chiang, 2017; Shishlov et al., 2016) .", [["Product PerformanceThree key elements", "DNA", 125, 162], ["improving green bonds' financial performance", "PROBLEM", 30, 74], ["improvement", "OBSERVATION_MODIFIER", 178, 189], ["green bonds", "OBSERVATION", 401, 412]]], ["The first contradiction is that lowering capital costs misaligns the interests of issuers and investors (Shishlov et al., 2016) .", [["lowering", "OBSERVATION_MODIFIER", 32, 40]]], ["Green bonds need to provide cheaper debt than regular bonds to stimulate additional investment in environmentally beneficial projects.", [["Green bonds", "PROBLEM", 0, 11]]], ["Issuing green bonds incurs added transaction costs for external verification, monitoring use-of-proceeds, and post-issuance reporting that can reach $US 100,000 (Banga, 2019; OECD, 2017) .", [["external verification", "TEST", 55, 76], ["green bonds", "OBSERVATION", 8, 19]]], ["This means some borrowers face higher transaction costs and higher interest rates for issuing green bonds.", [["green bonds", "SIMPLE_CHEMICAL", 94, 105], ["green bonds", "OBSERVATION", 94, 105]]], ["The procedures for protecting product integrity can therefore increase the cost of capital when a decrease is needed to achieve additionality.", [["The procedures", "TREATMENT", 0, 14], ["protecting product integrity", "TREATMENT", 19, 47]]], ["Conflicting imperatives could be nullified if the weight of investor demand, or their willingness to accept lower yields for environmental benefit, gives green bonds a price advantage over regular bonds.Enhancing Product PerformanceIn the absence of higher yields, growing investor demand would be supported by increasing liquidity and improving the debt market's evaluation infrastructure.", [["higher yields", "PROBLEM", 250, 263], ["growing investor demand", "PROBLEM", 265, 288], ["increasing liquidity", "PROBLEM", 311, 331], ["higher yields", "OBSERVATION_MODIFIER", 250, 263], ["increasing", "OBSERVATION_MODIFIER", 311, 321], ["liquidity", "OBSERVATION", 322, 331]]], ["The limited secondary markets for trading green bonds are thus identified as a handbrake on demand (OECD, 2017).", [["green bonds", "OBSERVATION", 42, 53]]], ["Some U.S. investors are deterred by the market's illiquidity (Chiang, 2017) .", [["investors", "OBSERVATION", 10, 19]]], ["Our initial interviews with Australasian fund managers suggests the same, though emerging evidence from Europe indicates anxiety about illiquidity may be waning there (Febi et al., 2018) .", [["anxiety", "DISEASE", 121, 128], ["illiquidity", "DISEASE", 135, 146], ["anxiety", "PROBLEM", 121, 128]]], ["The preferred solution, in any case, is increasing the size of new green bond issues (Chiang, 2017; Timbers et al., 2014) . $US 200-250 million is seen as the minimum size needed to support liquidity, though many issuers cannot initiate environmental projects that support that volume (Banga, 2019; Chiang, 2017) .", [["new green bond issues", "PROBLEM", 63, 84], ["size", "OBSERVATION_MODIFIER", 55, 59], ["new", "OBSERVATION_MODIFIER", 63, 66], ["green bond", "OBSERVATION", 67, 77]]], ["This is one area where state intervention can make a profound difference.", [["a profound difference", "PROBLEM", 51, 72]]], ["The New South Wales government increased supply in the Australian market by 20% with an $AU 1.8 billion issue for public transport and water recycling projects (KangaNews, 2018).Enhancing Product PerformanceImproving fixed-income evaluation is another way of enhancing market performance and investor demand.", [["an $AU 1.8 billion issue", "TREATMENT", 85, 109], ["public transport", "TREATMENT", 114, 130], ["income evaluation", "TEST", 223, 240], ["New", "OBSERVATION_MODIFIER", 4, 7], ["South", "OBSERVATION_MODIFIER", 8, 13], ["enhancing", "OBSERVATION_MODIFIER", 259, 268]]], ["While green bond and ESG 2 conscious indices continue to develop, their penetration into conventional portfolio allocation remains marginal (HLEGSF, 2018b).", [["conscious indices", "TEST", 27, 44], ["marginal", "OBSERVATION_MODIFIER", 131, 139]]], ["Traditional benchmarks also fail to reflect the opportunities and risks of environmental change as they are not adequately incorporated into the valuation of exchange-traded bonds.", [["environmental change", "PROBLEM", 75, 95]]], ["This inhibits green bond demand as investors following traditional benchmarks will tend to allocate capital to assets that are not aligned with environmental imperatives (HLEGSF, 2018b).", [["green bond demand", "PROBLEM", 14, 31], ["traditional benchmarks", "TREATMENT", 55, 77], ["green bond", "OBSERVATION", 14, 24]]], ["ESG data was first developed for equities and so it's not quite fit for purpose when investors want to assess the credit materiality of ESG issues (Hurley, 2019b) .", [["ESG data", "TEST", 0, 8]]], ["This helps explain why credit rating agencies currently fail to adequately consider the influence of long-term environmental risks on future creditworthiness (HLEGSF, 2018b; Hurley, 2019b).Globalising the MarketThe third challenge for growing green bonds is globalising the market by increasing the number of countries where green bonds can be issued and purchased.", [["The third challenge", "TREATMENT", 211, 230], ["growing green bonds", "PROBLEM", 235, 254], ["growing", "OBSERVATION_MODIFIER", 235, 242], ["green bonds", "OBSERVATION", 243, 254], ["increasing", "OBSERVATION_MODIFIER", 284, 294]]], ["Two key issues are identified in discussions of how to globalise the green bond market: improving local access for foreign investment and developing market capacity in countries of the global south.", [["foreign investment", "TREATMENT", 115, 133]]], ["Low-income countries of the global south have the greatest need for green finance, but they currently receive very limited proceeds from green bonds.", [["green bonds", "SIMPLE_CHEMICAL", 137, 148]]], ["Only 6.5% of global green issuance flowed to Africa and Asia (excluding China) between 2007 and 2016 (Banga, 2019) .Globalising the MarketA key challenge for growing green bonds is enhancing local market access for an emerging class of global green investors (OECD, 2017).", [["the MarketA key challenge", "TREATMENT", 128, 153], ["growing green bonds", "PROBLEM", 158, 177], ["6.5%", "OBSERVATION_MODIFIER", 5, 9], ["green bonds", "OBSERVATION", 166, 177], ["enhancing", "OBSERVATION_MODIFIER", 181, 190]]], ["In the U.S., for example, the country's tax settings limit foreign access to the green component of their multi-trillion dollar municipal bond market (Bigger, 2017; Chiang, 2017) .", [["green", "OBSERVATION_MODIFIER", 81, 86], ["component", "OBSERVATION_MODIFIER", 87, 96]]], ["Capital gains from municipal bonds are generally tax exempt and so the market is primarily patronised by domestic investors who use it as a tax shield.", [["tax", "PROTEIN", 49, 52], ["municipal bonds", "OBSERVATION", 19, 34]]], ["Lower rates make municipal bonds less desirable to major international investors, like foreign pension funds and insurance companies, who do not have U.S. tax liabilities to offset smaller returns.", [["tax", "PROTEIN", 155, 158], ["municipal bonds", "OBSERVATION", 17, 32]]], ["The tax exemption is thus described as an \"important hindrance\" to greening the municipal bond market and using it to finance the massive climate-related infrastructure needs in the U.S. (Bigger, 2017; Chiang, 2017, p.", [["tax", "PROTEIN", 4, 7]]], ["Firstly, limited market access for international investors can be self-imposed by their own conditions of fiduciary responsibility (Bigger, 2017) .", [["international investors", "TREATMENT", 35, 58]]], ["Many U.S. and European pension funds are only authorised to invest in AA/AAA rated bonds 3 .", [["AA", "CHEMICAL", 70, 72], ["European pension funds", "TREATMENT", 14, 36], ["AAA", "ANATOMY", 73, 76]]], ["Debt issued in the global south, with smaller projects and lower credit ratings, is therefore off-limits to major institutional investors from the global north (Bigger, 2017) .", [["smaller projects and lower credit ratings", "PROBLEM", 38, 79], ["global", "OBSERVATION_MODIFIER", 19, 25], ["south", "OBSERVATION_MODIFIER", 26, 31], ["smaller", "OBSERVATION_MODIFIER", 38, 45], ["lower", "OBSERVATION_MODIFIER", 59, 64], ["credit", "OBSERVATION", 65, 71]]], ["Secondly, countries with inconvertible currencies-such as the Angolan kwanza or the Chilean peso-limit foreign access to their domestic debt markets (Banga, 2019) .Globalising the Market2 ESG refers to the Environmental, Social, and Governance criteria investors may use to evaluate and predict an investee's performance.", [["Market2 ESG", "DNA", 180, 191], ["inconvertible currencies", "PROBLEM", 25, 49], ["the Angolan kwanza", "TREATMENT", 58, 76]]], ["Performance can be defined in ethical terms, financial terms, or both.Globalising the Market3 AA/AAA are the best ratings a bond offering can receive from the major credit rating agencies.", [["AAA", "PROBLEM", 97, 100], ["AAA", "OBSERVATION", 97, 100]]], ["These agencies consider AA/AAA issuers the least likely to default i.e. fail to repay their investors.Globalising the MarketInconvertible currency is money that cannot be converted to another country's legal tender and traded on foreign exchanges (Chen, 2019) .", [["AA", "CHEMICAL", 24, 26], ["AA/AAA issuers", "TREATMENT", 24, 38], ["Market", "OBSERVATION_MODIFIER", 118, 124], ["Inconvertible currency", "OBSERVATION", 124, 146]]], ["This protects local economies from rapid capital outflow (Chen, 2017) , but it also hinders green bond growth by creating a currency risk for foreign investors (Banga, 2019) .", [["green bond growth", "PROBLEM", 92, 109], ["local", "OBSERVATION_MODIFIER", 14, 19], ["economies", "OBSERVATION", 20, 29], ["rapid", "OBSERVATION_MODIFIER", 35, 40], ["capital outflow", "ANATOMY", 41, 56], ["green bond", "OBSERVATION", 92, 102]]], ["Small domestic credit markets in developing countries means they would typically need to issue green bonds in foreign currencies to raise large amounts of capital in international markets.", [["Small domestic credit markets", "PROBLEM", 0, 29], ["green bonds in foreign currencies", "PROBLEM", 95, 128], ["domestic", "OBSERVATION_MODIFIER", 6, 14], ["credit markets", "OBSERVATION", 15, 29], ["foreign currencies", "OBSERVATION", 110, 128], ["large", "OBSERVATION_MODIFIER", 138, 143], ["amounts", "OBSERVATION_MODIFIER", 144, 151], ["capital", "OBSERVATION_MODIFIER", 155, 162]]], ["With the revenue flows of financed projects held in local currency, borrowers and lenders may not be able to convert repayments of interest and principal back into foreign currencies (Banga, 2019) .", [["financed projects", "TREATMENT", 26, 43]]], ["The second issue in the global south is the institutional and market barriers of minimum size, transaction costs, and technical capacity.", [["second", "OBSERVATION_MODIFIER", 4, 10], ["issue", "OBSERVATION", 11, 16], ["minimum", "OBSERVATION_MODIFIER", 81, 88], ["size", "OBSERVATION_MODIFIER", 89, 93]]], ["Minimum size is the minimum value a green bond should bear to support liquidity and appeal to bond underwriters (Banga, 2019) . $US 200-250 million is generally considered the minimum value needed to support liquidity, interest the underwriters, and be eligible for green bond indices (Banga, 2019; Chiang, 2017) .", [["green bond indices", "TEST", 266, 284], ["size", "OBSERVATION_MODIFIER", 8, 12]]], ["Low-income countries of the global south generally have smaller, standalone projects with financing needs that will not satisfy minimum size (Banga, 2019; Berensmann et al., 2018) .", [["smaller", "OBSERVATION_MODIFIER", 56, 63]]], ["Transaction costs for verification, monitoring, and reporting also impede market growth (Banga, 2019; OECD, 2017) .", [["verification, monitoring", "TEST", 22, 46]]], ["Without a pricing benefit for green bonds, this would be a significant barrier for smaller borrowers (Banga, 2019; OECD, 2017) .", [["green bonds", "SIMPLE_CHEMICAL", 30, 41], ["green bonds", "PROBLEM", 30, 41]]], ["They may also lack some of the technical assessment and administration skills needed to ensure projects are implemented according to international standards (Banga, 2019) .Political ConcernsThe practical challenges outlined above highlight the key hurdles to increasing the size and impact of the green bond market.", [["the technical assessment", "TEST", 27, 51], ["administration skills", "TREATMENT", 56, 77], ["The practical challenges", "TREATMENT", 190, 214], ["size", "OBSERVATION_MODIFIER", 274, 278], ["green bond", "OBSERVATION", 297, 307]]], ["What's typically left unconsidered is green bonds' socio-political context and wider questions about finance's place in the transition towards sustainability.", [["green bonds", "OBSERVATION", 38, 49]]], ["These issues are starting points for the emerging critical scholarship on green bonds.", [["green bonds", "SIMPLE_CHEMICAL", 74, 85], ["green bonds", "OBSERVATION", 74, 85]]], ["This literature has primarily focused on how value and risk is being (re)produced and (re)distributed by green bonds.", [["green bonds", "OBSERVATION", 105, 116]]], ["Initial observations suggest green bonds risk prioritising financial profits over environmental outcomes, as well as amplifying inequality with lopsided ratios of financial and environmental risk and reward.Incomes over OutcomesThe first political concern emerges from the scholarship on value and evaluation in the green bond market (Tripathy, 2017) .", [["evaluation", "TEST", 298, 308], ["green bonds", "OBSERVATION", 29, 40]]], ["This initial research suggests green bond profitability has no strict, commensurate relationship with their environmental benefit.", [["green bond profitability", "PROBLEM", 31, 55], ["green bond profitability", "OBSERVATION", 31, 55]]], ["This disconnection therefore risks creating a situation where green bonds favour incomes over outcomes.Incomes over OutcomesThis concern is best demonstrated in the work of Bracking (2015) and Hilbrandt and Grubbauer's (2020) study of standard setting organisations (SSOs).", [["This disconnection", "PROBLEM", 0, 18]]], ["As we saw earlier, the GBPs and the CBS are the two frameworks that set standards of environmental benefit by specifying project eligibility for green bonds.", [["green bonds", "SIMPLE_CHEMICAL", 145, 156], ["the GBPs", "TEST", 19, 27], ["the CBS", "TEST", 32, 39]]], ["Green bonds essentially relabelled projects and debt that were already planned as part of the city's existing development and capital expenditure programs.", [["capital expenditure programs", "TREATMENT", 126, 154], ["bonds", "OBSERVATION_MODIFIER", 6, 11]]], ["This observation lends credence to Bracking's (2015) speculative analysis of green bond use value.", [["This observation", "TEST", 0, 16]]], ["In this case, Bracking uses the example of the Clean Development Mechanism (CDM) in South Africa to consider the 'fictive' effect of green bond certification.", [["green bond certification", "TREATMENT", 133, 157], ["green bond", "OBSERVATION", 133, 143]]], ["The CDM is a Kyoto protocol mechanism.", [["CDM", "CHEMICAL", 4, 7], ["The CDM", "PROBLEM", 0, 7], ["CDM", "OBSERVATION", 4, 7]]], ["It allows for developing countries to produce carbon credits that can be sold into emission trading schemes overseas.", [["carbon", "CHEMICAL", 46, 52], ["carbon credits", "TREATMENT", 46, 60]]], ["At least 15 CDM projects had weak cases of additionality.", [["CDM", "CHEMICAL", 12, 15], ["weak cases of additionality", "PROBLEM", 29, 56], ["weak", "OBSERVATION_MODIFIER", 29, 33]]], ["For example, one project captured waste gases from a closed mine furnace even though that measure was already mandated by South Africa's air quality laws.", [["a closed mine furnace", "TREATMENT", 51, 72], ["mine furnace", "OBSERVATION", 60, 72]]], ["A second gas project was also included with the claim it reduced carbon emissions by allowing a company to cancel their plans for a new coal mine.", [["carbon", "CHEMICAL", 65, 71], ["coal", "CHEMICAL", 136, 140], ["A second gas project", "TREATMENT", 0, 20], ["a new coal mine", "TREATMENT", 130, 145], ["carbon emissions", "OBSERVATION", 65, 81]]], ["However, there was only weak proof the mine would have ever been built (Bracking, 2015) .Incomes over OutcomesOne lesson Bracking (2015) takes from the South African CDM is that carbon credits can be produced, sold, and traded with only weak evidence of environmental improvement.", [["carbon", "CHEMICAL", 178, 184], ["weak", "OBSERVATION_MODIFIER", 24, 28]]], ["Carbon markets had no strong institutional reason for trade to reflect the quality of the underlying assets beyond the issue of reputational risk.", [["Carbon", "CHEMICAL", 0, 6], ["Carbon markets", "TREATMENT", 0, 14], ["no", "UNCERTAINTY", 19, 21]]], ["This is because:Incomes over OutcomesIn the case of carbon trading\u2026the value of the underlying asset, the dirty industry 'cleaning up' or sequestrating part of 'nature', is of little temporal interest after the initial rating or certification, or scientific confirmation of carbon to be 'saved', has been made (Bracking, 2015 (Bracking, , p.", [["carbon", "CHEMICAL", 52, 58], ["carbon", "CHEMICAL", 274, 280], ["carbon trading", "TREATMENT", 52, 66]]], ["2341 .Incomes over OutcomesThis temporal disinterest is partly explained by the fact that, for some actors at least, a carbon credit's value is determined by its certification more than the projects that produced it.", [["2341", "CHEMICAL", 0, 4], ["carbon", "CHEMICAL", 119, 125], ["a carbon credit's value", "TEST", 117, 140]]], ["Certification is what makes the carbon credit tradeable-evaluation partially generates the asset itself-so there is little institutional incentive to check on the impact of the underlying projects once the credits are certified.", [["carbon", "CHEMICAL", 32, 38], ["evaluation", "TEST", 56, 66]]], ["Carbon credits, produced by dubious projects with weak proof of additionality, could be freely traded and profited from so long as they were certified.", [["Carbon", "CHEMICAL", 0, 6], ["Carbon credits", "TEST", 0, 14]]], ["Green bonds have not achieved additionality and already have a record of financing environmentally dubious projects.", [["Green bonds", "SIMPLE_CHEMICAL", 0, 11]]], ["Reputational risk is also the primary reason for green bond trade to bear some connection to the green-ness of the projects they finance.", [["green bond trade", "PROBLEM", 49, 65]]], ["This risk is currently managed by several different regimes of evaluation-enshrined in the CBS, the GBPs, and eligibility criteria for green bond indices (see: GBP DIWG, 2017)-that vary in stringency and technical specification.", [["evaluation", "TEST", 63, 73], ["the CBS", "TEST", 87, 94], ["the GBPs", "TEST", 96, 104], ["green bond indices", "TEST", 135, 153], ["GBP DIWG", "TEST", 160, 168], ["technical specification", "OBSERVATION", 204, 227]]], ["This can add further complexity to the temporal distance observed in the carbon market.", [["carbon", "CHEMICAL", 73, 79], ["temporal", "OBSERVATION_MODIFIER", 39, 47], ["carbon market", "OBSERVATION", 73, 86]]], ["2347 .Incomes over OutcomesIf evaluation partially generates the financial asset itself, then green bonds will trade with varying degrees of fidelity to the environmental value of their underlying projects.", [["evaluation", "TEST", 30, 40]]], ["Green bonds could therefore favour financial incomes over environmental outcomes.", [["Green bonds", "PROBLEM", 0, 11], ["bonds", "OBSERVATION", 6, 11]]], ["The environmental value of the underlying projects could remain quite modest, even while the monetary value of the green bond market rises rapidly (Bracking, 2015) .Amplifying InequalityThe second political concern emerges from scholarship on value and risk in the green bond market.", [["green bond", "OBSERVATION", 265, 275]]], ["This analysis has primarily focused on the relation between risk and surplus value (Christophers, 2018b) ; the way risk may coordinate multiple units of value in the green economy (Bracking, 2019) ; as well as the (re)constitution of risk across different scales and social groups (Bigger and Millington, 2019; .", [["This analysis", "TEST", 0, 13]]], ["Initial research suggests green bonds can heavily skew the risk-reward ratio in favour of investors while exposing different publics to increased financial and environmental risk.Amplifying InequalityThe risk of amplifying inequality is demonstrated most clearly in two recent articles.", [["green bonds", "PROBLEM", 26, 37], ["green bonds", "OBSERVATION", 26, 37], ["increased", "OBSERVATION_MODIFIER", 136, 145]]], ["In New York City, green bonds were issued by the local government to finance repairs and upgrades to the subway system after Super-storm Sandy in 2012.", [["finance repairs", "TREATMENT", 69, 84], ["New", "OBSERVATION_MODIFIER", 3, 6], ["green bonds", "OBSERVATION", 18, 29]]], ["The subway is critical infrastructure for the city's low-income workers-particularly women and people of colour in the service industry-as they have limited transportation options relative to the subway's whiter, higher-income commuters.", [["women", "ORGANISM", 85, 90], ["people", "ORGANISM", 95, 101], ["women", "SPECIES", 85, 90], ["people", "SPECIES", 95, 101], ["critical", "OBSERVATION_MODIFIER", 14, 22], ["infrastructure", "OBSERVATION", 23, 37]]], ["The New York City subway system is a scarce asset and retail bondholders would derive an income from it.", [["New", "OBSERVATION_MODIFIER", 4, 7]]], ["11) .Amplifying InequalityThe second case is Christophers' (2018a) analysis of green bonds used to finance the Clean Rivers Project (CRP) in Washington D.C. The 2005 CRP was DC Water's solution to the sewer overflows polluting the Potomac River, the Anacostia River, and Rock Creek.", [["green bonds", "TREATMENT", 79, 90], ["CRP", "TEST", 166, 169], ["DC Water's solution", "TREATMENT", 174, 193]]], ["It was initially designed as a $US 2.5 billion grey infrastructure scheme that would install deep tunnel systems on each of the waterways to store sewerage for treatment.", [["deep tunnel systems", "TREATMENT", 93, 112], ["treatment", "TREATMENT", 160, 169]]], ["By 2015, however, project debt had ballooned before the first tunnel was even completed.", [["the first tunnel", "TREATMENT", 52, 68]]], ["DC Water's long-term debt grew from $US 785 million (2004) to $2.5 billion (2014).", [["DC", "ANATOMY", 0, 2]]], ["This precipitated a two-fold change to the CRP.", [["CRP", "GENE_OR_GENE_PRODUCT", 43, 46], ["CRP", "PROTEIN", 43, 46], ["a two-fold change", "PROBLEM", 18, 35], ["the CRP", "TEST", 39, 46], ["two-fold", "OBSERVATION_MODIFIER", 20, 28]]], ["Firstly, there was a shift from grey to green infrastructure solutions.", [["a shift from grey to green infrastructure solutions", "PROBLEM", 19, 70], ["green infrastructure", "OBSERVATION", 40, 60]]], ["The Potomac River Tunnel would be reduced, and the Rock Creek Tunnel replaced, with a network of rain gardens and permeable paving designed to reduce storm water inflows.", [["The Potomac River Tunnel", "TREATMENT", 0, 24], ["the Rock Creek Tunnel", "TREATMENT", 47, 68], ["storm water inflows", "TREATMENT", 150, 169], ["River Tunnel", "OBSERVATION", 12, 24], ["reduced", "OBSERVATION_MODIFIER", 34, 41], ["Creek Tunnel", "OBSERVATION", 56, 68]]], ["DC Water issued $US 1.5 billion in conventional municipal bonds between 2007 and 2013.", [["DC", "ANATOMY", 0, 2], ["DC", "CELL_TYPE", 0, 2]]], ["This was followed by green bond issues of $US 350 million (2014), $100 million (2015), $25 million (2016), and $100 million (2017).Amplifying InequalityThe 2016 issue is particularly noteworthy as it was a much-lauded, first-of-its-kind environmental impact bond (EIB).", [["EIB", "DISEASE", 264, 267]]], ["The EIB was for the Rock Creek projects only.", [["EIB", "DISEASE", 4, 7]]], ["It was issued for 30 years, with an interest rate of 3.43%, and a $US 3.3 million payment contingent on the project's performance in 2021.", [["an interest rate", "TEST", 33, 49], ["the project's performance", "TEST", 104, 129]]], ["The green infrastructure was expected to achieve runoff reductions between 18.6% and 41.3%.", [["runoff reductions", "TEST", 49, 66], ["green infrastructure", "OBSERVATION", 4, 24], ["runoff", "OBSERVATION_MODIFIER", 49, 55], ["reductions", "OBSERVATION_MODIFIER", 56, 66]]], ["If the project exceeds these expectations, DC Water will make the contingent payment to investors.", [["DC", "ANATOMY", 43, 45], ["DC", "CELL_TYPE", 43, 45]]], ["If the project underperforms, then bondholders will collectively pay $3.3 million to DC Water.", [["DC", "ANATOMY", 85, 87], ["DC", "CELL_TYPE", 85, 87]]], ["The latter scenario principally provides a compensation payment that DC Water could use to address deficiencies with the green infrastructure.", [["DC", "ANATOMY", 69, 71], ["DC", "CELL_TYPE", 69, 71], ["a compensation payment", "TREATMENT", 41, 63], ["the green infrastructure", "PROBLEM", 117, 141], ["green infrastructure", "OBSERVATION", 121, 141]]], ["The Rock Creek EIB, then is ostensibly structured as a hedge against performance risk for DC Water.Amplifying InequalityChristophers (2018a) suggests the modified plan heavily favours investors while amplifying the financial and environmental risk to the public.", [["DC", "ANATOMY", 90, 92], ["DC", "CELL_TYPE", 90, 92], ["The Rock Creek EIB", "TEST", 0, 18], ["Creek EIB", "OBSERVATION", 9, 18]]], ["This meant investors charged DC Water an extra $US 210,000 for a green label that has no discernible effect on sewerage overflows.", [["DC", "ANATOMY", 29, 31], ["no discernible", "UNCERTAINTY", 86, 100], ["effect", "OBSERVATION_MODIFIER", 101, 107], ["sewerage overflows", "OBSERVATION", 111, 129]]], ["The proposition looks even worse for the EIB, which Christophers compares to the 0.98% coupon on a similarly rated, five-year municipal bond.", [["EIB", "DISEASE", 41, 44]]], ["In the underperformance scenario, where investors pay DC Water $3.3 million, the effective interest rate would be 0.81%.", [["DC", "CELL_TYPE", 54, 56]]], ["If the green infrastructure performs to expectation, the interest rate will be 3.43%.", [["the interest rate", "TEST", 53, 70], ["green infrastructure", "OBSERVATION", 7, 27]]], ["In the over-performance scenario, where DC Water pays investors $3.3 million, the effective interest rate would rise to 5.8%.", [["DC", "ANATOMY", 40, 42], ["DC", "CELL_TYPE", 40, 42]]], ["This means DC Water could end up paying almost six times the market rate to borrow with the EIB.", [["DC", "ANATOMY", 11, 13], ["EIB", "DISEASE", 92, 95], ["DC", "CELL_TYPE", 11, 13]]], ["The financial risk is overwhelmingly carried by DC Water and the public that ultimately services its debt.Amplifying InequalityThis inequity is made worse by the fact the EIB would not provide underperformance insurance for anything but minor deficiencies to the green infrastructure.", [["DC", "ANATOMY", 48, 50], ["EIB", "DISEASE", 171, 174], ["minor deficiencies", "PROBLEM", 237, 255], ["green infrastructure", "OBSERVATION", 263, 283]]], ["In the event of major failure, DC Water's Chief Financial Officer admitted the $3.3 million payment would only partially cover the cost of testing the green infrastructure solution.", [["DC", "ANATOMY", 31, 33], ["major failure", "PROBLEM", 16, 29], ["major", "OBSERVATION_MODIFIER", 16, 21], ["failure", "OBSERVATION", 22, 29]]], ["Even if it did cover construction costs, DC Water would still face the added expense of reverting to the tunnel systems in the original plan.", [["DC", "ANATOMY", 41, 43], ["DC", "CELL_TYPE", 41, 43]]], ["There would also be the amplified environmental risk to DC residents as sewer overflows continued to enter Rock Creek in the intervening years.", [["DC", "ANATOMY", 56, 58], ["DC", "CELL_TYPE", 56, 58]]], ["The waterways and ratepayers of Washington D.C. would ultimately bear the cost of failure though an increased debt and pollution burden.", [["Washington D.C.", "TREATMENT", 32, 47], ["failure", "PROBLEM", 82, 89], ["an increased debt", "PROBLEM", 97, 114], ["pollution burden", "PROBLEM", 119, 135], ["waterways", "OBSERVATION_MODIFIER", 4, 13], ["failure", "OBSERVATION", 82, 89], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["debt", "OBSERVATION", 110, 114], ["pollution burden", "OBSERVATION", 119, 135]]], ["These inequities are why Christophers (2018a) suggests green is not necessarily good when it comes to financial products.ConclusionThe globally inequitable demand for environmental resources and services has driven us into an ecological deficit that is diminishing the planet's ability to support life as we know it.", [["an ecological deficit", "PROBLEM", 223, 244]]], ["Green bonds, for their part, herald the promise of treating this ecological deficit with debt.", [["Green bonds", "SIMPLE_CHEMICAL", 0, 11], ["this ecological deficit", "PROBLEM", 60, 83], ["bonds", "OBSERVATION", 6, 11]]], ["Offering to redirect investment capital, their advanced market size places them in the vanguard of green financial innovation, and their successes and failures may well have far reaching socio-spatial consequences at a range of scales.", [["size", "OBSERVATION_MODIFIER", 63, 67]]], ["We also argue it provides a fuller picture of a green bond market still growing and open to further innovation.", [["a green bond market", "PROBLEM", 46, 65]]], ["We end with some conclusions afforded by this point of view.ConclusionFirstly, it is not yet clear whether green bonds can meaningfully contribute to addressing the environmental crisis.", [["green bonds", "PROBLEM", 107, 118], ["the environmental crisis", "PROBLEM", 161, 185], ["environmental crisis", "OBSERVATION", 165, 185]]], ["Competing interests and market imperatives are crystallised by the need to lower capital costs for green bonds.", [["green bonds", "SIMPLE_CHEMICAL", 99, 110], ["green bonds", "OBSERVATION", 99, 110]]], ["Future research could test these claims empirically and consider whether the results have any bearing on how we think about green bonds' efficacy or political substance.ConclusionSecondly, policy actors and applied researchers should heed the warning that green is not necessarily good for financing low-carbon public infrastructure.", [["carbon", "CHEMICAL", 304, 310], ["green bonds' efficacy", "PROBLEM", 124, 145], ["financing low-carbon public infrastructure", "PROBLEM", 290, 332], ["carbon public infrastructure", "OBSERVATION", 304, 332]]], ["Sustainable development is typically rendered as three pillars of social, economic, and environmental sustainability (Purvis et al., 2019) .", [["pillars", "OBSERVATION_MODIFIER", 55, 62]]], ["By amplifying inequality, green bonds risk undermining the first two pillars in pursuit of the third.", [["green bonds risk", "PROBLEM", 26, 42], ["green bonds", "OBSERVATION", 26, 37], ["pillars", "OBSERVATION_MODIFIER", 69, 76]]], ["This poses the risk of greenwashing in quite different terms.", [["greenwashing", "PROBLEM", 23, 35]]], ["An important line of inquiry, then, is whether green bonds can be structured to smooth out these imbalances or whether there are viable alternatives we need to nurture.ConclusionTo this end, the paper finally suggests the design and governance of green bond markets may well determine whether they lean towards healthy credit or become another case of bad debt.", [["green bond markets", "TREATMENT", 247, 265]]], ["Additionality, for example, is more likely with preferential tax treatments or an investment culture willing to pay a green premium.", [["preferential tax treatments", "TREATMENT", 48, 75], ["an investment culture", "TEST", 79, 100], ["more likely", "UNCERTAINTY", 31, 42]]], ["This will be a tough nut to crack in the 10 years we have to limit global warming to 1.5 \u25cb C. Nonetheless, the rise of citizen debt audits suggest we might begin to address inequalities with measures that re-democratise public borrowing and development planning (see: Montgomerie & Tepe-Belfrage, 2019) .", [["global warming", "TREATMENT", 67, 81]]]], "17e65e5ee1427a61375b03b51013d7e1b4cf9bdd": [["Supplementary TablesSupplementaryFollow-up time ResultsCruz-Valdez *This trial compared adjuvanted and non-adjuvanted vaccine formulations with unequal hemagglutinin antigen dose.", [["hemagglutinin antigen", "GENE_OR_GENE_PRODUCT", 152, 173], ["hemagglutinin antigen", "PROTEIN", 152, 173], ["This trial compared adjuvanted", "TREATMENT", 68, 98], ["non-adjuvanted vaccine formulations", "TREATMENT", 103, 138], ["unequal hemagglutinin antigen dose", "TREATMENT", 144, 178]]], ["The hemagglutinin antigen dose was reduced in the adjuvanted arm (antigen-sparing design). \u2020This trial compared adjuvanted influenza vaccines and non-adjuvanted influenza vaccines from different manufacturers.", [["hemagglutinin antigen", "GENE_OR_GENE_PRODUCT", 4, 25], ["hemagglutinin antigen", "PROTEIN", 4, 25], ["The hemagglutinin antigen dose", "TREATMENT", 0, 30], ["adjuvanted influenza vaccines", "TREATMENT", 112, 141], ["non-adjuvanted influenza vaccines", "TREATMENT", 146, 179], ["arm", "ANATOMY", 61, 64]]]], "4f7b612fcf0520e849e7a2e317e211b9033b9f8f": [["Differences in alleles frequency patterns between Africans and non-Africans have beendocumented and attributed to the large African population effective size (Watkins et al., 2001; Elhassan et al. , 2014) genetic drift (Wang et al.,2010) and possible selection episodes that might have occurred during or prior to the exodus from the continent.", [["Africans and non-Africans", "PROBLEM", 50, 75], ["genetic drift", "PROBLEM", 205, 218], ["selection episodes", "PROBLEM", 251, 269], ["large", "OBSERVATION_MODIFIER", 118, 123], ["size", "OBSERVATION_MODIFIER", 153, 157]]], ["These differences may help shed light on hitherto hidden chapters and dangling questions on evolutionary history and the genetic basis of phenotypic variations (Tishkoff et al., 2002) .", [["phenotypic variations", "PROBLEM", 138, 159]]], ["Here we report on an interesting situation of a contrasting genotype and allele frequency pattern between Africans and non-Africans in the Duffy antigen gene.", [["Duffy antigen", "GENE_OR_GENE_PRODUCT", 139, 152], ["Duffy antigen gene", "DNA", 139, 157], ["a contrasting genotype and allele frequency pattern", "PROBLEM", 46, 97], ["Africans and non-Africans", "PROBLEM", 106, 131]]], ["The pattern was originally observed in a 812 sample of 812 Sudanese from the MalariaGen genotype panel (Masalit & Hausa) .", [["the MalariaGen genotype panel", "TEST", 73, 102]]], ["Allele \"C\" was found to be most frequent among Africans almost reaching fixation (100%) in the majority of groups.", [["Allele \"C\"", "PROBLEM", 0, 10], ["fixation", "TREATMENT", 72, 80]]], ["The reverse was observed in non-Africans with the C allele at a frequency of 1% in Europeans (Iberians) and Amerindians (Mayan).", [["C allele", "DNA", 50, 58], ["the C allele", "PROBLEM", 46, 58]]], ["In contrast, the T allele frequency was as high as (100%) in Europeans (figure 1.a).", [["T", "GENE_OR_GENE_PRODUCT", 17, 18]]], ["The total genotype data of this locus comprises 3533 individuals from global populations, of which 2504 were from the 1000 genomes project (phase 3) (https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes), and 217 genotypes from published data of Sudanese (Shaygia & Manasir) (Kempinska-Podhorodecka et al ., 2012) .", [["Sudanese", "TEST", 250, 258], ["global", "OBSERVATION_MODIFIER", 70, 76], ["populations", "OBSERVATION_MODIFIER", 77, 88]]], ["Based on such allele and genotype frequencies, and accordingly we set to examine the likelihood of an interesting scenario related to human migrations.", [["human", "ORGANISM", 134, 139], ["allele", "DNA", 14, 20], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["such allele and genotype frequencies", "PROBLEM", 9, 45]]], ["The polymorphism within the Duffy antigen gene (rs2814778) seems rather a relic of past extreme selection that conferred an adaptive advantage to humans in a specific environment during their exodus out of Africa, ~40KYB, with frequencies and impact aggravated thereafter by the sheer relatively small number of migrants under the influence of genetic drifts.", [["rs2814778", "CHEMICAL", 48, 57], ["Duffy antigen", "GENE_OR_GENE_PRODUCT", 28, 41], ["humans", "ORGANISM", 146, 152], ["Duffy antigen gene", "DNA", 28, 46], ["rs2814778", "DNA", 48, 57], ["humans", "SPECIES", 146, 152], ["humans", "SPECIES", 146, 152], ["The polymorphism", "PROBLEM", 0, 16], ["small", "OBSERVATION_MODIFIER", 296, 301]]], ["Generally speaking, diseases are among the most J o u r n a l P r e -p r o o f recognizable forces exerting selection pressure, with the malaria parasite being a notable example.", [["malaria parasite", "DISEASE", 137, 153], ["the malaria parasite", "PROBLEM", 133, 153], ["pressure", "OBSERVATION_MODIFIER", 118, 126], ["malaria", "OBSERVATION", 137, 144]]], ["Malaria influence on the human genome has a history estimated to fall in a range of 10-15,000 years ago concurrent with the advent of agriculture (Kwiatkowski et al., 2005) which makes it much later to the first out of Africa episode.", [["Malaria", "DISEASE", 0, 7], ["human", "ORGANISM", 25, 30], ["human genome", "DNA", 25, 37], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["Malaria influence", "PROBLEM", 0, 17], ["Africa episode", "PROBLEM", 219, 233]]], ["It has been widely documented that malaria was one of the factors determining population diversity manifested in atypical variants of hemoglobin, such as hemoglobin S (HbS), C (HBC) or E (HBE), as well as variability in the Duffy blood group system (Kempinska-Podhorodecka et al., 2012) .", [["blood", "ANATOMY", 230, 235], ["malaria", "DISEASE", 35, 42], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 134, 144], ["hemoglobin S", "GENE_OR_GENE_PRODUCT", 154, 166], ["HbS", "SIMPLE_CHEMICAL", 168, 171], ["C", "SIMPLE_CHEMICAL", 174, 175], ["blood", "ORGANISM_SUBSTANCE", 230, 235], ["hemoglobin", "PROTEIN", 134, 144], ["hemoglobin S", "PROTEIN", 154, 166], ["HbS", "PROTEIN", 168, 171], ["malaria", "PROBLEM", 35, 42], ["atypical variants of hemoglobin", "PROBLEM", 113, 144], ["hemoglobin S", "TEST", 154, 166], ["HbS", "TEST", 168, 171], ["C (HBC)", "PROBLEM", 174, 181], ["E (HBE)", "PROBLEM", 185, 192], ["the Duffy blood group system", "TEST", 220, 248], ["widely", "OBSERVATION_MODIFIER", 12, 18], ["malaria", "OBSERVATION", 35, 42], ["atypical variants", "OBSERVATION", 113, 130], ["hemoglobin", "OBSERVATION_MODIFIER", 134, 144]]], ["DARC has also recently been associated with susceptibility to HIV infection and rate of progression to AIDS (He et al., 2008) , and is shown to be prognostic for WBCs count and neutrophil count (benign ethnic neutropenia) in African Americans (Reich et al.,2009) as well as susceptibility to several other conditions capable of inducing equally significant selective pressure (Carvalho et al.,2011) .", [["WBCs", "ANATOMY", 162, 166], ["neutrophil", "ANATOMY", 177, 187], ["HIV infection", "DISEASE", 62, 75], ["AIDS", "DISEASE", 103, 107], ["neutropenia", "DISEASE", 209, 220], ["DARC", "GENE_OR_GENE_PRODUCT", 0, 4], ["HIV", "ORGANISM", 62, 65], ["WBCs", "CELL", 162, 166], ["neutrophil", "CELL", 177, 187], ["DARC", "PROTEIN", 0, 4], ["WBCs", "CELL_TYPE", 162, 166], ["HIV", "SPECIES", 62, 65], ["HIV", "SPECIES", 62, 65], ["HIV infection", "PROBLEM", 62, 75], ["AIDS", "PROBLEM", 103, 107], ["WBCs count", "TEST", 162, 172], ["neutrophil count", "TEST", 177, 193], ["benign ethnic neutropenia", "PROBLEM", 195, 220], ["HIV", "OBSERVATION_MODIFIER", 62, 65], ["infection", "OBSERVATION", 66, 75], ["neutrophil count", "OBSERVATION", 177, 193], ["benign", "OBSERVATION_MODIFIER", 195, 201]]], ["Such contrasting pattern is unique and the utility of rs2814778 with its spectacular frequency distribution ( Figure.", [["rs2814778", "GENE_OR_GENE_PRODUCT", 54, 63], ["spectacular", "OBSERVATION_MODIFIER", 73, 84]]], ["Masalit as manifested in this locus had sustained no major gene flow from non-Africans chromosomes or b) gene flow has taken place but the introgression of the introduced allele has seized and disappeared due to a combined effect of drift and selection.", [["chromosomes", "ANATOMY", 87, 98], ["locus", "CELLULAR_COMPONENT", 30, 35], ["chromosomes", "CELLULAR_COMPONENT", 87, 98], ["non-Africans chromosomes", "DNA", 74, 98], ["allele", "DNA", 171, 177], ["Masalit", "TREATMENT", 0, 7], ["major gene flow from non-Africans chromosomes", "PROBLEM", 53, 98], ["gene flow", "TEST", 105, 114], ["drift and selection", "PROBLEM", 233, 252], ["flow", "OBSERVATION", 110, 114], ["drift", "OBSERVATION", 233, 238]]], ["Masalit according to Y chromosome data (Hassan et al ., 2008) is around 71.9% E1b1b paternal haplogroup, mainly the V32 subclade, and approximately 6.3% also belong to the haplogroup J1 considered a par excellence marker of Afro-Asiatic ancestry and back migration.", [["E1b1b", "GENE_OR_GENE_PRODUCT", 78, 83], ["Y chromosome", "DNA", 21, 33], ["V32 subclade", "DNA", 116, 128], ["haplogroup J1", "DNA", 172, 185], ["Afro-Asiatic ancestry", "PROBLEM", 224, 245], ["back migration", "PROBLEM", 250, 264], ["Afro-Asiatic ancestry", "OBSERVATION", 224, 245], ["back migration", "OBSERVATION", 250, 264]]], ["This might insinuate significant patrilineal gene flow from neighboring Afro-Asiatic-speaking populations, although it does not tally with the historical time frame of 500-1500 years for the migration of Arab speaking populations into the Sahel and a hypothesized subsequent admixture scenario (Bereir et al ., 2007) .", [["significant patrilineal gene flow", "PROBLEM", 21, 54], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["patrilineal", "OBSERVATION_MODIFIER", 33, 44], ["gene flow", "OBSERVATION", 45, 54]]], ["To further consider other possible scenarios of an older back to Africa at a different time frame like the hypothetical introduction into Africa by Neolithic farmers of the Y haplogroup R1b common among Hausa in this case (40%) followed by selection episode and losing the accompanying T allele due to decreased fitness, we modeled similar scenarios using the program PopG (Felsenstein/Kuhner lab).", [["Hausa", "CHEMICAL", 203, 208], ["T", "GENE_OR_GENE_PRODUCT", 286, 287], ["T allele", "DNA", 286, 294], ["selection episode", "PROBLEM", 240, 257], ["decreased fitness", "PROBLEM", 302, 319]]], ["The analysis shows that even with extreme selection/fitness values, complete fixation in the absence of drift required 300 generations (~7500 years), and ~10000 years with less extreme fitness values seen in major human epidemics and outbreaks ( figure.2a,b) at a frequency of 0.01 of the minor allele (T in this case).Differences in alleles frequency patterns between Africans and non-Africans have beenWhile a frequency of 0.001 which is more comparable to the present values will require 1400-1600 generations (~30-40000 years) to reach fixation (figure.2c).", [["human", "ORGANISM", 214, 219], ["b", "GENE_OR_GENE_PRODUCT", 256, 257], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["The analysis", "TEST", 0, 12], ["extreme selection/fitness values", "PROBLEM", 34, 66], ["complete fixation", "TREATMENT", 68, 85], ["less extreme fitness values", "PROBLEM", 172, 199], ["fixation", "TREATMENT", 540, 548], ["fixation", "OBSERVATION", 77, 85]]], ["A back to Africa scenario seems even less likely given the abundance of very old ancestral mitochondria and Y chromosome haplogroups with no or very low-frequency distribution out of Africa in Hausa and Masalit like A and B haplogroups (Hassan et al ., 2008) 11 .", [["mitochondria", "ANATOMY", 91, 103], ["chromosome", "ANATOMY", 110, 120], ["mitochondria", "CELLULAR_COMPONENT", 91, 103], ["Y chromosome", "CELLULAR_COMPONENT", 108, 120], ["Y chromosome haplogroups", "DNA", 108, 132], ["A back to Africa scenario", "PROBLEM", 0, 25], ["very old ancestral mitochondria", "PROBLEM", 72, 103]]], ["It has been previously shown by us that J o u r n a l P r e -p r o o f the Y chromosome can be a reliable marker for allele introgression into a population genome and in dating of such events (Bereir et al .,2007) .ConclusionThe Duffy mutation (rs2814778) seems an insightful marker for African non-African ancestry and population admixture exemplified in admixture patterns in African Americans (Estalote et al.,2005) and some northern and east Africans.", [["chromosome", "ANATOMY", 77, 87], ["chromosome", "CELLULAR_COMPONENT", 77, 87], ["Duffy", "GENE_OR_GENE_PRODUCT", 229, 234], ["P", "DNA", 54, 55], ["Y chromosome", "DNA", 75, 87], ["allele", "DNA", 117, 123], ["population genome", "DNA", 145, 162], ["allele introgression", "PROBLEM", 117, 137], ["such events", "PROBLEM", 180, 191]]], ["It would be interesting to use biomarkers such as Y-chromosome and/or mtDNA to the quantity and inform on such admixture patterns of hypothesized mixed ancestry groups in continental sets and at the fringes of population interactions.", [["Y-chromosome", "CELLULAR_COMPONENT", 50, 62], ["mtDNA", "CELLULAR_COMPONENT", 70, 75], ["biomarkers", "TREATMENT", 31, 41]]], ["Manasir (from Sudan) seemingly consistent with an admixture between Africans and non-Africans in a population known to have such mixed ancestry.Figure 2:Simulation of allele frequency change over time for a scenario of allele T into Africa 2.a) an initial frequency of 0.001 similar to the current frequencies and fitness of extreme selection at", [["allele T", "DNA", 219, 227], ["Simulation of allele frequency change", "TREATMENT", 153, 190], ["extreme selection", "TREATMENT", 325, 342], ["consistent with", "UNCERTAINTY", 31, 46]]]], "1983875bd9c1144830609d85fd6957aeb0a90cda": [["Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first appeared in Wuhan province, China, in December 2019.", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["SARS-CoV-2", "ORGANISM", 61, 71], ["severe acute respiratory syndrome coronavirus", "SPECIES", 12, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 12, 57], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["Since then, the outbreak has spread worldwide and precipitated into a global pandemic.", [["a global pandemic", "PROBLEM", 68, 85], ["global", "OBSERVATION_MODIFIER", 70, 76], ["pandemic", "OBSERVATION", 77, 85]]], ["The mortality rate of SARS-CoV-2 disease (coronavirus disease 2019 ) in different countries has been reported to be between 1 and 4%, with increased risk of severe disease among the elderly and those with preexisting health conditions [1] .", [["SARS-CoV-2 disease", "DISEASE", 22, 40], ["coronavirus disease", "DISEASE", 42, 61], ["SARS-CoV-2", "ORGANISM", 22, 32], ["coronavirus", "ORGANISM", 42, 53], ["SARS-CoV", "SPECIES", 22, 30], ["The mortality rate", "TEST", 0, 18], ["SARS", "PROBLEM", 22, 26], ["CoV-2 disease (coronavirus disease", "PROBLEM", 27, 61], ["severe disease", "PROBLEM", 157, 171], ["SARS", "OBSERVATION", 22, 26], ["coronavirus disease", "OBSERVATION", 42, 61], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["disease", "OBSERVATION", 164, 171]]], ["The demographic profile of COVID-19 reveals disproportionately higher number of males with severe disease and deaths [1] .", [["deaths", "DISEASE", 110, 116], ["The demographic profile", "TEST", 0, 23], ["COVID", "TEST", 27, 32], ["severe disease", "PROBLEM", 91, 105], ["disproportionately", "OBSERVATION_MODIFIER", 44, 62], ["higher", "OBSERVATION_MODIFIER", 63, 69], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["disease", "OBSERVATION", 98, 105]]]], "05cad2251eec680744110bac4ec0b8f99c7aaf9d": [["APM PerspectivesThe Association of Professors of Medicine (APM) is the national organization of departments of internal medicine at the US medical schools and numerous affiliated teaching hospitals as represented by chairs and appointed leaders.", [["internal medicine", "TREATMENT", 111, 128]]], ["As the official sponsor of The American Journal of Medicine, the association invites authors to publish commentaries on issues concerning academic internal medicine.APM PerspectivesFor the latest information about departments of internal medicine, please visit APM's website at www.im.org/APM.", [["academic internal medicine", "TREATMENT", 138, 164], ["internal medicine", "TREATMENT", 229, 246]]], ["The day begins at 7:00 AM with a layer of mosquito repellent and boiled coffee in a tin cup.", [["tin", "CHEMICAL", 84, 87], ["tin", "CHEMICAL", 84, 87]]], ["Our medical clinic in the small village of Rancho Pedro along the Dominican Republic-Haiti border is a small hut composed of dilapidated wooden planks fastened together under a thatched reed roof.", [["small", "OBSERVATION_MODIFIER", 26, 31], ["small", "OBSERVATION_MODIFIER", 103, 108]]], ["Patients with a variety of ailments line up daily outside the clinic door in anticipation of seeing a physician, often for the first time.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ailments line", "TREATMENT", 27, 40]]], ["Most patients have been waiting for hours, usually after enduring an overnight mountainous trek from a neighboring Haitian or Dominican village.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Many of the medical problems encountered can be treated effectively with simple measures of wound debridement, bandages, analgesics, or antibiotics; however, some are more complex with no referral options.", [["wound", "ANATOMY", 92, 97], ["wound", "PATHOLOGICAL_FORMATION", 92, 97], ["the medical problems", "PROBLEM", 8, 28], ["simple measures", "TREATMENT", 73, 88], ["wound debridement", "TREATMENT", 92, 109], ["bandages", "TREATMENT", 111, 119], ["analgesics", "TREATMENT", 121, 131], ["antibiotics", "TREATMENT", 136, 147], ["wound", "ANATOMY", 92, 97], ["debridement", "OBSERVATION", 98, 109]]], ["The work is intense but inspiring, rewarding but often frustrating as the limitations of our abilities quickly become apparent.Rules of EngagementMany such medical programs generate unique personal experiences for volunteer healthcare providers; however, we continue to wonder whether any of our efforts have any meaningful and lasting benefit.", [["intense", "OBSERVATION_MODIFIER", 12, 19]]], ["For the local rural communities that we temporarily serve, have any of our interventions subsequently reduced the burden of illness or death?", [["illness", "DISEASE", 124, 131], ["death", "DISEASE", 135, 140], ["our interventions", "TREATMENT", 71, 88], ["illness", "PROBLEM", 124, 131], ["death", "PROBLEM", 135, 140]]], ["The breakdown in local public health and prevalence of hunger detract from most educational opportunities, reducing financial and societal stability.", [["The breakdown", "PROBLEM", 0, 13], ["breakdown", "OBSERVATION_MODIFIER", 4, 13], ["local", "OBSERVATION_MODIFIER", 17, 22], ["societal stability", "OBSERVATION", 130, 148]]], ["Preventable deaths from childhood diarrhea, inadequate obstetric and neonatal care, infectious diseases, and neglected chronic conditions, including cardiovascular disease, diabetes, and hypertension, all dramatically reduce a community's potential for economic and social productivity.", [["cardiovascular", "ANATOMY", 149, 163], ["deaths", "DISEASE", 12, 18], ["diarrhea", "DISEASE", 34, 42], ["infectious diseases", "DISEASE", 84, 103], ["cardiovascular disease", "DISEASE", 149, 171], ["diabetes", "DISEASE", 173, 181], ["hypertension", "DISEASE", 187, 199], ["childhood diarrhea", "PROBLEM", 24, 42], ["inadequate obstetric and neonatal care", "PROBLEM", 44, 82], ["infectious diseases", "PROBLEM", 84, 103], ["neglected chronic conditions", "PROBLEM", 109, 137], ["cardiovascular disease", "PROBLEM", 149, 171], ["diabetes", "PROBLEM", 173, 181], ["hypertension", "PROBLEM", 187, 199], ["economic and social productivity", "PROBLEM", 253, 285], ["childhood", "OBSERVATION_MODIFIER", 24, 33], ["diarrhea", "OBSERVATION", 34, 42], ["infectious", "OBSERVATION", 84, 94], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["conditions", "OBSERVATION", 127, 137], ["cardiovascular disease", "OBSERVATION", 149, 171], ["diabetes", "OBSERVATION", 173, 181], ["hypertension", "OBSERVATION", 187, 199], ["social productivity", "OBSERVATION", 266, 285]]], ["In addition, desperate economic and unstable political conditions entice many local health providers to move away.Rules of EngagementMany reasons have been identified to engage in underserved healthcare projects.", [["desperate economic and unstable political conditions", "PROBLEM", 13, 65], ["unstable", "OBSERVATION_MODIFIER", 36, 44]]], ["Individual providers and relief organizations may feel an inherent responsibility to improve healthcare delivery in both domestic and international underserved communities.", [["healthcare delivery", "TREATMENT", 93, 112]]], ["On a larger scale, the Centers for Disease Control and Prevention and the US Department for Homeland Security recognize that public health is never an isolated concern.", [["a larger scale", "TREATMENT", 3, 17], ["Disease Control", "TREATMENT", 35, 50]]], ["Modernized air travel and international commerce provide efficient avenues for the global spread of select infectious diseases.", [["infectious diseases", "DISEASE", 107, 126], ["Modernized air travel", "PROBLEM", 0, 21], ["infectious diseases", "PROBLEM", 107, 126], ["air travel", "OBSERVATION", 11, 21], ["infectious", "OBSERVATION", 107, 117]]], ["New strains of influenza virus (including novel and avian influenza virus), Severe Acute Respiratory Syndrome coronavirus, and drugresistant tuberculosis, as well as vaccine-preventable communicable illnesses, can flourish in regions lacking adequate public health infrastructure.Rules of EngagementThere are numerous international healthcare and humanitarian programs working in developing countries and no apparent paucity of medical volunteers or financial donations.", [["influenza virus", "DISEASE", 15, 30], ["avian influenza virus", "DISEASE", 52, 73], ["Acute Respiratory Syndrome coronavirus", "DISEASE", 83, 121], ["tuberculosis", "DISEASE", 141, 153], ["communicable illnesses", "DISEASE", 186, 208], ["influenza virus", "ORGANISM", 15, 30], ["avian influenza virus", "ORGANISM", 52, 73], ["volunteers", "ORGANISM", 436, 446], ["influenza virus", "SPECIES", 15, 30], ["avian influenza virus", "SPECIES", 52, 73], ["influenza virus", "SPECIES", 15, 30], ["avian influenza virus", "SPECIES", 52, 73], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 76, 121], ["influenza virus", "PROBLEM", 15, 30], ["novel and avian influenza virus", "PROBLEM", 42, 73], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 76, 121], ["drugresistant tuberculosis", "PROBLEM", 127, 153], ["vaccine", "TREATMENT", 166, 173], ["preventable communicable illnesses", "PROBLEM", 174, 208], ["humanitarian programs", "TREATMENT", 347, 368], ["influenza virus", "OBSERVATION", 15, 30], ["Severe", "OBSERVATION_MODIFIER", 76, 82], ["Acute", "OBSERVATION_MODIFIER", 83, 88], ["Respiratory Syndrome coronavirus", "OBSERVATION", 89, 121], ["tuberculosis", "OBSERVATION", 141, 153], ["adequate", "OBSERVATION_MODIFIER", 242, 250], ["no apparent", "UNCERTAINTY", 405, 416]]], ["Indeed, many US medical centers and medical schools have been developing their own global health programs that attract prospective physicians, scientists, and philanthropic donors.", [["donors", "ORGANISM", 173, 179]]], ["2 Such programs sponsored by US medical centers can facilitate student and resident participation in medical volunteer efforts, provide on-site training for supervisory physicians, and allow development for possible clinical research projects.Rules of EngagementThe global health programs at these medical centers also enhance their appeal to prospective medical school and residency applicants.", [["Engagement", "OBSERVATION", 252, 262], ["global", "OBSERVATION_MODIFIER", 266, 272]]], ["In turn, most medical students participating in a structured international health fellowship program find such experiences beneficial to their profession through enhanced cultural sensitivity, improved patient communication and examination skills, the opportunity to see a wide variety of pathology, and more appropriate medical resource use.", [["patient", "ORGANISM", 202, 209], ["patient", "SPECIES", 202, 209], ["examination skills", "TEST", 228, 246]]], ["3, 4, 5 Such international health experiences also correlate with increased student selection of primary care medicine and careers in public health and future work with underserved populations.", [["primary care medicine", "TREATMENT", 97, 118]]], ["6 Table 1 lists a number of benefits and values cited by participants of international clinical rotations.POTENTIAL RISKS AND CONCERNSDespite the abundance of interest and altruistic passion for international underserved healthcare work, there are a number of risks and potential harm that can result from ill-equipped, shortsighted, and unstructured proj-ects ( Table 2) .", [["participants", "SPECIES", 57, 69]]], ["For any project, one must first determine whether direct patient care is even warranted or whether the focus is better placed on alternative measures in public and preventative health (eg, vaccinations).", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["alternative measures", "TREATMENT", 129, 149], ["preventative health (eg, vaccinations", "TREATMENT", 164, 201]]], ["7 In the absence of appropriate supervision, visiting medical students and residents may quickly over-reach their clinical abilities and may not fully understand select diseases or managerial approaches appropriate for a select region.", [["managerial approaches", "TREATMENT", 181, 202]]], ["8, 9 Different languages, local customs, and religious beliefs can pose barriers to well-intentioned healthcare delivery and community acceptance of public health measures.", [["public health measures", "TREATMENT", 149, 171]]], ["Quality patient care, education, and research depend on an integrated understanding of the medical needs identified and expressed by local providers and community leaders.", [["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15]]], ["Using medications and materials predominately supplied by volunteer medical teams rather than what is locally available may prohibit thePERSPECTIVES VIEWPOINTS\u2022 Interest and participation in global health projects by students and health providers are increasing throughout the United States.PERSPECTIVES VIEWPOINTS\u2022 Significant harm to communities may occur through the lack of public health focus, appropriate skills, medical supervision, familiarity with local diseases and customs, and the subsequent creation of community dependency.PERSPECTIVES VIEWPOINTS\u2022 To reduce the risk of harm, we suggest a set of guiding principles: quality service, sustainability, professionalism, and safety.", [["medications", "TREATMENT", 6, 17], ["materials", "TREATMENT", 22, 31], ["community dependency", "PROBLEM", 516, 536], ["Significant", "OBSERVATION_MODIFIER", 316, 327], ["harm", "OBSERVATION", 328, 332], ["community dependency", "OBSERVATION", 516, 536]]], ["Opportunity to encounter diseases not typically encountered in United States Opportunity to see more advanced stages of select diseases not commonly seen in United States Opportunity to improve physical examination skills and procedural skill sets (via less reliance on laboratory, radiology, or consultation options) Opportunity to understand the fragile socioeconomic relationship among local government, hospital, and local medical clinics Greater awareness of cultural sensitivity and importance of patient communication development of a sustainable medical and pharmaceutical supply chain.", [["patient", "ORGANISM", 503, 510], ["patient", "SPECIES", 503, 510], ["physical examination", "TEST", 194, 214], ["cultural sensitivity", "TEST", 464, 484], ["a sustainable medical and pharmaceutical supply chain", "PROBLEM", 540, 593]]], ["10 Inappropriate dispensing of available medications, including nonsteroidal anti-inflammatory drugs, vitamins, and antibiotics, can both harm patients and create a false community perception that there is \"a pill for every problem.\"", [["nonsteroidal", "ANATOMY", 64, 76], ["vitamins", "CHEMICAL", 102, 110], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 64, 100], ["vitamins", "SIMPLE_CHEMICAL", 102, 110], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["available medications", "TREATMENT", 31, 52], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 64, 100], ["vitamins", "TREATMENT", 102, 110], ["antibiotics", "TREATMENT", 116, 127]]], ["Performing complex surgical and other invasive procedures until the time of team departure prohibits any subsequent opportunity to adequately manage potential complications (including infection and excessive bleeding).", [["infection", "DISEASE", 184, 193], ["bleeding", "DISEASE", 208, 216], ["complex surgical", "TREATMENT", 11, 27], ["other invasive procedures", "TREATMENT", 32, 57], ["potential complications", "PROBLEM", 149, 172], ["infection", "PROBLEM", 184, 193], ["excessive bleeding", "PROBLEM", 198, 216]]], ["10 The unfortunate end result that can develop from shortsighted activities is the unintentional development of community or regional dependency on returning external medical organizations rather than any meaningful progression toward local health system autonomy and quality.DEVELOPING GUIDING PRINCIPLESAs underserved health and volunteer programs continue to develop, it becomes increasingly important to establish a set of guiding principles by which to operate.", [["regional dependency", "PROBLEM", 125, 144], ["external medical organizations", "TREATMENT", 158, 188], ["volunteer programs", "TREATMENT", 331, 349]]], ["Whether the focus is on patient care delivery, vaccinations, preventative health measures, healthcare training, or research, 4 fundamental principles should be considered in the development of any such program: service, sustainability, professionalism, and safety ( Table 3) .ServiceThe quality of healthcare delivered within an underserved location should be the highest possible al-lowed by the resource constraints.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["patient care delivery", "TREATMENT", 24, 45], ["vaccinations", "TREATMENT", 47, 59], ["preventative health measures", "TREATMENT", 61, 89], ["healthcare training", "TREATMENT", 91, 110]]], ["The needs of the patients should always come first.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["Before embarking on a trip, efforts should be made to adequately learn and prepare to manage diseases of poverty.", [["poverty", "DISEASE", 105, 112]]], ["Welldesigned service projects fulfill a supporting or assisting role in partnership with local healthcare organizations and avoid the missteps of ignorance, arrogance, and paternalism toward both patients and local providers within a community.", [["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204]]], ["11 Frustration and helplessness will be encountered while working in under-resourced conditions as many readily preventable and curable diseases often prove fatal.", [["helplessness", "DISEASE", 19, 31], ["helplessness", "PROBLEM", 19, 31], ["curable diseases", "PROBLEM", 128, 144]]], ["For patients and clinics without referral options, visiting providers must be able to acknowledge their limitations, uphold patient dignity, and provide comfort care measures.", [["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 124, 131], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 124, 131], ["comfort care measures", "TREATMENT", 153, 174]]], ["In addition to patient care, service may include support of local healthcare systems with continuing medical education, assistance in their research endeavors, and teaching providers how to train others (a model of \"training the trainers\").SustainabilityThe development of a sustainable program requires a clear identification of project goals, objectives, and systems for measuring outcomes composed within an infrastructure that enables and promotes autonomous function.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["local healthcare systems", "TREATMENT", 60, 84], ["continuing medical education", "TREATMENT", 90, 118], ["measuring outcomes", "PROBLEM", 373, 391], ["autonomous function", "OBSERVATION", 452, 471]]], ["The primary objective is to avoid the development of any sense of external dependency or learned helplessness, often fueled by a reliance on external medicine, equipment, or other donated resources to solve problems.", [["helplessness", "DISEASE", 97, 109], ["external dependency", "PROBLEM", 66, 85], ["learned helplessness", "PROBLEM", 89, 109], ["external medicine", "TREATMENT", 141, 158]]], ["The identification and development of partnerships with local providers and organizations focusing on longitudinal engagement with the target com- Embarking on medical volunteerism without first considering alternative or supplemental activities to improve local community health Allowing untrained volunteers to perform healthcare Overreaching or mismatching providers' medical knowledge base and skill sets Not incorporating or recruiting the services and expertise of local providers Focusing on the medical and scientific interests of the visiting team rather than the needs and requests of local providers Being unfamiliar with local languages, cultures, or system of beliefs Being unfamiliar with prevalent regional diseases and management strategies used by local providers Relying on medications (including non-WHO Essential Medicines), equipment, and other supplies donated externally rather than what is locally available Dispensing inappropriate medications (eg, vitamins, NSAIDS, and antibiotics) Performing surgery and other invasive procedures without adequate patient follow-up to address possible complications Donating medical equipment that is not required and is beyond the capacity of local providers or healthcare center and without a plan for maintenance Having inadequate pre-travel preparation (ie, updating vaccinations and taking precautions for vector-borne and possible blood-borne infections) and education regarding appropriate food and water consumption and sun exposure Creating local community health dependency on external medical team NSAIDS \u03ed nonsteroidal anti-inflammatory drugs; WHO \u03ed World Health Organization. munity can help reduce this risk.", [["blood", "ANATOMY", 1398, 1403], ["NSAIDS", "CHEMICAL", 984, 990], ["blood-borne infections", "DISEASE", 1398, 1420], ["NSAIDS", "CHEMICAL", 984, 990], ["volunteers", "ORGANISM", 299, 309], ["vitamins", "SIMPLE_CHEMICAL", 974, 982], ["NSAIDS", "SIMPLE_CHEMICAL", 984, 990], ["patient", "ORGANISM", 1075, 1082], ["blood", "ORGANISM_SUBSTANCE", 1398, 1403], ["patient", "SPECIES", 1075, 1082], ["alternative or supplemental activities", "TREATMENT", 207, 245], ["local providers", "TREATMENT", 595, 610], ["cultures", "TEST", 650, 658], ["prevalent regional diseases", "PROBLEM", 703, 730], ["management strategies", "TREATMENT", 735, 756], ["medications", "TREATMENT", 792, 803], ["inappropriate medications (eg", "TREATMENT", 943, 972], ["vitamins", "TREATMENT", 974, 982], ["NSAIDS", "TREATMENT", 984, 990], ["antibiotics", "TREATMENT", 996, 1007], ["Performing surgery", "TREATMENT", 1009, 1027], ["other invasive procedures", "TREATMENT", 1032, 1057], ["complications", "PROBLEM", 1113, 1126], ["medical equipment", "TREATMENT", 1136, 1153], ["inadequate pre-travel preparation", "TREATMENT", 1284, 1317], ["updating vaccinations", "TREATMENT", 1323, 1344], ["precautions", "TREATMENT", 1356, 1367], ["vector-borne", "TREATMENT", 1372, 1384], ["blood-borne infections", "PROBLEM", 1398, 1420], ["external medical team NSAIDS", "TREATMENT", 1548, 1576], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 1579, 1615]]], ["Sustainable outcomes rely on the empowerment of local providers and the communities themselves to provide a higher quality of healthcare.SustainabilityEducation and preventive health measures have a pivotal role with sustainable healthcare interventions and can nicely complement clinical patient care duties or research initiatives.", [["patient", "ORGANISM", 289, 296], ["patient", "SPECIES", 289, 296], ["SustainabilityEducation", "TREATMENT", 137, 160], ["sustainable healthcare interventions", "TREATMENT", 217, 253], ["research initiatives", "TREATMENT", 312, 332]]], ["Whether the teaching objective is to demonstrate new surgical techniques, didactically convey new scientific discoveries, refresh vital skill sets (eg, wound care, basic life support, and advanced cardiac life support training), or address community practices of food handling, hygiene, and waste management, education can have an enduring effect.SustainabilityMedical equipment and medication donations are typically well received; however, strategies for integration into the local practice, repair, and maintenance are crucial for any long-term benefit.", [["wound", "ANATOMY", 152, 157], ["cardiac", "ANATOMY", 197, 204], ["wound", "PATHOLOGICAL_FORMATION", 152, 157], ["new surgical techniques", "TREATMENT", 49, 72], ["wound care", "TREATMENT", 152, 162], ["basic life support", "TREATMENT", 164, 182], ["advanced cardiac life support training", "TREATMENT", 188, 226], ["waste management", "TREATMENT", 291, 307], ["SustainabilityMedical equipment", "TREATMENT", 347, 378], ["medication donations", "TREATMENT", 383, 403], ["repair", "TREATMENT", 494, 500]]], ["Interaction with the local supply chain management may help ensure availability of some basic equipment, replacement parts, and essential medicines as outlined by the World Health Organization's biennial publication.", [["the local supply chain management", "TREATMENT", 17, 50], ["some basic equipment", "TREATMENT", 83, 103], ["replacement parts", "TREATMENT", 105, 122], ["essential medicines", "TREATMENT", 128, 147]]], ["The profession of medicine has not only an inherent societal responsibility to improve the quality of health but also a responsibility to deliver the best care possible to every patient.", [["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185]]], ["In 1910, during his commencement address at Rush Medical College, William J. Mayo, MD, summarized the inherent responsibility of medical providers and societies to work together.ProfessionalismThe sum-total of medical knowledge is now so great and wide-spreading that it would be futile for one man to attempt to acquire, or for any one man to assume that he has, even a good working knowledge of any large part of the whole.", [["man", "ORGANISM", 295, 298], ["man", "SPECIES", 295, 298], ["man", "SPECIES", 337, 340]]], ["13 Chase and Evert 14 outline 3 ethical principles fundamental to professionalism: the primacy of patient welfare, respect for patient autonomy, and commit- The best interests and needs of each patient should always be the primary objective.", [["patient", "ORGANISM", 98, 105], ["patient", "ORGANISM", 127, 134], ["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 98, 105], ["patient", "SPECIES", 127, 134], ["patient", "SPECIES", 194, 201]]], ["17 Health providers should appropriately apply their training and acknowledge their limitations.", [["their training", "TREATMENT", 47, 61]]], ["Visiting teams must have the capacity to exert flexibility in practice, accommodate local health provider and patients' needs, and have patience with project development.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118]]], ["SustainabilityProfessionalismDevelop outcome assessments of patient care activities, patient safety, quality control, and overall mission impact.", [["patient", "ORGANISM", 60, 67], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 60, 67], ["patient", "SPECIES", 85, 92], ["patient care activities", "TREATMENT", 60, 83]]], ["17 Use education and \"training the trainers\" as a model of intervention.", [["a model of intervention", "TREATMENT", 48, 71]]], ["Develop partnerships with local health agencies and supporting nongovernmental organizations.", [["nongovernmental organizations", "OBSERVATION", 63, 92]]], ["Use medications available locally or through the WHO's list of Essential Medicines.", [["medications", "TREATMENT", 4, 15], ["Essential Medicines", "TREATMENT", 63, 82]]], ["Develop a global health program curriculum with structured didactic sessions, peer-led seminars, journal clubs, and competency assessments.", [["competency assessments", "TEST", 116, 138]]], ["18ProfessionalismEnsure that the same ethical patient care standards practiced in the United States are upheld to the same standards in underserved locations.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53]]], ["Ensure that the exploitation of 1 partner (local health providers or patients) for the benefit of another is avoided at all cost.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77]]], ["19 Ensure that medical students, residents, and other visiting trainees have adequate supervision and mentorship to ensure quality of patient care.", [["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141]]], ["Ensure that team lodging, transportation, food and water, and security measures have been confirmed before travel.", [["security measures", "TREATMENT", 62, 79]]], ["Team members should be familiar with local laws, customs, and religious beliefs that directly affect interactions with patients.", [["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127]]], ["Obtain appropriate approvals by local health organizations if visiting teams will be involved in direct patient care.ProfessionalismOutline an appropriate \"exit strategy\" in case of medical emergency or sudden political unrest.ProfessionalismWHO \u03ed World Health Organization. ment to social justice.", [["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["ProfessionalismOutline", "TREATMENT", 117, 139]]], ["The core principles of how we practice medicine in our own hospitals and clinics, including respect for patient autonomy, privacy, dignity, and confidentiality, should be upheld.", [["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111]]], ["11 For some patients, the best medicine applied may be in the form of just listening, making eye contact, producing a smile, and touching in a culturally appropriate way.", [["eye", "ANATOMY", 93, 96], ["patients", "ORGANISM", 12, 20], ["eye", "ORGAN", 93, 96], ["patients", "SPECIES", 12, 20]]], ["15 By using whatever time is available, such measures help establish empathy, respect, and appreciation for the patients for whom we care.SafetyNot to be undervalued, the safety of all team members must be adequately addressed.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120]]], ["A well-structured program focuses not only on the well-being of the patients and community but also on the volunteer medical providers, residents, and students themselves.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["Table 3 lists a number of pre-travel considerations that participants should address.", [["participants", "SPECIES", 57, 69], ["pre-travel considerations", "TREATMENT", 26, 51]]], ["This preparation begins by ensuring that each member of a medical volunteer team has a formal pre-travel assessment (eg, through a local travel clinic).", [["a formal pre-travel assessment", "TEST", 85, 115]]], ["Such services include appropriate pre-travel and routine vaccinations, anti-malaria prophylaxis, precautions against mosquitos and other vectors of infection, and information on food handling, sun exposure, prevalent local diseases, and how to register with the US embassy in a foreign country.", [["infection", "DISEASE", 148, 157], ["appropriate pre-travel", "TREATMENT", 22, 44], ["routine vaccinations", "TREATMENT", 49, 69], ["anti-malaria prophylaxis", "TREATMENT", 71, 95], ["precautions", "TREATMENT", 97, 108], ["mosquitos", "PROBLEM", 117, 126], ["infection", "PROBLEM", 148, 157], ["prevalent local diseases", "PROBLEM", 207, 231], ["infection", "OBSERVATION", 148, 157]]], ["Personal safety and team security should be addressed and appropriate measures taken to ensure a positive experience.", [["team security", "TREATMENT", 20, 33]]], ["Depending on the types of service planned, select personal protective equipment (including gloves, hand sanitizers, and face masks) may need to be acquired.", [["hand", "ANATOMY", 99, 103], ["hand", "ORGANISM_SUBDIVISION", 99, 103], ["personal protective equipment", "TREATMENT", 50, 79], ["gloves, hand sanitizers", "TREATMENT", 91, 114], ["face masks", "TREATMENT", 120, 130]]], ["An important but often overlooked item is outlining a reliable \"exit strategy\" in case of medical emergency or sudden development of local political instability.PUTTING IT ALL TOGETHERIn acknowledgment of the array of potential benefits and significant risks of underserved health activities, many residency training programs are introducing more formalized global health training into their curricula.", [["ALL", "DISEASE", 172, 175], ["local political instability", "PROBLEM", 133, 160], ["local", "OBSERVATION_MODIFIER", 133, 138], ["political instability", "OBSERVATION", 139, 160]]], ["It has been shown that optimal, productive, and responsible educational experiences for students and residents are generated through the combination of comprehensive educational courses on select global health issues with subsequent international overseas medical electives.", [["productive", "OBSERVATION_MODIFIER", 32, 42]]], ["16 Many centers have developed global health tracks within their residency programs to train future health providers interested in underserved domestic and international healthcare.", [["global", "OBSERVATION_MODIFIER", 31, 37], ["health tracks", "OBSERVATION", 38, 51]]], ["17 Such programs focus not only on the diagnostics and management of novel diseases but also on the interrelationships with poverty, education, religion, and cultural beliefs.PUTTING IT ALL TOGETHERMedical and surgical brigades that address readily correctable ailments in communities with inadequate local healthcare may provide a valuable service.", [["ALL", "DISEASE", 186, 189], ["the diagnostics", "TEST", 35, 50], ["management", "TREATMENT", 55, 65], ["novel diseases", "PROBLEM", 69, 83], ["readily correctable ailments", "PROBLEM", 241, 269], ["diseases", "OBSERVATION", 75, 83]]], ["Despite the popularity of medical care volunteerism, focusing on vaccinations, provisions for clean water, and improvements in community hygiene may actually have a larger, more profound, and enduring impact.", [["medical care volunteerism", "TREATMENT", 26, 51], ["vaccinations", "TREATMENT", 65, 77], ["larger", "OBSERVATION_MODIFIER", 165, 171], ["more profound", "OBSERVATION_MODIFIER", 173, 186]]], ["Direct patient care by volunteers may still have a worthy role, but only in the appropriate context.", [["patient", "ORGANISM", 7, 14], ["volunteers", "ORGANISM", 23, 33], ["patient", "SPECIES", 7, 14]]], ["Enhancing autonomy through training local providers and expanding medication and equipment supply chains will require time and patience.", [["expanding medication", "TREATMENT", 56, 76], ["equipment supply chains", "TREATMENT", 81, 104], ["autonomy", "OBSERVATION", 10, 18]]], ["Both domestically and abroad, there are communities in dire need of medical services.", [["medical services", "TREATMENT", 68, 84]]]], "PMC7488514": [["Relatively inexpensive prevention programs manage to reach a large part of the population avoiding risks and diseases that are very expensive to treat once developed.", [["diseases", "PROBLEM", 109, 117], ["large", "OBSERVATION_MODIFIER", 61, 66]]], ["Recent pandemics, especially COVID-19, have further potentiated this area.", [["Recent pandemics", "PROBLEM", 0, 16], ["COVID", "TEST", 29, 34], ["pandemics", "OBSERVATION", 7, 16]]], ["One of the most relevant areas of public and preventive health is that of addiction, given that it is a problem that affects a large part of the population and with very adverse consequences (Mann et al., 2017).Public Health and Prevention ::: IntroductionCurrently it is possible to observe neural changes, analyze neuro-images and better understand how the mechanisms that determine the cognitive or behavioral processes of addiction operate.", [["neural", "ANATOMY", 292, 298], ["neural changes", "PROBLEM", 292, 306], ["most relevant", "OBSERVATION_MODIFIER", 11, 24], ["areas", "OBSERVATION_MODIFIER", 25, 30], ["large", "OBSERVATION_MODIFIER", 127, 132]]], ["Thanks to these advances, current knowledge about the factors that influence addictive behaviors has taken a qualitative leap, better identifying some of the neurobiological processes through which biological and sociocultural factors contribute to addiction (Volkow and Boyle, 2018).", [["addictive behaviors", "DISEASE", 77, 96]]], ["These innovative lines of research play a very relevant role in the design of prevention programs that target more precisely the mechanisms that determine behavioral health problems and, therefore, are essential to prevent behaviors linked to addiction (Fishbein and Dariotis, 2019).Public Health and Prevention ::: IntroductionThe prevention of addictions consists of persuading large population groups through social persuasion programs developed, fundamentally, through social media.", [["prevention programs", "TREATMENT", 78, 97], ["behavioral health problems", "PROBLEM", 155, 181]]], ["Health communication is a field whose constant evolution confirms that it is a strategic tool that, when used correctly, can be very effective in influencing the behavior of individuals (Goldstein et al., 2015).Public Health and Prevention ::: IntroductionThe report released by the United States Department of Health and Human Service, Healthy People 2020, highlights the importance of research in the development of health communication programs, an aspect that is confirmed in studies that demonstrate the effectiveness of communication in the prevention of tobacco addictions (Kimber et al., 2020), to gambling (Parham et al., 2019) or to different substances (Timko and Cucciare, 2019).Public Health and Prevention ::: IntroductionHowever, there is currently a lack of basic neurocognitive research that makes it possible to better base prevention and communication programs.", [["tobacco addictions", "DISEASE", 561, 579], ["Human", "ORGANISM", 322, 327], ["tobacco", "ORGANISM", 561, 568], ["Human", "SPECIES", 322, 327], ["People", "SPECIES", 345, 351], ["tobacco", "SPECIES", 561, 568], ["communication programs", "TREATMENT", 857, 879]]], ["Only a deep knowledge of the mechanisms underlying the behavior to be modified will allow the design of adequate preventive programs.", [["adequate preventive programs", "TREATMENT", 104, 132]]], ["In this sense, neuroscience can provide very important data, especially in areas as relevant as addictions, where neurocognitive mechanisms play an essential role.Public Health and Prevention ::: IntroductionA communication campaign must be based on the rigor and evidence provided by scientific knowledge (Kumkale et al., 2010), the key being to identify through solid methodologies the neurocognitive factors that intervene in addictions in order to articulate messages that really target those variables that promote a change in behavior.", [["IntroductionA communication campaign", "TREATMENT", 196, 232], ["a change in behavior", "PROBLEM", 520, 540]]], ["No communication strategy is effective if the messages are not built on a frame of reference that is defined by adequate knowledge of the motivating concepts that provoke the reaction of the brain receptors (Gallagher and Updegraff, 2013).", [["brain", "ANATOMY", 191, 196], ["brain", "ORGAN", 191, 196], ["brain receptors", "PROTEIN", 191, 206], ["communication strategy", "TREATMENT", 3, 25], ["brain", "ANATOMY", 191, 196]]], ["As these authors say: \u201cA growing literature on the neural correlates of persuasion has emerged within the past decade\u2026with the majority of studies in this literature focused on the neural correlates of behavior change following exposure to a persuasive appeal\u2026 but there are important remaining questions to address and major opportunities to be pursued that should attract and ignite research attention\u201d (Cacioppo et al., 2018, p.165).", [["neural", "ANATOMY", 51, 57], ["neural", "ANATOMY", 181, 187]]], ["These investigations will not only increase our knowledge of brain and behavior interaction, but will also allow us to better understand the mechanisms of persuasion and social influence.Addiction and Behavioral Addiction ::: IntroductionAddiction is one of the biggest public health problems in the contemporary world.", [["brain", "ANATOMY", 61, 66], ["brain", "ORGAN", 61, 66], ["These investigations", "TEST", 0, 20], ["brain", "ANATOMY", 61, 66], ["biggest", "OBSERVATION_MODIFIER", 262, 269]]], ["The different existing addictions cause a large number of deaths and physical and psychological diseases, also causing disorders of behavior, personality, affectivity and social integration (San Juan, 2019).Addiction and Behavioral Addiction ::: IntroductionIn order to comprehend the basic principles of addiction, the most recent studies focus their interest in understanding how the prefrontal lobe works and what are the associated cognitive functions, in order to assess what role dopaminergic reinforcement systems play in the process, inhibitory control, decision making, the search for experiences or social relationships and other factors.", [["prefrontal lobe", "ANATOMY", 386, 401], ["deaths", "DISEASE", 58, 64], ["physical and psychological diseases", "DISEASE", 69, 104], ["disorders of behavior", "DISEASE", 119, 140], ["personality, affectivity and social integration", "DISEASE", 142, 189], ["prefrontal lobe", "MULTI-TISSUE_STRUCTURE", 386, 401], ["physical and psychological diseases", "PROBLEM", 69, 104], ["disorders of behavior", "PROBLEM", 119, 140], ["large", "OBSERVATION_MODIFIER", 42, 47], ["number", "OBSERVATION_MODIFIER", 48, 54], ["prefrontal lobe", "ANATOMY", 386, 401]]], ["Goldstein and Volkow (2002) explain how addiction occurs when the motivational system and the prefrontal inhibitory control system are decompensated and the former gives an exaggerated value to the substance consumed repeatedly while the individual is unable to inhibit a behavior that generates an immediate reward and disregard the risks of this addiction.", [["prefrontal", "ANATOMY", 94, 104], ["decompensated", "PROBLEM", 135, 148], ["an exaggerated value", "PROBLEM", 170, 190], ["decompensated", "OBSERVATION", 135, 148]]], ["The increased interest in addictions, more recent research has emerged regarding behavioral addictions.", [["behavioral addictions", "DISEASE", 81, 102], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["interest", "OBSERVATION_MODIFIER", 14, 22]]], ["In 2013, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders was modified to include a subdivision of non-substance-related disorders in the Substance-Related and Addictive disorders category (Goldstein and Volkow, 2002).", [["Addictive disorders", "DISEASE", 190, 209], ["Mental Disorders", "PROBLEM", 71, 87], ["related disorders", "PROBLEM", 143, 160]]], ["This subdivision is specifically focused on addictive disorders that do not involve the use of substances and is often called behavioral addictions.Addiction and Behavioral Addiction ::: IntroductionIn addition, in recent years the WHO has introduced behavioral addictions into its classification.", [["addictive disorders", "DISEASE", 44, 63], ["behavioral addictions", "DISEASE", 126, 147], ["addictive disorders", "PROBLEM", 44, 63]]], ["In this new list, internet addiction is one of the most widespread and could be the cause of important emotional and psychological disorders in the individual (Demetrovics et al., 2008; Vondr\u00e1ckov\u00e1 and Gabrhel\u00edk, 2016).", [["internet addiction", "DISEASE", 18, 36], ["emotional and psychological disorders", "DISEASE", 103, 140], ["important emotional and psychological disorders", "PROBLEM", 93, 140]]], ["There is solid evidence that indicates that problematic consumption of pornography as well as addiction to pornography is increasing, especially in young men (Castro et al., 2019; de Alarc\u00f3n et al., 2019), causing serious difficulties in this population.Pornography Addiction ::: IntroductionThanks to neuroscience, it has been possible to investigate the reasons why adolescents are more likely to develop substance use disorders than adults.", [["substance use disorders", "DISEASE", 407, 430], ["men", "ORGANISM", 154, 157], ["adolescents", "ORGANISM", 368, 379], ["men", "SPECIES", 154, 157], ["serious difficulties in this population", "PROBLEM", 214, 253], ["increasing", "OBSERVATION_MODIFIER", 122, 132], ["serious", "OBSERVATION_MODIFIER", 214, 221]]], ["The results explain how during adolescence the reward/motivation mechanisms and the limbic-emotional circuits exhibit a state of hyperactivity that fosters greater emotional reactivity and drives the search for behaviors that generate immediate reward.", [["limbic", "ANATOMY", 84, 90], ["hyperactivity", "DISEASE", 129, 142], ["hyperactivity", "PROBLEM", 129, 142]]], ["Furthermore, the prefrontal cortex cannot fully self-regulate, leading to increased impulsivity and risk taking (Jordan and Andersen, 2017).", [["prefrontal cortex", "ANATOMY", 17, 34], ["impulsivity", "DISEASE", 84, 95], ["prefrontal cortex", "CANCER", 17, 34], ["increased impulsivity", "PROBLEM", 74, 95], ["prefrontal cortex", "ANATOMY", 17, 34], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["impulsivity", "OBSERVATION", 84, 95]]], ["Through studies based on neuroimaging methodologies, it has been possible to observe the neural circuits that are activated during addictive behaviors, the gratifying responses, as well as all those processes that activate conditioning to the substance, mood, anxiety or reactivity during withdrawal symptom period (Volkow et al., 2016; Zilverstand et al., 2016).Pornography Addiction ::: IntroductionThere are multiple studies based on knowledge of substance-related addictions (Addicott, 2020; Votaw et al., 2020), however, research related to behavioral addiction is much more scarce, highlighting those focused on understanding the relationship between addictive behavior and activation of the Dorsolateral Prefrontal Cortex and its effects on working memory and inhibition of the control of impulsive responses (Alizadehgoradel et al., 2020; Maheux-Caron et al., 2020).", [["neural", "ANATOMY", 89, 95], ["Prefrontal Cortex", "ANATOMY", 711, 728], ["anxiety", "DISEASE", 260, 267], ["behavioral addiction", "DISEASE", 546, 566], ["addictive behavior", "DISEASE", 657, 675], ["neuroimaging methodologies", "TEST", 25, 51], ["mood", "PROBLEM", 254, 258], ["anxiety", "PROBLEM", 260, 267], ["withdrawal symptom", "PROBLEM", 289, 307], ["multiple studies", "TEST", 411, 427], ["the Dorsolateral Prefrontal Cortex", "TREATMENT", 694, 728], ["neural circuits", "ANATOMY", 89, 104], ["Dorsolateral", "ANATOMY_MODIFIER", 698, 710], ["Prefrontal Cortex", "ANATOMY", 711, 728]]], ["One of the behavioral addictions that has attracted the most attention in recent years is pornography addiction.", [["behavioral addictions", "DISEASE", 11, 32]]], ["The increased use of the internet may have led to increased consumption and acceptance of pornography (D\u2019Orlando, 2011).", [["increased", "OBSERVATION_MODIFIER", 4, 13]]], ["As a consequence of the increased pornography use worldwide, there has been much focus on compulsive internet pornography as a subdomain of hypersexuality (Carroll et al., 2008; D\u00f6ring, 2009; Griffiths, 2013).", [["hypersexuality", "DISEASE", 140, 154], ["hypersexuality", "PROBLEM", 140, 154], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["On the other hand, individuals who consume cybersex increasingly show younger profiles, and the consumption of online pornography causes a decrease in self-esteem and an increase in stress levels in young people (Ainsworth-Masiello and Evans, 2019).", [["people", "ORGANISM", 205, 211], ["people", "SPECIES", 205, 211], ["a decrease in self-esteem", "PROBLEM", 137, 162], ["an increase in stress levels", "PROBLEM", 167, 195], ["decrease", "OBSERVATION_MODIFIER", 139, 147], ["increase", "OBSERVATION_MODIFIER", 170, 178]]], ["According to the report of the Association for Media Research (AIMC), \u201cInternet Audience March 2020,\u201d 15.3% of users in Spain are young people between 14 and 24 years old, highlighting the progressive growth of included in the section from 14 to 19 years.", [["people", "ORGANISM", 136, 142], ["people", "SPECIES", 136, 142], ["the progressive growth", "PROBLEM", 185, 207], ["progressive", "OBSERVATION_MODIFIER", 189, 200], ["growth", "OBSERVATION_MODIFIER", 201, 207]]], ["In addition, the Internet consumption habit by adolescents is characterized by impulsive and uncontrolled behavior in which the need to repeat addictive behaviors prevails, generating a high degree of irritation if browsing is interrupted (Xanidis and Brignell, 2016; Rojas et al., 2018).", [["addictive behaviors", "DISEASE", 143, 162], ["adolescents", "SPECIES", 47, 58], ["impulsive and uncontrolled behavior", "PROBLEM", 79, 114], ["irritation", "PROBLEM", 201, 211], ["high degree", "OBSERVATION_MODIFIER", 186, 197], ["irritation", "OBSERVATION", 201, 211]]], ["If we consider that one of the main personality traits of adolescents trained in the digital age is the urgent need to obtain immediate pleasure, we will better understand the activities risk that the consumption of online porn content can pose for individuals still in maturation process of gratification.Pornography Addiction ::: IntroductionEmpirical evidence seems to support the notion that abusive online pornography use leads to adverse behavioral (couple-related behavioral changes, reduced social interaction, modified goal standards), physiological (modification of sexual psychophysiological patterns such as erection) and emotional effects (guilt, negative chains of thought, reduction of self-esteem) (de Alarc\u00f3n et al., 2019).", [["adverse behavioral", "PROBLEM", 436, 454], ["behavioral changes", "PROBLEM", 471, 489], ["sexual psychophysiological patterns", "TREATMENT", 576, 611], ["emotional effects", "PROBLEM", 634, 651]]], ["There is also strong evidence that indicates the effects that porn consumption causes on the brain (Muller, 2018).", [["brain", "ANATOMY", 93, 98], ["brain", "ORGAN", 93, 98], ["brain", "ANATOMY", 93, 98]]], ["Inh\u00f3f et al. (2019) have recently presented strong evidence on gender differences in activation of the prefrontal cortex in internet addiction.", [["prefrontal cortex", "ANATOMY", 103, 120], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 103, 120], ["prefrontal cortex", "ANATOMY", 103, 120]]], ["Sometimes, this behavior ends up becoming a behavioral addiction, which may in turn increase its adverse effects.", [["behavioral addiction", "DISEASE", 44, 64]]], ["Behavioral addictions are becoming more prevalent, especially among young adults (e.g., online gambling, excessive smartphone use, and online porn addiction).", [["Behavioral addictions", "DISEASE", 0, 21]]], ["There exists evidence indicating that women are joining the use of these websites and devices (Shaughnessy et al., 2011, 2017; French and Hamilton, 2018).Pornography Addiction ::: IntroductionOn the other hand, health organizations are generating research projects that allow to develop primary and secondary (treatment) prevention programs based on already-existing intervention programs on this field (Vondr\u00e1ckov\u00e1 and Gabrhel\u00edk, 2016; Sniewski et al., 2018).", [["women", "ORGANISM", 38, 43], ["women", "SPECIES", 38, 43], ["primary and secondary (treatment) prevention programs", "TREATMENT", 287, 340], ["intervention programs", "TREATMENT", 367, 388], ["evidence indicating", "UNCERTAINTY", 13, 32]]], ["Nevertheless, there is no robust empirical evidence on women\u2019s online porn use habits nor on the neurocognitive mechanisms involved in this behavior, which in turn is hurting the creation of these prevention programs.Pornography Addiction ::: IntroductionThis research is carried out within the emerging area of \u201cneuroscience of addiction and prevention\u201d (Volkow and Boyle, 2018).", [["women", "ORGANISM", 55, 60], ["women", "SPECIES", 55, 60], ["these prevention programs", "TREATMENT", 191, 216], ["no", "UNCERTAINTY", 23, 25]]], ["In this frame of reference, it has been proposed that the addiction cycle is articulated in three stages and involves three fundamental brain regions: (1) the anticipatory response, mainly caused by stimuli (internal or external) involving the prefrontal cortex and which is responsible of craving, the irrepressible impulse that starts the behavior, (2) the execution of the behavior (with or without substance intake) that involves the base ganglia and the reward circuit, and (3) the extended circuit of the amygdala responsible for withdrawal and restoring balance to the stress response (United States Department of Health and human service, 2016).Pornography Addiction ::: IntroductionThe goal of primary prevention is to persuade the target population to prevent the problem behavior from occuring.", [["brain", "ANATOMY", 136, 141], ["prefrontal cortex", "ANATOMY", 244, 261], ["base ganglia", "ANATOMY", 438, 450], ["amygdala", "ANATOMY", 511, 519], ["brain regions", "MULTI-TISSUE_STRUCTURE", 136, 149], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 244, 261], ["ganglia", "MULTI-TISSUE_STRUCTURE", 443, 450], ["amygdala", "MULTI-TISSUE_STRUCTURE", 511, 519], ["human", "ORGANISM", 632, 637], ["human", "SPECIES", 632, 637], ["human", "SPECIES", 632, 637], ["stimuli (internal or external) involving the prefrontal cortex", "PROBLEM", 199, 261], ["craving", "PROBLEM", 290, 297], ["the irrepressible impulse", "PROBLEM", 299, 324], ["withdrawal", "PROBLEM", 536, 546], ["primary prevention", "TREATMENT", 703, 721], ["the target population", "TREATMENT", 737, 758], ["the problem behavior", "PROBLEM", 770, 790], ["brain", "ANATOMY", 136, 141], ["prefrontal cortex", "ANATOMY", 244, 261], ["base", "ANATOMY_MODIFIER", 438, 442], ["ganglia", "ANATOMY", 443, 450], ["reward circuit", "OBSERVATION", 459, 473]]], ["Since addictive behavior consists of very powerful learning due to the intensity of the reward, the triggering stimulus acts as a discriminating stimulus.", [["addictive behavior", "DISEASE", 6, 24]]], ["The discriminative stimulus is defined by the psychology of learning as that stimulus that signals to the subject the availability of reinforcement in operant conditioning.", [["reinforcement in operant conditioning", "TREATMENT", 134, 171], ["discriminative stimulus", "OBSERVATION", 4, 27]]], ["When reinforcement involves the dopaminergic brain systems as intensely as it does in addictions, discriminative stimulation and craving play an essential role.", [["brain", "ANATOMY", 45, 50], ["brain", "ORGAN", 45, 50], ["discriminative stimulation", "TREATMENT", 98, 124]]], ["This research focuses on studying the importance of the discriminative stimulus consisting of sexually explicit images (cue exposure) and the craving response (cue reactivity) in young women who watch a clip with pornographic content versus a clip with neutral content.", [["women", "ORGANISM", 185, 190], ["women", "SPECIES", 185, 190], ["sexually explicit images", "TEST", 94, 118], ["a clip with pornographic content", "TREATMENT", 201, 233], ["a clip", "TREATMENT", 241, 247], ["neutral content", "OBSERVATION", 253, 268]]], ["This paradigm has been used in the study of substance addictions, such as smoking (Kroczek et al., 2017), but it has not been developed in the field of behavioral addictions such as the consumption of pornography.Pornography Addiction ::: IntroductionRecently, Strahler et al. (2018) have studied the neural correlates of gender differences in distractibility by sexual stimuli.", [["neural", "ANATOMY", 301, 307], ["substance addictions", "DISEASE", 44, 64], ["behavioral addictions", "DISEASE", 152, 173], ["sexual stimuli", "TEST", 363, 377]]], ["These authors researched neural activity specific to sexual images in brain regions implicated in motivation and reward processing.", [["neural", "ANATOMY", 25, 31], ["brain", "ANATOMY", 70, 75], ["brain regions", "MULTI-TISSUE_STRUCTURE", 70, 83], ["sexual images", "TEST", 53, 66], ["brain", "ANATOMY", 70, 75]]], ["They found that men as compared to women showed stronger responses in the nucleus caudatus, the anterior cingulate cortex, and the nucleus accumbens.", [["nucleus caudatus", "ANATOMY", 74, 90], ["anterior cingulate cortex", "ANATOMY", 96, 121], ["nucleus accumbens", "ANATOMY", 131, 148], ["men", "ORGANISM", 16, 19], ["women", "ORGANISM", 35, 40], ["nucleus caudatus", "MULTI-TISSUE_STRUCTURE", 74, 90], ["anterior cingulate cortex", "CANCER", 96, 121], ["nucleus accumbens", "MULTI-TISSUE_STRUCTURE", 131, 148], ["men", "SPECIES", 16, 19], ["women", "SPECIES", 35, 40], ["stronger responses in the nucleus caudatus", "PROBLEM", 48, 90], ["nucleus caudatus", "ANATOMY", 74, 90], ["anterior", "ANATOMY_MODIFIER", 96, 104], ["cingulate cortex", "ANATOMY", 105, 121], ["nucleus accumbens", "ANATOMY", 131, 148]]], ["Sexually-motived traits were selectively correlated with nucleus caudatus activity.Pornography Addiction ::: IntroductionThe goal of our research is to analyze the role of the dorsolateral prefrontal cortex during pornography cue exposure in young women.", [["nucleus caudatus", "ANATOMY", 57, 73], ["dorsolateral prefrontal cortex", "ANATOMY", 176, 206], ["dorsolateral prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 176, 206], ["women", "ORGANISM", 248, 253], ["women", "SPECIES", 248, 253], ["caudatus activity", "OBSERVATION", 65, 82], ["dorsolateral", "ANATOMY_MODIFIER", 176, 188], ["prefrontal cortex", "ANATOMY", 189, 206]]], ["By achieving this goal, we intend to provide with knowledge on the neurocognitive fundamentals of this behavior, which will set the foundations of future developments of useful prevention programs.", [["useful prevention programs", "TREATMENT", 170, 196]]], ["This research may also help to consolidate already-initiated communication programs within health organizations in the field.", [["communication programs", "TREATMENT", 61, 83]]], ["This study tested whether the prefrontal cortex of participants high (vs. low) in porn consumption showed more activation when exposed to pornographic content relative to a no-treatment condition.", [["prefrontal cortex", "ANATOMY", 30, 47], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 30, 47], ["participants", "SPECIES", 51, 63], ["This study", "TEST", 0, 10], ["a no-treatment condition", "PROBLEM", 171, 195], ["prefrontal cortex", "ANATOMY", 30, 47]]], ["In line with previous research (K\u00fchn and Gallinat, 2014; Zangemeister et al., 2019) we expected participants high (vs. low) in porn consumption to increase their activity (cue reactivity) in the prefrontal cortex area when being exposed to footage with pornographic content (cue exposure).", [["prefrontal cortex area", "ANATOMY", 195, 217], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 195, 212], ["participants", "SPECIES", 96, 108], ["prefrontal cortex", "ANATOMY", 195, 212]]], ["We analyzed the activity of the prefrontal cortex using the fNIRS (functional near infrared spectroscopy) technique, which has been shown to be effective in this type of study (Karthikeyan et al., 2020).", [["prefrontal cortex", "ANATOMY", 32, 49], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 32, 49], ["activity", "OBSERVATION_MODIFIER", 16, 24], ["prefrontal", "ANATOMY_MODIFIER", 32, 42], ["cortex", "ANATOMY_MODIFIER", 43, 49]]], ["There is also similar evidence in neuroimaging studies using fNIRS in the field of addictions (Leong et al., 2019).Pornography Addiction ::: IntroductionAs noted, previous research has shown that higher levels of right pars triangularis reactivity as measured by fNIRS in the prefrontal cortex area are associated with self-regulatory endeavors.", [["right pars triangularis", "ANATOMY", 213, 236], ["prefrontal cortex area", "ANATOMY", 276, 298], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 276, 293], ["neuroimaging studies", "TEST", 34, 54], ["right pars triangularis reactivity", "PROBLEM", 213, 247], ["higher", "OBSERVATION_MODIFIER", 196, 202], ["right", "ANATOMY_MODIFIER", 213, 218], ["pars", "ANATOMY_MODIFIER", 219, 223], ["triangularis", "ANATOMY_MODIFIER", 224, 236], ["prefrontal", "ANATOMY_MODIFIER", 276, 286], ["cortex", "ANATOMY_MODIFIER", 287, 293]]], ["Of course, it is possible that other stimuli in the lab context might be responsible for such potential difference in activation (e.g., cover story, brain-measuring apparatus, lab environment).", [["brain", "ANATOMY", 149, 154], ["brain", "ORGAN", 149, 154], ["brain", "ANATOMY", 149, 154]]], ["Thus, an important goal of the current study was to compare the extent to which the prefrontal cortex activation differs as a function of the type of video (control vs. porn) participants were exposed to.", [["prefrontal cortex", "ANATOMY", 84, 101], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 84, 101], ["participants", "SPECIES", 175, 187], ["the current study", "TEST", 27, 44], ["video (control vs. porn)", "TREATMENT", 150, 174]]], ["The hypothesis to be investigated proposes that certain areas of the prefrontal cortex will be activated to a greater extent during the viewing of pornography (vs. control).", [["prefrontal cortex", "ANATOMY", 69, 86], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 69, 86], ["pornography", "TEST", 147, 158], ["prefrontal cortex", "ANATOMY", 69, 86], ["greater extent", "OBSERVATION_MODIFIER", 110, 124]]], ["Finally, an interaction effect is also hypothesized: That is, the effect of cue reactivity in the presence of the discriminating stimulus (porn clip) will be greater the higher the rate of pornography consumption and, therefore, the more intense the operant learning has been (Ferrari and Quaresima, 2012).", [["cue reactivity", "PROBLEM", 76, 90], ["porn clip", "TREATMENT", 139, 148]]], ["As a research question, the specific prefrontal area where the greatest activation will appear in each circumstance will be considered.Internet Pornography Use ::: Materials and MethodsFirst, participants were told that they were going to be involved in a study exploring personality variables and reactions to certain stimuli.", [["prefrontal area", "ANATOMY", 37, 52], ["prefrontal area", "MULTI-TISSUE_STRUCTURE", 37, 52], ["participants", "SPECIES", 192, 204], ["a study", "TEST", 254, 261], ["personality variables", "PROBLEM", 272, 293], ["certain stimuli", "TEST", 311, 326], ["greatest", "OBSERVATION_MODIFIER", 63, 71]]], ["Participants then responded to some ancillary questions that served to support the cover story, and then responded to the item (e.g., \u201cWith what frequency do you usually watch porn per week?\u201d) on which responses ranged from \u201c0\u201d to \u201c6\u201d with higher numbers reflecting more porn consumption indicating if they had viewed pornography.", [["Participants", "SPECIES", 0, 12]]], ["This measure of pornography consumption has been previously used (with a slightly different scale) and has demonstrated its validity and reliability for this type of study (Grubbs et al., 2015).Stimulus ::: Materials and MethodsDuring fNIRS recording, subjects were instructed to sit and focus on a blank screen.", [["a slightly different scale", "TREATMENT", 71, 97], ["MethodsDuring fNIRS recording", "TEST", 221, 250], ["a blank screen", "TEST", 297, 311]]], ["Then a 20-second clip was then presented, preceded by a 2-second fixation point and followed by a 20-second blank screen as baseline, in an uninterrupted sequence.", [["20-second clip", "DNA", 7, 21], ["a 20-second clip", "TREATMENT", 5, 21], ["a 2-second fixation point", "TREATMENT", 54, 79], ["second blank screen", "TEST", 101, 120], ["an uninterrupted sequence", "TEST", 137, 162]]], ["Once these 20-second of white screen are finished, another 20-second begin with a neutral clip followed by another 20-second of blank screen as a baseline.Stimulus ::: Materials and MethodsTo generate a sexual arousal clip, we selected a Roman orgy scene from the film Caligula, by Tinto Brass, explicitly depicting sex.", [["white screen", "TEST", 24, 36], ["a neutral clip", "TREATMENT", 80, 94], ["blank screen", "TEST", 128, 140], ["Methods", "TREATMENT", 182, 189], ["a sexual arousal clip", "TREATMENT", 201, 222]]], ["For the neutral clip, we chose a standard TV interview with a similar stimulus complexity with the same blank screen as baseline.", [["the neutral clip", "TREATMENT", 4, 20], ["the same blank screen", "TEST", 95, 116]]], ["The choice for a pornographic scene was able to provoke sexual arousal as it was confirmed in a previous pilot study with similar subjects.Stimulus ::: Materials and MethodsIn order to avoid cumulative error, the stimuli were presented in random order.Measurement of Prefrontal Activity: fNIRS ::: Materials and MethodsData collection using fNIRS was carried out in the neurocommunication laboratory of the School of Communication of the Complutense University of Madrid2.", [["a pornographic scene", "TREATMENT", 15, 35], ["sexual arousal", "PROBLEM", 56, 70], ["a previous pilot study", "TEST", 94, 116], ["Methods", "TREATMENT", 166, 173], ["cumulative error", "PROBLEM", 191, 207], ["the stimuli", "TEST", 209, 220], ["MethodsData collection", "TEST", 312, 334], ["fNIRS", "TEST", 341, 346], ["Madrid2", "TREATMENT", 464, 471]]], ["Participants were then connected individually to the fNIRS devices to record the prefrontal activity while watching the stimuli.Measurement of Prefrontal Activity: fNIRS ::: Materials and MethodsThe prefrontal activity data was recorded using a NIRSport2 fNIRS system by NIRx (NIRx Medical Technologies LLC) which assesses cognitive activation by recording brain oxygenation.", [["prefrontal", "ANATOMY", 81, 91], ["prefrontal", "ANATOMY", 199, 209], ["brain", "ANATOMY", 357, 362], ["prefrontal", "MULTI-TISSUE_STRUCTURE", 81, 91], ["brain", "ORGAN", 357, 362], ["Participants", "SPECIES", 0, 12], ["the fNIRS devices", "TREATMENT", 49, 66], ["a NIRSport2 fNIRS system", "TREATMENT", 243, 267], ["recording brain oxygenation", "TEST", 347, 374]]], ["Light-emitting diodes (LEDs) in optodes held to the scalp by a tight cap emit light from 650 to 1000 nm.", [["scalp", "ANATOMY", 52, 57], ["scalp", "ORGAN", 52, 57], ["Light-emitting diodes (LEDs", "TREATMENT", 0, 27], ["emitting diodes", "OBSERVATION", 6, 21], ["scalp", "ANATOMY", 52, 57]]], ["This light passes through the skull and the first layer of the cortex before being picked up by corresponding detectors.", [["skull", "ANATOMY", 30, 35], ["cortex", "ANATOMY", 63, 69], ["skull", "ORGAN", 30, 35], ["cortex", "CANCER", 63, 69], ["skull", "ANATOMY", 30, 35], ["first", "ANATOMY_MODIFIER", 44, 49], ["layer", "ANATOMY_MODIFIER", 50, 55], ["cortex", "ANATOMY_MODIFIER", 63, 69]]], ["Some of this light is absorbed by chromophores, but human tissue is relatively \u201ctransparent\u201d in this spectral range (Ferrari and Quaresima, 2012).", [["tissue", "ANATOMY", 58, 64], ["human", "ORGANISM", 52, 57], ["tissue", "TISSUE", 58, 64], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["human tissue", "PROBLEM", 52, 64], ["human tissue", "OBSERVATION_MODIFIER", 52, 64]]], ["Hemoglobin, the transport protein that allows red blood cells to carry oxygen, is one such chromophore.", [["red blood cells", "ANATOMY", 46, 61], ["oxygen", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 71, 77], ["Hemoglobin", "GENE_OR_GENE_PRODUCT", 0, 10], ["red blood cells", "CELL", 46, 61], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["Hemoglobin", "PROTEIN", 0, 10], ["transport protein", "PROTEIN", 16, 33], ["red blood cells", "CELL_TYPE", 46, 61], ["Hemoglobin", "TEST", 0, 10], ["the transport protein", "TEST", 12, 33], ["red blood cells", "TEST", 46, 61], ["oxygen", "TREATMENT", 71, 77]]], ["A higher concentration of oxygenated hemoglobin results in more light being absorbed.", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 37, 47], ["oxygenated hemoglobin", "PROTEIN", 26, 47], ["oxygenated hemoglobin", "TEST", 26, 47], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22], ["oxygenated hemoglobin", "OBSERVATION", 26, 47]]], ["The fNIRS system displays the degree of oxygenation in real-time to researchers based on this principal.", [["The fNIRS system", "TEST", 0, 16], ["degree", "OBSERVATION_MODIFIER", 30, 36], ["oxygenation", "OBSERVATION", 40, 51]]], ["The presence of increased oxygenated hemoglobin is interpreted to be the result of more neural resources being used in that area.", [["neural", "ANATOMY", 88, 94], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 37, 47], ["hemoglobin", "PROTEIN", 37, 47], ["increased oxygenated hemoglobin", "PROBLEM", 16, 47], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["oxygenated hemoglobin", "OBSERVATION", 26, 47], ["neural resources", "OBSERVATION", 88, 104]]], ["Other technologies and techniques are also routinely used to assess neural activity.", [["neural", "ANATOMY", 68, 74]]], ["As a neuroimaging technique, fNIRS is a much less expensive alternative to traditional Functional Magnetic Resonance Imaging (fMRI).", [["a neuroimaging technique", "TEST", 3, 27], ["MRI", "TEST", 127, 130]]], ["Despite its lower signal-to-noise (SNR) ratio, fNIRS correlates highly with fMRI measures (Cui et al., 2011), making it a reliable alternative for use in psychophysiological studies. fNIRS is both mobile and less sensitive to movement artifacts than fMRI (Cui et al., 2011), which allows for neuroimaging experiments that would otherwise be impossible, such as full-body motion studies.", [["body", "ANATOMY", 366, 370], ["fMRI measures", "TEST", 76, 89], ["psychophysiological studies", "TEST", 154, 181], ["movement artifacts", "TEST", 226, 244], ["fMRI", "TEST", 250, 254], ["neuroimaging experiments", "TEST", 292, 316], ["full-body motion studies", "TEST", 361, 385], ["mobile", "OBSERVATION_MODIFIER", 197, 203]]], ["The ability of fNIRS to be used in a mobile modality is vital to naturalistic studies, since the goal of a naturalistic study is to be as close to real-world activity as possible.", [["naturalistic studies", "TEST", 65, 85], ["a naturalistic study", "TEST", 105, 125]]], ["For investigations of cue reactivity there are several benefits in using fNIRS, e.g., subjects are sitting in a realistic upright position and can handle real objects to elicit CR by triggering several senses (visual, tactile, olfactory and interoception during movement).", [["olfactory", "MULTI-TISSUE_STRUCTURE", 227, 236], ["fNIRS", "TEST", 73, 78], ["CR", "TEST", 177, 179]]], ["Although fNIRS cannot measure hemodynamic activity in subcortical structures, it can assess both the dlPFC involved in inhibitory processes and the OFC involved in the processing of emotional valence (Ehlis et al., 2014).Measurement of Prefrontal Activity: fNIRS ::: Materials and MethodsThe fNIRS shows the relative changes in hemoglobin levels, calculated using the modified Beer-Lambert law (Figure 1): oxygenated hemoglobin change: delta O2Hb (\u03bcmol/L), deoxygenated hemoglobin change: delta HHb (\u03bcmol/L) and total hemoglobin change: delta cHb (\u03bcmol/L).Measurement of Prefrontal Activity: fNIRS ::: Materials and MethodsIn order to measure changes in cerebral oxygenation this study utilized the NIRSport2 system.", [["subcortical structures", "ANATOMY", 54, 76], ["dlPFC", "ANATOMY", 101, 106], ["cerebral", "ANATOMY", 654, 662], ["subcortical structures", "MULTI-TISSUE_STRUCTURE", 54, 76], ["dlPFC", "CANCER", 101, 106], ["OFC", "CANCER", 148, 151], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 328, 338], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 417, 427], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 470, 480], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 518, 528], ["cerebral", "ORGAN", 654, 662], ["dlPFC", "PROTEIN", 101, 106], ["hemoglobin", "PROTEIN", 328, 338], ["hemoglobin", "PROTEIN", 417, 427], ["delta O2Hb", "PROTEIN", 436, 446], ["hemoglobin", "PROTEIN", 470, 480], ["delta HHb", "PROTEIN", 489, 498], ["hemoglobin", "PROTEIN", 518, 528], ["The fNIRS", "TEST", 288, 297], ["the relative changes in hemoglobin levels", "PROBLEM", 304, 345], ["oxygenated hemoglobin change", "TEST", 406, 434], ["delta O2Hb", "TEST", 436, 446], ["deoxygenated hemoglobin change", "TREATMENT", 457, 487], ["delta HHb (\u03bcmol/L)", "TREATMENT", 489, 507], ["total hemoglobin change", "TREATMENT", 512, 535], ["delta cHb", "TREATMENT", 537, 546], ["Methods", "TREATMENT", 616, 623], ["cerebral oxygenation", "TEST", 654, 674], ["this study", "TEST", 675, 685], ["subcortical", "ANATOMY_MODIFIER", 54, 65], ["hemoglobin levels", "OBSERVATION", 328, 345], ["cerebral oxygenation", "OBSERVATION", 654, 674]]], ["(NIRSport2 8-8, NIRx Medical Technologies LLC, United States) which is a portable, wearable, multichannel fNIRS system consisting of 8 LED illumination sources and 8 active detection sensors.", [["NIRSport2", "TEST", 1, 10], ["multichannel fNIRS system", "TEST", 93, 118], ["LLC", "ANATOMY", 42, 45]]], ["Emitters were placed on positions F1, AF3, FC3, F5, F6, AF4, FC4, and F2 while detectors were placed on positions F3, AF7, FC5, F7, F8, AF8, FC6, and F4 (Figure 2).", [["AF4", "GENE_OR_GENE_PRODUCT", 56, 59], ["FC4", "GENE_OR_GENE_PRODUCT", 61, 64], ["AF8", "GENE_OR_GENE_PRODUCT", 136, 139], ["AF3", "DNA", 38, 41], ["FC3", "DNA", 43, 46], ["F5", "DNA", 48, 50], ["F6", "DNA", 52, 54], ["AF4", "DNA", 56, 59], ["FC4", "DNA", 61, 64], ["F2", "DNA", 70, 72], ["F3", "DNA", 114, 116], ["AF7", "DNA", 118, 121], ["FC5", "DNA", 123, 126], ["F7", "DNA", 128, 130], ["F8", "DNA", 132, 134], ["AF8", "DNA", 136, 139], ["FC6", "DNA", 141, 144], ["F4", "DNA", 150, 152], ["AF7", "TEST", 118, 121], ["AF8", "TEST", 136, 139], ["FC6", "TEST", 141, 144]]], ["Eighteen channels were set up covering the prefrontal cortex.", [["prefrontal cortex", "ANATOMY", 43, 60], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 43, 60], ["Eighteen channels", "TREATMENT", 0, 17], ["prefrontal", "ANATOMY_MODIFIER", 43, 53], ["cortex", "ANATOMY_MODIFIER", 54, 60]]], ["The source\u2014detector distance was 3 cm.", [["3 cm", "OBSERVATION_MODIFIER", 33, 37]]], ["Optodes were placed on the participant\u2019s head using an Easycap relative to the international 10/20 system (Jasper, 1958).", [["head", "ANATOMY", 41, 45], ["head", "ORGANISM_SUBDIVISION", 41, 45], ["participant", "SPECIES", 27, 38]]], ["The data was acquired with the Aurora 1.4. acquisition Software (v2014 NIRx Medical Technologies LLC) at two near infra-red light wavelengths of 760 and 850 nm, with a sampling rate of 7.81 Hz.Measurement of Prefrontal Activity: fNIRS ::: Materials and MethodsParticipants were then sat in front of a screen, and were told that video footage was going to be shown.", [["Aurora", "GENE_OR_GENE_PRODUCT", 31, 37], ["Aurora 1.4", "PROTEIN", 31, 41], ["The data", "TEST", 0, 8], ["the Aurora", "TEST", 27, 37], ["a sampling rate", "TEST", 166, 181], ["MethodsParticipants", "TREATMENT", 253, 272], ["a screen", "TEST", 299, 307], ["video footage", "TEST", 328, 341], ["LLC", "ANATOMY", 97, 100], ["850 nm", "OBSERVATION_MODIFIER", 153, 159]]], ["They were instructed to watch it while the apparatus measured their brain activity, and to wait for about 20 s after the video was over so a return to baseline could also be collected.", [["brain", "ANATOMY", 68, 73], ["brain", "ORGAN", 68, 73]]], ["After data collection was completed, participants were debriefed, thanked and dismissed.ResultsThe NIRSport2 comes together with Aurora fNIRS: a software platform designed to record the signal.", [["Aurora", "GENE_OR_GENE_PRODUCT", 129, 135], ["NIRSport2", "DNA", 99, 108], ["Aurora fNIRS", "DNA", 129, 141], ["participants", "SPECIES", 37, 49], ["Aurora fNIRS", "TEST", 129, 141], ["a software platform", "TEST", 143, 162]]], ["The automated signal optimization algorithm ensures optimal signal quality before a measurement is started.", [["a measurement", "TEST", 82, 95]]], ["Once data is being recorded, HbO and Hb concentration changes can be visualized in real-time in several display modes.", [["HbO", "CHEMICAL", 29, 32], ["HbO", "SIMPLE_CHEMICAL", 29, 32], ["Hb", "SIMPLE_CHEMICAL", 37, 39], ["Hb", "PROTEIN", 37, 39], ["HbO", "TREATMENT", 29, 32], ["Hb concentration changes", "PROBLEM", 37, 61]]], ["In addition, high-end whole-head visualizations are immediately available.ResultsAlso, the nirsLAB package is available: is a MATLAB-based software analysis environment developed to support the study of time-varying near infrared measurements of tissue using the NIRSport2 system.", [["head", "ANATOMY", 28, 32], ["tissue", "ANATOMY", 246, 252], ["head", "ORGANISM_SUBDIVISION", 28, 32], ["tissue", "TISSUE", 246, 252], ["nirsLAB package", "DNA", 91, 106], ["the study", "TEST", 190, 199], ["the NIRSport2 system", "TREATMENT", 259, 279]]], ["It is composed of modules for: Importing NIRS measurement data.", [["Importing NIRS measurement data", "TEST", 31, 62]]], ["Creating files that contain the optode-position.", [["optode", "OBSERVATION_MODIFIER", 32, 38], ["position", "OBSERVATION_MODIFIER", 39, 47]]], ["Preprocessing of measurement data using software programs that exclude data channels having excessive noise, deleting experimentally irrelevant time intervals, removing artifacts from data and filtering to exclude experimentally irrelevant frequency bands.", [["measurement data", "TEST", 17, 33], ["software programs", "TREATMENT", 40, 57], ["excessive noise", "PROBLEM", 92, 107], ["artifacts from data", "TEST", 169, 188], ["experimentally irrelevant frequency bands", "PROBLEM", 214, 255]]], ["Computing hemodynamic states using wavelength and path length dependent parameter settings.", [["wavelength and path length dependent parameter settings", "TREATMENT", 35, 90]]], ["The Data Analysis uses functions found in the SPM (Statistical Parametric Mapping) package to extend the capabilities of nirsLAB to include statistical analysis of hemodynamic-state time series.", [["nirsLAB", "PROTEIN", 121, 128], ["The Data Analysis", "TEST", 0, 17], ["Statistical Parametric Mapping) package", "TREATMENT", 51, 90], ["statistical analysis", "TEST", 140, 160]]], ["The functions include: Level-1 general linear model (GLM) analysis of fNIRS hemodynamic-state time series, to evaluate the position-dependent relationships between computed data-channel responses and user-specified temporal models.", [["Level", "TEST", 23, 28], ["fNIRS hemodynamic", "TEST", 70, 87], ["computed data", "TEST", 164, 177]]], ["Level-1 and Level-2 assessment of the statistical significance of the GLM model-fitting coefficients (t-test, ANOVA), or of user-defined contrasts of two or more models.ResultsFigure 3 shows the SPM contrast manager beta image display at a 0.01 p-value.", [["Level", "TEST", 0, 5], ["Level", "TEST", 12, 17], ["the GLM model", "TEST", 66, 79], ["fitting coefficients", "TEST", 80, 100], ["t-test", "TEST", 102, 108]]], ["The colors denote the magnitude of oxygenated hemoglobin response to pornographic clip vs. non-pornographic clip and the specific area of the prefrontal cortex that was activated (p-value = 0.01).", [["prefrontal cortex", "ANATOMY", 142, 159], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 46, 56], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 142, 159], ["hemoglobin", "PROTEIN", 46, 56], ["oxygenated hemoglobin response", "PROBLEM", 35, 65], ["pornographic clip", "TREATMENT", 69, 86], ["non-pornographic clip", "TREATMENT", 91, 112], ["p-value", "TEST", 180, 187], ["oxygenated hemoglobin", "OBSERVATION", 35, 56], ["prefrontal cortex", "ANATOMY", 142, 159]]], ["The only area that was activated significantly more when viewing the pornographic clip compared to the non-pornographic clip was that corresponding to channel FC6 (optode D07) and F6 (optode S05) corresponding to channel N12 (Figure 3).", [["channel FC6", "PROTEIN", 151, 162], ["optode D07", "PROTEIN", 164, 174], ["F6", "PROTEIN", 180, 182], ["optode S05", "PROTEIN", 184, 194], ["channel N12", "PROTEIN", 213, 224], ["the pornographic clip", "TREATMENT", 65, 86], ["the non-pornographic clip", "TEST", 99, 124]]], ["This channel records right Brodmann area 45 (BA45), more specifically the pars triangularis.", [["right Brodmann area", "ANATOMY", 21, 40], ["pars triangularis", "ANATOMY", 74, 91], ["pars triangularis", "CANCER", 74, 91], ["right Brodmann area", "TEST", 21, 40], ["right", "ANATOMY_MODIFIER", 21, 26], ["Brodmann", "ANATOMY_MODIFIER", 27, 35], ["pars", "ANATOMY_MODIFIER", 74, 78], ["triangularis", "ANATOMY_MODIFIER", 79, 91]]], ["In the video that appears as Figure 4, the activation of the prefrontal cortex in a consuming person can be seen dynamically during the viewing of the porn clip.", [["prefrontal cortex", "ANATOMY", 61, 78], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 61, 78], ["person", "SPECIES", 94, 100], ["the porn clip", "TREATMENT", 147, 160], ["prefrontal cortex", "ANATOMY", 61, 78]]], ["The heatmap in the video shows the highest intensity in the activation of the right BA453.", [["right BA453", "ANATOMY", 78, 89], ["BA453", "GENE_OR_GENE_PRODUCT", 84, 89], ["BA453", "PROTEIN", 84, 89], ["The heatmap in the video", "TEST", 0, 24], ["highest", "OBSERVATION_MODIFIER", 35, 42], ["intensity", "OBSERVATION_MODIFIER", 43, 52], ["right", "ANATOMY_MODIFIER", 78, 83]]], ["When the subjects were grouped into two clusters (non-consumers vs. consumers) based on the self-report of consumption of pornographic material, the SPM2 analysis produced the same result regarding the activated area (right pars triangularis) verifying the interaction effect (p < 0.01): high consumption subjects show more right BA45 activity when viewing the pornographic clip than non-consumer subjects (Figure 5).", [["right pars triangularis", "ANATOMY", 218, 241], ["right BA45", "ANATOMY", 324, 334], ["BA45", "GENE_OR_GENE_PRODUCT", 330, 334], ["SPM2", "DNA", 149, 153], ["pornographic material", "PROBLEM", 122, 143], ["the SPM2 analysis", "TEST", 145, 162], ["the interaction effect", "PROBLEM", 253, 275], ["high consumption subjects", "PROBLEM", 288, 313], ["the pornographic clip", "TREATMENT", 357, 378], ["right", "ANATOMY_MODIFIER", 218, 223], ["right", "ANATOMY_MODIFIER", 324, 329]]], ["This figure shows how the right activity is lower than the left activity in non-consumers.ResultsFigures 6A\u2013C show the relative changes in hemoglobin levels for channel 12 that can be seen during the viewing of the pornographic clip (Figure 6A) in a subject with high consumption scores of pornographic material (consumer) and (Figure 6B) a subject with low consumption scores (non-consumer).", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 139, 149], ["hemoglobin", "PROTEIN", 139, 149], ["the relative changes in hemoglobin levels", "PROBLEM", 115, 156], ["the pornographic clip", "TREATMENT", 211, 232], ["right", "ANATOMY_MODIFIER", 26, 31], ["lower", "OBSERVATION_MODIFIER", 44, 49], ["left", "ANATOMY_MODIFIER", 59, 63]]], ["In Figure 6C we can see the levels of oxygenated and deoxygenated hemoglobin referred to right BA 45 in consumer during the porn clip.ResultsOnce the nirsLAB indicated that the only significant effects appeared in channel 12, we conducted a linear regression analysis using the PROCESS 2.16 macro Model 1 for SPSS (SPSS, RRID:SCR_002865) with porn consumption (centered), porn footage as a multicategorical predictor (Control Video, Return to Baseline Control, Porn Video, Return to Baseline Porn), and the interaction of the two variables on participant\u015b blood flow in the channel 12 of prefrontal cortex (right pars triangularis).", [["blood", "ANATOMY", 556, 561], ["prefrontal cortex", "ANATOMY", 588, 605], ["right pars triangularis", "ANATOMY", 607, 630], ["BA", "CHEMICAL", 95, 97], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 66, 76], ["blood", "ORGANISM_SUBSTANCE", 556, 561], ["prefrontal cortex", "CANCER", 588, 605], ["right pars triangularis", "CANCER", 607, 630], ["hemoglobin", "PROTEIN", 66, 76], ["nirsLAB", "DNA", 150, 157], ["deoxygenated hemoglobin", "TEST", 53, 76], ["the porn clip", "TREATMENT", 120, 133], ["a linear regression analysis", "TEST", 239, 267], ["macro Model", "TEST", 291, 302], ["SPSS (SPSS", "TEST", 309, 319], ["SCR", "TEST", 326, 329], ["a multicategorical predictor", "TREATMENT", 388, 416], ["blood flow", "TEST", 556, 566], ["right", "ANATOMY_MODIFIER", 89, 94], ["prefrontal cortex", "ANATOMY", 588, 605], ["right", "ANATOMY_MODIFIER", 607, 612], ["pars", "ANATOMY_MODIFIER", 613, 617], ["triangularis", "ANATOMY_MODIFIER", 618, 630]]], ["This required transforming the independent variable into three different dichotomous variables (D1, D2, and D3).", [["D1", "PROTEIN", 96, 98]]], ["We report all possible comparisons between conditions (Control vs. Control Baseline, Control vs. Porn, Control vs. Porn Baseline, Control Baseline vs. Porn, Control Baseline vs. Porn Baseline, and Porn vs. Porn Baseline).ResultsThe regression revealed a significant two-way interaction between porn consumption and video footage, \u0394R2 = 0.019, F(3,23427) = 154.67, p < 0.001, meaning that the relationship between reported porn consumption and right pars triangularis reactivity varied as a function of the different videos and baselines (see Figure 7 for the entire two-way interaction).ResultsSpecifically, when comparing control video and the control baseline, a significant two-way interaction emerged, B = \u2212408.79, t(23427) = \u221210.963, p < 0.001, 95% CI: \u2212481.881, \u2212335.708.", [["right pars triangularis", "ANATOMY", 443, 466], ["The regression", "TEST", 228, 242], ["video footage", "TEST", 315, 328], ["\u0394R2", "TEST", 330, 333], ["right pars triangularis reactivity", "PROBLEM", 443, 477], ["p", "TEST", 739, 740], ["CI", "TEST", 754, 756], ["significant", "OBSERVATION_MODIFIER", 254, 265], ["right", "ANATOMY_MODIFIER", 443, 448], ["pars", "ANATOMY_MODIFIER", 449, 453], ["triangularis", "ANATOMY_MODIFIER", 454, 466]]], ["As can be seen in Table 1, there was no relationship between self-reported porn consumption and right pars triangularis reactivity in the control video, B = \u221216.31, t(23427) = \u22120.60, p = 0.543, 95% CI: \u221268.968, 36.337.", [["right pars triangularis", "ANATOMY", 96, 119], ["the control video", "TEST", 134, 151], ["p", "TEST", 183, 184], ["CI", "TEST", 198, 200], ["right", "ANATOMY_MODIFIER", 96, 101], ["pars triangularis", "ANATOMY", 102, 119]]], ["However, porn consumption was negatively associated with right pars triangularis reactivity in the control baseline, B = \u2212425.11, t(23427) = \u221216.43, p < 0.001, 95% CI: \u2212475.799, \u2212374.422, indicating that participants who reported high (+1 SD) porn consumption showed lower right pars triangularis reactivity than those who reported low (\u22121 SD) porn consumption.ResultsA two-way interaction in the opposite direction emerged when comparing the control video with the porn video, B = 396.634, t(23427) = 10.321, p < 0.001, 95% CI: 321.309, 471.959.", [["right pars triangularis", "ANATOMY", 57, 80], ["right pars triangularis", "ANATOMY", 273, 296], ["participants", "SPECIES", 204, 216], ["right pars triangularis reactivity", "PROBLEM", 57, 91], ["p", "TEST", 149, 150], ["CI", "TEST", 164, 166], ["porn consumption", "TEST", 243, 259], ["lower right pars triangularis reactivity", "PROBLEM", 267, 307], ["p", "TEST", 510, 511], ["CI", "TEST", 525, 527], ["right", "ANATOMY_MODIFIER", 57, 62], ["pars triangularis", "ANATOMY", 63, 80], ["lower", "ANATOMY_MODIFIER", 267, 272], ["right", "ANATOMY_MODIFIER", 273, 278], ["pars triangularis", "ANATOMY", 279, 296]]], ["There was no relationship between self-reported porn consumption and right pars triangularis reactivity in the control video, B = \u221216.31, t(23427) = \u22120.60, p = 0.543, 95% CI: \u221268.968, 36.337.", [["right pars triangularis", "ANATOMY", 69, 92], ["the control video", "TEST", 107, 124], ["p", "TEST", 156, 157], ["CI", "TEST", 171, 173], ["no", "UNCERTAINTY", 10, 12], ["right", "ANATOMY_MODIFIER", 69, 74], ["pars triangularis", "ANATOMY", 75, 92]]], ["However, porn consumption was positively associated with right pars triangularis reactivity in the porn video, B = 380.31, t(23427) = 13.83, p < 0.001, 95% CI: 326.453, 434.184, indicating that participants who reported high (+1 SD) porn consumption showed higher right pars triangularis reactivity than those who reported low (\u22121 SD) porn consumption.ResultsA similar marginally significant two-way interaction emerged when comparing the control video with the porn baseline, B = 74.60, t(23427) = 1.824, p = 0.068, 95% CI: \u22125.569, 154.772.", [["right pars triangularis", "ANATOMY", 57, 80], ["right pars triangularis", "ANATOMY", 264, 287], ["participants", "SPECIES", 194, 206], ["right pars triangularis reactivity", "PROBLEM", 57, 91], ["p", "TEST", 141, 142], ["CI", "TEST", 156, 158], ["porn consumption", "TEST", 233, 249], ["higher right pars triangularis reactivity", "PROBLEM", 257, 298], ["p", "TEST", 506, 507], ["CI", "TEST", 521, 523], ["right", "ANATOMY_MODIFIER", 57, 62], ["pars triangularis", "ANATOMY", 63, 80], ["right", "ANATOMY_MODIFIER", 264, 269], ["pars triangularis", "ANATOMY", 270, 287], ["marginally", "OBSERVATION_MODIFIER", 369, 379], ["significant", "OBSERVATION_MODIFIER", 380, 391]]], ["Specifically, there was no relationship between self-reported porn consumption and right pars triangularis reactivity in the control video, B = \u221216.31, t(23427) = \u22120.60, p = 0.543, 95% CI: \u221268.968, 36.337.", [["right pars triangularis", "ANATOMY", 83, 106], ["the control video", "TEST", 121, 138], ["p", "TEST", 170, 171], ["CI", "TEST", 185, 187], ["right", "ANATOMY_MODIFIER", 83, 88], ["pars triangularis", "ANATOMY", 89, 106]]], ["However, porn consumption was marginally associated with right pars triangularis reactivity in the porn baseline, B = 58.28, t(23427) = 1.88, p = 0.058, 95% CI: \u22122.171, 118.743, indicating that participants who reported high (+1 SD) porn consumption showed marginally higher right pars triangularis reactivity than those who reported low (\u22121 SD) porn consumption.ResultsWhen comparing the control baseline with the porn video, a significant two-way interaction also emerged, B = 805.43, t(23427) = 21.34, p < 0.001, 95% CI: 731.464, 879.394 (Table 2).", [["right pars triangularis", "ANATOMY", 57, 80], ["right pars triangularis", "ANATOMY", 275, 298], ["participants", "SPECIES", 194, 206], ["right pars triangularis reactivity", "PROBLEM", 57, 91], ["p", "TEST", 142, 143], ["CI", "TEST", 157, 159], ["porn consumption", "TEST", 233, 249], ["marginally higher right pars triangularis reactivity", "PROBLEM", 257, 309], ["p", "TEST", 505, 506], ["CI", "TEST", 520, 522], ["right", "ANATOMY_MODIFIER", 57, 62], ["pars triangularis", "ANATOMY", 63, 80], ["right", "ANATOMY_MODIFIER", 275, 280], ["pars triangularis", "ANATOMY", 281, 298]]], ["Reported porn consumption was negatively associated with right pars triangularis reactivity in the control baseline, B = \u2212425.11, t(23427) = \u221216.43, p < 0.001, 95% CI: \u2212475.799, \u2212374.422.", [["right pars triangularis", "ANATOMY", 57, 80], ["right pars triangularis reactivity", "PROBLEM", 57, 91], ["p", "TEST", 149, 150], ["CI", "TEST", 164, 166], ["right", "ANATOMY_MODIFIER", 57, 62], ["pars triangularis", "ANATOMY", 63, 80]]], ["However, porn consumption was positively associated with right pars triangularis reactivity in the porn video, B = 380.31, t(23427) = 13.83, p < 0.001, 95% CI: 326.453, 434.184.ResultsA significant two-way interaction also emerged between the porn video and the porn baseline, B = \u2212322.033, t(23427) = \u22127.79, p < 0.001, 95% CI: \u2212403.006, \u2212241.060, where porn consumption was positively associated with right pars triangularis reactivity in the porn video, B = 380.31, t(23427) = 13.83, p < 0.001, 95% CI: 326.453, 434.184.", [["right pars triangularis", "ANATOMY", 57, 80], ["right pars triangularis", "ANATOMY", 402, 425], ["right pars triangularis reactivity", "PROBLEM", 57, 91], ["p", "TEST", 141, 142], ["CI", "TEST", 156, 158], ["p", "TEST", 309, 310], ["CI", "TEST", 324, 326], ["right pars triangularis reactivity", "PROBLEM", 402, 436], ["p", "TEST", 486, 487], ["CI", "TEST", 501, 503], ["right", "ANATOMY_MODIFIER", 57, 62], ["pars triangularis", "ANATOMY", 63, 80], ["right", "ANATOMY_MODIFIER", 402, 407]]], ["However, porn consumption was marginally associated with right pars triangularis reactivity in the porn baseline, B = 58.28, t(23427) = 1.88, p = 0.058, 95% CI: \u22122.171, 118.743.", [["right pars triangularis", "ANATOMY", 57, 80], ["right pars triangularis reactivity", "PROBLEM", 57, 91], ["p", "TEST", 142, 143], ["CI", "TEST", 157, 159], ["right", "ANATOMY_MODIFIER", 57, 62], ["pars triangularis", "ANATOMY", 63, 80]]], ["Lastly, a significant two-way interaction also emerged between the control baseline and the porn baseline, B = 483.396, t(23427) = 12.00, p < 0.001, 95% CI: 404.501, 562.291.", [["p", "TEST", 138, 139], ["CI", "TEST", 153, 155], ["significant", "OBSERVATION_MODIFIER", 10, 21]]], ["As can be seen in Table 1, reported porn consumption was negatively associated with right pars triangularis reactivity in the control baseline, B = \u2212425.11, t(23427) = \u221216.43, p < 0.001, 95% CI: \u2212475.799, \u2212374.422.", [["right pars triangularis", "ANATOMY", 84, 107], ["right pars triangularis reactivity", "PROBLEM", 84, 118], ["p", "TEST", 176, 177], ["CI", "TEST", 191, 193], ["right", "ANATOMY_MODIFIER", 84, 89], ["pars triangularis", "ANATOMY", 90, 107]]], ["However, porn consumption was marginally associated with right pars triangularis reactivity in the porn video, B = 58.28, t(23427) = 1.88, p = 0.058, 95% CI: \u22122.171, 118.743 (see Figure 7 for the entire two-way interaction).ResultsAs can be seen in Table 3, the results of the analysis of variance show statistically significant values at all levels of analysis (p < 0.01) for both main effects and interaction, confirming the data previously obtained by the multiple regression.ResultsIn the following figure (Figure 8) the independent variable \u201cconsumption level\u201d has been transformed into a dichotomous variable: subjects who have never consumed pornographic material and subjects who have consumed it.", [["right pars triangularis", "ANATOMY", 57, 80], ["right pars triangularis reactivity", "PROBLEM", 57, 91], ["p", "TEST", 139, 140], ["CI", "TEST", 154, 156], ["the analysis of variance", "TEST", 273, 297], ["statistically significant values", "PROBLEM", 303, 335], ["analysis", "TEST", 353, 361], ["the data", "TEST", 423, 431], ["right", "ANATOMY_MODIFIER", 57, 62], ["pars triangularis", "ANATOMY", 63, 80], ["multiple", "OBSERVATION_MODIFIER", 459, 467]]], ["The new dichotomous variable generated two practically identical groups regarding the number of subjects.ResultsThe analysis of variance performed (Table 4) indicated that there are main effects (p < 0.01) of the factor \u201ctype of clip viewed\u201d (control vs. porn) but there are no main effects (p < 0.144) of the factor \u201clevel consumption\u201d (consumer vs. non-consumer) as well as interaction effect (p < 0.01).", [["The analysis", "TEST", 112, 124], ["variance", "TEST", 128, 136], ["clip", "TEST", 229, 233], ["the factor", "TEST", 306, 316], ["new", "OBSERVATION_MODIFIER", 4, 7], ["dichotomous", "OBSERVATION", 8, 19], ["main", "OBSERVATION_MODIFIER", 182, 186], ["no", "UNCERTAINTY", 275, 277], ["main", "OBSERVATION_MODIFIER", 278, 282]]], ["That is, the interaction effect is strong enough to override the main effect of the type of viewing: subjects who have never seen porn decrease their cortical activation in N12 (BA45, right pars triangularis) while those who have seen it some increase cortical activation significantly in right BA45.DiscussionThe objective was to find evidence that allows us to contribute knowledge not only to the foundations of neuroscience, but also to the foundations of persuasion neuroscience and communication and health.", [["cortical", "ANATOMY", 150, 158], ["right pars triangularis", "ANATOMY", 184, 207], ["cortical", "ANATOMY", 252, 260], ["right BA45", "ANATOMY", 289, 299], ["cortical", "MULTI-TISSUE_STRUCTURE", 150, 158], ["cortical", "MULTI-TISSUE_STRUCTURE", 252, 260], ["BA45", "PROTEIN", 295, 299], ["some increase cortical activation", "PROBLEM", 238, 271], ["main", "OBSERVATION_MODIFIER", 65, 69], ["cortical activation", "OBSERVATION", 150, 169], ["right", "ANATOMY_MODIFIER", 184, 189], ["increase", "OBSERVATION_MODIFIER", 243, 251], ["cortical activation", "OBSERVATION", 252, 271], ["right", "ANATOMY_MODIFIER", 289, 294]]], ["Thus, the final objective of this research is to find certainties that allow the design of health prevention programs.", [["health prevention programs", "TREATMENT", 91, 117]]], ["More specifically, in the area of prevention of problematic consumption of pornographic material by young women, who have recently joined the problematic consumption of pornography (Shaughnessy et al., 2011, 2017; Serrano, 2017; French and Hamilton, 2018).DiscussionThe increased use of the internet may have led to increased consumption and acceptance of pornography (D\u2019Orlando, 2011).", [["women", "ORGANISM", 106, 111], ["women", "SPECIES", 106, 111], ["increased", "OBSERVATION_MODIFIER", 270, 279]]], ["As a consequence of the increased pornography use worldwide, there has been much focus on compulsive internet pornography as a subdomain of hypersexuality (Carroll et al., 2008; D\u00f6ring, 2009; Griffiths, 2013).DiscussionPrevention programs manage to reach a large part of the population avoiding risks and diseases.", [["hypersexuality", "DISEASE", 140, 154], ["hypersexuality", "PROBLEM", 140, 154], ["diseases", "PROBLEM", 305, 313], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["Only a knowledge of the mechanisms underlying the behavior to be modified will allow the design of adequate preventive programs.DiscussionThis research focuses on studying the importance of the discriminative stimulus consisting of sexually explicit images (cue exposure) and the craving response (cue reactivity) in young women consumers and non-consumers of porn videos.", [["women", "ORGANISM", 323, 328], ["women", "SPECIES", 323, 328], ["adequate preventive programs", "TREATMENT", 99, 127], ["sexually explicit images", "TEST", 232, 256]]], ["This paradigm has been frequently used in the study of substance addictions (Kroczek et al., 2017), but it has been much less developed in the field of behavioral addictions such as the consumption of pornography.DiscussionThe underlying idea is the following: in order to develop effective prevention programs on porn consumption, it is necessary to know how the discriminative stimuli that trigger the onset of behavior.", [["substance addictions", "DISEASE", 55, 75], ["behavioral addictions", "DISEASE", 152, 173]]], ["It is important to consider that the environment in which the behavior of young people develops constantly presents stimuli of high erotic charge that can act as discriminating stimuli.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["high erotic charge", "PROBLEM", 127, 145]]], ["Not only advertising stimuli, but many others, such as those that appear on social networks such as Instagram or TikTok, present a large amount of erotic content that can act as discriminatory stimuli causing behavior and strengthening the learning of problematic behavior.", [["problematic behavior", "PROBLEM", 252, 272], ["large", "OBSERVATION_MODIFIER", 131, 136], ["amount", "OBSERVATION_MODIFIER", 137, 143]]], ["There is also strong evidence that indicates the effects that porn consumption causes on the brain (Muller, 2018).", [["brain", "ANATOMY", 93, 98], ["brain", "ORGAN", 93, 98], ["brain", "ANATOMY", 93, 98]]], ["This study tested whether the prefrontal cortex of participants high (vs. low) in porn consumption showed more activation when exposed to pornographic content relative to a no-treatment condition.", [["prefrontal cortex", "ANATOMY", 30, 47], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 30, 47], ["participants", "SPECIES", 51, 63], ["This study", "TEST", 0, 10], ["a no-treatment condition", "PROBLEM", 171, 195], ["prefrontal cortex", "ANATOMY", 30, 47]]], ["In line with previous research (K\u00fchn and Gallinat, 2014; Zangemeister et al., 2019) we expected participants high (vs. low) in porn consumption to increase their activity (cue reactivity) in the prefrontal cortex area when being exposed to footage with pornographic content (cue exposure).", [["prefrontal cortex area", "ANATOMY", 195, 217], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 195, 212], ["participants", "SPECIES", 96, 108], ["prefrontal cortex", "ANATOMY", 195, 212]]], ["We analyzed the activity of the prefrontal cortex using the fNIRS (functional near infrared spectroscopy) technique, which has been shown to be effective in this type of study (Leong et al., 2019; Karthikeyan et al., 2020).DiscussionIn the current research, 28 young college women self-reported their porn consumption habits and viewed two 20-second video clips (porn vs. control) while the activity of their prefrontal cortex was recorded using fNIRS.", [["prefrontal cortex", "ANATOMY", 32, 49], ["prefrontal cortex", "ANATOMY", 409, 426], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 32, 49], ["women", "ORGANISM", 275, 280], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 409, 426], ["women", "SPECIES", 275, 280], ["second video clips (porn vs. control", "TREATMENT", 343, 379], ["activity", "OBSERVATION_MODIFIER", 16, 24], ["prefrontal", "ANATOMY_MODIFIER", 32, 42], ["cortex", "ANATOMY_MODIFIER", 43, 49], ["clips", "OBSERVATION", 356, 361], ["prefrontal cortex", "ANATOMY", 409, 426]]], ["The results obtained indicated that the discriminative stimulus caused greater cortical activity in Brodmann\u2019s area 45 (right BA45, pars triangularis) of the right hemisphere in women consumer, but not in non-consuming women (p < 0.01).", [["cortical", "ANATOMY", 79, 87], ["Brodmann\u2019s area", "ANATOMY", 100, 115], ["right BA45", "ANATOMY", 120, 130], ["pars triangularis", "ANATOMY", 132, 149], ["right hemisphere", "ANATOMY", 158, 174], ["cortical", "MULTI-TISSUE_STRUCTURE", 79, 87], ["Brodmann\u2019s area 45", "CANCER", 100, 118], ["pars triangularis", "TISSUE", 132, 149], ["women", "ORGANISM", 178, 183], ["women", "ORGANISM", 219, 224], ["women", "SPECIES", 178, 183], ["women", "SPECIES", 219, 224], ["the discriminative stimulus", "TEST", 36, 63], ["greater cortical activity", "PROBLEM", 71, 96], ["Brodmann\u2019s area", "TEST", 100, 115], ["greater", "OBSERVATION_MODIFIER", 71, 78], ["cortical activity", "OBSERVATION", 79, 96], ["right", "ANATOMY_MODIFIER", 120, 125], ["pars", "ANATOMY_MODIFIER", 132, 136], ["triangularis", "ANATOMY_MODIFIER", 137, 149], ["right", "ANATOMY_MODIFIER", 158, 163], ["hemisphere", "ANATOMY_MODIFIER", 164, 174]]], ["They also indicated that this effect occurs in the experimental group compared to the control group and that the porn stimulus causes a greater effect depending on the degree of consumption.", [["the porn stimulus", "TREATMENT", 109, 126], ["a greater effect", "PROBLEM", 134, 150], ["greater effect", "OBSERVATION_MODIFIER", 136, 150]]], ["Consistent with our expectations, women who have never consumed pornographic material do not increase the degree of activation of right BA45 compared to the control group.", [["right BA45", "ANATOMY", 130, 140], ["women", "ORGANISM", 34, 39], ["BA45", "GENE_OR_GENE_PRODUCT", 136, 140], ["right BA45", "PROTEIN", 130, 140], ["women", "SPECIES", 34, 39], ["activation of right BA45", "PROBLEM", 116, 140], ["right", "ANATOMY_MODIFIER", 130, 135]]], ["This result is consistent with the interpretation of the porn stimulus as a discriminative stimulus of operant learning \u201cpornography consumption\u201d: if the person has never consumed pornography, the learning has not started, so the stimulus is not discriminatory, but neutral (it could even be aversive).", [["person", "SPECIES", 154, 160], ["the porn stimulus", "TREATMENT", 53, 70], ["consistent with", "UNCERTAINTY", 15, 30]]], ["In addition, it should be analyzed using different types of addictions such as gambling, social networks, etc. Given that one of the priority interests of this research is to provide evidence for the foundation of prevention programs in health and consumption of pornography in women, it is important to deepen the interpretation of the result: the activation of pars triangularis (area 45 of Brodmann) prefrontal of the right hemisphere.", [["pars triangularis", "ANATOMY", 363, 380], ["prefrontal", "ANATOMY", 403, 413], ["right hemisphere", "ANATOMY", 421, 437], ["women", "ORGANISM", 278, 283], ["pars triangularis", "MULTI-TISSUE_STRUCTURE", 363, 380], ["prefrontal", "MULTI-TISSUE_STRUCTURE", 403, 413], ["right hemisphere", "MULTI-TISSUE_STRUCTURE", 421, 437], ["women", "SPECIES", 278, 283], ["prevention programs", "TREATMENT", 214, 233], ["prefrontal", "ANATOMY_MODIFIER", 403, 413], ["right", "ANATOMY_MODIFIER", 421, 426], ["hemisphere", "ANATOMY_MODIFIER", 427, 437]]], ["Although this line of research is very recent, there is already some bibliography where more activity of the right pars triangularis has been found in addictions.", [["right pars triangularis", "ANATOMY", 109, 132], ["very", "OBSERVATION_MODIFIER", 34, 38], ["more", "OBSERVATION_MODIFIER", 88, 92], ["activity", "OBSERVATION_MODIFIER", 93, 101], ["right", "ANATOMY_MODIFIER", 109, 114], ["pars", "ANATOMY_MODIFIER", 115, 119], ["triangularis", "ANATOMY_MODIFIER", 120, 132]]], ["For example, Irizar et al. (2020) has found that the right lower frontal gyrus volume (i.e., pars triangularis) was significantly larger in both the pathological gambling and cocaine dependency versus control groups.", [["right lower frontal gyrus", "ANATOMY", 53, 78], ["pars triangularis", "ANATOMY", 93, 110], ["cocaine", "CHEMICAL", 175, 182], ["cocaine", "CHEMICAL", 175, 182], ["frontal gyrus", "MULTI-TISSUE_STRUCTURE", 65, 78], ["cocaine", "SIMPLE_CHEMICAL", 175, 182], ["right", "ANATOMY_MODIFIER", 53, 58], ["lower", "ANATOMY_MODIFIER", 59, 64], ["frontal gyrus", "ANATOMY", 65, 78], ["volume", "ANATOMY_MODIFIER", 79, 85], ["significantly", "OBSERVATION_MODIFIER", 116, 129], ["larger", "OBSERVATION_MODIFIER", 130, 136], ["pathological", "OBSERVATION_MODIFIER", 149, 161], ["gambling", "OBSERVATION", 162, 170], ["cocaine dependency", "OBSERVATION", 175, 193]]], ["There is an abundant bibliography that links this area with mirror neurons and empathy (Uribe et al., 2019; Krautheim et al., 2019; Rymarczyk et al., 2019).", [["mirror neurons", "ANATOMY", 60, 74], ["neurons", "CELL", 67, 74], ["abundant", "OBSERVATION_MODIFIER", 12, 20], ["bibliography", "OBSERVATION", 21, 33], ["mirror neurons", "OBSERVATION", 60, 74]]], ["Recently it has been empirically confirmed that the right hemisphere plays an important role in the interpretation of gestures and non-verbal language, especially Brodmann\u2019s area 45 (Inh\u00f3f et al., 2019; Krautheim et al., 2019).", [["right hemisphere", "ANATOMY", 52, 68], ["right hemisphere", "MULTI-TISSUE_STRUCTURE", 52, 68], ["right", "ANATOMY_MODIFIER", 52, 57]]], ["These data could imply that Brodmann\u2019s area 45, traditionally associated with verbal language in the left hemisphere, is complemented by the functions developed in the right hemisphere.", [["left hemisphere", "ANATOMY", 101, 116], ["right hemisphere", "ANATOMY", 168, 184], ["Brodmann\u2019s area", "PROBLEM", 28, 43], ["left hemisphere", "ANATOMY", 101, 116], ["right", "ANATOMY_MODIFIER", 168, 173], ["hemisphere", "ANATOMY_MODIFIER", 174, 184]]], ["In this way, the left hemisphere would have a role more linked to semantic memory and the understanding of linguistic meanings, while the right hemisphere would deal with the understanding of non-linguistic meanings.", [["left hemisphere", "ANATOMY", 17, 32], ["right hemisphere", "ANATOMY", 138, 154], ["left", "ANATOMY_MODIFIER", 17, 21], ["right", "ANATOMY_MODIFIER", 138, 143]]], ["Both would work together with working memory but linked to different functions.DiscussionOn the other hand, neocortical correlates have also been found for the cognitive empathy dimension, while affective empathy would be related to subcortical structures.", [["neocortical", "ANATOMY", 108, 119], ["subcortical structures", "ANATOMY", 233, 255], ["affective empathy", "DISEASE", 195, 212], ["hand", "ORGANISM_SUBDIVISION", 102, 106], ["neocortical", "MULTI-TISSUE_STRUCTURE", 108, 119], ["subcortical structures", "MULTI-TISSUE_STRUCTURE", 233, 255], ["affective empathy", "PROBLEM", 195, 212], ["subcortical", "ANATOMY_MODIFIER", 233, 244]]], ["Functionally, affective empathy appears to be linked to the connectivity between the orbital and cingulate cortices and deeper structures of the limbic system (Uribe et al., 2019; Xiong et al., 2019).", [["orbital", "ANATOMY", 85, 92], ["cingulate cortices", "ANATOMY", 97, 115], ["deeper structures", "ANATOMY", 120, 137], ["limbic system", "ANATOMY", 145, 158], ["affective empathy", "DISEASE", 14, 31], ["orbital", "MULTI-TISSUE_STRUCTURE", 85, 92], ["cingulate cortices", "MULTI-TISSUE_STRUCTURE", 97, 115], ["limbic", "ANATOMICAL_SYSTEM", 145, 151], ["system", "ANATOMICAL_SYSTEM", 152, 158], ["affective empathy", "PROBLEM", 14, 31], ["orbital", "ANATOMY", 85, 92], ["cingulate cortices", "ANATOMY", 97, 115], ["deeper", "ANATOMY_MODIFIER", 120, 126], ["limbic system", "ANATOMY", 145, 158]]], ["A very plausible hypothesis could be that the BA45\u2019s neo-cortical structure acts as an interface between the cognitive and emotional aspects of empathy and the interpretation of the non-verbal behavior of others.", [["BA45", "GENE_OR_GENE_PRODUCT", 46, 50], ["BA45", "PROTEIN", 46, 50], ["A very plausible hypothesis", "PROBLEM", 0, 27], ["empathy", "PROBLEM", 144, 151]]], ["Furthermore, this hypothesis is consistent with the fact that a significant number of mirror neurons are found in this area, which would be highly involved in empathy (Gallese, 2001; Decety, 2002; Preston and De Waal, 2002; Decety and Jackson, 2004; Keysers and Gazzola, 2010).", [["neurons", "ANATOMY", 93, 100], ["area", "ANATOMY", 119, 123], ["neurons", "CELL", 93, 100], ["mirror neurons", "CELL_TYPE", 86, 100], ["mirror neurons", "PROBLEM", 86, 100], ["consistent with", "UNCERTAINTY", 32, 47], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["number", "OBSERVATION_MODIFIER", 76, 82], ["mirror neurons", "OBSERVATION", 86, 100]]], ["In reality, this brain area, and others very close, such as the anterior insula, the anterior cingulate cortex, the inferior frontal cortex, are closely linked to the experience of emotions such as disgust, happiness or pain, especially when viewing another person experiencing these emotions (Botvinick et al., 2005; Lamm et al., 2007).", [["brain area", "ANATOMY", 17, 27], ["anterior insula", "ANATOMY", 64, 79], ["anterior cingulate cortex", "ANATOMY", 85, 110], ["inferior frontal cortex", "ANATOMY", 116, 139], ["pain", "DISEASE", 220, 224], ["brain area", "CANCER", 17, 27], ["anterior insula", "MULTI-TISSUE_STRUCTURE", 64, 79], ["anterior cingulate cortex", "CANCER", 85, 110], ["inferior frontal cortex", "MULTI-TISSUE_STRUCTURE", 116, 139], ["person", "SPECIES", 258, 264], ["disgust", "PROBLEM", 198, 205], ["happiness", "PROBLEM", 207, 216], ["pain", "PROBLEM", 220, 224], ["brain", "ANATOMY", 17, 22], ["area", "ANATOMY_MODIFIER", 23, 27], ["anterior", "ANATOMY_MODIFIER", 64, 72], ["insula", "ANATOMY_MODIFIER", 73, 79], ["anterior", "ANATOMY_MODIFIER", 85, 93], ["cingulate", "ANATOMY_MODIFIER", 94, 103], ["cortex", "ANATOMY_MODIFIER", 104, 110], ["inferior", "ANATOMY_MODIFIER", 116, 124], ["frontal cortex", "ANATOMY", 125, 139]]], ["Aesthetic experiences are considered as experiences of perception, creation and evaluation of stimuli that evoke very intense feelings (Chatterjee, 2011; Pearce et al., 2016).", [["creation and evaluation of stimuli", "TEST", 67, 101]]], ["Christian Keysers at the Social Brain Lab and colleagues have shown that people who are more empathic according to self-report questionnaires have stronger activations for emotions, providing more direct support for the idea that the mirror system is linked to empathy.", [["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["direct support", "TREATMENT", 197, 211], ["Brain", "ANATOMY", 32, 37]]], ["It is possible that the mirror system does not passively respond to the observation of actions but is influenced by the mindset of the observer (Molenberghs et al., 2012).DiscussionThese investigations allow us to propose the following interpretation of the results of our research: the subjects who consume pornography, according to their self-report questionnaires, may show greater empathy for pornographic images.", [["pornographic images", "TEST", 397, 416]]], ["In other words, the \u201ccue exposure\u201d would provoke a greater reaction due to the activation of a kind of \u201cvicarious eroticism\u201d linked to empathy rather than to the pure dopaminergic pleasure provided by brain pleasure systems.", [["brain", "ANATOMY", 201, 206], ["brain", "ORGAN", 201, 206], ["a greater reaction", "PROBLEM", 49, 67], ["\u201cvicarious eroticism", "PROBLEM", 103, 123]]], ["Although there is not yet enough empirical evidence, it could be thought that mirror neurons are involved in sexual behavior, especially in its empathic component.", [["neurons", "ANATOMY", 85, 92], ["neurons", "CELL", 85, 92], ["mirror neurons", "CELL_TYPE", 78, 92], ["mirror neurons", "PROBLEM", 78, 92]]], ["As we have pointed out, this interpretive hypothesis would also be supported by the fact that it is the right cerebral hemisphere that shows BA45 activity.", [["right cerebral hemisphere", "ANATOMY", 104, 129], ["cerebral hemisphere", "MULTI-TISSUE_STRUCTURE", 110, 129], ["BA45", "GENE_OR_GENE_PRODUCT", 141, 145], ["BA45", "PROTEIN", 141, 145], ["right", "ANATOMY_MODIFIER", 104, 109], ["cerebral hemisphere", "ANATOMY", 110, 129], ["BA45 activity", "OBSERVATION", 141, 154]]], ["As indicated, the right hemisphere seems to be in charge of processing cognitive interpretations of non-semantic aspects of communication.", [["right hemisphere", "ANATOMY", 18, 34], ["right", "ANATOMY_MODIFIER", 18, 23]]], ["On the other hand, very clear gender differences have been found in this brain area.", [["brain area", "ANATOMY", 73, 83], ["brain area", "CANCER", 73, 83], ["clear", "OBSERVATION", 24, 29], ["brain", "ANATOMY", 73, 78]]], ["For example, Kurth et al. (2017) found significantly larger gray matter volumes in females than males for right BA 44 and BA 45 bilaterally but no significant sex differences with respect to BA 44/45 asymmetry.", [["gray matter", "ANATOMY", 60, 71], ["right BA", "ANATOMY", 106, 114], ["BA", "CHEMICAL", 191, 193], ["gray matter", "MULTI-TISSUE_STRUCTURE", 60, 71], ["significantly larger gray matter volumes", "PROBLEM", 39, 79], ["right BA", "TEST", 106, 114], ["BA", "TEST", 122, 124], ["larger", "OBSERVATION_MODIFIER", 53, 59], ["right", "ANATOMY_MODIFIER", 106, 111], ["bilaterally", "ANATOMY_MODIFIER", 128, 139], ["no", "UNCERTAINTY", 144, 146]]], ["This could explain the difference between men and women in terms of semantic and empathic capacity in many aspects of psychosocial relationships.DiscussionDespite the novelty of this proposal, other authors have found data that supports the idea that right Brodmann\u2019s area 45 of the right hemisphere could be linked to behavioral addictions closely linked to empathy and social relationships.", [["right Brodmann\u2019s area", "ANATOMY", 251, 272], ["right hemisphere", "ANATOMY", 283, 299], ["behavioral addictions", "DISEASE", 319, 340], ["men", "ORGANISM", 42, 45], ["women", "ORGANISM", 50, 55], ["men", "SPECIES", 42, 45], ["women", "SPECIES", 50, 55], ["empathic capacity", "PROBLEM", 81, 98], ["right", "ANATOMY_MODIFIER", 251, 256], ["right", "ANATOMY_MODIFIER", 283, 288]]], ["For example, Schmitgen et al. (2020) found that subjects with Smartphone addiction showed greater activation in the right prefrontal cortex, specifically in the pars triangularis (right BA 45).", [["right prefrontal cortex", "ANATOMY", 116, 139], ["pars triangularis", "ANATOMY", 161, 178], ["right BA", "ANATOMY", 180, 188], ["Smartphone addiction", "DISEASE", 62, 82], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 122, 139], ["pars triangularis", "TISSUE", 161, 178], ["right BA 45", "CANCER", 180, 191], ["Smartphone addiction", "TEST", 62, 82], ["greater activation in the right prefrontal cortex", "PROBLEM", 90, 139], ["right", "ANATOMY_MODIFIER", 116, 121], ["prefrontal cortex", "ANATOMY", 122, 139], ["pars", "ANATOMY_MODIFIER", 161, 165], ["triangularis", "ANATOMY_MODIFIER", 166, 178], ["right", "ANATOMY_MODIFIER", 180, 185]]], ["In a very similar sense, Inh\u00f3f et al. (2019) has shown that women who self-reported problematic use or addiction to social networks on the Internet showed greater activation in the same area: the pars triangularis (right BA 45) of the right hemisphere and also in the right pars opercularis.", [["pars triangularis", "ANATOMY", 196, 213], ["right BA", "ANATOMY", 215, 223], ["right hemisphere", "ANATOMY", 235, 251], ["right pars opercularis", "ANATOMY", 268, 290], ["women", "ORGANISM", 60, 65], ["pars triangularis", "TISSUE", 196, 213], ["right BA 45", "CANCER", 215, 226], ["right hemisphere", "CANCER", 235, 251], ["women", "SPECIES", 60, 65], ["pars", "ANATOMY_MODIFIER", 196, 200], ["triangularis", "ANATOMY_MODIFIER", 201, 213], ["right", "ANATOMY_MODIFIER", 215, 220], ["right", "ANATOMY_MODIFIER", 235, 240], ["hemisphere", "ANATOMY_MODIFIER", 241, 251], ["right", "ANATOMY_MODIFIER", 268, 273], ["pars", "ANATOMY_MODIFIER", 274, 278], ["opercularis", "ANATOMY_MODIFIER", 279, 290]]], ["The first is to delve into the difference between \u201cnon-consumers\u201d and \u201cconsumers\u201d: the data seems to indicate that the reactions to discriminating stimuli (erotic stimuli), responsible for cue exposure, act very differently in non-consumers compared to the rest.", [["the reactions", "PROBLEM", 115, 128], ["discriminating stimuli", "TEST", 132, 154], ["erotic stimuli", "TEST", 156, 170], ["cue exposure", "PROBLEM", 189, 201]]], ["In non-consumer participants, right BA 45 (pars triangularis) from the right hemisphere does not appear to be activated, compared to the erotic stimulus, which is very consistent with the idea that it is a discriminative stimulus.", [["right BA", "ANATOMY", 30, 38], ["pars triangularis", "ANATOMY", 43, 60], ["right hemisphere", "ANATOMY", 71, 87], ["pars triangularis", "MULTI-TISSUE_STRUCTURE", 43, 60], ["participants", "SPECIES", 16, 28], ["right BA", "TEST", 30, 38], ["the erotic stimulus", "TEST", 133, 152], ["right", "ANATOMY_MODIFIER", 30, 35], ["right", "ANATOMY_MODIFIER", 71, 76], ["not appear to be", "UNCERTAINTY", 93, 109], ["activated", "OBSERVATION", 110, 119], ["very consistent with", "UNCERTAINTY", 163, 183]]], ["It\u2019s initiation would quickly provoke a sensitization of this cortical prefrontal area, with the consequences of possible craving before discriminative erotic stimuli.", [["cortical prefrontal area", "ANATOMY", 62, 86], ["cortical prefrontal area", "MULTI-TISSUE_STRUCTURE", 62, 86], ["a sensitization of this cortical prefrontal area", "PROBLEM", 38, 86], ["discriminative erotic stimuli", "TEST", 137, 166], ["cortical", "ANATOMY_MODIFIER", 62, 70], ["prefrontal", "ANATOMY_MODIFIER", 71, 81]]], ["In the case of secondary \u201cprevention,\u201d persuasion programs should focus on modifying the attitudes of the subject to eliminate or modify the consumer behavior.", [["persuasion programs", "TREATMENT", 39, 58]]], ["In the case of young women, the result of this research seems to indicate that an important motivation in the behavior of consumption of pornography may be the vicarious search for empathic links of an erotic nature that is highly driven by the mirror neuron system.", [["women", "ORGANISM", 21, 26], ["women", "SPECIES", 21, 26], ["erotic", "OBSERVATION", 202, 208]]], ["In other words, we would find two variables: the limbic pleasure system characteristic of erotic behavior and the mirror neuron system characteristic of empathic behavior involved.DiscussionIf these hypotheses are correct, prevention programs in young women should focus on modifying attitudes linked to the search for \u201cerotic empathy\u201d or \u201cvicarious eroticism.\u201d", [["limbic", "ANATOMY", 49, 55], ["neuron system", "ANATOMY", 121, 134], ["women", "ORGANISM", 252, 257], ["women", "SPECIES", 252, 257], ["erotic behavior", "PROBLEM", 90, 105], ["\u201cerotic empathy", "PROBLEM", 319, 334], ["vicarious eroticism", "PROBLEM", 340, 359], ["vicarious eroticism", "OBSERVATION", 340, 359]]], ["Said in terms of communication theory: the target\u2019s insight indicates that the axis of communication and the strategy of preventive programs should focus on these aspects of human behavior.", [["human", "ORGANISM", 174, 179], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["preventive programs", "TREATMENT", 121, 140]]], ["In the same sense, the RW (Reason Why) should provide the subject with new reinforcement incentives to replace the cognitive and emotional pleasure provided by \u201cvicarious/empathic eroticism.\u201dDiscussionTherefore, in this sense, future lines of research should be developed: analyzing, using neuroimaging techniques (fNIRS, fMRI), how the brain mechanisms of the subjects behave against different preventive communication messages in this area of pornography consumption.", [["brain", "ANATOMY", 337, 342], ["cognitive and emotional pleasure", "DISEASE", 115, 147], ["brain", "ORGAN", 337, 342], ["new reinforcement incentives", "TREATMENT", 71, 99], ["neuroimaging techniques", "TEST", 290, 313]]], ["The procedure may consist of manipulating, as an independent variable, the type of message, the USP and the RW, using the neuroimaging results as the dependent variable.", [["The procedure", "TREATMENT", 0, 13], ["the neuroimaging results", "TEST", 118, 142]]], ["If the hypothesis is correct, it is reasonable to hypothesize that different areas of the prefrontal cortex are activated in men compared to women, in the face of pornographic stimuli.DiscussionThe limitations of this research refer to the size of the sample: although the number of subjects is considerable for this type of neuroimaging research, especially considering that the sample is very homogeneous (young Spanish female college students).", [["prefrontal cortex", "ANATOMY", 90, 107], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 90, 107], ["men", "ORGANISM", 125, 128], ["women", "ORGANISM", 141, 146], ["men", "SPECIES", 125, 128], ["women", "SPECIES", 141, 146], ["pornographic stimuli", "TEST", 163, 183], ["neuroimaging research", "TEST", 325, 346], ["different", "OBSERVATION_MODIFIER", 67, 76], ["areas", "OBSERVATION_MODIFIER", 77, 82], ["prefrontal cortex", "ANATOMY", 90, 107], ["homogeneous", "OBSERVATION_MODIFIER", 395, 406]]], ["However, an expansion of the sample size could make it possible to better differentiate between the different degrees of addiction and between \u201cnon-consumers\u201d and consumers.DiscussionOur paradigm is interesting in several ways.", [["addiction", "DISEASE", 121, 130], ["an expansion of the sample size", "PROBLEM", 9, 40], ["expansion", "OBSERVATION_MODIFIER", 12, 21], ["size", "OBSERVATION_MODIFIER", 36, 40], ["different degrees", "OBSERVATION_MODIFIER", 100, 117]]], ["First, it shows that, in young women, BA 45 (pars triangularis) from the right prefrontal cortex plays an important role in the behavior of pornography consumption.", [["right prefrontal cortex", "ANATOMY", 73, 96], ["BA", "CHEMICAL", 38, 40], ["women", "ORGANISM", 31, 36], ["BA 45", "ORGANISM", 38, 43], ["pars triangularis", "ORGANISM", 45, 62], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 79, 96], ["women", "SPECIES", 31, 36], ["right", "ANATOMY_MODIFIER", 73, 78], ["prefrontal cortex", "ANATOMY", 79, 96]]], ["This finding could explain the cue reactivity caused by the cue exposure that would be responsible for the craving which, in turn, would trigger consumption behavior.", [["the craving", "PROBLEM", 103, 114]]], ["Secondly, these data could be considered a foundation for secondary prevention programs where the communication strategy, the Reason Why and the Unique Selling Proposition were \u201cvicarious/empathic eroticism.\u201d", [["secondary prevention programs", "TREATMENT", 58, 87], ["vicarious/empathic eroticism", "PROBLEM", 178, 206], ["empathic eroticism", "OBSERVATION", 188, 206]]], ["In contrast, for primary prevention programs, the communication strategy should focus on explaining the modifications in the circuits of the right prefrontal cortex that cause the onset of this behavior and its cognitive and emotional consequences.", [["right prefrontal cortex", "ANATOMY", 141, 164], ["cognitive and emotional consequences", "DISEASE", 211, 247], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 147, 164], ["primary prevention programs", "TREATMENT", 17, 44], ["the communication strategy", "TREATMENT", 46, 72], ["this behavior", "PROBLEM", 189, 202], ["its cognitive and emotional consequences", "PROBLEM", 207, 247], ["right", "ANATOMY_MODIFIER", 141, 146], ["prefrontal cortex", "ANATOMY", 147, 164]]], ["Finally, this research can be useful, if research continues in this direction, to find biological markers in this problematic or addictive behavior, in line with other similar research (Man et al., 2019).Data Availability StatementThe raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.Ethics StatementThe experimental procedure of the study was reviewed and approved by the commission of investigation and ethical protocol of the Department of Theories and Analysis of Communication of the Complutense University of Madrid.", [["the study", "TEST", 397, 406]]], ["The patients or participants provided their written informed consent to participate in this study.Author ContributionsUC aided in the conceptualization and execution of the study, primarily responsible for data analysis and partial drafting of the manuscript and critically reviewed the manuscript and approved its final form.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["participants", "SPECIES", 16, 28], ["this study", "TEST", 87, 97], ["the study", "TEST", 169, 178], ["data analysis", "TEST", 206, 219]]], ["JN aided in the conceptualization of the study, partial drafting of the manuscript, and critically revised the manuscript and approved its final form.", [["the study", "TEST", 37, 46]]], ["LM assisted in data recollection and interpretation, drafting of the manuscript and critical revisions, and approved the final manuscript.", [["critical revisions", "TREATMENT", 84, 102], ["revisions", "OBSERVATION", 93, 102]]], ["BP assisted in data analysis and interpretation and critical review of the manuscript.", [["BP", "PROTEIN", 0, 2], ["BP assisted in data analysis", "TEST", 0, 28]]]], "PMC7417269": [["Search terms included cardiac magnetic resonance imaging or c-MRI, LGE, arrhythmia, hypertrophic cardiomyopathy, ICM, NICM, cardiac ventricular tachycardia, ventricular fibrillation/tachycardia or death, sudden death, cardiac death, cardiac defibrillators, implantable defibrillator or implantable device intervention.", [["cardiac", "ANATOMY", 22, 29], ["ICM", "ANATOMY", 113, 116], ["cardiac ventricular", "ANATOMY", 124, 143], ["ventricular", "ANATOMY", 157, 168], ["cardiac", "ANATOMY", 218, 225], ["cardiac", "ANATOMY", 233, 240], ["arrhythmia", "DISEASE", 72, 82], ["hypertrophic cardiomyopathy", "DISEASE", 84, 111], ["ICM", "DISEASE", 113, 116], ["NICM", "DISEASE", 118, 122], ["cardiac ventricular tachycardia", "DISEASE", 124, 155], ["ventricular fibrillation", "DISEASE", 157, 181], ["tachycardia", "DISEASE", 182, 193], ["death", "DISEASE", 197, 202], ["sudden death", "DISEASE", 204, 216], ["cardiac death", "DISEASE", 218, 231], ["ventricular", "MULTI-TISSUE_STRUCTURE", 132, 143], ["ventricular", "MULTI-TISSUE_STRUCTURE", 157, 168], ["cardiac magnetic resonance imaging", "TEST", 22, 56], ["MRI", "TEST", 62, 65], ["LGE", "PROBLEM", 67, 70], ["arrhythmia", "PROBLEM", 72, 82], ["hypertrophic cardiomyopathy", "PROBLEM", 84, 111], ["ICM", "PROBLEM", 113, 116], ["NICM", "PROBLEM", 118, 122], ["cardiac ventricular tachycardia", "PROBLEM", 124, 155], ["ventricular fibrillation", "PROBLEM", 157, 181], ["tachycardia", "PROBLEM", 182, 193], ["death", "PROBLEM", 197, 202], ["sudden death", "PROBLEM", 204, 216], ["cardiac death", "PROBLEM", 218, 231], ["cardiac defibrillators", "TREATMENT", 233, 255], ["implantable defibrillator", "TREATMENT", 257, 282], ["implantable device intervention", "TREATMENT", 286, 317], ["arrhythmia", "OBSERVATION", 72, 82], ["hypertrophic", "OBSERVATION_MODIFIER", 84, 96], ["cardiomyopathy", "OBSERVATION", 97, 111], ["cardiac ventricular", "ANATOMY", 124, 143], ["tachycardia", "OBSERVATION", 144, 155], ["ventricular", "ANATOMY", 157, 168], ["fibrillation", "OBSERVATION", 169, 181], ["tachycardia", "OBSERVATION", 182, 193], ["cardiac", "ANATOMY", 233, 240], ["defibrillators", "OBSERVATION", 241, 255], ["implantable defibrillator", "OBSERVATION", 257, 282], ["implantable device", "OBSERVATION", 286, 304]]], ["The search was subsequently narrowed and limited to prospective studies comprised of human participants greater than 18 years old with ischemic cardiomyopathy (ICM) and a primary or secondary prevention ICD, had a sample size >30 participants, had at least 6 months follow-up.", [["ischemic cardiomyopathy", "DISEASE", 135, 158], ["ICM", "DISEASE", 160, 163], ["human", "ORGANISM", 85, 90], ["human", "SPECIES", 85, 90], ["participants", "SPECIES", 91, 103], ["participants", "SPECIES", 230, 242], ["human", "SPECIES", 85, 90], ["prospective studies", "TEST", 52, 71], ["ischemic cardiomyopathy", "PROBLEM", 135, 158], ["secondary prevention ICD", "TREATMENT", 182, 206], ["a sample size", "TEST", 212, 225], ["narrowed", "OBSERVATION", 28, 36], ["ischemic", "OBSERVATION_MODIFIER", 135, 143], ["cardiomyopathy", "OBSERVATION", 144, 158], ["secondary", "OBSERVATION_MODIFIER", 182, 191], ["prevention ICD", "OBSERVATION", 192, 206]]], ["Additionally, only studies on ICM that report on sustained and spontaneous ventricular arrhythmias were included in this analysis.", [["ventricular", "ANATOMY", 75, 86], ["ventricular arrhythmias", "DISEASE", 75, 98], ["ventricular", "ORGAN", 75, 86], ["spontaneous ventricular arrhythmias", "PROBLEM", 63, 98], ["this analysis", "TEST", 116, 129], ["ventricular", "ANATOMY", 75, 86], ["arrhythmias", "OBSERVATION", 87, 98]]], ["Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination of our research.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Lastly, our study and all original studies included herein were conducted prior to the current COVID-19 pandemic and thus do not include any known subjects with SARS-CoV-2.Study selection and Data collection ::: MethodsA total of 2646 articles were identified (Figure 1).", [["CoV-2", "ORGANISM", 166, 171], ["SARS-CoV", "SPECIES", 161, 169], ["our study", "TEST", 8, 17], ["all original studies", "TEST", 22, 42], ["the current COVID", "TEST", 83, 100]]], ["Two authors extracted selected studies independently for relevant studies on ICM, NICM and hypertrophic cardiomyopathy.", [["NICM", "DISEASE", 82, 86], ["hypertrophic cardiomyopathy", "DISEASE", 91, 118], ["selected studies", "TEST", 22, 38], ["relevant studies", "TEST", 57, 73], ["hypertrophic cardiomyopathy", "PROBLEM", 91, 118], ["hypertrophic", "OBSERVATION_MODIFIER", 91, 103], ["cardiomyopathy", "OBSERVATION", 104, 118]]], ["A total of 306 articles were then retrieved, fully reviewed and categorized as either pertaining to hypertrophic, ICM, or NICM.", [["ICM", "ANATOMY", 114, 117], ["ICM", "DISEASE", 114, 117], ["NICM", "DISEASE", 122, 126], ["hypertrophic", "OBSERVATION", 100, 112]]], ["A total of 8 studies met all of our inclusion criteria and were included in the final analysis.", [["8 studies", "TEST", 11, 20], ["the final analysis", "TEST", 76, 94]]], ["The first author thoroughly reviewed the 8 studies and extracted pertinent details including baseline demographic and clinical characteristics and clinical outcomes from each study.", [["the 8 studies", "TEST", 37, 50], ["each study", "TEST", 170, 180]]], ["Specifics regarding the approach used for data collection are detailed in Figure 1.Study selection and Data collection ::: MethodsOutcomes of interest were SCD, sustained and spontaneous ventricular tachyarrhythmias such as ventricular tachycardia, ventricular fibrillation, aborted SCD, appropriate ICD therapy including shocks and anti-tachycardia pacing, and all-cause mortality.", [["ventricular", "ANATOMY", 187, 198], ["ventricular", "ANATOMY", 224, 235], ["ventricular", "ANATOMY", 249, 260], ["SCD", "DISEASE", 156, 159], ["ventricular tachyarrhythmias", "DISEASE", 187, 215], ["ventricular tachycardia", "DISEASE", 224, 247], ["ventricular fibrillation", "DISEASE", 249, 273], ["SCD", "DISEASE", 283, 286], ["ventricular", "MULTI-TISSUE_STRUCTURE", 187, 198], ["ventricular", "MULTI-TISSUE_STRUCTURE", 224, 235], ["ventricular", "MULTI-TISSUE_STRUCTURE", 249, 260], ["data collection", "TEST", 42, 57], ["SCD", "PROBLEM", 156, 159], ["spontaneous ventricular tachyarrhythmias", "PROBLEM", 175, 215], ["ventricular tachycardia", "PROBLEM", 224, 247], ["ventricular fibrillation", "PROBLEM", 249, 273], ["aborted SCD", "PROBLEM", 275, 286], ["appropriate ICD therapy", "TREATMENT", 288, 311], ["shocks", "TREATMENT", 322, 328], ["anti-tachycardia pacing", "TREATMENT", 333, 356], ["ventricular", "ANATOMY", 187, 198], ["tachyarrhythmias", "OBSERVATION", 199, 215], ["ventricular", "ANATOMY", 224, 235], ["tachycardia", "OBSERVATION", 236, 247], ["ventricular", "ANATOMY", 249, 260], ["fibrillation", "OBSERVATION", 261, 273]]], ["We included studies with composite primary or secondary outcomes/events if they reported separately on the individual outcomes.", [["studies", "TEST", 12, 19], ["secondary outcomes/events", "PROBLEM", 46, 71]]], ["Data from those studies were then extracted and collected for the analysis.", [["those studies", "TEST", 10, 23], ["the analysis", "TEST", 62, 74]]], ["Studies with composite primary or secondary outcomes of interest that did not report separately on the individual outcomes of interest were not included in the pooled analysis.", [["Studies", "TEST", 0, 7], ["the pooled analysis", "TEST", 156, 175]]], ["Studies that reported on inducible arrhythmias during an electrophysiology study were also excluded.", [["arrhythmias", "DISEASE", 35, 46], ["Studies", "TEST", 0, 7], ["inducible arrhythmias", "PROBLEM", 25, 46], ["an electrophysiology study", "TEST", 54, 80], ["arrhythmias", "OBSERVATION", 35, 46]]], ["Of special Interest to us were aspects of the myocardial scar that the investigators found to be most predictive of outcomes and the reported pattern of scar.Statistical analysis ::: MethodsPatient's baseline characteristics are reported using median with interquartile range and mean +/\u2212 standard deviation (SD), as reported in the original studies.", [["myocardial scar", "ANATOMY", 46, 61], ["scar", "ANATOMY", 153, 157], ["myocardial scar", "DISEASE", 46, 61], ["myocardial scar", "PATHOLOGICAL_FORMATION", 46, 61], ["scar", "PATHOLOGICAL_FORMATION", 153, 157], ["the myocardial scar", "PROBLEM", 42, 61], ["scar", "PROBLEM", 153, 157], ["Statistical analysis", "TEST", 158, 178], ["mean", "TEST", 280, 284], ["the original studies", "TEST", 329, 349], ["myocardial", "ANATOMY", 46, 56], ["scar", "OBSERVATION", 57, 61], ["scar", "OBSERVATION", 153, 157]]], ["Follow-up periods are reported in months, and clinical outcomes including the ventricular arrhythmic events were extracted and reported as simple counts.", [["ventricular", "ANATOMY", 78, 89], ["ventricular arrhythmic", "DISEASE", 78, 100], ["ventricular", "MULTI-TISSUE_STRUCTURE", 78, 89], ["the ventricular arrhythmic events", "PROBLEM", 74, 107], ["simple counts", "TEST", 139, 152], ["ventricular", "ANATOMY", 78, 89], ["arrhythmic", "OBSERVATION", 90, 100]]], ["To estimate the importance of myocardial fibrosis across various studies, pooled sensitivity and specificity analyses were conducted using a random-effects model (DerSimonian-Laird estimator).", [["myocardial", "ANATOMY", 30, 40], ["myocardial fibrosis", "DISEASE", 30, 49], ["myocardial", "MULTI-TISSUE_STRUCTURE", 30, 40], ["myocardial fibrosis", "PROBLEM", 30, 49], ["various studies", "TEST", 57, 72], ["pooled sensitivity", "TEST", 74, 92], ["specificity analyses", "TEST", 97, 117], ["myocardial", "ANATOMY", 30, 40], ["fibrosis", "OBSERVATION", 41, 49]]], ["Proportions (sensitivity and specificity) were converted to corresponding log odds and summarized on this scale.", [["specificity", "TEST", 29, 40], ["this scale", "TREATMENT", 101, 111]]], ["Subsequently, the summary values were converted back to the reported proportions.", [["the summary values", "TEST", 14, 32]]], ["Heterogeneity statistics for the meta-analysis were also generated.", [["the meta-analysis", "TEST", 29, 46]]], ["Individual study sensitivities and specificities were displayed with exact 95% confidence intervals.", [["Individual study sensitivities", "TEST", 0, 30], ["specificities", "TEST", 35, 48]]], ["Meta-analysis was performed with the \u201cmetafor\u201d package (version 2.0) within R statistical software version 3.4.2 (The R Foundation, Vienna, Austria, 2017).", [["Meta-analysis", "TEST", 0, 13]]], ["IRB approval was not needed for this study.Statistical analysis ::: MethodsNo extramural funding was used to support this work.Clinical and demographics data ::: ResultsEight studies comprised of 1085 participants with median/mean follow-up of 8.5\u201364.8 months, were included in the final analysis.", [["participants", "SPECIES", 201, 213], ["IRB approval", "TREATMENT", 0, 12], ["this study", "TEST", 32, 42], ["MethodsNo extramural funding", "TREATMENT", 68, 96], ["Eight studies", "TEST", 169, 182], ["the final analysis", "TEST", 278, 296]]], ["The total population age and male gender percentage ranged from 43\u201383 years and 64\u201388% respectively (Table I).Clinical and demographics data ::: ResultsThe most commonly reported co-morbidities were prior history of diabetes (22\u201362%), hyperlipidemia (40\u201386%), and hypertension (35\u201388%).", [["diabetes", "DISEASE", 216, 224], ["hyperlipidemia", "DISEASE", 235, 249], ["hypertension", "DISEASE", 264, 276], ["diabetes", "PROBLEM", 216, 224], ["hyperlipidemia", "PROBLEM", 235, 249], ["hypertension", "PROBLEM", 264, 276], ["total", "OBSERVATION_MODIFIER", 4, 9], ["diabetes", "OBSERVATION", 216, 224], ["hyperlipidemia", "OBSERVATION", 235, 249], ["hypertension", "OBSERVATION", 264, 276]]], ["The ejection fraction was reported as mean or median in each study, and it varied from 22\u201335% (Table I).", [["The ejection fraction", "TEST", 0, 21], ["ejection fraction", "OBSERVATION", 4, 21]]], ["The rate of use of beta-blockers ranged from 49% to 94% while the rate of use of angiotensin-converting-enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARB) ranged from 51% to 100%.", [["angiotensin", "CHEMICAL", 81, 92], ["ACE-i", "CHEMICAL", 123, 128], ["angiotensin", "CHEMICAL", 133, 144], ["ARB", "CHEMICAL", 164, 167], ["beta-blockers", "SIMPLE_CHEMICAL", 19, 32], ["angiotensin-converting-enzyme", "GENE_OR_GENE_PRODUCT", 81, 110], ["ACE-i", "SIMPLE_CHEMICAL", 123, 128], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 133, 162], ["ARB", "SIMPLE_CHEMICAL", 164, 167], ["beta", "PROTEIN", 19, 23], ["beta-blockers", "TREATMENT", 19, 32], ["angiotensin", "TREATMENT", 81, 92], ["enzyme inhibitors", "TREATMENT", 104, 121], ["ACE-i", "TREATMENT", 123, 128], ["angiotensin receptor blockers", "TREATMENT", 133, 162], ["ARB", "TREATMENT", 164, 167]]], ["The rate of use of aldosterone antagonists was reported in five of the eight studies and ranged from 13.8% to 56%.12., 13., 14., 15., 16.", [["aldosterone", "CHEMICAL", 19, 30], ["aldosterone", "CHEMICAL", 19, 30], ["aldosterone antagonists", "GENE_OR_GENE_PRODUCT", 19, 42], ["aldosterone antagonists", "TREATMENT", 19, 42]]], ["All studies included participants meeting criteria for primary prevention ICDs.12., 13., 14., 15., 16., 17., 18., 19.", [["participants", "SPECIES", 21, 33], ["All studies", "TEST", 0, 11], ["primary prevention ICDs", "TREATMENT", 55, 78]]], ["Three of the eight studies also enrolled patients receiving secondary prevention ICD.4,15,18 The study that reported the number of patients with primary and secondary prevention ICDs included only 10 out of 91 patients with a secondary prevention ICDs4.", [["4,15,18", "CHEMICAL", 85, 92], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 210, 218], ["the eight studies", "TEST", 9, 26], ["secondary prevention ICD", "TREATMENT", 60, 84], ["The study", "TEST", 93, 102], ["primary and secondary prevention ICDs", "TREATMENT", 145, 182], ["a secondary prevention ICDs4", "TREATMENT", 224, 252], ["ICD", "OBSERVATION", 81, 84]]], ["The remaining two studies did not provide specific breakdown of patients with primary vs secondary prevention ICDs.15,18 Interestingly, all of the studies were conducted in European countries or Australia with one study also enrolling participants from North America.15", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["participants", "SPECIES", 235, 247], ["The remaining two studies", "TEST", 0, 25], ["primary vs secondary prevention ICDs", "TREATMENT", 78, 114], ["the studies", "TEST", 143, 154], ["one study", "TEST", 210, 219]]]], "de2d6c4212b43ddee4e629d7b15ea23efbc7047f": [["Figure 2:Coronal reconstruction chest CT image shows ill-defined peripheral ground-glass opacities in both lungs (arrowheads).", [["lungs", "ANATOMY", 107, 112], ["lungs", "ORGAN", 107, 112], ["Coronal reconstruction chest CT image", "TEST", 9, 46], ["ill-defined peripheral ground-glass opacities in both lungs", "PROBLEM", 53, 112], ["chest", "ANATOMY", 32, 37], ["ill", "OBSERVATION_MODIFIER", 53, 56], ["peripheral", "ANATOMY_MODIFIER", 65, 75], ["ground-glass opacities", "OBSERVATION", 76, 98], ["both", "ANATOMY_MODIFIER", 102, 106], ["lungs", "ANATOMY", 107, 112]]]]}